<SEC-DOCUMENT>0001193805-20-000960.txt : 20200805
<SEC-HEADER>0001193805-20-000960.hdr.sgml : 20200805
<ACCEPTANCE-DATETIME>20200805172317
ACCESSION NUMBER:		0001193805-20-000960
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200805
DATE AS OF CHANGE:		20200805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		201078678

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>adma_10q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:adma="http://admabiologics.com/20200630"><head><title>adma_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:justify;font:10pt times new roman"><div style='display:none;text-align:justify;font:10pt times new roman;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2020-01-01to2020-06-30">0001368514</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2020-01-01to2020-06-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2020-01-01to2020-06-30">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2020-01-01to2020-06-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2020-01-01to2020-06-30">Q2</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2020-01-01to2020-06-30">2020</ix:nonNumeric><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="4">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-12-31" unitRef="Shares" decimals="0">10000000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-06-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2019-12-31" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-06-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2019-12-31" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="4">0.0001</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-12-31" unitRef="Shares" decimals="0">150000000</ix:nonFraction><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2019-12-31_adma_BiotestMember" unitRef="USD" decimals="6">15.0</ix:nonFraction><ix:nonFraction name="adma:AmortizationExpense" contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="6">0.2</ix:nonFraction><ix:nonFraction name="adma:AmortizationExpense" contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="6">0.4</ix:nonFraction><ix:nonFraction name="us-gaap:SubordinatedDebt" contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">14925760</ix:nonFraction><ix:nonFraction name="us-gaap:SubordinatedDebt" contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">14908053</ix:nonFraction><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-01to2019-06-30_adma_MarathonHealthcareFinanceFundLPMember" unitRef="USD" decimals="0" sign="-">9962495</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-06-30_adma_PlasmaCentersMember" unitRef="USD" decimals="0">15754</ix:nonFraction><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2019-12-31" unitRef="Shares" decimals="0">2138160</ix:nonFraction><ix:nonFraction name="adma:CompensationExpense" contextRef="From2019-04-01to2019-06-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="6">0.1</ix:nonFraction><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-01-01to2020-06-30_adma_ArethLLCMember" unitRef="USD" decimals="0">60000</ix:nonFraction><ix:nonFraction name="adma:CapitalExpenditure" contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember" unitRef="USD" decimals="0">6243284</ix:nonFraction><ix:nonFraction name="adma:CapitalExpenditure" contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember" unitRef="USD" decimals="0">6243284</ix:nonFraction><ix:nonFraction name="adma:CapitalExpenditure" contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember" unitRef="USD" decimals="0">245675</ix:nonFraction><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember" unitRef="USD" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="6">0.1</ix:nonFraction><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-01-01to2019-06-30" unitRef="USD" decimals="6">0.2</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='adma-20200630.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2020-01-01to2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-08-03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2004-06-01to2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2004-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_us-gaap_StockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_us-gaap_StockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_us-gaap_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_us-gaap_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_adma_JanuaryOneTwoThousandNineteenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">adma:JanuaryOneTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_adma_BiotestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adma:BiotestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_adma_BiotestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adma:BiotestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_CustomerThreeMember_us-gaap_AccountsReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">adma:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-12-31_adma_CustomerTwoMember_us-gaap_AccountsReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">adma:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_CustomerThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">adma:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_adma_CustomerThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">adma:CustomerThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_TrademarksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_TrademarksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_adma_RightToIntermediatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_adma_RightToIntermediatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_CustomerContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_CustomerContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_us-gaap_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_PropertyAndEquipmentMember_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adma:PropertyAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-11to2019-05-03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-02-01to2019-02-11_adma_PerceptiveCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_BPCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:BPCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-11to2019-05-02_adma_PerceptiveTrancheIIIWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">adma:PerceptiveTrancheIIIWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-11to2019-05-03_adma_MarathonHealthcareFinanceFundLPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:MarathonHealthcareFinanceFundLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_adma_MarathonHealthcareFinanceFundLPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:MarathonHealthcareFinanceFundLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-05-03_adma_MarathonHealthcareFinanceFundLPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:MarathonHealthcareFinanceFundLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-04-11to2019-05-03_adma_PerceptiveTrancheIIILoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">adma:PerceptiveTrancheIIILoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-11to2019-05-03_adma_PerceptiveTrancheIILoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">adma:PerceptiveTrancheIILoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_PerceptiveTrancheILoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">adma:PerceptiveTrancheILoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_adma_PlasmaCentersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">adma:PlasmaCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_PlasmaCentersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">adma:PlasmaCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_adma_PlasmaCentersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">adma:PlasmaCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_adma_PlasmaCentersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">adma:PlasmaCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_us-gaap_CostOfGoodsTotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_us-gaap_CostOfGoodsTotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_us-gaap_CostOfGoodsTotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_us-gaap_CostOfGoodsTotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-02-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-02-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-02-01to2020-02-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-02-01to2020-02-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_adma_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_adma_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_us-gaap_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_ArethLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_adma_ArethLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2017-09-09to2017-10-01_adma_ArethLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-09</xbrli:startDate><xbrli:endDate>2017-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_adma_ConsolidatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ConsolidatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_ConsolidatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ConsolidatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_adma_ConsolidatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ConsolidatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_adma_ConsolidatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ConsolidatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_us-gaap_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_us-gaap_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_us-gaap_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_us-gaap_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:AdmaBiomanufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:AdmaBiomanufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:AdmaBiomanufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:AdmaBiomanufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-01-01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2020-07-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_adma_JefferiesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:SaleAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_srt_MaximumMember_adma_JefferiesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:SaleAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%" cellpadding="1"><tbody><tr><td style="border-bottom:5px solid;padding:1px;"></td></tr><tr><td style="border-bottom:2px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;padding-right:1px;padding:1px;"></td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><p style="MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>WASHINGTON </strong><strong>, D.C. 20549</strong></p><p style="MARGIN: 0px; text-align:justify;"><strong>&#160; </strong></p><p style="MARGIN: 0px; text-align:center;"><strong><strong><span style="font-size:18pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2020-01-01to2020-06-30">10-Q</ix:nonNumeric></span></strong></strong></p><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><p style="MARGIN: 0px; text-align:justify;">(Mark One)</p><p style="MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="From2020-01-01to2020-06-30" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric> </td><td style="vertical-align:top;"><span style="mso-tab-count:1">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160; </p><p style="MARGIN: 0px; text-align:center;">For the quarterly period ended <span style="text-decoration:underline"><strong><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2020-01-01to2020-06-30" format="ixt:datemonthdayyearen">June 30, 2020</ix:nonNumeric></strong></span>&#160; </p><p style="MARGIN: 0px; text-align:center;">OR</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="From2020-01-01to2020-06-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> </td><td style="vertical-align:top;"><span style="mso-tab-count:1">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;">For the transition period from ________ to ________</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><p style="MARGIN: 0px; text-align:center;">Commission file number <span style="text-decoration:underline"><strong><ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2020-01-01to2020-06-30">001-36728</ix:nonNumeric></strong></span></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:50%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:90%;vertical-align:top;" colspan="3"><p style="MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2020-01-01to2020-06-30">ADMA BIOLOGICS, INC.</ix:nonNumeric></span></strong> </p></td></tr><tr style="height:15px"><td colspan="3" style="width:90%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">(Exact Name of Registrant as Specified in Its Charter) </p></td></tr></tbody></table><p style="margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:bottom;" colspan="2"><p style="MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2020-01-01to2020-06-30" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></strong> </p></td><td style="width:10%;"><p style="MARGIN: 0px; text-align:center;">&#160; </p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:bottom;"><p style="MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2020-01-01to2020-06-30">56-2590442</ix:nonNumeric></strong> </p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">(State or Other Jurisdiction of Incorporation or Organization) </p></td><td><p style="MARGIN: 0px; text-align:center;">&#160; </p></td><td style="vertical-align:bottom;"><p style="MARGIN: 0px; text-align:center;">(I.R.S. Employer Identification No.) </p></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2020-01-01to2020-06-30">465 State Route 17,</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2020-01-01to2020-06-30">Ramsey</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="From2020-01-01to2020-06-30" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></strong> </p></td><td style="width:10%;"><p style="MARGIN: 0px; text-align:center;"><strong>&#160;</strong> </p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;" colspan="3"><p style="MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2020-01-01to2020-06-30">07446</ix:nonNumeric></strong> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">(Address of Principal Executive Offices) </p></td><td><p style="MARGIN: 0px; text-align:center;">&#160; </p></td><td colspan="3" style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">(Zip Code) </p></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong style="MARGIN: 0px"><span style="text-decoration:underline">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2020-01-01to2020-06-30">201</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2020-01-01to2020-06-30">478-5552</ix:nonNumeric></span></strong></p><p style="MARGIN: 0px; text-align:center;">(Registrant&#8217;s Telephone Number, Including Area Code)&#160;&#160;&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><p style="MARGIN: 0px; text-align:center;">_______________________________________________________________________</p><p style="MARGIN: 0px; text-align:center;">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)&#160;&#160;&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; &#160;</p><p style="MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="1"><tbody><tr style="height:15px"><td style="border-top:#000000 1px solid;border-left:#000000 1px solid;padding:1px;width:33%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">Title of each class </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:22%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">Trading Symbol(s) </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:33%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">Name of each exchange on which registered </p></td></tr><tr style="height:15px"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2020-01-01to2020-06-30">Common Stock </ix:nonNumeric></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2020-01-01to2020-06-30">ADMA</ix:nonNumeric> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2020-01-01to2020-06-30" format="ixt-sec:exchnameen">Nasdaq Global Market</ix:nonNumeric> </p></td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="From2020-01-01to2020-06-30">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160; No &#9744;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="From2020-01-01to2020-06-30">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160; No &#9744;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:top;">Large accelerated filer </td><td style="width:20%;">&#9744; </td><td style="width:30%;vertical-align:top;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="From2020-01-01to2020-06-30" format="ixt-sec:entityfilercategoryen">Accelerated filer</ix:nonNumeric> </td><td style="width:20%;">&#9746; </td></tr><tr style="height:15px"><td style="vertical-align:top;">Non-accelerated filer </td><td>&#9744; </td><td style="vertical-align:top;">Smaller reporting company </td><td><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="From2020-01-01to2020-06-30" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric> </td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td style="vertical-align:top;">Emerging growth company </td><td>&#9744; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="MARGIN: 0px; text-align:justify;">&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="From2020-01-01to2020-06-30" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160; No &#9746;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of August 3, 2020, there were <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2020-08-03" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,349,981</ix:nonFraction> shares of the issuer&#8217;s common stock outstanding.</p><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;&#160; </p><table style="font-size:1px;width:100%" cellpadding="1"><tbody><tr><td style="border-bottom:2px solid;padding:1px;"></td></tr><tr><td style="border-bottom:5px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;padding-right:1px;padding:1px;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong><strong><span class="atag" id="toc11">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span></strong></strong></p><p style="MARGIN: 0px; text-align:center;">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong><strong>INDEX</strong></strong></p><p style="MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="3" style="vertical-align:top;"><strong><a href="#p1">PART I FINANCIAL INFORMATION </a></strong></td><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td colspan="3">&#160; </td><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:3%;"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:top;"><a href="#i1">Item 1. </a></td><td style="vertical-align:top;"><a href="#i1">Financial Statements </a></td><td style="width:1%;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="width:9%;"><p style="MARGIN: 0px; text-align:right;">1</p></td><td style="width:1%;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td>&#160; </td><td style="vertical-align:top;"><a href="#bs">Condensed Consolidated Balance Sheets as of June 30, 2020 (Unaudited) and December 31, 2019 </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">1</p></td><td><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px">&#160;</p></td><td>&#160; </td><td style="vertical-align:top;"><a href="#so">Condensed Consolidated Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2020 and 2019 </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">2</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td>&#160; </td><td style="vertical-align:top;"><a href="#eq">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (Unaudited) for the Three and Six months Ended June 30, 2020 and 2019 </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">3</p></td><td><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px">&#160;</p></td><td>&#160; </td><td style="vertical-align:top;"><a href="#cf">Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2020 and 2019 </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">4</p></td><td><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td>&#160; </td><td style="vertical-align:top;"><a href="#nt">Notes to (Unaudited) Condensed Consolidated Financial Statements </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">5</p></td><td><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="#i2">Item 2. </a></td><td style="vertical-align:top;"><a href="#i2">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">23</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="#i3">Item 3. </a></td><td style="vertical-align:top;"><a href="#i3">Quantitative and Qualitative Disclosures About Market Risk. </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">35</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="#i4">Item 4. </a></td><td style="vertical-align:top;"><a href="#i4">Controls and Procedures. </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">35</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="3">&#160; </td><td>&#160; </td><td><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="3" style="vertical-align:top;"><strong><a href="#p2">PART II OTHER INFORMATION </a></strong></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">36</p></td><td><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="3">&#160; </td><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="#p21">Item 1. </a></td><td style="vertical-align:top;"><a href="#p21">Legal Proceedings. </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">36</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="#p21a">Item 1A. </a></td><td style="vertical-align:top;"><a href="#p21a">Risk Factors. </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">36</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="#p22">Item 2. </a></td><td style="vertical-align:top;"><a href="#p22">Unregistered Sales of Equity Securities and Use of Proceeds. </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">64</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="#p23">Item 3. </a></td><td style="vertical-align:top;"><a href="#p23">Defaults Upon Senior Securities. </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">64</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="#p24">Item 4. </a></td><td style="vertical-align:top;"><a href="#p24">Mine Safety Disclosures.&#160; </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">64</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="#p25">Item 5. </a></td><td style="vertical-align:top;"><a href="#p25">Other Information.&#160; </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">64</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><a href="#p26">Item 6.&#160; </a></td><td style="vertical-align:top;"><a href="#p26">Exhibits.&#160; </a></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">64</p></td><td>&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="3" style="vertical-align:top;"><strong><a href="#sig">SIGNATURES</a></strong></td><td>&#160; </td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">65</p></td><td>&#160; </td></tr></tbody></table><p style="margin:0px">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">This Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, such as &#8220;ASCENIV<sup>&#8482;</sup>,&#8221; &#8220;Nabi-HB<sup>&#174;</sup>&#8221; and &#8220;BIVIGAM<sup>&#174;</sup>,&#8221; which are protected under applicable intellectual property laws and are the property of ADMA Biologics, Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the <sup>&#174;</sup>, <sup>&#8482;</sup> or <sup>SM</sup> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">i</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;&#160;&#160; </p><p style="MARGIN: 0px; text-align:center;"><strong>Special Note Regarding Forward-Looking Statements</strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; &#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Some of the information in this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These statements include, among others, statements about: </p><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our ability to manufacture BIVIGAM on a commercial scale and commercialize this product as a result of the approval of the Prior Approval Supplement for BIVIGAM by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) on May 9, 2019; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our ability to manufacture ASCENIV on a commercial scale and commercialize this product as a result of the FDA approval of ASCENIV&#8217;s Biologics License Application on April 1, 2019; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our plans to develop, manufacture, market, launch and expand our commercial infrastructure and commercialize our current and future products and the success of such efforts; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">the safety, efficacy and expected timing of and our ability to obtain and maintain regulatory approvals for our current products and product candidates, and the labeling or nature of any such approvals; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">the achievement of or expected timing, progress and results of clinical development, clinical trials and potential regulatory approvals for our product candidates; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our dependence upon our third-party customers and vendors and their compliance with applicable regulatory requirements; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our belief that we have addressed the delays experienced with final drug product GMP release testing by our third-party vendors by adding additional release testing laboratories to our FDA-approved consortium listed in our drug approval documents; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our ability to obtain adequate quantities of FDA-approved plasma with proper specifications; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our plans to increase our supplies of source plasma, which include plasma collection center expansion and reliance on third-party supply agreements as well as any extensions to such agreements; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">the potential indications for our products and product candidates; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">potential investigational new product applications; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">the acceptability of any of our products, including Nabi-HB, BIVIGAM and ASCENIV, for any purpose, including FDA-approved indications, by physicians, patients or payers; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our plans to evaluate the clinical and regulatory paths to grow the ASCENIV franchise through expanded FDA-approved uses; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">Federal, state and local regulatory and business review processes and timing by such governmental and regulatory agencies of our business and regulatory submissions; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">concurrence by the FDA with our conclusions concerning our products and product candidates; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">the comparability of results of our hyperimmune and immune globulin products to other comparably run hyperimmune and immune globulin clinical trials; </td></tr></tbody></table><p style="margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">the potential for ASCENIV and BIVIGAM to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease, Primary Humoral Immunodeficiency Disease (&#8220;PIDD&#8221; or &#8220;PI&#8221;)or other immune deficiencies or any other condition for which the products may be prescribed or evaluated; </td></tr></tbody></table><p style="margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">ii</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our ability to market and promote Nabi-HB in a highly competitive environment with increasing competition from other antiviral therapies and to generate meaningful revenues from this product; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our intellectual property position and the defense thereof, including our expectations regarding the scope of patent protection with respect to ASCENIV or other future pipeline product candidates; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our manufacturing capabilities, third-party contractor capabilities and vertical integration strategy; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our plans related to the expansion of our manufacturing capacity, yield improvements, supply-chain robustness, distribution and other collaborative agreements and the success of such endeavors; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">our estimates regarding revenues, expenses, capital requirements, timing to profitability and the need for and availability of additional financing; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">possible or likely reimbursement levels for our currently marketed products; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">estimates regarding market size, projected growth and sales of our existing products as well as our expectations of market acceptance of ASCENIV and BIVIGAM; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">effects of the coronavirus (COVID-19) pandemic on our business, financial condition, liquidity and results of operations, and our ability to continue operations in the same manner as previously conducted prior to the macroeconomic effects of the COVID-19 pandemic; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">future domestic and global economic conditions or performance; and </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"></td><td style="width:4%;vertical-align:top;"><span style="font-family:symbol"><span style="mso-char-type:symbol;mso-symbol-font-family:symbol">&#183;</span></span> </td><td style="vertical-align:top;">expectations for future capital requirements. </td></tr></tbody></table><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">These statements may be found under the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of this Quarterly Report on Form 10-Q. Forward-looking statements may be identified by the use of terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; or &#8220;should&#8221; or the negative thereof or other variations thereof or comparable terminology. Our actual results could differ materially from those contained in the forward-looking statements due to the factors described in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019 and in this Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Any forward-looking statement included or incorporated by reference in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions related to our operations, industry and future growth. These forward-looking statements speak only as of the dates such statements are made and we undertake no obligation to publicly update any forward-looking statements or to publicly announce revisions to any of the forward-looking statements, unless otherwise required by the federal securities laws.</p><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">iii</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong><span class="atag" id="p1">PART I </span></strong></p><p style="MARGIN: 0px; text-align:center;"><strong>FINANCIAL INFORMATION</strong></p><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160; </p><p style="MARGIN: 0px; text-align:justify;"><strong><span class="atag" id="i1">Item 1. Financial Statements.</span></strong></p><p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160; </p><p style="MARGIN: 0px; text-align:center;"><strong><span class="atag" id="bs">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span></strong></p><p style="MARGIN: 0px; text-align:center;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>June 30,</strong> </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>December 31,</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><strong>ASSETS</strong> </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">(Unaudited) </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;"></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td style="vertical-align:top;">Current assets: </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Cash and cash equivalents </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_467" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,781,122</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_468" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,752,135</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Accounts receivable, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_469" name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,514,165</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_470" name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,469,919</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Inventories </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_471" name="us-gaap:InventoryNet" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,001,348</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_472" name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,064,734</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="MARGIN: 0px 0px 0px 15px; TEXT-INDENT: 15px;vertical-align:top;">Prepaid expenses and other current assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_473" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,693,427</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_474" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,533,593</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Total current assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_475" name="us-gaap:AssetsCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,990,062</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_476" name="us-gaap:AssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,820,381</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="MARGIN: 0px;vertical-align:top;">Property and equipment, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_477" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,373,366</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_478" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,741,317</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px;vertical-align:top;">Intangible assets, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_479" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,801,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_480" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,159,474</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="MARGIN: 0px;vertical-align:top;">Goodwill </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_481" name="us-gaap:Goodwill" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,529,509</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_482" name="us-gaap:Goodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,529,509</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px;vertical-align:top;">Deposits and other assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_483" name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,846,834</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_484" name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,840,044</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>TOTAL ASSETS</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_485" name="us-gaap:AssetsNet" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,541,568</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_486" name="us-gaap:AssetsNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,090,725</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY </strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Current liabilities: </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Accounts payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_489" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,909,659</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_490" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,174,591</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Accrued expenses and other current liabilities </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_491" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,616,666</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_492" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,481,395</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Current portion of deferred revenue </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_493" name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,834</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_494" name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,834</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Current portion of lease obligations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_495" name="us-gaap:CapitalLeaseObligationsCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,870</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_496" name="us-gaap:CapitalLeaseObligationsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,073</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Total current liabilities </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_497" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,880,029</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_498" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,027,893</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Senior notes payable, net of discount </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_499" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,648,187</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_500" name="us-gaap:LongTermNotesPayable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,291,163</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Deferred revenue, net of current portion </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_501" name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,190,115</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_502" name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,261,532</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Subordinated note payable, net of discount </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_503" name="us-gaap:SubordinatedLongTermDebt" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,925,760</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_504" name="us-gaap:SubordinatedLongTermDebt" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,908,053</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Lease obligations, net of current portion </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_505" name="us-gaap:CapitalLeaseObligationsNoncurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,937,292</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_506" name="us-gaap:CapitalLeaseObligationsNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,302,361</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other non-current liabilities </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_507" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,730</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_508" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,574</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>TOTAL LIABILITIES</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_509" name="us-gaap:Liabilities" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,662,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_510" name="us-gaap:Liabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,897,576</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>COMMITMENTS AND CONTINGENCIES</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>STOCKHOLDERS' EQUITY </strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Preferred Stock, $<ix:nonFraction id="fid_526" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-06-30" decimals="4" unitRef="USDPShares">0.0001</ix:nonFraction> par value, <ix:nonFraction id="fid_528" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000,000</ix:nonFraction> shares authorized, no shares issued and outstanding </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_512" name="us-gaap:PreferredStockValue" contextRef="AsOf2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_513" name="us-gaap:PreferredStockValue" contextRef="AsOf2019-12-31" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Common Stock, $<ix:nonFraction id="fid_534" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-06-30" decimals="4" unitRef="USDPShares">0.0001</ix:nonFraction> par value, <ix:nonFraction id="fid_536" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">150,000,000</ix:nonFraction> shares authorized, <ix:nonFraction id="fid_538" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">86,349,981</ix:nonFraction> and <ix:nonFraction id="fid_537" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">59,318,355</ix:nonFraction> shares issued and outstanding </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_514" name="us-gaap:CommonStockValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,635</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_515" name="us-gaap:CommonStockValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,932</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Additional paid-in capital </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_516" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">381,010,696</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_517" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,903,772</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accumulated deficit </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_518" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">304,139,876</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_519" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">264,716,555</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>TOTAL STOCKHOLDERS' EQUITY </strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_520" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,879,455</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_521" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,193,149</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY </strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_522" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,541,568</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_523" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,090,725</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="margin:0px">&#160; </p><p style="MARGIN: 0px; text-align:center;">&#160;The accompanying notes are an integral part of these condensed consolidated financial statements.</p><p style="margin:0px">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong><span class="atag" id="so">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span></strong></p><p style="MARGIN: 0px; text-align:center;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS <br />(Unaudited)</strong></p><p style="margin:0px">&#160;&#160;&#160;&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><strong>Three Months Ended June 30,</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><strong>Six Months Ended June 30,</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td></tr><tr style="height:15px"><td><strong>&#160;</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td style="vertical-align:top;"><strong>REVENUES:</strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Product revenue </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_879" name="adma:ProductRevenue" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,751,885</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_880" name="adma:ProductRevenue" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,525,233</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_881" name="adma:ProductRevenue" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,915,921</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_882" name="adma:ProductRevenue" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,018,114</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">License revenue </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_883" name="adma:LicenseRevenue" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,709</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_884" name="adma:LicenseRevenue" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,709</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_885" name="adma:LicenseRevenue" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,417</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_886" name="adma:LicenseRevenue" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,417</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;"><strong>Total Revenues</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_887" name="us-gaap:Revenues" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,787,594</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_888" name="us-gaap:Revenues" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,560,942</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_889" name="us-gaap:Revenues" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,987,338</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_890" name="us-gaap:Revenues" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,089,531</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>OPERATING EXPENSES:</strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Cost of product revenue (exclusive of amortization expense shown below) </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_892" name="us-gaap:CostOfRevenue" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,495,629</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_893" name="us-gaap:CostOfRevenue" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,491,236</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_894" name="us-gaap:CostOfRevenue" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,324,855</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_895" name="us-gaap:CostOfRevenue" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,896,415</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Research and development </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_896" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,656,420</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_897" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">516,986</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_898" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,185,158</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_899" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,387,621</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Plasma center operating expenses </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_900" name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">877,902</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_901" name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">594,113</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_902" name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,378,546</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_903" name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,248,599</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Amortization of intangible assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_904" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,838</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_905" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,234</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_906" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,676</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_907" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">422,469</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Selling, general and administrative </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_908" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,702,630</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_909" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,086,047</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_910" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,634,714</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_911" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,681,517</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;"><strong>Total operating expenses</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_912" name="us-gaap:OperatingExpenses" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,911,419</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_913" name="us-gaap:OperatingExpenses" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,899,616</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_914" name="us-gaap:OperatingExpenses" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,880,949</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_915" name="us-gaap:OperatingExpenses" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,636,621</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>LOSS FROM OPERATIONS</strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_916" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">17,123,825</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_917" name="us-gaap:OperatingIncomeLoss" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,338,674</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_918" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">33,893,611</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_919" name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">24,547,090</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>OTHER INCOME (EXPENSE):</strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Interest and other income </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_921" name="us-gaap:InterestIncomeOther" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,411</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_922" name="us-gaap:InterestIncomeOther" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209,808</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_923" name="us-gaap:InterestIncomeOther" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,479</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_924" name="us-gaap:InterestIncomeOther" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">337,207</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Interest expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_925" name="us-gaap:InterestExpense" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,067,306</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_926" name="us-gaap:InterestExpense" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,072,578</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_927" name="us-gaap:InterestExpense" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,784,397</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_928" name="us-gaap:InterestExpense" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,613,085</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Loss on extinguishment of debt </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_929" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-04-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_931" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_930" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-04-01to2019-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_932" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,962,495</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Gain on transfer of plasma center assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_933" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2020-04-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_934" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2019-04-01to2019-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_935" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_936" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,527,421</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Other expense, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_937" name="us-gaap:OtherIncome" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,371</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_938" name="us-gaap:OtherIncome" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">10,428</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_939" name="us-gaap:OtherIncome" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">12,792</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_940" name="us-gaap:OtherIncome" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">21,785</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;"><strong>Other expense, net</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_941" name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,054,266</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_942" name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,873,198</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_943" name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">5,529,710</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_944" name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,732,737</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>NET LOSS</strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_945" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,178,091</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_946" name="us-gaap:NetIncomeLoss" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,211,872</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_947" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">39,423,321</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_948" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,279,827</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>BASIC AND DILUTED LOSS PER COMMON SHARE</strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_949" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-04-01to2020-06-30" decimals="2" unitRef="USDPShares" sign="-">0.23</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_950" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-04-01to2019-06-30" decimals="2" unitRef="USDPShares" sign="-">0.25</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_951" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-01to2020-06-30" decimals="2" unitRef="USDPShares" sign="-">0.49</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_952" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-01-01to2019-06-30" decimals="2" unitRef="USDPShares" sign="-">0.53</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;"><strong>Basic and Diluted</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_953" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">86,347,467</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_954" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">52,206,204</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_955" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">80,064,641</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_956" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">49,295,805</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160; &#160;</p><p style="MARGIN: 0px; text-align:center;">&#160;The accompanying notes are an integral part of these condensed consolidated financial statements.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong><span class="atag" id="eq">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span></strong></p><p style="MARGIN: 0px; text-align:center;"><strong><span style="mso-bookmark:ole_link2">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN<br />STOCKHOLDERS&#8217; EQUITY <br /></span><span style="mso-bookmark:ole_link2">(Unaudited)</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong>For the Three and Six Months Ended June 30, 2020</strong> </p></td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>&#160;Additional </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>Total</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><strong>&#160;Common Stock </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>&#160;Paid-in </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>&#160;Accumulated </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>Stockholders'</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>&#160;Shares </strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>&#160;Amount </strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>&#160;Capital </strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>&#160;Deficit </strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Equity</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2019 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_971" name="us-gaap:SharesIssued" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">59,318,355</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_972" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,932</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_973" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,903,772</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_974" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">264,716,555</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_975" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,193,149</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock-based compensation </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_976" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_977" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,548</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_978" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_979" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,548</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Issuance of common stock, net of offering expenses </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_980" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">27,025,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_981" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,703</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_982" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,701,336</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_983" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_984" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,704,039</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercise of stock options </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_985" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,958</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_986" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_987" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_988" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_989" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_990" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_991" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_992" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">19,245,230</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_993" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">19,245,230</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at March 31, 2020 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_994" name="us-gaap:SharesIssued" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">86,345,313</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_995" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,635</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_996" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">380,288,833</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_997" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">283,961,785</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_998" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,335,683</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock-based compensation </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_999" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1000" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">715,608</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1001" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1002" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">715,608</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercise of stock options </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1003" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,668</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1004" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1005" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,255</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1006" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1007" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,255</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1008" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1009" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1010" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,178,091</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1011" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,178,091</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at June 30, 2020 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1012" name="us-gaap:SharesIssued" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">86,349,981</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1013" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,635</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1014" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">381,010,696</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1015" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">304,139,876</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1016" name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,879,455</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="margin:0px">&#160;&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="21" style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong>For the Three and Six Months Ended June 30, 2019</strong> </p></td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>&#160;Additional </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>Total</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><strong>&#160;Common Stock </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>&#160;Paid-in </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>&#160;Accumulated </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><strong>Stockholders'</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>&#160;Shares </strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>&#160;Amount </strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>&#160;Capital </strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>&#160;Deficit </strong></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Equity</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2018 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1017" name="us-gaap:SharesIssued" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">46,353,068</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1018" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,635</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1019" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,203,041</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1020" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">216,437,238</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1021" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,770,438</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock-based compensation </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1022" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1023" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">637,263</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1024" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1025" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-01to2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">637,263</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants issued in connection with note payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1026" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1027" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,699,208</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1028" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1029" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-01-01to2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,699,208</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1030" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1031" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1032" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,067,955</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1033" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,067,955</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at March 31, 2019 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1034" name="us-gaap:SharesIssued" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">46,353,068</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1035" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,635</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1036" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,539,512</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1037" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">229,505,193</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1038" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,038,954</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercise of stock options </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1039" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">27,238</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1040" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1041" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,045</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1042" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1043" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,048</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Issuance of common stock, net of offering expenses </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1044" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">12,937,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1045" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,294</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1046" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,395,794</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1047" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1048" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,397,088</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Warrants issued in connection with note payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1049" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1050" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,907</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1051" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1052" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,907</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock-based compensation </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1053" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1054" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">726,736</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1055" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1056" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">726,736</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1057" name="us-gaap:NetIncomeLoss" contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1058" name="us-gaap:NetIncomeLoss" contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1059" name="us-gaap:NetIncomeLoss" contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,211,872</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1060" name="us-gaap:NetIncomeLoss" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,211,872</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at June 30, 2019 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1061" name="us-gaap:SharesIssued" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">59,317,806</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1062" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,932</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1063" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,616,994</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1064" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">242,717,065</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1065" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,905,861</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="margin:0px">&#160;<span style="mso-bookmark:ole_link2">&#160;</span></p><p style="MARGIN: 0px; text-align:center;"><span style="mso-bookmark:ole_link2">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><p style="margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:center;"><span style="mso-bookmark:ole_link2"><span class="atag" id="cf"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong> </span></span></p><p style="MARGIN: 0px; text-align:center;"><span style="mso-bookmark:ole_link2"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<br />(Unaudited)</strong> </span></p><p style="MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><strong>Six Months Ended June 30,</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td style="vertical-align:top;"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_715" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">39,423,321</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_716" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,279,827</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Adjustments to reconcile net loss to net cash used in operating activities: </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Depreciation and amortization </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_718" name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,674,490</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_719" name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,611,422</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Loss on disposal of fixed assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_720" name="us-gaap:GainLossOnDispositionOfAssets" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,518</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_721" name="us-gaap:GainLossOnDispositionOfAssets" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,788</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Stock-based compensation </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_722" name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,392,156</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_723" name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,363,999</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Gain on transfer of plasma center assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_724" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_725" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,527,421</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Amortization of debt discount </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_726" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">874,732</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_727" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,481</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Loss on extinguishment of debt </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_728" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_729" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,962,495</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Amortization of license revenue </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_730" name="adma:AmortizationOfLicenseRevenue" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">71,417</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_731" name="adma:AmortizationOfLicenseRevenue" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">71,417</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Changes in operating assets and liabilities, net of acquisition: </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Accounts receivable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_733" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,044,246</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_734" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,694,222</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Inventories </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_735" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,936,614</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_736" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">5,175,148</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Prepaid expenses and other current assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_737" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,159,834</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_738" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,747</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Deposits and other assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_739" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">283,195</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_740" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,832</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Accounts payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_741" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,264,932</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_742" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">887,753</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Accrued expenses </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_743" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,295</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_744" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">529,589</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Other current and non-current liabilities </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_745" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">92,067</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_746" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">91,029</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Net cash used in operating activities </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_747" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">45,931,435</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_748" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">32,911,136</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Purchase of property and equipment </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_750" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,243,284</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_751" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">245,675</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Proceeds from the sale of property and equipment </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_752" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_753" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2019-01-01to2019-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Net cash used in investing activities </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_754" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,241,284</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_755" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">245,675</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Principal payments on notes payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_757" name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_758" name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,000,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Payment of end of term fee </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_759" name="us-gaap:PaymentsForFees" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_760" name="us-gaap:PaymentsForFees" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,760,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Payment of debt refinancing fees </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_761" name="adma:PaymentOfDebtRefinancingFees" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_762" name="adma:PaymentOfDebtRefinancingFees" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,499,867</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Proceeds from issuance of note payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_763" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,500,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_764" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,500,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Payment of debt issuance costs </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_766" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_765" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,679,661</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Proceeds from the issuance of common stock, net of offering expenses </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_767" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,704,039</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_768" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,397,088</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Proceeds from the exercise of stock options </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_769" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,432</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_770" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,048</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Payments on finance lease obligations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_771" name="us-gaap:PaymentsForLeasingCosts" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,765</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_772" name="us-gaap:PaymentsForLeasingCosts" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">14,740</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Net cash provided by financing activities </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_774" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,201,706</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_775" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,017,868</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Net increase in cash and cash equivalents</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_776" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,028,987</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_777" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,861,057</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><strong>Cash and cash equivalents, including restricted cash - beginning of period</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_778" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,752,135</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_779" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,754,852</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Cash and cash equivalents - end of period</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_780" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,781,122</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_781" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,615,909</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these condensed consolidated financial statements.&#160;</p><p style="margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="margin:0px">&#160;<span class="atag" id="nt">&#160;&#160;</span></p><ix:nonNumeric id="fid_782" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="From2020-01-01to2020-06-30" continuedAt="cont_7c9a19" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">1.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">ORGANIZATION AND BUSINESS</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#8217;s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA BioManufacturing&#8221;) and ADMA BioCenters Georgia Inc. (&#8220;ADMA BioCenters&#8221;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (&#8220;BTBU&#8221;) from BPC Plasma, Inc. (formerly Biotest Pharmaceuticals Corporation) (&#8220;BPC&#8221; and, together with Biotest AG, &#8220;Biotest&#8221;) as more fully described below. BTBU had been the Company&#8217;s third-party manufacturer for its then-lead pipeline product candidate, ASCENIV, previously referred to as &#8220;RI-002.&#8221; ADMA BioCenters is the Company&#8217;s source plasma collection business with a plasma collection facility located in the U.S., which holds an approved license with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company has three FDA-approved products, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;), and for which we received FDA approval on May 9, 2019 for the commercial re-launch of the product and commenced the commercial re-launch in August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin products, the Company provides contract manufacturing services for certain clients and generates revenues from the sale of intermediate by-products that result from the immunoglobulin production process. The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On June 6, 2017, ADMA completed the acquisition of certain assets (the &#8220;Biotest Assets&#8221;) of BTBU, which included the FDA-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;) (the &#8220;Biotest Transaction&#8221;).</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of June 30, 2020, the Company had working capital of $<ix:nonFraction id="fid_5" name="adma:WorkingCapital" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">130.1</ix:nonFraction> million, including $75.8 million of cash and cash equivalents. Based upon the Company&#8217;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#8217;s commercialization and expansion activities, as well as certain other assumptions, the Company&#8217;s management currently believes that its cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund ADMA&#8217;s operations, as currently conducted, into the second quarter of 2021. In order to have sufficient cash to fund its operations thereafter, the Company anticipates it will need to raise additional capital before the end of the second quarter of 2021. These estimates may change based upon several factors, including the success of the Company&#8217;s commercial sales of its products, manufacturing ramp-up activities, the acceptability of ADMA&#8217;s immune globulin products by physicians, patients or payers and the various financing options that may be available to the Company. In addition, the Company&#8217;s end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months, requiring substantial investments in raw material plasma and other manufacturing materials. The Company currently has no firm commitments for additional financing, and there can be no assurance that the Company will be able to secure additional financing on terms that are acceptable to the Company, or at all. Furthermore, if the Company&#8217;s assumptions underlying its estimated expenses and revenues are incorrect, it may have to raise additional capital sooner than currently anticipated. </p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><ix:continuation id="cont_7c9a19"><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Due to numerous risks and uncertainties associated with FDA approvals related to the Company&#8217;s products or the labeled indications of such products, ongoing compliance requirements and capacity expansion efforts at the Company&#8217;s Boca Facility and future commercialization of the Company&#8217;s products, including the Company&#8217;s ability to obtain adequate quantities of FDA-approved plasma with proper specifications on acceptable terms for use in the Company&#8217;s manufacturing process, as well as the additional uncertainties surrounding the COVID-19 pandemic (see Note 9) the Company is unable to estimate with certainty the amounts of increased capital outlays and operating expenditures required to fund its commercial and development activities. The Company&#8217;s current estimates may be subject to change as circumstances regarding its business requirements evolve. Failure to secure any necessary financing in a timely manner and on commercially reasonable terms could have a material adverse effect on the Company&#8217;s business plan and financial performance and it could be forced to delay or discontinue its commercialization, product development or clinical activities or delay or discontinue the approval efforts for any of the Company&#8217;s products or product candidates. The Company has reported cumulative losses since inception in June 2004 through June 30, 2020 of $<ix:nonFraction id="fid_1066" name="us-gaap:NetIncomeLoss" contextRef="From2004-06-01to2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">304.1</ix:nonFraction> million. As such, these factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of asset carrying amounts and the classification of liabilities that might be necessary from the outcome of this uncertainty.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company may decide to raise capital through public or private equity offerings or debt financings, or obtain a bank credit facility or enter into corporate collaboration and licensing arrangements. The sale of additional equity or debt securities, if convertible, could result in dilution to the Company&#8217;s existing stockholders and, in such event, the market value of its common stock may decline. The incurrence of additional indebtedness would result in increased fixed obligations and could also result in covenants that would restrict the Company&#8217;s operations or other financing alternatives. In addition, the Company is exploring additional contract manufacturing arrangements and other business development opportunities, which may provide additional liquidity to the Company. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">There can be no assurance that the Company&#8217;s approved products will be commercially viable, or that research and development, plant capacity expansion, plasma center build-outs or other capital improvements will be successfully completed or that any product developed in the future will be approved. The Company is subject to risks common to companies in the biotechnology and pharmaceutical manufacturing industries including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.</p></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_783" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="From2020-01-01to2020-06-30" continuedAt="cont_717713" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">2.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><ix:nonNumeric id="fid_795" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Basis of presentation</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 13, 2020.The accompanying consolidated balance sheet as of December 31, 2019 was derived from the audited financial statements for the year ended December 31, 2019. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of June 30, 2020 and its results of operations, changes in equity and cash flows for the three and six months ended June 30, 2020. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">During the three and six months ended June 30, 2020 and 2019, comprehensive loss was equal to the net loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year. </p></ix:nonNumeric></ix:nonNumeric><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:continuation id="cont_717713" continuedAt="cont_fc42af"><ix:nonNumeric id="fid_796" name="us-gaap:UseOfEstimates" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Use of estimates</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#8217;s deferred tax assets.</p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_797" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Fair value of financial instruments</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#8217;s senior secured term loan (see Note 6) approximates fair value due to the variable interest rate on this debt. With respect to the subordinated note payable in the amount of $<ix:nonFraction id="fid_19" name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2020-06-30_adma_BiotestMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">15.0</ix:nonFraction> million as of June 30, 2020 and December 31, 2019 held by Biotest, a principal stockholder of the Company at the time the note was issued concurrent with an acquisition transaction with an affiliate of such stockholder (see Note 6), the Company has concluded that an estimation of fair value for this note is not practicable.</p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_798" name="us-gaap:ReceivablesPolicyTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Accounts receivable</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers based upon an evaluation of each customer's financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis. Based on these evaluations, the Company has concluded that its credit risk is minimal. At June 30, 2020, three customers accounted for an aggregate of <ix:nonFraction id="fid_1067" name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-01to2020-06-30_adma_CustomerThreeMember_us-gaap_AccountsReceivableMember" decimals="INF" unitRef="Pure" scale="0">76</ix:nonFraction>% of the Company&#8217;s total accounts receivable, and at December 31, 2019, two customers accounted for <ix:nonFraction id="fid_22" name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-01to2019-12-31_adma_CustomerTwoMember_us-gaap_AccountsReceivableMember" decimals="INF" unitRef="Pure" scale="0">89</ix:nonFraction>% of the Company&#8217;s total accounts receivable.</p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_799" name="us-gaap:InventoryPolicyTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Inventories</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Due to previous uncertainties surrounding certain prior submissions made to the FDA, all costs related to the production of BIVIGAM and ASCENIV prior to their FDA approval dates of May 9, 2019 and April 1, 2019, respectively, have been charged to cost of product revenue in the accompanying consolidated statements of operations during the period the product was produced. In addition, costs associated with the production of conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_800" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Goodwill</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at June 30, 2020 and December 31, 2019 was $3.5 million. All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment and is related to a 2017acquisition transaction.&#160;</p><p style="margin:0px">&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Goodwill is not amortized, but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company&#8217;s annual goodwill impairment test as of October 1, 2019 did not result in a goodwill impairment charge, and the Company did not record any impairment charges related to goodwill for the three and six months ended June 30, 2020 and 2019.</p></ix:nonNumeric></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="margin:0px">&#160;</p><ix:continuation id="cont_fc42af" continuedAt="cont_c47e04"><ix:nonNumeric id="fid_801" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Impairment of long-lived assets</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and definite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the three and six months ended June 30, 2020 and 2019, the Company determined that there was no impairment of its long-lived assets.</p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_802" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Revenue recognition</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Revenues for the three and six months ended June 30, 2020 and 2019 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">For the six months ended June 30, 2020, three customers represented an aggregate of <ix:nonFraction id="fid_28" name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-01to2020-06-30_adma_CustomerThreeMember" decimals="INF" unitRef="Pure" scale="0">81</ix:nonFraction>% of the Company&#8217;s consolidated revenues. For the six months ended June 30, 2019, three customers represented an aggregate of <ix:nonFraction id="fid_26" name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-01to2019-06-30_adma_CustomerThreeMember" decimals="INF" unitRef="Pure" scale="0">84</ix:nonFraction>% of the Company&#8217;s consolidated revenues.</p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><ix:nonNumeric id="fid_803" name="us-gaap:CostOfSalesPolicyTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Cost of product revenue</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA approved products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses. </p></ix:nonNumeric></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="margin:0px">&#160; </p><ix:continuation id="cont_c47e04" continuedAt="cont_65b24b"><ix:nonNumeric id="fid_804" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Loss per common share</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts as the Company reported a net loss for all periods presented. For the six months ended June 30, 2020 and 2019, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><ix:nonNumeric id="fid_808" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><strong>For the Six Months Ended June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock options</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-01to2020-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,801,779</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_12" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-01to2019-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,624,603</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Restricted stock units</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_15" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">326,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_16" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-01to2019-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:zerodash" decimals="0" unitRef="Shares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_13" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,138,160</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_14" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-01to2019-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,138,160</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,265,939</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,762,763</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_805" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Stock-based compensation</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a four-year vesting period and a term of <ix:nonNumeric id="fid_1069" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="From2020-01-01to2020-06-30" format="ixt-sec:duryear">10</ix:nonNumeric> years. Pursuant to ASU No. 2016-09, <em>Improvements to Employee Share-Based Payment Accounting (Topic 718)</em>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_806" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Income Taxes</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2015 and for previous periods as it relates to the Company&#8217;s net operating loss carryforwards. </p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of June 30, 2020 and December 31, 2019, and during the three and six months ended June 30, 2020 and 2019, the Company recognized no adjustments for uncertain tax positions.</p></ix:nonNumeric></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="margin:0px">&#160; </p><ix:continuation id="cont_65b24b"><ix:nonNumeric id="fid_807" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Recent Accounting Pronouncements </span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In June 2016, the FASB issued ASU No. 2016-13, <em>Financial Instruments &#8211; Credit Losses (Topic 326)</em> (&#8220;ASU 2016-13&#8221;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#8217;s statement of operations is required to reflect the measurement of credit losses for newly recognized financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.The Company adopted ASU No. 2016-13, and the adoption of this update did not have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In February 2016, the FASB issued ASU No. 2016-02, <em>Leases (Topic 842)</em> (&#8220;ASU 2016-02&#8221;), which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company adopted ASU 2016-02 on January 1, 2019 using the option to recognize the cumulative-effect adjustment, if any, as of the date of application, which was also January 1, 2019. The Company recognized right-to-use assets of $<ix:nonFraction id="fid_1089" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-06-30_adma_JanuaryOneTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.4</ix:nonFraction> million and corresponding lease liabilities of approximately $<ix:nonFraction id="fid_1090" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-06-30_adma_JanuaryOneTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.6</ix:nonFraction> million at the date of adoption (see Note 12). The Company also elected the &#8220;package of practical expedients,&#8221; which permits the Company to not reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease recognition exemption for all leases that qualify, including the agreement under which the Company occupies certain office space as discussed in Note 8. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), <em>Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815)</em>&#8221; (&#8220;ASU 2017-11&#8221;). ASU 2017-11 changed the classification analysis of certain equity-linked financial instruments (or embedded features within such instruments) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) will no longer be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (&#8220;EPS&#8221;) in accordance with ASC 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. In addition, convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features in ASC 470-20, &#8220;Debt&#8212;Debt with Conversion and Other Options.&#8221; ASU 2017-11 became effective for the Company on January 1, 2019, and this update did not have a significant impact on the Company&#8217;s consolidated financial statements.</p></ix:nonNumeric></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_784" name="us-gaap:InventoryDisclosureTextBlock" contextRef="From2020-01-01to2020-06-30" continuedAt="cont_0fb130" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">3.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">INVENTORIES</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;">The following table provides the components of inventories:&#160;</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><ix:nonNumeric id="fid_809" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>June 30,<br />2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>December 31,<br />2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Raw materials</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_32" name="us-gaap:InventoryRawMaterials" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,830,796</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_31" name="us-gaap:InventoryRawMaterials" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,381,806</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Work-in-progress</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_34" name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,066,417</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_33" name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,455,665</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_36" name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,104,135</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_35" name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,227,263</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total inventories</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">56,001,348</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">53,064,734</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB, as there are alternative uses for these materials that provide a probable future benefit or will be consumed in the production of goods expected to be available for sale. All other activities and materials associated with the production of inventories used in research and development activities are expensed as incurred. </p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><ix:continuation id="cont_0fb130"><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#8217;s immunoglobulin products. Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection center which is expected to be sold to third-party customers. </p></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_785" name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">4.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">INTANGIBLE ASSETS </span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 30px; text-align:left;">Intangible assets at June 30, 2020 and December 31, 2019 consist of the following:</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><ix:nonNumeric id="fid_811" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="10"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="10"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Accumulated </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Accumulated </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Cost </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Amortization</strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Net </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Cost </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Amortization</strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Net</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Trademark and other intangible rights related to Nabi-HB</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_59" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-06-30_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,100,046</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_67" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-06-30_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,805,973</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_75" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-06-30_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,294,073</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_60" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,100,046</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_68" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,513,112</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_76" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,586,934</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Rights to intermediates</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_61" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-06-30_adma_RightToIntermediatesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,421</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_69" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-06-30_adma_RightToIntermediatesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,697</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_77" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-06-30_adma_RightToIntermediatesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,724</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_62" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_adma_RightToIntermediatesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,421</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_70" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_adma_RightToIntermediatesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,881</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_78" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_adma_RightToIntermediatesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">572,540</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Customer contract</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_63" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-06-30_us-gaap_CustomerContractsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,076,557</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_71" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-06-30_us-gaap_CustomerContractsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,076,557</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_79" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-06-30_us-gaap_CustomerContractsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_64" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_us-gaap_CustomerContractsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,076,557</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_72" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_us-gaap_CustomerContractsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,076,557</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_80" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_us-gaap_CustomerContractsMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_57" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,084,024</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_66" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,282,227</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_74" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,801,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_58" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,084,024</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_65" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,924,550</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_73" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,159,474</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">All of the Company&#8217;s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets for the three months ended June 30, 2020 and 2019 was $<ix:nonFraction id="fid_286" name="adma:AmortizationExpense" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million, and amortization expense for the six months ended June 30, 2020 and 2019 was $<ix:nonFraction id="fid_284" name="adma:AmortizationExpense" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.4</ix:nonFraction> million. Estimated aggregate future aggregate amortization expense for the next five years is expected to be as follows:</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_810" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><strong>Remainder of 2020 </strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_81" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,676</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2021 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_82" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">715,352</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2022 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_83" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">715,352</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2023 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_84" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">715,352</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2024 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_85" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,065</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;&#160;</p><ix:nonNumeric id="fid_786" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">5.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">PROPERTY AND EQUIPMENT</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Property and equipment and related accumulated depreciation are summarized as follows:</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_812" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Manufacturing and laboratory equipment </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_88" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-06-30_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,898,186</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_89" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,831,817</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Office equipment and computer software </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_90" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-06-30_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,220,856</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_91" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,690,248</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Furniture and fixtures </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_92" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-06-30_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,400,129</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_93" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">582,088</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Construction in process </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_100" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-06-30_us-gaap_ConstructionInProgressMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,672,211</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_101" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_ConstructionInProgressMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,285,915</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Leasehold improvements </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_94" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-06-30_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,011,009</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_95" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,673,084</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Land </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_96" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-06-30_us-gaap_LandMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,339,441</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_97" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_LandMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,339,441</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Buildings and building improvements </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_98" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-06-30_us-gaap_BuildingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,869,821</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_99" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_BuildingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,063,680</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_87" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,411,653</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_86" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,466,273</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: Accumulated depreciation </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_103" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,038,287</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_102" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,724,956</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total property and equipment, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">37,373,366</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">31,741,317</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#8217;s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of <ix:nonNumeric id="fid_290" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="From2020-01-01to2020-06-30_us-gaap_BuildingMember" format="ixt-sec:duryear">30</ix:nonNumeric> years. Property and equipment other than land and buildings have useful lives ranging from three to <ix:nonNumeric id="fid_291" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="From2020-01-01to2020-06-30_adma_PropertyAndEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear">10</ix:nonNumeric> years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The Company recorded depreciation expense on property and equipment for the three and six months ended June 30, 2020 of $<ix:nonFraction id="fid_288" name="us-gaap:Depreciation" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.7</ix:nonFraction> million and $<ix:nonFraction id="fid_106" name="us-gaap:Depreciation" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.3</ix:nonFraction> million, respectively. Depreciation expense for the three and six months ended June 30, 2019 was $<ix:nonFraction id="fid_289" name="us-gaap:Depreciation" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.6</ix:nonFraction> million and $<ix:nonFraction id="fid_107" name="us-gaap:Depreciation" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.2</ix:nonFraction> million, respectively. </p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="margin:0px">&#160;</p><ix:nonNumeric id="fid_787" name="us-gaap:LongTermDebtTextBlock" contextRef="From2020-01-01to2020-06-30" continuedAt="cont_18e10b" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">6.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">DEBT</span></strong></p><p style="margin:0px">&#160; </p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Senior Notes Payable</span></em></p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">A summary of outstanding senior notes payable is as follows:&#160;</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><ix:nonNumeric id="fid_814" name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_109" name="us-gaap:NotesPayable" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_108" name="us-gaap:NotesPayable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,500,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Debt discount </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_112" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,351,813</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_111" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,208,837</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Senior notes payable</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">81,648,187</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">68,291,163</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">On February 11, 2019 (the &#8220;Perceptive Closing Date&#8221;), the Company and all of its subsidiaries entered into a Credit Agreement and Guaranty (the &#8220;Perceptive Credit Agreement&#8221;) with Perceptive Credit Holdings II, LP, as the lender and administrative agent (&#8220;Perceptive&#8221;). The Perceptive Credit Agreement, as amended, provides for a senior secured term loan facility in a principal amount of up to $<ix:nonFraction id="fid_875" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2019-02-01to2019-02-11_adma_PerceptiveCreditAgreementMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">85.0</ix:nonFraction> million (the &#8220;Perceptive Credit Facility&#8221;), comprised of (i) a term loan made on the Perceptive Closing Date in the principal amount of $<ix:nonFraction id="fid_826" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2020-01-01to2020-06-30_adma_PerceptiveTrancheILoanMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">45.0</ix:nonFraction> million, as evidenced by the Company&#8217;s issuance of a promissory note (the &#8220;Perceptive Tranche I Note&#8221;) in favor of Perceptive on the Perceptive Closing Date (the &#8220;Perceptive Tranche I Loan&#8221;), (ii) a term loan in the principal amount of up to $<ix:nonFraction id="fid_830" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2019-04-11to2019-05-03_adma_PerceptiveTrancheIILoanMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">27.5</ix:nonFraction> million (the &#8220;Perceptive Tranche II Loan&#8221;) evidenced by the Company&#8217;s issuance of a promissory note (the &#8220;Perceptive Tranche II Note&#8221;) in favor of Perceptive on May 3, 2019; and (iii) a term loan in the principal amount of up to $<ix:nonFraction id="fid_832" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2019-04-11to2019-05-03_adma_PerceptiveTrancheIIILoanMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">12.5</ix:nonFraction> million evidenced by the Company&#8217;s issuance of a promissory note (the &#8220;Perceptive Tranche III Note&#8221;) in favor of Perceptive on March 20, 2020 (the &#8220;Perceptive Tranche III Loan,&#8221; and together with the Perceptive Tranche I Loan and the Perceptive Tranche II Loan, the &#8220;Perceptive Loans&#8221;). The Perceptive Tranche III Loan is the result of an amendment to the Perceptive Credit Agreement (the &#8220;Perceptive Amendment&#8221;) that the Company and Perceptive entered into on May 3, 2019, and the Perceptive Tranche III Loan became available to the Company upon the approval of BIVIGAM on May 9, 2019. The Perceptive Credit Facility has a maturity date of March 1, 2022 (the &#8220;Maturity Date&#8221;), subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default (as defined in the Perceptive Credit Agreement).</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On the Perceptive Closing Date, the Company used $<ix:nonFraction id="fid_1074" name="adma:PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">30.0</ix:nonFraction> million of the Perceptive Tranche I Loan to terminate and pay in full all of the outstanding obligations under its previously existing credit agreement with Marathon Healthcare Finance Fund, L.P. (&#8220;Marathon&#8221;) (the &#8220;Marathon Credit Facility&#8221;). The Company also used proceeds from the Perceptive Tranche I Loan to: (i) pay a deferred facility fee to Marathon in the amount of $<ix:nonFraction id="fid_834" name="adma:DeferredFacilityFee" contextRef="From2019-04-11to2019-05-03_adma_MarathonHealthcareFinanceFundLPMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.8</ix:nonFraction> million, (ii) pay a prepayment penalty to Marathon in the amount of $<ix:nonFraction id="fid_835" name="adma:PrepaymentPenalty" contextRef="From2019-04-11to2019-05-03_adma_MarathonHealthcareFinanceFundLPMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">6.5</ix:nonFraction> million, (iii) pay outstanding accrued interest to Marathon in the amount of $<ix:nonFraction id="fid_838" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2019-05-03_adma_MarathonHealthcareFinanceFundLPMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.7</ix:nonFraction> million, and (iv) pay certain fees and expenses incurred in connection with the Perceptive Credit Facility of approximately $<ix:nonFraction id="fid_839" name="us-gaap:LegalFees" contextRef="From2019-04-11to2019-05-03_adma_MarathonHealthcareFinanceFundLPMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.5</ix:nonFraction> million. In addition, Marathon released $<ix:nonFraction id="fid_840" name="adma:DebtServiceReserve" contextRef="AsOf2019-05-03_adma_MarathonHealthcareFinanceFundLPMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">4.0</ix:nonFraction> million of cash to the Company that was held in a debt service reserve account per the terms of the Marathon Credit Facility. In connection with the Perceptive Amendment, the Company paid an additional facility fee to Perceptive in the amount of $<ix:nonFraction id="fid_841" name="adma:AdditionalFacilityFee" contextRef="From2019-04-11to2019-05-03_adma_MarathonHealthcareFinanceFundLPMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million on May 3, 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As a result of the Company&#8217;s entering into the Perceptive Credit Agreement and terminating the Marathon Credit Facility, the Company recognized a loss on the extinguishment of debt for the six months ended June 30, 2019 in the amount of approximately $10.0 million, comprised of the $<ix:nonFraction id="fid_1071" name="adma:PrepaymentPenalty" contextRef="From2019-01-01to2019-06-30_adma_MarathonHealthcareFinanceFundLPMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">6.5</ix:nonFraction> million prepayment penalty and the write-off of unamortized debt discount related to the Marathon Credit Facility in the amount of $<ix:nonFraction id="fid_1072" name="adma:UnamortizedDebtDiscount" contextRef="From2019-01-01to2019-06-30_adma_MarathonHealthcareFinanceFundLPMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">3.5</ix:nonFraction> million.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Borrowings under the <ix:nonNumeric id="fid_866" name="adma:InterestRateDescription" contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember">Perceptive Credit Agreement bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will automatically increase by an additional 400 basis points. Accrued interest is payable to Perceptive on the last day of each month during the term of the Perceptive Credit Facility.The rate of interest in effect as of the Perceptive Closing Date and at June 30, 2020 was 11.0%. </ix:nonNumeric></p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong>&#160;</p><p style="margin:0px">&#160; </p><ix:continuation id="cont_18e10b" continuedAt="cont_684e62"><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On the Maturity Date, the Company will pay Perceptive the entire outstanding principal amount underlying the Perceptive Loans and any accrued and unpaid interest thereon. Prior to the Maturity Date, there will be no scheduled principal payments on the Perceptive Loans. The Company may prepay outstanding principal on the Perceptive Loans at any time and from time to time upon three business days&#8217; prior written notice, subject to the payment to Perceptive of (A) any accrued but unpaid interest on the prepaid principal amount plus (B) a redemption premium amount equal to <ix:nonNumeric id="fid_1073" name="adma:DescriptionOfPrepaidPrincipalAmount" contextRef="From2020-01-01to2020-06-30">(i) 5.0% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Perceptive Closing Date, (ii) 4.0% of the prepaid principal amount, if prepaid after the first anniversary of the Perceptive Closing Date and on or prior to the second anniversary of the Perceptive Closing Date, or (iii) 3.0% of the prepaid principal amount, if prepaid after the second anniversary of the Perceptive Closing Date and on or prior to the third anniversary of the Perceptive Closing Date.</ix:nonNumeric></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">All of the Company&#8217;s obligations under the Perceptive Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#8217;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s subsidiaries. The Perceptive Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among other things and subject to certain exceptions contained in the Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or its subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#8217;s ability to make loan repayments under the Perceptive Credit Agreement. <ix:nonNumeric id="fid_868" name="adma:AdditionlalDescription" contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember">In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ended June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $7.0 million for the fiscal quarter ended June 30, 2019 to $55.0 million for the fiscal quarter ending December 31, 2021.</ix:nonNumeric> At June 30, 2020, the Company was in compliance with all of the covenants contained in the Perceptive Credit Agreement. </p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As consideration for the Perceptive Credit Agreement, the Company issued to Perceptive a warrant to purchase <ix:nonFraction id="fid_848" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,360,000</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Perceptive Warrant&#8221;) on the Perceptive Closing Date. The Perceptive Warrant has an exercise price equal to $<ix:nonFraction id="fid_850" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember" decimals="2" unitRef="USDPShares">3.28</ix:nonFraction> per share, which is equal to the trailing 10-day volume weighted average price (&#8220;VWAP&#8221;) of the Company&#8217;s common stock on the business day immediately prior to the Perceptive Closing Date multiplied by 1.15. The Company valued the Perceptive Warrant at $<ix:nonFraction id="fid_852" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.7</ix:nonFraction> million as of the Perceptive Closing Date and it has an expiration date of <ix:nonNumeric id="fid_854" name="adma:ExpirationDate" contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember">February 11, 2029</ix:nonNumeric>. In connection with the Perceptive Amendment, the Company issued an additional warrant (the &#8220;Perceptive Tranche III Warrant&#8221; and, together with the Perceptive Warrant, the &#8220;Perceptive Warrants&#8221;) to purchase <ix:nonFraction id="fid_858" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="From2019-04-11to2019-05-02_adma_PerceptiveTrancheIIIWarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">250,000</ix:nonFraction> shares of the Company&#8217;s common stock to Perceptive with an exercise price equal to $<ix:nonFraction id="fid_861" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-04-11to2019-05-02_adma_PerceptiveTrancheIIIWarrantMember" decimals="2" unitRef="USDPShares">4.64</ix:nonFraction> per share, which represents the trailing 10-day VWAP of the Company&#8217;s common stock as of May 2, 2019. The Perceptive Tranche III Warrant was valued by the Company at $<ix:nonFraction id="fid_864" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-04-11to2019-05-02_adma_PerceptiveTrancheIIIWarrantMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.9</ix:nonFraction> million and has an expiration date of May 3, 2029. Perceptive has represented to the Company, among other things, that it was an &#8220;accredited investor&#8221; (as such term is defined in Rule 501(a) of Regulation D under the Securities Act) and the Company issued the Perceptive Warrants in reliance upon an exemption from registration contained in Section 4(2) under the Securities Act. The Perceptive Warrants and the shares of common stock issuable thereunder may not be offered, sold, pledged or otherwise transferred in the U.S. absent registration or an applicable exemption from the registration requirements under the Securities Act.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As a result of the fees paid to Perceptive and the value of the Perceptive Warrants, the Company recognized an aggregate discount on the Perceptive Tranche I Note and Perceptive Tranche II Note in the amount of $<ix:nonFraction id="fid_845" name="adma:PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" contextRef="From2019-04-11to2019-05-03" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">5.3</ix:nonFraction> million. The Company records debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. Based on the fair value of the Perceptive Warrants and the aggregate amount of fees and expenses associated with obtaining the Perceptive Credit Facility, the effective interest rate on the Perceptive Loans as of May 3, 2019 was approximately <ix:nonFraction id="fid_846" name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2019-04-11to2019-05-03" decimals="INF" unitRef="Pure" scale="-1">14.1</ix:nonFraction>%. </p></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="margin:0px">&#160; </p><ix:continuation id="cont_684e62"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Subordinated Note Payable</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">A summary of the outstanding subordinated note payable is as follows:</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><ix:nonNumeric id="fid_813" name="us-gaap:ScheduleOfSubordinatedBorrowingTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Subordinated note payable to Biotest</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_115" name="adma:SubordinatedDebtCarryingValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_116" name="adma:SubordinatedDebtCarryingValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Debt discount </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_119" name="adma:SubordinatedDebtInstrumentUnamortizedDiscount" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">74,240</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_118" name="adma:SubordinatedDebtInstrumentUnamortizedDiscount" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">91,947</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Subordinated note payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">14,925,760</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">14,908,053</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In connection with the acquisition of the Biotest Assets (see Note 1), ADMA BioManufacturing issued a subordinated note payable to BPC and in connection therewith received cash proceeds of $<ix:nonFraction id="fid_870" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2020-01-01to2020-06-30_adma_BPCMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">15.0</ix:nonFraction> million. This note has since been assigned from BPC to Biotest AG. The note bears interest at a rate of <ix:nonFraction id="fid_872" name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2020-01-01to2020-06-30_adma_BPCMember" decimals="INF" unitRef="Pure" scale="-1">6.0</ix:nonFraction>% per annum and matures on <ix:nonNumeric id="fid_873" name="adma:ExpirationDate" contextRef="From2020-01-01to2020-06-30_adma_BPCMember">June 6, 2022</ix:nonNumeric>.The Company is obligated to make semi-annual interest payments, with all principal and unpaid interest due at maturity. The note is subordinate to all amounts outstanding under the Perceptive Credit Agreement. In the event of default, all principal and unpaid interest is due on demand. The subordinated note also contains several non-financial covenants with which the Company was in compliance as of June 30, 2020.</p></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_788" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="From2020-01-01to2020-06-30" continuedAt="cont_18b245" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">7.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY </span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Preferred Stock</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company is currently authorized to issue up to 10 million shares of preferred stock, $<ix:nonFraction id="fid_165" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-06-30" decimals="4" unitRef="USDPShares">0.0001</ix:nonFraction>, par value per share. There were no shares of preferred stock outstanding at June 30, 2020 and December 31, 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Common Stock</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of June 30, 2020 and December 31, 2019, the Company was authorized to issue <ix:nonFraction id="fid_175" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">150,000,000</ix:nonFraction> shares of its common stock, $<ix:nonFraction id="fid_173" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-06-30" decimals="4" unitRef="USDPShares">0.0001</ix:nonFraction> par value per share, and <ix:nonFraction id="fid_179" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">86,349,981</ix:nonFraction> and <ix:nonFraction id="fid_178" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">59,318,355</ix:nonFraction> shares of common stock were outstanding as of June 30, 2020 and December 31, 2019, respectively. After giving effect to the <ix:nonFraction id="fid_305" name="adma:CommonStockReservedForOutstanding" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,265,939</ix:nonFraction> shares reserved for outstanding warrants and awards issued under the Company&#8217;s equity incentive plans, as of June 30, 2020 there were <ix:nonFraction id="fid_306" name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">54,384,080</ix:nonFraction> shares of common stock available for issuance.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On February 11, 2020, the Company completed an underwritten public offering of <ix:nonFraction id="fid_310" name="adma:UnderwrittenPublicOffering" contextRef="AsOf2020-02-11" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">23,500,000</ix:nonFraction> shares of its common stock for gross proceeds of $<ix:nonFraction id="fid_308" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2020-02-01to2020-02-11" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">82.3</ix:nonFraction> million. On February 21, 2020, the Company sold an additional <ix:nonFraction id="fid_314" name="adma:UnderwrittenPublicOffering" contextRef="AsOf2020-02-21" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,525,000</ix:nonFraction> shares pursuant to the underwriters&#8217; exercise of their option to purchase additional shares of the Company&#8217;s common stock for additional gross proceeds of $<ix:nonFraction id="fid_312" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2020-02-01to2020-02-21" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">12.3</ix:nonFraction> million. The Company received net proceeds, after underwriting discounts and other expenses associated with the offering, of approximately $<ix:nonFraction id="fid_316" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">88.7</ix:nonFraction> million.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Warrants</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">At June 30, 2020 and December 31, 2019, the Company had outstanding warrants to purchase an aggregate of <ix:nonFraction id="fid_317" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,138,160</ix:nonFraction> shares of common stock, with a weighted average exercise price of $<ix:nonFraction id="fid_319" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2020-06-30" decimals="2" unitRef="USDPShares">3.81</ix:nonFraction> per share and expiration dates ranging between June 2022 and May 2029.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Equity Incentive Plans</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The fair value of stock options granted under the Company&#8217;s 2007 Employee Stock Option Plan (the &#8220;2007 Plan&#8221;) and the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan, as amended and restated (the &#8220;2014 Plan&#8221;), was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2020 and 2019:</p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong>&#160;</p><p style="MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_18b245" continuedAt="cont_1d2cc6"><ix:nonNumeric id="fid_815" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160; </p></td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:bottom;text-align:center;" colspan="6"><strong>Six Months Ended June 30, </strong></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td style="width:77%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020 </strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019 </strong></td><td style="width:2%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Expected term</td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><ix:nonNumeric id="fid_122" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="From2020-01-01to2020-06-30_srt_MinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric> - <ix:nonNumeric id="fid_124" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="From2020-01-01to2020-06-30_srt_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><ix:nonNumeric id="fid_123" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="From2019-01-01to2019-06-30_srt_MinimumMember" format="ixt-sec:duryear">5.8</ix:nonNumeric> - <ix:nonNumeric id="fid_125" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="From2019-01-01to2019-06-30_srt_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Volatility</td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><ix:nonFraction id="fid_1080" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-01to2020-06-30_srt_MinimumMember" decimals="INF" unitRef="Pure" scale="0">62</ix:nonFraction>%-<ix:nonFraction id="fid_1079" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-01to2020-06-30_srt_MaximumMember" decimals="INF" unitRef="Pure" scale="0">67</ix:nonFraction>% </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><ix:nonFraction id="fid_1082" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-01-01to2019-06-30_srt_MinimumMember" decimals="INF" unitRef="Pure" scale="0">54</ix:nonFraction>%-<ix:nonFraction id="fid_1081" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-01-01to2019-06-30_srt_MaximumMember" decimals="INF" unitRef="Pure" scale="0">62</ix:nonFraction>% </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Dividend yield</td><td style="white-space: nowrap;">&#160; </td><td colspan="2" style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_128" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-01to2020-06-30" decimals="INF" unitRef="Pure" scale="-2">0.0 </ix:nonFraction></p></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td colspan="2" style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_129" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-01to2019-06-30" decimals="INF" unitRef="Pure" scale="-2">0.0 </ix:nonFraction></p></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="white-space: nowrap;">&#160; </td><td colspan="2"><p style="MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1076" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-01to2020-06-30_srt_MinimumMember" decimals="INF" unitRef="Pure" scale="-2">0.38</ix:nonFraction>-<ix:nonFraction id="fid_1075" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-01to2020-06-30_srt_MaximumMember" decimals="INF" unitRef="Pure" scale="-2">1.68</ix:nonFraction>% </p></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td colspan="2"><p style="MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1077" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-01-01to2019-06-30_srt_MinimumMember" decimals="INF" unitRef="Pure" scale="-2">1.80</ix:nonFraction>-<ix:nonFraction id="fid_1078" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-01-01to2019-06-30_srt_MaximumMember" decimals="INF" unitRef="Pure" scale="-2">2.92</ix:nonFraction>% </p></td><td style="white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">During the six months ended June 30, 2020 and 2019, the Company granted options to purchase an aggregate of <ix:nonFraction id="fid_320" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2020-01-01to2020-06-30_adma_EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,232,500</ix:nonFraction> and <ix:nonFraction id="fid_322" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2019-01-01to2019-06-30_adma_EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,429,100</ix:nonFraction> shares of common stock, respectively, to its directors, employees and certain third-party service providers. The weighted average remaining contractual life of stock options outstanding and expected to vest at June 30, 2020 is <ix:nonNumeric id="fid_324" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="From2020-01-01to2020-06-30_adma_EquityIncentivePlanMember" format="ixt-sec:duryear">6.9</ix:nonNumeric> years. The weighted average remaining contractual life of stock options exercisable at June 30, 2020 is <ix:nonNumeric id="fid_326" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="From2020-01-01to2020-06-30_adma_EquityIncentivePlanMember" format="ixt-sec:duryear">5.6</ix:nonNumeric> years.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="margin:0px">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">A summary of the Company&#8217;s option activity under the 2007 Plan and 2014 Plan and related information is as follows: </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_817" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Shares </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Weighted Average Exercise Price</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2019</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_135" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,630,351</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_145" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31" decimals="2" unitRef="USDPShares">4.76</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_137" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">47,683</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_147" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-06-30" decimals="2" unitRef="USDPShares">3.51</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_138" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">6,763</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_148" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-06-30" decimals="2" unitRef="USDPShares">4.34</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_139" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,232,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_149" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-06-30" decimals="2" unitRef="USDPShares">2.96</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_140" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">6,626</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_150" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-06-30" decimals="2" unitRef="USDPShares">2.03</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at June 30, 2020</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_142" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,801,779</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_152" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-06-30" decimals="2" unitRef="USDPShares">4.45</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercisable</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1083" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030,098</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1084" name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-06-30" decimals="2" unitRef="USDPShares">5.19</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">As of June 30, 2020, the Company had $<ix:nonFraction id="fid_180" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2020-06-30_adma_EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">5.1</ix:nonFraction> million of unrecognized compensation expense related to options granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of <ix:nonNumeric id="fid_315" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="From2020-01-01to2020-06-30_adma_EquityIncentivePlanMember" format="ixt-sec:duryear">2.6</ix:nonNumeric> years.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">During the six months ended June 30, 2020, the Company granted Restricted Stock Units (&#8220;RSUs&#8221;) to members of the Company&#8217;s Board of Directors and to certain management employees of the Company. The total RSUs granted during the period represent an aggregate of <ix:nonFraction id="fid_327" name="adma:CommonStockGranted" contextRef="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">341,000</ix:nonFraction> shares of the Company&#8217;s common stock. The RSUs vest semi-annually over a period of one year for directors and annually over a period of four years for employees. Total compensation expense related to unvested RSUs for the three and six months ended June 30, 2020 was $<ix:nonFraction id="fid_329" name="adma:CompensationExpense" contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million. A summary of the Company&#8217;s unvested RSU activity and related information is as follows:</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><ix:nonNumeric id="fid_816" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Shares</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Weighted Average Grant Date Fair Value</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2019 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_436" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:zerodash" decimals="0" unitRef="Shares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_441" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:zerodash" decimals="0" unitRef="Shares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_443" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">341,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_459" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vested </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_452" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:zerodash" decimals="0" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_457" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:zerodash" decimals="0" unitRef="USDPShares">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_439" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">15,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_455" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" unitRef="USDPShares">2.92</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at June 30, 2020 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">326,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_464" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of June 30, 2020, the Company had $<ix:nonFraction id="fid_333" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.8</ix:nonFraction> million of unrecognized compensation expense related to unvested RSUs granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of <ix:nonNumeric id="fid_332" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">3.5</ix:nonNumeric> years.</p></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="margin:0px">&#160;&#160;</p><ix:continuation id="cont_1d2cc6"><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three and six months ended June 30, 2020 and 2019 is as follows:</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><ix:nonNumeric id="fid_818" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><strong>Three Months Ended June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><strong>Six Months Ended June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Research and development</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_297" name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-01to2020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,029</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_301" name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-01to2019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,543</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">198,603</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_157" name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-01to2019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,066</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Plasma centers</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_298" name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-01to2020-06-30_adma_PlasmaCentersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,510</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_302" name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-01to2019-06-30_adma_PlasmaCentersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,213</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_156" name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,754</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_159" name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-01to2019-06-30_adma_PlasmaCentersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,753</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Selling, general and administrative</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_299" name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-01to2020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">539,256</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_303" name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-01to2019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">569,349</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_160" name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,063,145</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_161" name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-01to2019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,067,820</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cost of product revenue</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_300" name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-01to2020-06-30_us-gaap_CostOfGoodsTotalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,813</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_304" name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-01to2019-06-30_us-gaap_CostOfGoodsTotalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,631</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_162" name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-06-30_us-gaap_CostOfGoodsTotalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,654</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_163" name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-01to2019-06-30_us-gaap_CostOfGoodsTotalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,360</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Total stock-based compensation expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_295" name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">715,608</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_296" name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">726,736</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_969" name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,392,156</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_970" name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,363,999</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_789" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">8.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The Company leases an office building and equipment from Areth, LLC (&#8220;Areth&#8221;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time. Effective October 1, 2017, <ix:nonNumeric id="fid_1087" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" contextRef="From2017-09-09to2017-10-01_adma_ArethLLCMember">monthly</ix:nonNumeric> rent on this facility was set at $<ix:nonFraction id="fid_1086" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" contextRef="From2017-09-09to2017-10-01_adma_ArethLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction>. On November 7, 2019, an additional amendment was entered into between Areth and the Company to extend the term of this agreement through September 30, 2020, and to provide for automatic one-year renewals unless ADMA gives written notice of termination to Areth 60 days prior to the end of the term, which expires each year on September 30. The Company did not provide a written notice of termination to Areth as of July 31, 2020. Rent expense for the six months ended June 30, 2020 and 2019 amounted to $<ix:nonFraction id="fid_1085" name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-01-01to2019-06-30_adma_ArethLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction>. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#8217;s Board of Directors, and Adam S. Grossman, the Company&#8217;s President and Chief Executive Officer. The Company also reimburses Areth for office and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the three and six months ended June 30, 2020 and 2019. </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">See Note 6 for a discussion of the Company&#8217;s credit facility and related transactions with Perceptive, a holder of more than <ix:nonFraction id="fid_335" name="adma:CreditFacilityPercentage" contextRef="From2020-01-01to2020-06-30" decimals="INF" unitRef="Pure" scale="0">10</ix:nonFraction>% of the Company&#8217;s common stock.</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">In connection with the February 2020 public offering of the Company&#8217;s common stock (see Note 7) on February 11, 2020: <ix:nonNumeric id="fid_336" name="adma:PublicOfferingDescription" contextRef="From2020-01-01to2020-06-30">(i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an entity he controls (v) Brian Lenz, the Company&#8217;s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common stock, and (vi) James Mond, the Company&#8217;s Chief Scientific Officer and Chief Medical Officer, purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share.</ix:nonNumeric></p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_790" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="From2020-01-01to2020-06-30" continuedAt="cont_3035f5" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">9.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">General Legal Matters</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">From time to time the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s liquidity, results of operations or financial condition. </p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">COVID-19 Pandemic</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">The Company continues to monitor the ongoing developments related to &#160;the COVID-19 pandemic,&#160;and its impacts to&#160;the Company&#8217;s supply-chain operations, including procurement of raw materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale.&#160; A substantial portion of such testing has historically been performed by contract laboratories outside the United States.&#160;</p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong>&#160;</p><p style="margin:0px">&#160;</p><ix:continuation id="cont_3035f5" continuedAt="cont_2b610a"><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">The Company has experienced some delays with final drug product release testing by third-party vendors. In response to these delays, the Company added additional release testing laboratories to its FDA approved consortium listed in its drug approval documents which the Company believes has adequately addressed this issue. In addition, due to previous state and local &#8220;shelter-in-place&#8221; orders, the Company experienced lower than normal donor collections at its FDA approved plasma collection center during the three months ended June 30, 2020. The Company was also subject to delays in shipments of source plasma from its contracted third-party suppliers, as well as delays in deliveries for personal protective equipment, reagents and other non-plasma raw materials and supplies used in the manufacture of its products. The COVID-19 pandemic has also impacted, to a certain degree, the Company&#8217;s customer engagement initiatives, whereby ADMA&#8217;s sales and medical affairs field personnel have faced difficulties communicating directly with physicians and other healthcare professionals, as well as the cancellation or postponement of a number of key scientific and medical meetings, further limiting the Company&#8217;s ability to communicate with potential customers.&#160; The Company has implemented a comprehensive suite of virtual engagement initiatives, however, clinician engagement has been reduced due to rapidly evolving COVID-19 priorities at U.S. medical centers.</p><p style="margin:0px 0px 0px 0in;text-indent:0.5in">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on the Company&#8217;s financial condition or results of operations, and the Company does not believe that its production operations at the Boca Facility, the Company&#8217;s contract fill/finishers or its plasma collection facility have been significantly impacted by the COVID-19 pandemic. As a result, the Company does not anticipate any material impairments with respect to any of its long-lived assets, including the Company&#8217;s property and equipment, goodwill or intangible assets.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Although the COVID-19 pandemic has not, to date, materially adversely impacted the Company&#8217;s capital and financial resources, because the Company is unable to determine the ultimate severity or duration of the pandemic or its long-term effects on, among other things, the global, national or local economies, the capital and credit markets or the Company&#8217;s workforce, customers or our suppliers, at this time the Company is unable to predict whether COVID-19 will have a material adverse impact on the Company&#8217;s business, financial condition, liquidity and results of operations.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Vendor and Licensor Commitments</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Pursuant to the terms of a plasma purchase agreement with BPC dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase Agreement&#8221;), the Company agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum volume from BPC, but may also collect high-titer RSV plasma from up to five wholly-owned ADMA plasma collection facilities. During 2015, the Company and BPC amended the 2011 Plasma Purchase Agreement to allow the Company the ability to collect its raw material RSV high-titer plasma from other third-party collection organizations, thus allowing the Company to expand its reach for raw material supply as it continues its commercialization activities for ASCENIV. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June 2027, after which it may be renewed for two additional five-year periods if agreed to by the parties. As part of the closing of the Biotest Transaction, the parties amended the 2011 Plasma Purchase Agreement to extend the initial term through the ten-year anniversary of the closing date of the Biotest Transaction. On December 10, 2018, BPC assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. On January 1, 2019, Grifols and the Company entered into an additional amendment to the 2011 Plasma Purchase Agreement for the purchase of source plasma containing antibodies to RSV from Grifols. Pursuant to this amendment, until January 1, 2022, the Company may purchase RSV plasma from Grifols from the two plasma collection centers that were transferred to BPC on January 1, 2019 at a price equal to cost plus 5% without any additional increase due to inflation.</p></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="margin:0px">&#160;&#160;</p><ix:continuation id="cont_2b610a"><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On June 6, 2017, the Company and BPC entered into a Plasma Supply Agreement pursuant to which BPC supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a <ix:nonNumeric id="fid_1088" name="adma:PlasmaSupplyAgreementTerm" contextRef="From2020-01-01to2020-06-30" format="ixt-sec:duryear">10</ix:nonNumeric>-year term. On July 19, 2018, the Company and BPC entered into an amendment to the Plasma Supply Agreement to provide, among other things, that in the event BPC elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double digit percentage of the price that ADMA BioManufacturing pays to BPC, then BPC shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On June 6, 2017, the Company and BPC entered into a Plasma Purchase Agreement (the &#8220;2017 Plasma Purchase Agreement&#8221;), pursuant to which ADMA BioManufacturing purchases normal source plasma (&#8220;NSP&#8221;) from BPC at agreed upon annual quantities and prices. The 2017 Plasma Purchase Agreement had an initial term of five years after which the 2017 Plasma Purchase Agreement may be renewed for two additional terms of two years each upon the mutual written consent of the parties. On July 19, 2018, the Company and BPC entered into an amendment to the 2017 Plasma Purchase Agreement to, among other things, provide agreed upon amounts of NSP to be supplied by BPC to ADMA BioManufacturing in calendar year 2019 at a specified price per liter, provided that ADMA BioManufacturing delivers a valid purchase order to BPC. Additionally, pursuant to the amendment to the 2017 Plasma Purchase Agreement, BPC agrees that, for calendar years 2020 and 2021, it shall supply no less than a high double digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts, provided that such requested NSP amounts are within an agreed range, at a price per liter to be mutually determined. Furthermore, pursuant to the amendment to the 2017 Plasma Purchase Agreement, in the event BPC fails to supply ADMA BioManufacturing with at least a high double digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts, BPC shall promptly reimburse ADMA BioManufacturing the difference in price ADMA BioManufacturing incurs due to BPC&#8217;s election not to supply NSP to ADMA BioManufacturing in such amounts as requested. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Purchase Agreement to Grifols, effective January 1, 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company purchases substantially all of its raw material plasma from Grifols. For the six months ended June 30, 2020, plasma purchases from Grifols totaled approximately $<ix:nonFraction id="fid_338" name="adma:PurchaseOfRawMaterial" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">3.7</ix:nonFraction> million, representing approximately <ix:nonFraction id="fid_342" name="adma:PurchasePercentageFromInventory" contextRef="From2020-01-01to2020-06-30" decimals="INF" unitRef="Pure" scale="0">42</ix:nonFraction>% of the Company&#8217;s total inventory purchases. For the six months ended June 30, 2019, plasma purchases from BPC totaled $<ix:nonFraction id="fid_340" name="adma:PurchaseOfRawMaterial" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">5.0</ix:nonFraction> million, or approximately <ix:nonFraction id="fid_341" name="adma:PurchasePercentageFromInventory" contextRef="From2019-01-01to2019-06-30" decimals="INF" unitRef="Pure" scale="0">67</ix:nonFraction>% of the Company&#8217;s total inventory purchases.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Post-marketing commitments</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In connection with the approval of the BLA for BIVIGAM, on December 19, 2012 Biotest committed to perform two additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in BIVIGAM-treated patients with primary humoral immunodeficiency. These studies are still pending completion, as such ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and development expenses. The Company currently expects both studies to be completed by the end of 2021. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In connection with the FDA&#8217;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. This study is required to be completed by June of 2023.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><span style="text-decoration:underline">Employment contracts </span></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company has entered into employment agreements with its executive management team consisting of its President and Chief Executive Officer, its Executive Vice President, Chief Medical Officer and Chief Scientific Officer and its Executive Vice President and Chief Financial Officer.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Other commitments</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown as of June 30, 2020. The Company does not anticipate recognizing any significant losses relating to these arrangements.</p></ix:continuation><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong>&#160;</p><p style="margin:0px">&#160;&#160;</p><ix:nonNumeric id="fid_791" name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="From2020-01-01to2020-06-30" continuedAt="cont_1ab7e2" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">10.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">SEGMENTS</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company&#8217;s ADMA BioManufacturing segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1).The Plasma Collection Centers segment consists of one FDA-licensed source plasma collection facility, another plasma collection facility for which an FDA license is pending and a plasma collection center currently under construction. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) to analyze performance and allocate resources. The Company&#8217;s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><ix:nonNumeric id="fid_819" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="From2020-01-01to2020-06-30" continuedAt="cont_d4b6d2" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:top;" colspan="17"><p style="MARGIN: 0px; text-align:center;"><strong>Three Months Ended June 30, 2020 </strong></p></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>ADMA BioManufacturing </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Plasma Collection Centers </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Corporate </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Consolidated</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_189" name="us-gaap:Revenues" contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,502,865</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_184" name="us-gaap:Revenues" contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,249,020</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_186" name="us-gaap:Revenues" contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,709</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_182" name="us-gaap:Revenues" contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,787,594</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_197" name="us-gaap:CostOfRevenue" contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,237,141</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_192" name="us-gaap:CostOfRevenue" contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,258,488</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_194" name="us-gaap:CostOfRevenue" contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_190" name="us-gaap:CostOfRevenue" contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,495,629</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_205" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">12,852,835</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_200" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">919,309</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_202" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,351,681</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_198" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">17,123,825</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other expense, net</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_213" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">235,442</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_208" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">33</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_210" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,818,791</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_206" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,054,266</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_237" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,088,277</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_232" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">919,342</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_234" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,170,472</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_230" name="us-gaap:NetIncomeLoss" contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,178,091</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_253" name="us-gaap:DepreciationAndAmortization" contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">772,241</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_248" name="us-gaap:DepreciationAndAmortization" contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,106</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_250" name="us-gaap:DepreciationAndAmortization" contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,305</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_246" name="us-gaap:DepreciationAndAmortization" contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,652</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total assets</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_351" name="adma:TotalAssets" contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,105,418</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_347" name="adma:TotalAssets" contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,542,486</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_349" name="adma:TotalAssets" contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,893,664</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_345" name="adma:TotalAssets" contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,541,568</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="16"><p style="MARGIN: 0px; text-align:center;"><strong>Three Months Ended June 30, 2019</strong> </p></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>ADMA BioManufacturing</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Plasma Collection Centers</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Corporate</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Consolidated</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_188" name="us-gaap:Revenues" contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,002,445</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_185" name="us-gaap:Revenues" contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,522,788</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_187" name="us-gaap:Revenues" contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,709</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_183" name="us-gaap:Revenues" contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,560,942</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_196" name="us-gaap:CostOfRevenue" contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,170,381</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_193" name="us-gaap:CostOfRevenue" contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,320,855</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_195" name="us-gaap:CostOfRevenue" contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_191" name="us-gaap:CostOfRevenue" contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,491,236</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_204" name="us-gaap:OperatingIncomeLoss" contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,671,783</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_201" name="us-gaap:OperatingIncomeLoss" contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">392,181</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_203" name="us-gaap:OperatingIncomeLoss" contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,274,710</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_199" name="us-gaap:OperatingIncomeLoss" contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,338,674</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other expense, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_212" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">246,603</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_209" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">59</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_211" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,626,536</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_207" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,873,198</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_236" name="us-gaap:NetIncomeLoss" contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,918,386</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_233" name="us-gaap:NetIncomeLoss" contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">392,240</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_235" name="us-gaap:NetIncomeLoss" contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,901,246</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_231" name="us-gaap:NetIncomeLoss" contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,211,872</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_252" name="us-gaap:DepreciationAndAmortization" contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">688,848</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_249" name="us-gaap:DepreciationAndAmortization" contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">113,958</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_251" name="us-gaap:DepreciationAndAmortization" contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,287</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_247" name="us-gaap:DepreciationAndAmortization" contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">806,093</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_352" name="adma:TotalAssets" contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,236,416</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_348" name="adma:TotalAssets" contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,835,999</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_350" name="adma:TotalAssets" contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,201,705</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_346" name="adma:TotalAssets" contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,274,120</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="margin:0px">&#160;&#160;</p><ix:continuation id="cont_1ab7e2"><ix:continuation id="cont_d4b6d2"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="16"><p style="MARGIN: 0px; text-align:center;"><strong>Six Months Ended June 30, 2020</strong> </p></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>ADMA BioManufacturing</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Plasma Collection Centers</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Corporate</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Consolidated</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_378" name="us-gaap:Revenues" contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,246,139</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_366" name="us-gaap:Revenues" contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,669,782</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_373" name="us-gaap:Revenues" contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,417</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_343" name="us-gaap:Revenues" contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,987,338</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_379" name="us-gaap:CostOfRevenue" contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,689,094</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_367" name="us-gaap:CostOfRevenue" contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,635,761</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_214" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_353" name="us-gaap:CostOfRevenue" contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,324,855</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_380" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">25,328,980</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_368" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,376,464</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_374" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,188,167</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_354" name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">33,893,611</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other expense, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_381" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">474,314</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_369" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">33</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_375" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">5,055,363</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_355" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">5,529,710</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_382" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">25,803,294</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_370" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,376,497</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_376" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">12,243,530</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_356" name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">39,423,321</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Capital expenditures </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_383" name="adma:CapitalExpenditure" contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,064,494</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_371" name="adma:CapitalExpenditure" contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,178,790</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_242" name="adma:CapitalExpenditure" contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1102" name="adma:CapitalExpenditure" contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,243,284</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_384" name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,447,214</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_385" name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,395</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_377" name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,881</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_386" name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,674,490</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:top;" colspan="17"><p style="MARGIN: 0px; text-align:center;"><strong>Six Months Ended June 30, 2019 </strong></p></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>ADMA BioManufacturing </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Plasma Collection Centers </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Corporate </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Consolidated</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_387" name="us-gaap:Revenues" contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,346,428</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_402" name="us-gaap:Revenues" contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,671,686</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_396" name="us-gaap:Revenues" contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,417</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_344" name="us-gaap:Revenues" contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,089,531</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_388" name="us-gaap:CostOfRevenue" contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,110,727</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_403" name="us-gaap:CostOfRevenue" contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,785,688</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_216" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_358" name="us-gaap:CostOfRevenue" contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,896,415</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_389" name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">19,292,591</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_404" name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">362,601</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_397" name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,891,898</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_359" name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">24,547,090</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other (expense) income, net</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_390" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">416,216</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_405" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,560</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_398" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,895,007</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_360" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,297,663</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gain on transfer of plasma center assets</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_217" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_361" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,527,421</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_218" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_406" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,527,421</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss on extinguishment of debt</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_219" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_220" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_362" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">9,962,495</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_399" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">9,962,495</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net (loss) income </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_391" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">19,708,807</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_407" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,178,380</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_400" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">17,749,400</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_363" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">26,279,827</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Capital expenditures </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_392" name="adma:CapitalExpenditure" contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,440</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_408" name="adma:CapitalExpenditure" contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,235</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_243" name="adma:CapitalExpenditure" contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1103" name="adma:CapitalExpenditure" contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,675</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_393" name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,376,240</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_409" name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,199</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_401" name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,983</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_410" name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,611,422</ix:nonFraction></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:continuation></ix:continuation><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><ix:nonNumeric id="fid_792" name="adma:TransferOfPlasmaCenterAssetsDisclosureTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">11.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">TRANSFER OF PLASMA CENTER ASSETS</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As part of the purchase price for the Biotest Transaction (see Note 1), the Company transferred its Marietta, GA and Norcross, GA plasma collection centers to BPC effective January 1, 2019. The Company had estimated the combined fair value of the two facilities to be $<ix:nonFraction id="fid_411" name="us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">12.6</ix:nonFraction> million, and the Company recorded an obligation for this amount as of the date of the Biotest Transaction. On January 1, 2019, upon the transfer of the two plasma collection facilities to BPC, the Company recorded a gain in the amount of $<ix:nonFraction id="fid_414" name="adma:GainUponTransferFacilities" contextRef="AsOf2019-01-01" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">11.5</ix:nonFraction> million, which reflects the derecognition of the obligation to transfer ownership of the two facilities net of the carrying value of the assets associated with these facilities, primarily property and equipment and inventory, in the amount of $<ix:nonFraction id="fid_415" name="adma:NetCarryingValueOfAssets" contextRef="AsOf2019-01-01" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.1</ix:nonFraction> million. </p></ix:nonNumeric><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><ix:nonNumeric id="fid_793" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">12.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">LEASE OBLIGATIONS</span></strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company leases certain properties and equipment for its ADMA BioCenters subsidiary and certain equipment for its ADMA BioManufacturing subsidiary, which leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2030. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease. Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s incremental borrowing rate of <ix:nonFraction id="fid_418" name="adma:IncrementalBorrowingRate" contextRef="From2020-01-01to2020-06-30" decimals="INF" unitRef="Pure" scale="0">13</ix:nonFraction>%. The Company&#8217;s operating lease expense is recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. Aggregate lease expense and cash paid for the Company&#8217;s operating leases for the three months ended June 30, 2020 and 2019 was approximately $<ix:nonFraction id="fid_423" name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-01to2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million, and aggregate rent expense and cash paid for the Company&#8217;s operating leases for the six months ended June 30, 2020 and 2019 was approximately $<ix:nonFraction id="fid_419" name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In connection with the adoption of ASU 2016-02 on January 1, 2019 (see Note 2), the Company recognized right to use assets of $<ix:nonFraction id="fid_959" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-06-30_adma_JanuaryOneTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.4</ix:nonFraction> million and lease liabilities of approximately $<ix:nonFraction id="fid_964" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-06-30_adma_JanuaryOneTwoThousandNineteenMember" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.6</ix:nonFraction> million. During the six months ended June 30, 2020, the Company entered into two new property leases where the Company has opened or intends to open two new plasma collection facilities. In connection with these leases, the Company recognized aggregate lease liabilities and corresponding right-to-use assets in the approximate amount of $<ix:nonFraction id="fid_960" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.7</ix:nonFraction> million. The right-to-use assets are reflected in Deposits and other assets in the accompanying consolidated balance sheets. Including a finance lease the Company entered into in June 2018, the Company has aggregate lease liabilities of $<ix:nonFraction id="fid_1092" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">3.1</ix:nonFraction> million and $<ix:nonFraction id="fid_1094" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.5</ix:nonFraction> million as of June 30, 2020 and December 31, 2019, respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers and an administrative office lease in Roswell, GA related to the Company&#8217;s ADMA BioCenters subsidiary. The Company&#8217;s operating leases have a weighted average remaining term of <ix:nonNumeric id="fid_968" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="AsOf2020-06-30" format="ixt-sec:duryear">8.4</ix:nonNumeric> years. Scheduled payments under the Company&#8217;s lease obligations are as follows:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_820" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Remainder of 2020 </p></td><td style="width:60%;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="MARGIN: 0px; text-align:left;">$</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_263" name="us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,076</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Year ended December 31, 2021 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_264" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">699,752</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">2022 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_265" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">721,005</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">2023 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_266" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706,919</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">2024 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_267" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">603,858</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Thereafter </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_268" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,205,047</ix:nonFraction></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Total payments </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_269" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,198,657</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Less: imputed interest </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">(<ix:nonFraction id="fid_270" name="adma:InterestPortionOfMinimumLeasePayments" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,050,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="MARGIN: 0px; text-align:left;">)</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Current portion </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">(<ix:nonFraction id="fid_271" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">210,870</ix:nonFraction></p></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;"><p style="MARGIN: 0px; text-align:left;">)</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Balance at June 30, 2020 </p></td><td style="white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_272" name="adma:OperatingLeaseLiabilityTotal" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,937,292</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;">&#160; </td></tr></tbody></table></ix:nonNumeric><p style="margin:0px">&#160;&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of July 15, 2020, the Company had entered into two additional property leases where the Company intends to construct additional new plasma collection facilities. The Company has not taken possession of these two leased properties and their lease commencement dates have not been determined. <ix:nonNumeric id="fid_434" name="adma:LeaseDescription" contextRef="From2020-07-01to2020-07-15">With the exception of advance deposits and initial months&#8217; rent totaling approximately $74,000, no payments have been made under these leases. The initial terms of each lease are from 11 to 13 years with monthly rental payments varying between approximately $17,000 and $21,000, including common area maintenance charges.</ix:nonNumeric></p></ix:nonNumeric><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p><p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong>&#160;</p><p style="margin:0px">&#160; </p><ix:nonNumeric id="fid_794" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">13.<span style='font:7pt "times new roman"'> </span></span></strong><strong><span style="text-decoration:underline">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></strong> </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Supplemental cash flow information for the six months ended June 30, 2020 and 2019 is as follows:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><ix:nonNumeric id="fid_821" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td style="vertical-align:top;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Cash paid for interest </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_274" name="us-gaap:InterestPaidNet" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,912,165</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_275" name="us-gaap:InterestPaidNet" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,574,304</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Noncash Financing and Investing Activities:</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Equipment acquired reflected in accounts payable and accrued liabilities </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_277" name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,228,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_278" name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,389</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Right-to-use assets obtained in exchange for lease obligations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_279" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2020-01-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,723,594</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_280" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,421,669</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Warrants issued in connection with notes payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_281" name="adma:WarrantsIssuedInConnectionWithNotePayable" contextRef="From2020-01-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_282" name="adma:WarrantsIssuedInConnectionWithNotePayable" contextRef="From2019-01-01to2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,579,115</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160; </p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="margin:0px">&#160;</p><ix:nonNumeric id="fid_1097" name="us-gaap:SubsequentEventsTextBlock" contextRef="From2020-01-01to2020-06-30" escape="true"><strong style="MARGIN: 0px"><span style="mso-list:ignore">14.<span style='font:7pt "times new roman"'>&#160; </span></span></strong><strong><span style="text-decoration:underline">SUBSEQUENT EVENTS</span></strong><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;On August 5, 2020, the Company entered into an Open Market Sale Agreement<sup>SM</sup> (the &#8220;Sale Agreement&#8221;) with Jefferies LLC, as agent (the &#8220;Agent&#8221;), pursuant to which the Company may offer and sell (the &#8220;Offering&#8221;), from time to time, at its option, through or to the Agent, up to an aggregate of $<ix:nonFraction id="fid_1099" name="adma:CommonStockOffering" contextRef="From2020-01-01to2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_srt_MaximumMember_adma_JefferiesLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,000,000</ix:nonFraction> of shares of the Company&#8217;s common stock, par value $<ix:nonFraction id="fid_1100" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_adma_JefferiesLLCMember" decimals="4" unitRef="USDPShares">0.0001</ix:nonFraction> per share (the &#8220;Shares&#8221;). Any Shares to be offered and sold under the Sale Agreement will be issued and sold pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-234107), filed with the SEC on October 4, 2019, and declared effective on October 15, 2019 (the &#8220;Registration Statement&#8221;) and the prospectus supplement relating to the Offering, dated August 5, 2020, that will be filed with the SEC, by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, (the "Securities Act"), or if specified by the Company, by any other method permitted by law, including, but not limited to, in negotiated and block transactions. </p><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the terms of the Sale Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company cannot provide any assurances that it will issue any Shares pursuant to the Sale Agreement. <ix:nonNumeric id="fid_1101" name="adma:CommissionDescription" contextRef="From2020-01-01to2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_srt_MaximumMember_adma_JefferiesLLCMember">The Company will pay the Agent a commission of up to 3.0% of the gross proceeds from each sale of the Shares under the Sale Agreement.</ix:nonNumeric> The Company will also reimburse the Agent for certain expenses incurred in connection with the Sale Agreement and agreed to provide the Agent with customary indemnification rights with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. </span></p><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Through the date of this report, no shares have been sold under the Sale Agreement.</span></p></ix:nonNumeric><p style="margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i2">Item 2.<span style="mso-tab-count:1"> Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"><em>The following discussion of our financial condition and results of operations, which refers to our historical results, should be read in conjunction with the other sections of this Quarterly Report on Form 10-Q, including &#8220;Risk Factors&#8221; and our unaudited consolidated financial statements and the notes thereto appearing elsewhere herein, and in conjunction with the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, filed on March 13, 2020 (the &#8220;2019 10-K&#8221;). The various sections of this discussion contain a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risk factors described throughout or referenced within this Quarterly Report on Form 10-Q. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;Our actual results may differ materially from our current expectations.</em></p><p style="margin:0px">&#160; </p><p style="MARGIN: 0px; text-align:center;"><strong style="MARGIN: 0px"><span style="text-decoration:underline">OVERVIEW</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160; </p><p style="MARGIN: 0px; text-align:left;"><strong>Our Business</strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">ADMA Biologics, Inc. (the &#8220;Company,&#8221; &#8220;ADMA,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is an end-to-end commercial biopharmaceutical and specialty immunoglobulin company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We currently have three products with U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approval, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;), and for which we received FDA approval on May 9, 2019 for the commercial re-launch of the product and commenced the re-launch in August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), previously referred to as RI-002, an IVIG product indicated for the treatment of PI, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B. We seek to develop a pipeline of plasma-derived therapeutics, including a product based on our most recently approved patent application under U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection for an immunoglobulin manufactured to contain standardized antibodies to numerous serotypes of S. pneumonia. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="margin:0px;text-indent:45px">&#160;We manufacture our products at an FDA-licensed, 400,000-liter annual capacity plasma fractionation and purification facility located in Boca Raton, Florida (the &#8220;Boca Facility&#8221;). Based on current production yields, we believe this facility has the potential to produce quantities of our immune globulin (&#8220;IG&#8221;) products capable of generating more than $250 million in annual revenue as we ramp-up production over the next three to five years. Our products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Through our ADMA BioCenters subsidiary, we currently operate as an FDA-approved source plasma collection organization and have facilities located in the U.S. This business unit, which we refer to as our Plasma Collection Centers business segment, provides us with a portion of our blood plasma for the manufacture of our products and product candidates, and also allows us to sell certain quantities of source plasma to others for further manufacturing. We have embarked on a supply chain robustness plan and recently opened a new plasma collection center on June 30, 2020 for which an FDA license is pending, and we currently have additional plasma collection centers in various stages of development. We intend to open five to 10 additional plasma collection centers in the U.S. during the next three to five years. A typical plasma collection center, such as those operated by ADMA BioCenters, can collect approximately 30,000 to 50,000 liters of source plasma annually, which may be sold for different prices depending upon the type of plasma, quantity of purchase and market conditions at the time of sale. Plasma collected from ADMA BioCenters&#8217; facilities that is not used to manufacture our products or product candidates is sold to third-party customers in the U.S. and in other locations outside the U.S. where we are approved under supply agreements or in the open &#8220;spot&#8221; market. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We also sell plasma-derived intermediate fractions to certain customers, which are generated as part of our FDA-approved manufacturing process for IG and IVIG products. In January 2020, we announced our entry into a five-year manufacturing and supply agreement to produce and sell these intermediate by-products, which are used as the starting raw material to produce other plasma-derived biologics. In addition, from time to time we provide contract manufacturing services for certain historical clients.</p><p style="margin:0px;text-indent:0.5in">&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong>Our Products</strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>BIVIGAM</em></strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"><span style='mso-fareast-font-family:"times new roman"'>&#160;</span></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"><span style='mso-fareast-font-family:"times new roman"'>BIVIGAM is a plasma-derived IVIG that contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses, and help to protect PI patients against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin G antibodies indicated for the treatment of PI, a group of genetic disorders. This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These PIs are a group of genetic disorders. </span><span style='mso-fareast-font-family:"times new roman"'>Based on recent estimates, these disorders are no longer considered to be very rare, with as many as one in every 1,200 people in the United States having some form of PI. </span><span style='mso-fareast-font-family:"times new roman"'>BPC Plasma, Inc. (formerly Biotest Pharmaceuticals Corporation)</span> (&#8220;BPC&#8221;) <span style='mso-fareast-font-family:"times new roman"'>had originally received FDA approval for BIVIGAM on December 19, 2012, prior to our acquisition of the Boca Facility and related assets on June 6, 2017 (the &#8220;Biotest Transaction&#8221;), and product sales had commenced in the first quarter of 2013. On May 9, 2019, the FDA approved the Prior Approval Supplement (the &#8220;PAS&#8221;) for the use of our IVIG manufacturing process, thereby enabling us to re-launch and commercialize this product in the United States. We resumed production of BIVIGAM during the fourth quarter of 2017 and commercial production is ongoing, using our FDA-approved IVIG manufacturing process under U.S. Department of Health and Human Services (&#8220;HHS&#8221;) License No. 2019. The commercial re-launch and first commercial sales for this product commenced in August of 2019. </span></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em><span style='mso-fareast-font-family:"times new roman"'>ASCENIV </span></em></strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">ASCENIV is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies, which are proteins that are used by the body&#8217;s immune system to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. We manufacture ASCENIV under HHS License No. 2019 using a process known as fractionation. As part of our proprietary manufacturing process for ASCENIV, we leverage our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested to have high levels of neutralizing titers to RSV using our proprietary microneutralization assay. We are able to identify the high titer plasma that meets our internal specifications for ASCENIV with our patented testing methods and assay. This type of high titer plasma is typically found in less than 10% of the total donor collection samples we test. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">ASCENIV is approved for the treatment of PIDD, a class of inherited genetic disorders that causes a deficient or absent immune system in adults and adolescents (12 to 17 years of age). Our pivotal Phase 3 clinical trial in 59 PIDD patients met the primary endpoint of no Serious Bacterial Infections reported during 12 months of treatment. Secondary efficacy endpoints further demonstrated the benefits of ASCENIV in the low incidence of infection, therapeutic antibiotic use, days missed from work/school/daycare and unscheduled medical visits and hospitalizations. We believe this clinical data together with the FDA approval for the treatment of PIDD better positions ADMA to further evaluate ASCENIV in immune-compromised patients infected with or at-risk for RSV infection. We plan to work with the FDA and the immunology and infectious disease community to design a clinical trial to evaluate the use of ASCENIV in this patient population in the near future. Commercial sales of ASCENIV commenced in October of 2019. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Nabi-HB</em></strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Nabi-HB is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a Hepatitis B vaccine. Nabi-HB is indicated for the treatment of acute exposure to blood containing HBsAg, prenatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute Hepatitis B virus infection in specific, listed settings. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus. It is a major global health problem. It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer. Nabi-HB has a well-documented record of long-term safety and effectiveness since its initial market introduction. The FDA approved Nabi-HB on March 24, 1999.Production of Nabi-HB at the Boca Facility has continued under our leadership since the third quarter of 2017. In early 2018, we received authorization from the FDA for the release of our first commercial batch of Nabi-HB for commercial distribution in the U.S. and we continue to manufacture Nabi-HB under HHS License No. 2019.</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160; </p><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><strong><span style="text-decoration:underline"><span style='mso-bidi-font-family:"times new roman"'>IMPACT OF THE COVID-19 CRISIS</span></span></strong></strong></p><p style="MARGIN: 0px; text-align:center;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">We continue to closely monitor ongoing developments in connection with the COVID-19 global pandemic, and its impacts to our commercial and manufacturing operations, including but not limited to disruptions to our supply chain operations, including procurement of raw materials and packaging materials, a portion of which are sourced internationally, and testing of finished drug product that is required prior to its availability for commercial sale.Such testing has historically been performed by contract laboratories outside the United States. In addition, travel and other restrictions that have been implemented in the United States have impacted our commercial efforts with respect to&#160;some of our products, including BIVIGAM and ASCENIV, as trade shows, industry and medical conferences and other events we had been planning to utilize and exhibit and attend with our staff to increase awareness of our products by physicians and payers remain subject to reduction in scope, rescheduling or outright cancellation due to the pandemic.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Although our consolidated revenues for the three months ended June 30, 2020 were higher than our revenues from the same period of a year ago, they were lower than our revenues for the three months ended March 31, 2020. This decrease was due to certain unforeseen delays and the impact of COVID-19 experienced our by third-party vendors and testing laboratories which perform final drug product GMP release testing. In response to these delays, we have added additional release testing laboratories to our FDA approved consortium listed in our drug approval documents which we believe has adequately addressed this issue. In July 2020, we began receiving FDA lot releases with testing data from our new testing laboratory vendor. In addition, due to previous state and local &#8220;shelter-in-place&#8221; orders, we experienced lower than normal donor collections at our FDA-approved plasma collection center during the three months ended June 30, 2020. We were also subject to delays in shipments of source plasma from our contracted third-party suppliers, as well as delays in deliveries for personal protective equipment, reagents and other non-plasma raw materials and supplies used in the manufacture of our products. We have also experienced challenges with respect to our customer engagement initiatives, as our sales and medical affairs field forces face difficulties communicating directly with physicians and other healthcare professionals and the cancellation or postponement of a number of key scientific and medical meetings, further limiting our ability to communicate with potential customers.&#160; We have implemented a comprehensive suite of virtual engagement initiatives, though clinician engagement remains lower due to continuing COVID-19-related priorities at U.S. medical centers.&#160;&#160;</p><p style="margin:0px 0px 0px 0in;text-indent:0.5in">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">As of the date of this report, we do not believe that the operations and immunoglobulin and plasma products production at our Boca Facility, our contract fill/finishers or our plasma collection facility have been significantly impacted by the COVID-19 pandemic. As a result, as of the date of this report, we currently do not anticipate any material impairments with respect to any of our long-lived assets, including our property and equipment, goodwill or intangible assets.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Although the COVID-19 pandemic has not, to date, materially adversely impacted our capital and financial resources, due to the economic uncertainty that has resulted from the pandemic, and the potential impact of such to our stakeholders, we are unable to predict with certainty any potential impacts to our business. Additionally, because we are unable to determine the ultimate duration of the pandemic or its long-term effects on, among other things, the global, national or local economies, the capital and credit markets, our workforce, our customers or our suppliers, at this time we are unable to predict whether the COVID-19 crisis will have a material adverse impact on our business, financial condition, liquidity and results of operations. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">RESULTS OF OPERATIONS</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong>Critical Accounting Policies and Estimates</strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our consolidated financial statements, which have been prepared in accordance with Accounting Principles Generally Accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates and assumptions, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under our equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for our deferred tax assets.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Some of the estimates and assumptions we have to make under U.S. GAAP require difficult, subjective and/or complex judgments about matters that are inherently uncertain and, as a result, actual results could differ from those estimates. Due to the estimation processes involved, the following summary of accounting policies and their application are considered to be critical to understanding our business operations, financial condition and results of operations. For a detailed discussion on the application of these and our other accounting policies, see Note 2 to the Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Revenue Recognition</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Revenues for the six months ended June 30, 2020 and 2019 are comprised of (i) revenues from the sale of our FDA-approved immunoglobulin products, (ii) product revenues from the sale of human plasma collected from our Plasma Collection Centers business segment, (iii) product revenues from the sale of intermediate fractions, (iv) contract manufacturing revenue from certain clients, and (v) license revenues attributable to the out-licensing of ASCENIV in December 2012 to Biotest AG (&#8220;Biotest&#8221;) to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided us with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay us certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years. </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration we expect to receive in exchange. Revenue from the sale of immunoglobulin products is generally recognized when the product reaches the customer&#8217;s destination, and is recorded net of distributor fees, estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and we believe that such estimates are reasonable. For revenues associated with contract manufacturing and sales of our intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or a third-party warehouse that is utilized by the Company.</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Product revenues from the sale of human plasma collected at our plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if we retain control of the product during shipment. Payments received from customers where the foregoing revenue recognition criteria have not been satisfied are recorded as deferred revenue, which is reflected as a liability in our consolidated balance sheets.</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">For the six months ended June 30, 2020, three customers represented an aggregate of 81% of our consolidated revenues, with BioCARE, Inc. (&#8220;BioCare&#8221;), Biolife Plasma Services, L.P. (&#8220;Biolife&#8221;) and Reliance Life Sciences Pvt Limited (&#8220;Reliance&#8221;) representing approximately 47%, 20%, and 14%, respectively, of our consolidated revenues. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Accounts Receivable</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Accounts receivable are reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are recognized in the period the related revenue is recorded. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Cost of Product Revenue</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Cost of product revenue includes expenses related to process development as well as scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses. Costs of production for ASCENIV and BIVIGAM prior to their FDA approval dates of April 1, 2019 and May 9, 2019, respectively, were not capitalized into inventory but were instead expensed as incurred. In addition, costs associated with the production of conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue in the period the lots were produced.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Stock-Based Compensation </em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">All equity-based payments, including grants of stock options and restricted stock units (&#8220;RSUs&#8221;) are recognized at their estimated fair value at the grant date, and compensation expense is recognized on a straight-line basis over the grantee&#8217;s requisite vesting period. During the six months ended June 30, 2020, we granted RSUs to members of our Board of Directors and certain members of our management and employees representing an aggregate of 341,000 shares of common stock. For the purpose of valuing stock options granted to our employees, directors and officers, we use the Black-Scholes option pricing model. We granted options to purchase an aggregate of 1,232,500 and 1,429,100 shares of common stock during the six months ended June 30, 2020 and 2019, respectively. To determine the risk-free interest rate, we utilized the U.S. Treasury yield curve in effect at the time of the grant with a term consistent with the expected term of our awards. The expected term of the options granted is in accordance with SEC Staff Accounting Bulletins 107 and 110, and is based on the average between vesting terms and contractual terms. The expected dividend yield reflects our current and expected future policy for dividends on our common stock. The expected stock price volatility for our stock options was calculated by examining the historical volatility of our common stock since our common stock became publicly traded in the fourth quarter of 2013. We will continue to analyze the expected stock price volatility and expected term assumptions and will adjust our Black-Scholes option pricing assumptions as appropriate. In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-09, <em>Improvements to Employee Share-Based Payment Accounting (Topic 718)</em>, we have elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Research and Development Expenses</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our research and development (&#8220;R&amp;D&#8221;) costs consist of clinical research organization costs, costs related to clinical trials, testing and evaluation of new or alternative products or processes, studies for potentially extending a product&#8217;s approved and labeled expiration dating and other potential label expansions, post-marketing commitment studies for BIVIGAM and ASCENIV, wages, benefits and stock-based compensation for employees directly related to research and development activities and, prior to April 1, 2019, assay development and testing, storage and transportation costs for high-titer plasma used in the manufacture of ASCENIV. All research and development costs are expensed as incurred. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Impairment of Long-Lived Assets</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We assess the recoverability of our long-lived assets, which include property and equipment and definite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the six months ended June 30, 2020 and 2019, we determined that there was no impairment of our long-lived assets. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Goodwill is not amortized, but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. We have the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of the reporting unit associated with the goodwill is less than its carrying amount, including goodwill and other intangible assets. If we conclude that this is the case, then we must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value.An impairment charge is recorded to the extent the reporting unit&#8217;s carrying value exceeds its fair value, with the impairment loss recognized not to exceed the total amount of goodwill allocated to that reporting unit.We did not recognize any impairment charges related to goodwill for the six months ended June 30, 2020 and 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Recent Accounting Pronouncements </em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"><span style='mso-fareast-font-family:"times new roman"'>In June 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <em>Financial Instruments &#8211; Credit Losses (Topic 326)</em> (&#8220;ASU 2016-13&#8221;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#8217;s statement of operations is required to reflect the measurement of credit losses for newly recognized financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.We adopted ASU No. 2016-13, and the adoption of this update did not have a significant impact on our consolidated financial statements.</span></p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"><span style='mso-fareast-font-family:"times new roman"'>In July 2017, the FASB issued ASU No. 2017-11, </span><em>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815)</em>&#8221; (&#8220;ASU 2017-11&#8221;). ASU 2017-11 changed the classification analysis of certain equity-linked financial instruments (or embedded features within such instruments) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (&#8220;EPS&#8221;) in accordance with ASC 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. In addition, convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features in ASC 470-20, &#8220;<em>Debt&#8212;Debt with Conversion and Other Options.</em>&#8221; ASU 2017-11 became effective for us on January 1, 2019, and this update did not have a significant impact on our consolidated financial statements.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"><span style="mso-ansi-language:en">In February 2016, the FASB issued ASU No. 2016-02, <em>Leases</em> (Topic 842) (&#8220;ASU 2016-02&#8221;), which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance became effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We adopted ASU 2016-02 on January 1, 2019 using the option to recognize the cumulative-effect adjustment, if any, as of the date of application, which was also January 1, 2019. As a result, there was no restatement of comparative periods. We recognized right-to-use assets of approximately $1.4 million and corresponding lease liabilities of approximately $1.6 million at the date of adoption. We also elected the &#8220;package of practical expedients,&#8221; which permits us to not reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. In addition, we elected the short-term lease recognition exemption for all or embedded leases that qualify.</span>&#160;</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><strong><em><span style="font-style:normal;mso-bidi-font-style:italic">Three Months Ended June 30, 2020 Compared to Three Months Ended June 30, 2019</span></em></strong></strong>&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">The following table presents a summary of the changes in our results of operations for the three months ended June 30, 2020, our second fiscal quarter, compared to the three months ended June 30, 2019:</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="10"><strong>Three Months Ended June 30,</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td></td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td></td><td style="BORDER-BOTTOM: #000000 1px solid;"></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="MARGIN: 0px; text-align:center;"><strong>Increase (Decrease)</strong> </p></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,787,594</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,560,942</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,226,652</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cost of product revenue (exclusive of amortization expense shown below) </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,495,629</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,491,236</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,004,393</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gross loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,708,035</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,930,294</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,777,741</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development expenses </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,656,420</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">516,986</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,139,434</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Plasma center operating expenses </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">877,902</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">594,113</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">283,789</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Amortization of intangibles </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">178,838</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">211,234</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32,396</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Selling, general and administrative expenses </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,702,630</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,086,047</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,616,583</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Loss from operations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(17,123,825</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,338,674</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,785,151</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,067,306</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,072,578</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(994,728</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Interest and other income, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,040</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">199,380</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(186,340</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(20,178,091</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(13,211,872</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(6,966,219</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>&#160;</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Revenues</em></strong><span style='mso-fareast-font-family:"times new roman"'>&#160;</span></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"><span style='mso-fareast-font-family:"times new roman"'>&#160;</span></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"><span style='mso-fareast-font-family:"times new roman"'>We recorded total revenues of $7.8 million during the three months ended June 30, 2020, as compared to $6.6 million during the three months ended June 30, 2019, an increase of $1.2 million, or approximately 19%. The increase is mainly due to increased sales of our immunoglobulin products generated by our Boca Facility manufacturing operations in 2020 totaling $2.5 million, partially offset by a $1.3 million decrease in plasma revenues generated by our plasma collection facility. </span></p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our revenues for the second quarter of 2020 as compared to the second quarter of 2019 were favorably impacted by the FDA approvals of BIVIGAM and ASCENIV on May 9, 2019 and April 1, 2019, respectively, and by the manufacturing and supply agreement we entered into in January 2020 to produce and sell intermediate fractions to a certain customer. Our second quarter plasma center revenues were negatively impacted by the COVID-19 pandemic due to &#8220;shelter-in-place&#8221; orders in effect during the quarter, which resulted in lower than normal donor collections at our plasma collection facility. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Cost of Product Revenue</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Cost of product revenue was $13.5 million for the three months ended June 30, 2020, as compared to $10.5 million for the three months ended June 30, 2019. This increase reflects $2.7 million in production costs incurred for the manufacture of BIVIGAM conformance lots at an increased plasma pool production scale that pertains to our planned capacity expansion at the Boca Facility. Because we will require a new PAS from the FDA before the inventory comprising these conformance lots will be available for commercial sale, these costs were expensed as incurred and were not capitalized into inventory. We also experienced increased cost of product revenue in 2020 corresponding to the increase in immunoglobulin revenues of $4.4 million, partially offset by a decrease in unabsorbed manufacturing expenses at the Boca Facility of $3.0 million and lower cost of plasma product revenue of $1.1 million. &#160;&#160;&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Research and Development Expenses</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">R&amp;D expenses totaled $1.7 million for the three months ended June 30, 2020, as compared to $0.5 million for the three months ended June 30, 2019. The increase is primarily due to $0.8 million in costs incurred during 2020 for the testing and development of a new filling line at one of our third-party fill/finishers for a process that has not been approved by the FDA and $0.2 million of non-recurring costs associated with our participation in a third-party clinical research project. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Plasma Center Operating Expenses</em></strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Plasma center operating expenses were $0.9 million for the three months ended June 30, 2020, as compared to $0.6 million for the three months ended June 30, 2019. Plasma center operating expenses consist of certain general and administrative plasma center costs, including rent, maintenance, utilities, compensation and benefits for center and administrative staff, advertising and promotion expenses and computer software fees related to donor collections. The increase in plasma center operating expenses is mainly attributable to increased staffing and travel expenses related to our plasma center expansion activities. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Amortization of Intangibles</em></strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Amortization expense pertains to the amortization of intangible assets acquired in the Biotest Transaction, and was $0.2 million for the three months ended June 30, 2020 and 2019. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Selling, General and Administrative Expenses</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses were $8.7 million for the three months ended June 30, 2020, an increase of $2.6 million from the three months ended June 30, 2019. The increase was mainly due to higher employee compensation expenses of $1.3 million related to staffing increases in support of our commercialization efforts for BIVIGAM and ASCENIV, as well as the overall growth in the size and scope of our operations, $0.5 million in marketing and consulting fees associated with our ASCENIV commercialization efforts and $0.5 million in increased insurance expense. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Loss from Operations</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Our operating loss was $17.1 million for the second quarter of 2020, as compared to $11.3 million for the second quarter of 2019. The $5.8 million increase in operating loss was mainly due to the increases in cost of product revenue, R&amp;D and SG&amp;A expenses, partially offset by the increase in revenues.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Interest Expense</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Interest expense was $3.1 million for the three months ended June 30, 2020, as compared to $2.1 million for the three months ended June 30, 2019. Throughout the second quarter of 2020, we had $85.0 million in outstanding principal under our senior credit facility.During the same period of a year ago, our outstanding senior debt ranged from $45.0 to $72.5 million (see &#8220;Liquidity and Capital Resources&#8221;). </p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Net Loss</em></strong>&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Our net loss was $20.2 million for the three months ended June 30, 2020, as compared to $13.2 million for the three months ended June 30, 2019.The increase in net loss of $7.0 million was primarily due to the increase in operating loss for the quarter of $5.8 million and to $1.0 million of higher interest expense. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><strong>Six Months Ended June 30, 2020 Compared to Six Months Ended June 30, 2019</strong></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The following table presents a summary of the changes in our results of operations for the six months ended June 30, 2020, compared to the six months ended June 30, 2019:</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="10"><strong>Six Months Ended June 30, </strong></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td></td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="white-space: nowrap;"><strong>&#160;</strong> </td><td></td><td></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="MARGIN: 0px; text-align:center;"><strong>Increase (Decrease)</strong> </p></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,987,338</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,089,531</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,897,807</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cost of product revenue (exclusive of amortization expense shown below)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">30,324,855</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">19,896,415</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">10,428,440</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gross loss</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,337,517</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,806,884</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,530,633</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development expenses</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,185,158</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,387,621</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,797,537</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Plasma center operating expenses</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,378,546</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,248,599</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">129,947</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Amortization of intangibles</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,676</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">422,469</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(64,793</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Selling, general and administrative expenses</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">16,634,714</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">11,681,517</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">4,953,197</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Loss from operations</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(33,893,611</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(24,547,090</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,346,521</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest expense</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,784,397</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,613,085</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,171,312</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Loss on extinguishment of debt</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,962,495</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,962,495</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gain on transfer of plasma center assets</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,527,421</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,527,421</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Interest and other income, net</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">254,687</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">315,422</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(60,735</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">(39,423,321</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">(26,279,827</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">(13,143,494</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Revenues</em></strong>&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We recorded total revenues of approximately $18.0 million during the six months ended June 30, 2020, as compared to $10.1 million during the six months ended June 30, 2019, an increase of $7.9 million, or 78%. The increase is mainly due to increased sales of our immunoglobulin products generated by our Boca Facility manufacturing operations in 2020 totaling $8.9 million, partially offset by a $1.0 million decrease in plasma revenues generated by our plasma collection facility. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Cost of Product Revenue</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Cost of product revenue was $30.3 million for the six months ended June 30, 2020, as compared to $19.9 million for the six months ended June 30, 2019. This increase reflects $6.6 million in production costs incurred for the manufacture of BIVIGAM conformance lots at an increased plasma pool production scale in connection with our planned capacity expansion and other production initiatives and investments at the Boca Facility. Cost of product revenue for the first six months of 2020 also reflects increases in cost of product revenue of approximately $8.1 million related to the increase in revenues, partially offset by a $4.7 million reduction in unabsorbed manufacturing expenses resulting from increased production throughput at the Boca Facility. </p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Research and Development Expenses</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">R&amp;D expenses totaled $3.2 million for the six months ended June 30, 2020, as compared to $1.4 million for the six months ended June 30, 2019. The increase is primarily due to $0.8 million in costs incurred during 2020 for the testing and development of a new filling line at one of our third party fill/finishers for a process that has not been approved by the FDA, $0.4 million of costs incurred during 2020 for a study we commenced to potentially extend ASCENIV&#8217;s approved and labeled expiration dating, and to increased expenses for clinical studies related to post-marketing commitments for BIVIGAM, an obligation we assumed in the Biotest Transaction.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Plasma Center Operating Expenses</em></strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Plasma center operating expenses were $1.4 million for the six months ended June 30, 2020, as compared to $1.2 million for the six months ended June 30, 2019. The increase in plasma center operating expenses is mainly attributable to increased staffing and travel expenses related to our plasma center expansion activities as well as increases in donor fees, largely offset by increased donor collections and the related absorption at our FDA-approved plasma collection facility.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Amortization of Intangibles</em></strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Amortization expense for our intangible assets was $0.4 million for the six months ended June 30, 2020 and 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Selling, General and Administrative Expenses</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">SG&amp;A expenses were $16.6 million for the six months ended June 30, 2020, an increase of $5.0 million from the six months ended June 30, 2019. The increase was mainly due to higher employee compensation expenses of $2.7 million related to staffing increases in support of our commercialization efforts for BIVIGAM and ASCENIV, increased insurance expense of $0.9 million, marketing consulting fees incurred in connection with our ASCENIV commercialization efforts of $0.6 million and a $0.4 million increase professional services expense associated with the enhancements to our information technology infrastructure. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Loss from Operations</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Our operating loss was $33.9 million for the first six months of 2020, as compared to $24.5 million for the first six months of 2019. The $9.3 million increase in operating loss was mainly due to the increases in cost of product revenue, SG&amp;A and R&amp;D expenses, partially offset by the increase in revenues.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Interest Expense</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Interest expense was $5.8 million for the six months ended June 30, 2020, as compared to $3.6 million for the six months ended June 30, 2019. The increase is mainly due to higher average debt balances in 2020 as compared to 2019 resulting from additional loan proceeds we received from our senior lender in March of 2020 and May of 2019, when we drew down $12.5 million and $27.5 million, respectively, from our senior credit facility. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Non-recurring Items in the Six Months Ended June 30, 2019</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">In connection with the refinancing of our senior credit facility in February of 2019, we incurred a loss on the extinguishment debt of approximately $10.0 million for the retirement of our previously existing credit facility, consisting of a $6.5 million prepayment penalty, and the write-off of $3.5 million of unamortized debt discount related to the previous credit facility. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">In connection with the purchase of the Boca Facility and related assets, we agreed to transfer our Marietta, GA and Norcross, GA plasma collection centers to BPC effective January 1, 2019. We had estimated the combined fair value of the two facilities to be $12.6 million, and we recorded a liability in our financial statements for this amount as of the date of the Biotest Transaction. On January 1, 2019, the two plasma collection facilities were transferred to BPC and we recorded a gain on this transfer in the amount of $11.5 million, which reflects the derecognition of the obligation to transfer ownership of the two facilities net of the carrying value of the assets associated with these facilities, primarily property and equipment and inventory, in the amount of $1.1 million. </p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Net Loss</em></strong><strong><em>&#160;</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Our net loss was $39.4 million for the six months ended June 30, 2020, as compared to $26.3 million for the six months ended June 30, 2019.The increase in net loss of $13.1 million was primarily due to the increase in operating loss for the period of $9.3 million and to $2.2 million of higher interest expense. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline">LIQUIDITY AND CAPITAL RESOURCES</span></strong></p><p style="MARGIN: 0px; text-align:center;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">As of June 30, 2020, we had working capital of $130.1 million, including cash and cash equivalents of $75.8 million, and stockholders&#8217; equity of $76.9 million, as compared to working capital of $71.8 million, including cash and cash equivalents of $26.8 million, and stockholders&#8217; equity of $26.2 million as of December 31, 2019. We have incurred an accumulated deficit of $304.1 million since inception, had negative cash flows of $45.9 million and $32.9 million for the six months ended June 30, 2020 and 2019, respectively, and had negative cash flows from operations of $76.2 million and $62.7 million for the years ended December 31, 2019 and 2018, respectively. We have funded our operations over the past few years primarily from the sale of our equity and debt securities. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">We expect to continue to spend substantial amounts on procurement of raw material plasma and other raw materials necessary to scale up our manufacturing operations, commercial product launches, capacity expansion at the Boca Facility, building additional plasma collection facilities, product development, quality assurance, regulatory affairs and conducting clinical trials for our product candidates and purchasing clinical trial materials, some of which may be required by the FDA. In addition, our end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months, requiring substantial investments in raw material plasma and other manufacturing materials. We expect that we will not be able to generate a sufficient amount of product revenue to achieve profitability before 2021 and, as a result, we expect that we will need to finance our operations through additional equity or debt financings or corporate collaboration and licensing arrangements. Based upon our current projected revenue and expenditures, including capital expenditures and continued implementation of our commercialization and expansion activities, we currently believe that our cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund our operations, as currently conducted, into the second quarter of 2021. In order to have sufficient cash to fund our operations thereafter, we anticipate raising additional capital before the end of the second quarter of 2021. These estimates and timeframe may change based upon several factors, including the success of our commercial manufacturing ramp-up activities, the acceptability and reimbursement of BIVIGAM and ASCENIV by physicians, patients or payers, and the various financing options that may be available to us. We currently have no firm commitments for additional financing, and there can be no assurances that we will be able to secure additional financing on terms that are acceptable to us, or at all. Furthermore, if our assumptions underlying our estimated expenses and revenues are incorrect, we may have to raise additional capital sooner than currently anticipated.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Our long-term liquidity depends upon our ability to raise additional capital, fund capacity expansion and commercial programs and generate sufficient revenues from our products, several of which have only recently achieved commercial status, cover our operating expenses and meet our obligations on a timely basis. The COVID-19 pandemic has negatively affected the global economy and created significant volatility and disruption to the financial markets. Failure to secure any necessary financing in a timely manner and on commercially reasonable terms could have a material adverse effect on our business plan and financial performance and we could be forced to delay or discontinue our capacity expansion, commercialization, product development or clinical trial activities, delay or discontinue the approval efforts for any of our product candidates, or potentially cease operations. In addition, we could also be forced to reduce or forgo sales and marketing efforts and forgo attractive business opportunities. Due to numerous risks and uncertainties associated with the COVID-19 pandemic, FDA reviews and approvals related to our products, patient/payer acceptance of our products, ongoing compliance and maintenance requirements and capacity expansion efforts at the Boca Facility, we are unable to estimate with certainty the amounts of increased capital outlays and operating expenditures required to fund our commercialization and other development activities. Our current estimates may be subject to change as circumstances regarding our business requirements evolve and are also subject to the effect of potential new government orders, policies and procedures that we must comply with which are outside of our control. As such, these factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. </p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">We may decide to raise capital through public or private equity offerings or debt financings, or obtain a bank credit facility or enter into corporate collaboration and licensing arrangements. The sale of additional equity or debt securities, if convertible, could result in dilution to our stockholders and, in such event, the market value of our common stock may decline. The incurrence of additional indebtedness would result in increased fixed obligations and could also result in covenants that would restrict our operations or other financing alternatives. In addition, we are exploring additional contract manufacturing arrangements and other business development opportunities, which may provide additional liquidity to us.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On March 20, 2020, we drew down the third and final tranche of our existing Credit Agreement and Guaranty, dated February 11, 2019, as amended (the &#8220;Perceptive Credit Agreement&#8221;), with Perceptive Credit Holdings II, LP (&#8220;Perceptive&#8221;) and we received proceeds of $12.5 million which are being used for general corporate purposes. Borrowings under the Perceptive Credit Agreement bear interest at a rate per annum equal to the sum of 7.5% (the &#8220;Applicable Margin&#8221;) plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the Applicable Margin shall automatically increase by an additional 400 basis points. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We currently have an outstanding principal balance of $85.0 million under our Credit Agreement with Perceptive, all of which matures on March 1, 2022.We are required to pay interest to Perceptive in the approximate amount of $0.8 million per month. All of our obligations under the Perceptive Credit Agreement are secured by a first-priority lien and security interest in substantially all of our tangible and intangible assets, including intellectual property and all of the equity interests in our subsidiaries. The Perceptive Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The negative covenants restrict or limit our ability to, among other things and subject to certain exceptions contained in the Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to our business activities; make certain Investments or Restricted Payments (each as defined in the Perceptive Credit Agreement); change our fiscal year; pay dividends; repay certain other indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting our ability to make loan repayments under the Perceptive Credit Agreement. In addition, we must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ending June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $7.0 million for the fiscal quarter ending June 30, 2019 to $55.0 million for the fiscal quarter ending December 31, 2021. At June 30, 2020, we were in compliance with all of the covenants under the Perceptive Credit Facility.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In February 2020, we completed an underwritten public offering of 27,025,000 shares of our common stock and received net proceeds, after underwriting discounts and other expenses associated with the offering, of approximately $88.7 million. The proceeds from this offering are expected to be used (i) for the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV; (ii) to support the ongoing commercial sales of BIVIGAM and ASCENIV; (iii) to expand the manufacturing capacity of our Boca Facility and enhance our supply chain capabilities; (iv) to expand our plasma collection facility network; (v) for research and development and business development opportunities; and (vi) for general corporate purposes and other capital expenditures.</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We also have $15.0 million in principal amount of indebtedness outstanding under an unsecured subordinated note payable to Biotest, which note bears interest at a rate of 6.0% per annum and matures on June 6, 2022. We are obligated to make semi-annual interest payments to Biotest of approximately $0.5 million, with all principal and unpaid interest due at maturity.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><strong>Cash Flows</strong></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 60px; text-align:left;">The following table sets forth a summary of our cash flows for the periods indicated: </p><p style="MARGIN: 0px; TEXT-INDENT: 60px; text-align:left;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><strong>Six Months Ended </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><strong>June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net cash used in operating activities</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(45,931,435</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(32,911,136</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net cash used in investing activities</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,241,284</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(245,675</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net cash provided by financing activities</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">101,201,706</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">80,017,868</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net change in cash and cash equivalents</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,028,987</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">46,861,057</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cash and cash equivalents, including restricted cash - beginning of period </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,752,135</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">26,754,852</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cash and cash equivalents - end of period </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">75,781,122</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">73,615,909</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; TEXT-INDENT: 60px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Net Cash Used in Operating Activities</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Cash used in operations for the six months ended June 30, 2020 was $45.9 million, an increase of $13.0 million from the same period of a year ago, mainly due to the increase in net loss. The following table illustrates the primary components of our cash flows from operations:</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="margin:0px"><strong>Six Months Ended</strong></p></td><td style="white-space: nowrap;"><strong>&#160; </strong></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;"><p style="margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: black 1px solid;" colspan="6"><p style="MARGIN: 0px; text-align:center;">&#160;<strong>June 30, </strong></p></td><td style="PADDING-BOTTOM: 1px;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(39,423,321</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(26,279,827</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-cash expenses, gains and losses</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,873,479</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,688,347</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Changes in accounts receivable</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,044,246</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,694,222</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Changes in inventories</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,936,614</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,175,148</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Changes in prepaid expenses and other current assets</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,159,834</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">163,747</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Changes in accounts payable and accrued expenses </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,865,637</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">358,164</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(375,262</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">27,803</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cash used in operations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">(45,931,435</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">(32,911,136</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Net Cash Used in Investing Activities</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Net cash used in investing activities for the six months ended June 30, 2020 and 2019 was $6.2 million and $0.2 million, respectively, primarily consisting of capital expenditures at the Boca Facility, including the purchase and installation of our new filling and packaging machine, and, in the six months ended June 30, 2020, capital expenditures related to the build-out of our new plasma collection facility. Although we have no specific material commitments for capital expenditures as of June 30, 2020, we expect our total capital expenditures will be between $7.0 million and $12.0 million for the remainder of fiscal 2020.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><em>Net Cash Provided by Financing Activities</em></strong></p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Cash provided by financing activities for the six months ended June 30, 2020 was $101.2 million, which is comprised of the net proceeds received from our February 2020 equity offering in the amount of $88.7 million and the $12.5 million of loan proceeds received from the final tranche that was available under our senior credit facility. Net cash provided by financing activities for the six months ended June 30, 2019 of $80.0 million reflects $4.2 million related to the refinancing of the Marathon Credit Facility with our current senior credit facility provided by the Perceptive Credit Agreement in February of 2019, the drawdown of $27.5 million under this facility in May of 2019 and the $48.4 million of net proceeds from our May 2019 public offering of our common stock. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong>Effect of Inflation</strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Inflation or changing prices did not have a significant impact on our net sales, revenues or net loss for the six months ended June 30, 2020 or in 2019 or 2018.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:left;"><strong>Off-Balance Sheet Arrangements&#160;</strong>&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">None. </p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i3">Item 3.<span style="mso-tab-count:1"> Quantitative and Qualitative Disclosures About Market Risk.</span></span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Not applicable.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i4">Item 4.<span style="mso-tab-count:1"> Controls and Procedures.</span></span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><strong>Evaluation of Disclosure Controls and Procedures</strong></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We designed our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;), to provide reasonable assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s (the &#8220;SEC&#8221;) rules and forms, and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Under the supervision of and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures as of June 30, 2020. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures as of June 30, 2020 were functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding disclosures.</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">A control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. We do not expect that our disclosure controls and procedures or our internal control over financial reporting are able to prevent with certainty all errors and all fraud.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><strong>Changes in Internal Control Over Financial Reporting</strong></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong><span class="atag" id="p2">PART II </span></strong></p><p style="MARGIN: 0px; text-align:center;"><strong>OTHER INFORMATION</strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><span class="atag" id="p21"><strong>Item 1.<span style="mso-tab-count:1"> Legal Proceedings.</span></strong> </span></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We may become subject to certain legal proceedings and claims arising in connection with the normal course of our business. In the opinion of management, there are currently no material pending legal proceedings that would have a material adverse effect on our consolidated financial position, results of operations or cash flows.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><span class="atag" id="p21a">Item 1A. Risk Factors</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em>Described below are various significant risks and uncertainties that may affect our business. These risks and uncertainties are not the only ones we face. Other significant risks and uncertainties may arise in the future, which we cannot foresee at this time. Also, the risks that we now foresee might affect us to a greater or different degree than expected. Certain risks and uncertainties, including ones that we currently deem immaterial or that are similar to those faced by other companies in our industry or business in general, may also affect our business. If any of the risks described below actually occur, our business, financial condition or results of operations could be materially and adversely affected. </em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong>Risks Relating to our Business</strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>To date, we have generated limited product revenues, have a history of losses and will need to raise additional capital to operate our business, which may not be available on favorable terms, if at all.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Prior to the second half of 2019, we generated a substantial portion of our revenues from the sale of plasma by our plasma collections facilities. Following completion of the Biotest Transaction, we began generating revenues from the sale of our plasma-derived immune globulins which include: Nabi-HB, BIVIGAM, ASCENIV, intermediate fractions and the contract manufacturing of plasma-derived products for a third-party. On May 9, 2019 we received approval from the FDA for BIVIGAM, and the commercial re-launch of this product commenced in August 2019. On April 1, 2019, the FDA approved ASCENIV, formerly referred to as RI-002, and the first commercial sales of this product took place in October 2019. In October 2019, we generated initial sales of our plasma-derived intermediate fractions.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our long-term liquidity depends upon our ability to grow our commercial programs, expand our commercial operations at the Boca Facility, improve our supply-chain capabilities, improve production yields, provide more control and visibility for timing of commercial product releases, raise additional capital, fund and successfully implement our research and development and commercial programs, establish and build out a commercial sales force, medical affairs organization and commercial infrastructure and meet our ongoing obligations. In addition, our end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months, requiring substantial investments in raw material plasma and other manufacturing materials.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable, will be sufficient to fund our operations into the second quarter of 2021. This time frame may change based upon how quickly we are able to execute on our commercialization efforts and operational initiatives. However, if the assumptions underlying our estimated revenues and expenses prove to be incorrect, we may have to raise additional capital sooner than we currently expect. We anticipate that we will not be able to generate a sufficient amount of product revenue to achieve profitability before 2021 and, as a result, we anticipate that we will need to finance our operations through additional equity or debt financings or corporate collaboration and licensing arrangements. If we are unable to raise additional capital as needed, we will have to delay, curtail or eliminate our commercialization efforts as well as product development activities. Even if we are able to raise additional capital, such financings may only be available on unattractive terms, resulting in significant dilution of stockholders&#8217; interests and, in such event, the value and potential future market price of our common stock may decline. In addition, if we raise additional funds through license arrangements or through the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or assets or grant licenses on terms that are not favorable to us.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We are currently not profitable and may never become profitable.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We have a history of losses and expect to incur substantial losses and negative operating cash flow into fiscal 2021, and we may never achieve or maintain profitability. For the six months ended June 30, 2020 and 2019, we incurred net losses of $39.4 million and $26.3 million, respectively. For the years ended December 31, 2019 and 2018, we incurred net losses of $48.3 million and $65.7 million, respectively.From our inception in 2004 through June 30, 2020, we have incurred an accumulated deficit of $304.1 million. We expect that we will not be able to generate a sufficient amount of product revenue to achieve profitability before 2021 and, as a result, we expect that we will need to finance our operations through additional equity or debt financings or corporate collaboration and licensing agreements.We also expect to continue to incur significant operating and capital expenditures and anticipate that our operating expenses will increase substantially in the foreseeable future as we:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">expand commercialization and marketing efforts;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">implement additional internal systems, controls and infrastructure;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">hire additional personnel;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">expand and build out our plasma center network; and</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">expand production capacity at the Boca Facility.</td></tr></tbody></table><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As a result, we will need to generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability in the future. These factors raise substantial doubt about our ability to continue as a going concern. Our failure to achieve or maintain profitability could negatively impact the value of our securities.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>The COVID-19 pandemic and efforts to reduce its spread has significantly affected worldwide economic conditions, and could have a material adverse impact on our business, liquidity, financial condition and results of operations</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">The COVID-19 pandemic has the potential to adversely impact several aspects of our commercial and manufacturing operations, including but not limited to potential disruptions to our supply-chain operations, including procurement of raw materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale.Such testing has historically been performed by contract laboratories outside the United States. While we do not believe that the COVID-19 pandemic has significantly affected operations and immunoglobulin production at our Boca Facility at this time, we may experience adverse effects in the future, particularly in light of the recent increase in COVID-19 cases in the State of Florida. For example, our employees becoming ill, the imposition of additional mandatory remote working environments and federal, state and local responses to the COVID-19 virus could materially affect the efficiency and pace of our operations and manufacturing at our Boca Facility. In addition, travel and other restrictions that have been implemented in the United States could impact our commercial efforts with respect to any of our products, including BIVIGAM and ASCENIV, as trade shows, industry and medical conferences and other events we had been planning to utilize and exhibit and attend with our staff to increase awareness of our products by physicians and payers are subject to limitations, rescheduling or outright cancellation in response to the pandemic. Also, due to previous state and local &#8220;shelter-in-place&#8221; orders, we experienced lower than normal donor collections at our FDA approved plasma collection center during the three months ended June 30, 2020. We were also subject to delays in shipments of source plasma from our contracted third-party suppliers, as well as delays in deliveries or price increases for personal protective equipment, reagents and other non-plasma raw materials and supplies used in the manufacture of our products.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">37</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, operations, or financial condition, or on healthcare systems or the global economy as a whole. Although the COVID-19 pandemic has not adversely affected our capital and financial resources to date, the pandemic&#8217;s effects could have a material impact on our ability to access the capital markets as needed and on our operations and business, including those of the third parties on which we rely. Because we are unable to determine the ultimate severity or duration of the pandemic or its effects on, among other things, the global, national or local economies, the capital and credit markets, our workforce, our customers or our suppliers, at this time we are unable to predict whether COVID-19 will have a material adverse impact on our business, financial condition, liquidity and results of operations.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We contract with third parties for the filling, packaging, testing and labeling of the drug substance we manufacture. This reliance on third parties carries the risk that the services upon which we rely may not be performed in a timely manner or according to our specifications, which could delay the availability of our finished drug product and could adversely affect our commercialization efforts and our revenues.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><span style="mso-tab-count:1">Third-party fill/finish providers may not perform as agreed or in accordance with FDA requirements. Any significant problem that our fill/finish providers experience could delay or interrupt our supply of finished drug product until the service provider cures the problem or until we locate, negotiate for, validate and receive FDA approval for an alternative provider (when necessary), if one is available. Failure to obtain the needed fill/finish services could have a material and adverse effect on our business, financial condition, results from operations and prospects.</span></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Although in the future we plan to build our own fill/finish suite within the Boca Facility, we also intend to continue to utilize third parties to supplement our fill/finish process for final drug substance and we may, in any event, never be successful in developing our own fill/finish suite. Our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">we may be unable to identify contract fill/finishers on acceptable terms or at all because the number of potential service providers is limited and the FDA must inspect and qualify any contract manufacturers for current cGMP compliance as part of our marketing application;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">a new fill/finisher would have to be educated in, or develop substantially equivalent processes for, the production of our products and product candidates;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">the COVID-19 pandemic could adversely affect our contracted fill/finishers&#8217; operations, supply chain or workforce;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">our contracted fill/finishers&#8217; resources and level of expertise with plasma-derived biologics may be limited, and therefore they may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to deliver our finished drug product;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">our third-party fill/finishers might be unable to timely provide finished drug product in sufficient quantity to meet our commercial needs;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">contract manufacturers may not be able to execute our inspection procedures and required tests appropriately;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">contract manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations, and we do not have control over third-party providers&#8217; compliance with these regulations;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">our third-party fill-finishers could breach or terminate their agreements with us; and</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">our contract fill/finishers may have unacceptable or inconsistent drug product quality success rates and yields, and we have no direct control over our contract fill/finishers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel.</td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;">Each of these risks could delay or prevent the completion of our finished drug product and the release of finished drug product by the FDA, which could result in higher costs or adversely impact the commercialization of our products. In addition, our contract fill/finishers and our other third-party vendors may source their materials and supplies globally, and are therefore subject to supply disruptions in the event of fire, weather related events such as hurricanes, wind and rain, other acts of God or force majeure events or global health occurrences and emergencies, including the COVID-19 pandemic. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">38</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business could fail to grow at similar rates, if at all.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate, including as a result of changing circumstances during the ongoing COVID-19 pandemic. In particular, the size and growth of the overall U.S. IVIG and source plasma markets are subject to significant variables that can be difficult to measure, estimate or quantify. Our business depends on, among other things, successful commercialization of our existing products, market acceptance of such products and ensuring that our products are safe and effective. Further, there can be no assurance that we will be able to generate the revenue that we believe our products and plasma facilities are capable of generating. As a result, we may not be able to accurately forecast or predict revenue. For these reasons, the estimates and forecasts in our filings relating to revenue generation and growth may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and forecasted growth, our business could fail to grow at similar rates, if at all.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Our facilities are subject to periodic inspections by the FDA, which, depending on the outcome of such inspection, could result in certain FDA actions, including the issuance of observations, notices, citations or warning letters.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><span style="mso-tab-count:1">The FDA is authorized to perform inspections of our facilities, including the Boca Facility</span>. At the end of such an inspection, the FDA could issue a Form 483 Notice of Inspectional Observations, which could cause us to modify certain activities identified during the inspection. Following such inspections, the FDA may issue an untitled letter as an initial correspondence that cites violations that do not meet the threshold of regulatory significance of a warning letter. FDA guidelines also provide for the issuance of warning letters for violations of &#8220;regulatory significance&#8221; for which the failure to adequately and promptly achieve correction may be expected to result in an enforcement action. FDA also may issue warning letters and untitled letters in connection with events or circumstances unrelated to an FDA inspection.</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><span style="mso-tab-count:1">Following the completion of the Biotest Transaction, we gained control over the regulatory, quality, general operations and drug substance manufacturing process at the Boca Facility, which was the subject of an outstanding FDA warning letter issued when the Boca Facility was operated by BPC. To address the outstanding warning letter, we worked with a leading consulting firm with extensive experience in remediating compliance and inspection issues related to quality management systems that managed a robust team of subject matter experts in plasma-derived products and biologic drugs to assist us in addressing all identified CMC and cGMP issues and deficiencies. </span></p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><span style="mso-tab-count:1">We may not be able to timely resolve concerns raised by the FDA as a result of an inspection or without expending significant resources. We are unable to control the timing of FDA inspections, responses, meeting requests, teleconference requests, requests for clarifications and similar regulatory communications, as well as whether or not the FDA will change its requirements, guidance or expectations. If the FDA determines that we have not remediated the issues identified in a warning letter or any other inspection issues and deficiencies, any failure of ours to address or provide requested documentation of corrections for these issues could disrupt our business operations and the timing of our commercialization efforts and could have a material adverse effect on our financial condition and operating results.</span></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Business interruptions could adversely affect our business</em></strong><strong>.</strong> </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our operations, including our headquarters located in Ramsey, NJ, the Boca Facility and our plasma collection facilities, are vulnerable to interruption by fire, weather related events such as hurricanes, wind and rain, other acts of God or force majeure events, electric power loss, telecommunications failure, equipment failure and breakdown, human error, employee issues, global health occurrences, such as COVID-19, and emergencies, product liability claims and events beyond our control. While we maintain several insurance policies with reputable carriers that provide partial coverage for a variety of these risks, including replacing or rebuilding a part of our facilities, these policies are subject to the insurance carriers&#8217; final determination of compensation to us and we may not have adequate coverage if we need to rebuild or replace our inventory, infrastructure, business income or our entire facility. In addition, our disaster recovery plans for our facilities may not be adequate and we do not have an alternative manufacturing facility or contractual arrangements with other manufacturers in the event of a casualty to or destruction of any of our facilities. If we are required to rebuild or relocate any of our facilities, a substantial investment in improvements and equipment would be necessary. We carry only a limited amount of business interruption insurance, which may not sufficiently compensate us for losses that may occur. As a result, any significant business interruption could adversely affect our business and results of operations. </p><p style="MARGIN: 0px; text-align:left;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">39</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>If we are unsuccessful in obtaining regulatory approval for any of our product candidates or if any of our product candidates do not provide positive results, we may be required to delay or abandon development of such product, which would have a material adverse impact on our business.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Product candidates require extensive clinical data analysis and regulatory review and may require additional testing. Clinical trials and data analysis can be very expensive, time-consuming and difficult to design and implement. The conduct of preclinical studies and clinical trials is subject to numerous risks and results of the studies and trials are highly uncertain.<strong><em> </em></strong>Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. Furthermore, delays or setbacks can occur at any stage of the process, and we could encounter problems that cause us to abandon our product development programs and related INDs or biologics license applications, or to repeat clinical trials. <span style="mso-bidi-font-style:italic;mso-bidi-font-weight:bold">The evolving COVID-19 pandemic may directly or indirectly affect the pace of enrollment in clinical trials as patients may be restricted in traveling to and accessing healthcare facilities and physicians&#8217; offices. Additionally, such healthcare facilities and offices have their limited resources directed towards treating patients with COVID-19 symptoms. The commencement and completion of clinical trials for any current or future development product candidate may be delayed by several factors, including:</span></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;">&#8226; </td><td style="vertical-align:top;">unforeseen safety issues; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;">&#8226; </td><td style="vertical-align:top;">determination of dosing issues; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;">&#8226; </td><td style="vertical-align:top;">lack of effectiveness during clinical trials; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;">&#8226; </td><td style="vertical-align:top;">slower than expected rates of patient recruitment; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;">&#8226; </td><td style="vertical-align:top;">inability to monitor patients adequately during or after treatment </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;">&#8226; </td><td style="vertical-align:top;">inability or unwillingness of medical investigators to follow our clinical protocols; and </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;">&#8226; </td><td style="vertical-align:top;">temporary suspension resulting from the COVID-19 pandemic. </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We cannot be certain as to what type and how many clinical trials the FDA, or equivalent foreign regulatory agencies, will require us to conduct before we may successfully gain approval to market any of our product candidates that still require FDA approval. Prior to approving a new drug or biologic, the FDA generally requires that the effectiveness of the product candidate (which is not typically fully investigated until Phase 3) be demonstrated in two adequate and well-controlled clinical trials. However, if the FDA or an equivalent foreign regulatory authority determines that our Phase 3 clinical trial results do not demonstrate a statistically significant, clinically meaningful benefit with an acceptable safety profile, or if a relevant regulator requires us to conduct additional Phase 3 clinical trials in order to gain approval, we will incur significant additional development costs and commercialization of these products would be prevented or delayed and our business would be adversely affected.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In addition, the FDA or an independent institutional review board may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if the FDA finds deficiencies in our IND submissions or the conduct of these trials. Therefore, we cannot provide any assurance or predict with certainty the schedule for future clinical trials. In the event we do not ultimately receive regulatory approval for our product candidates, we may be required to terminate development of such product candidates. If we fail to obtain regulatory approval to market and sell our product candidates, or if approval is delayed, we will be unable to generate revenue from the sale of these products, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will increase. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">40</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>If the results of our clinical trials do not support our product candidate claims, completing the development of such product candidate may be significantly delayed or we may be forced to abandon development of such product candidate altogether.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We cannot be certain that the clinical trial results of our product candidates will support our product candidates&#8217; claims. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. The clinical trial process may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. This failure would cause us to abandon a product candidate and may delay development of other product candidates. Any delay in, or termination of, our clinical trials will delay our ability to commercialize our product candidates and generate product revenues. In addition, our clinical trials involve a relatively small patient population. Because of the small sample size, the results of these clinical trials may not be indicative of future results. In addition, certain portions of our clinical trials and product testing for our product candidates may be performed outside of the U.S., and therefore, may not be performed in accordance with standards normally required by the FDA and other regulatory agencies.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>If we do not obtain and maintain the necessary U.S. or international regulatory approvals to commercialize a product candidate, we will not be able to sell that product candidate, which would make it difficult for us to recover the costs of researching and developing such product candidate.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">If we are not be able to generate revenue from our products and product candidates, our sources of revenue may continue to be from a product mix consisting only of plasma collection and sales revenues, revenues generated from sales of our FDA-approved commercial products, revenues generated from ongoing contract manufacturing for third parties and revenues generated from the sales of manufacturing intermediates. We cannot assure you that we will receive the approvals necessary to commercialize any product candidate we may acquire or develop in the future. In order to obtain FDA approval of any product candidate requiring FDA approval, our clinical development must demonstrate that the product candidate is safe for humans and effective for its intended use, and we must successfully complete an FDA BLA review. Obtaining FDA approval of a product candidate generally requires significant research and testing, referred to as preclinical studies, as well as human tests, referred to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the type, complexity and novelty of the product candidate and requires substantial resources for research, development and testing. We cannot predict whether our research and clinical approaches will result in products that the FDA considers safe for humans and effective for indicated uses. The FDA has substantial discretion in the product approval process and may require us to conduct additional preclinical and clinical testing or to perform post-marketing studies, or may require additional CMC or other data and information, and the development and provision of this data and information may be time-consuming and expensive. There are numerous FDA personnel assigned to review different aspects of a BLA, and uncertainties can be presented by their ability to exercise judgment and discretion during the review process. The approval process may also be delayed by changes in government regulation, future legislation, diversion of resources for FDA review during the ongoing COVID-19 pandemic or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">delay commercialization of, and our ability to derive product revenues from, our product candidate;</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">impose costly procedures on us; and</td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">diminish any competitive advantages that we may otherwise enjoy.</td></tr></tbody></table><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Even if we comply with all FDA requests, the FDA may ultimately reject our product candidate&#8217;s BLA. In addition, the FDA could determine that we must test additional subjects and/or require that we conduct further studies with more subjects. We may never obtain regulatory approval for any future potential product candidate or label expansion activity. Failure to obtain FDA approval of any of our product candidates will severely undermine our business by leaving us without the ability to generate additional accretive revenues. There is no guarantee that we will ever be able to develop or acquire other product candidates. In foreign jurisdictions, we must receive approval from the appropriate regulatory authorities before we can commercialize any products or product candidates outside the U.S. Foreign regulatory approval processes generally include all of the risks and uncertainties associated with the FDA approval procedures described above. We cannot assure you that we will receive the approvals necessary to commercialize any product candidate for sale outside the U.S.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">41</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited, unless additional clinical trials are conducted successfully and the FDA approves a BLA or other required submission for review.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the Internet and off-label promotion. The FDA generally does not allow drugs to be promoted for &#8220;off-label&#8221; uses &#8212; that is, uses that are not described in the product&#8217;s labeling and that differ from those that were approved by the FDA. Generally, the FDA limits approved uses to those studied by a company in its clinical trials. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, we cannot be sure whether we will be able to obtain FDA approval for any desired future indications for ASCENIV.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">While physicians in the U.S. may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling, and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, our ability to promote our products is narrowly limited to those indications that are specifically approved by the FDA. &#8220;Off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the U.S. generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. If the FDA determines that our promotional activities fail to comply with the FDA&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines related to promotion and advertising may cause the FDA to issue warning letters or untitled letters, bring an enforcement action against us, suspend or withdraw an approved product from the market, require a recall or institute fines or civil fines, or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our reputation and our business.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>With the approval of ASCENIV, there can be no assurance that we will be successful in developing and expanding commercial operations or balancing our research and development activities with our commercialization activities.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Since receiving FDA approval for ASCENIV, we have been commercializing this product while also continuing our research and development activities. There can be no assurance that we will be able to successfully manage the balance of our research and development operations with our commercialization activities. Potential investors and stockholders should be aware of the problems, delays, expenses and difficulties frequently encountered by companies balancing development of product candidates, which can include problems such as unanticipated issues relating to clinical trials and receipt of approvals from the FDA and foreign regulatory bodies, with commercialization efforts, which can include problems related to managing manufacturing and supply, including supply chain constraints directly or indirectly caused by the ongoing COVID-19 pandemic and government responses thereto, reimbursement, marketing challenges, development of a comprehensive compliance program, and other related and additional costs. For example, the raw material plasma we collect and procure to manufacture ASCENIV using our patented proprietary microneutralization assay is comprised of plasma collected from donors which contains high titer antibodies to RSV. This high titer plasma which meets our internal specifications for the manufacture of ASCENIV that we are able to identify with our patented testing assay amounts to less than 10% of the total donor collection samples we test. Our product candidates will require significant additional research and clinical trials, and we will need to overcome significant regulatory burdens prior to commercialization in the U.S. and other countries. In addition, we may be required to spend significant funds on building out our commercial operations. There can be no assurance that after the expenditure of substantial funds and efforts, we will successfully develop and commercialize any of our product candidates, generate any significant revenues or ever achieve and maintain a substantial level of sales of our products.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">42</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We depend on third-party researchers, developers and vendors to develop, manufacture and test products and product candidates, and such parties are, to some extent, outside of our control.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We depend on independent investigators and collaborators, such as universities and medical institutions, contract laboratories, clinical research organizations, contract manufacturers, contract fill/finishers and consultants to conduct our preclinical, clinical trials, CMC testing and other activities under agreements with us. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs or the impact that the ongoing COVID-19 pandemic will have on such third parties. These investigators may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. If outside collaborators fail to devote sufficient time and resources to our product-development programs, or if their performance is substandard, the approval of our FDA application(s), if any, and our introduction of new products, if any, will be delayed. These collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators assist our competitors at our expense, our competitive position would be harmed. Additionally, any change in the regulatory compliance status of any of our vendors may impede our ability to receive approval for our product candidates.</p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or </em></strong><strong><em>increase our production capabilities through the addition of new equipment, including if we do not obtain the </em></strong><strong><em>requisite validation from the FDA.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We currently anticipate expanding the manufacturing capacity of our Boca Facility by approximately 50% or more. We also anticipate expanding our production capabilities through the addition of a fill-finish machine at our Boca Facility. Following the expansion of any of our manufacturing processes or the addition of new equipment, such as the fill-finish machine, we will need to validate the expanded facility and equipment and have it inspected by the FDA. Given the significant delays that may result during the validation process, including due to any diverted FDA attention during the COVID-19 pandemic, we may experience a significant supply shortage of our products or our production capabilities may be limited until completion of and validation of our facility expansion and new manufacturing equipment.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or withdrawal from the market and we could be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions, new FDA guidance, or other regulatory actions, such as withdrawal from the market. Such products, as well as the manufacturing processes, post-marketing studies and measures, labeling, advertising and promotional activities for such products, among other things, are subject to ongoing regulatory compliance requirements, and oversight, review, and inspection by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, adherence with labeling and promotional requirements and restrictions, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding safeguarding the drug supply chain as well as the distribution of samples to physicians and recordkeeping. For example, the FDA&#8217;s approval of our PAS to allow for the commercial relaunch of BIVIGAM requires us to conduct specified post-marketing studies related to our manufacturing controls and processes, and submit specified post-marketing reports to the FDA. If, during the post marketing period (after marketing approval) previously unknown adverse events or other potential concerns regarding our products or their manufacturing processes emerge, or we are observed in any way to fail to comply with the numerous regulatory requirements to which we are subject, those circumstances may yield various results, including:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">restrictions on such products or manufacturing processes; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">restrictions on the labeling or marketing of a product; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">restrictions on product distribution or use; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">43</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">requirements to conduct further post-marketing studies or clinical trials; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">warning letters or untitled letters; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">withdrawal of the products from the market; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">refusal to approve pending applications or supplements to approved applications that we submit; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">recall of products; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">restrictions on coverage by third-party payers; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">fines, restitution or disgorgement of profits or revenues; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">suspension or withdrawal of marketing approvals; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">refusal to permit the import or export of products; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">product seizure; or </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;">&#160; </td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">injunctions or the imposition of civil or criminal penalties. </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on our business, results of operations and financial condition.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">For the six months ended June 30, 2020, three customers represented an aggregate of 81% of our consolidated revenues, with BioCare, Biolife and Reliance representing approximately 47%, 20%, and 14%, respectively, of our consolidated revenues. For the year ended December 31, 2019, three customers represented an aggregate of 70% of our consolidated revenues, with BioCare, Biolife and Sanofi Pasteur S.A. (&#8220;Sanofi&#8221;) representing approximately 26%, 24%, and 20%, respectively, of our consolidated revenues.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of June 30, 2020, three customers represented a total of 76% of our consolidated accounts receivable, with BioCare, Reliance and Biolife representing approximately 55%, 11% and 10%, respectively, of our consolidated accounts receivable. At December 31, 2019, BioCare represented 77% of our consolidated accounts receivable and McKesson Corporation (&#8220;McKesson&#8221;) represented 13% of our consolidated accounts receivable. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The loss of any key customers or a material change in the revenue generated by any of these customers, with the exception of Sanofi, could have a material adverse effect on our business, results of operations and financial condition. The initial term of our Amended and Restated Plasma Supply Agreement with BPC, pursuant to which we supplied BPC with normal source plasma, expired by its terms on December 31, 2018 and was not renewed, and we fulfilled our commitment under our supply agreement with Sanofi during the year ended December 31, 2019. Moreover, we anticipate deriving increased revenue from BioCare over the next few years. Factors that could influence our relationships with our customers include, among other things:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">our ability to sell our products at competitive prices; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">our ability to maintain features and quality standards for our products sufficient to meet the expectations of our customers </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">our ability to produce and deliver a sufficient quantity of our products in a timely manner to meet our customers&#8217; requirements; and </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">the impact of the ongoing COVID-19 pandemic and government responses thereto on our customers and their businesses, operations and financial condition. </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">44</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;">Additionally, an adverse change in the financial condition of BioCare, Biolife, Reliance, McKesson, Cardinal Health or AmerisourceBergen could negatively affect revenue derived from such customer, which in turn could have a material adverse effect on our business and results of operations.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our success depends upon the quality of our products. Quality management plays an essential role in meeting customer requirements, preventing defects, improving our products and services and assuring the safety and efficacy of our products. Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in failure to obtain product approval, adverse inspection reports, warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses. An inability to address a quality or safety issue by us or by a third-party vendor in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully commercializing our current products and launching new products.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Even if the FDA approves a product made by us, physicians, payers and patients may not accept and use it. Acceptance and use of our products depends on a number of factors including:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">cost-effectiveness of our products relative to competing products; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">availability of reimbursement for our products from government or other healthcare payers; and </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">the effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any. </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;">The failure of our current or future products to find market acceptance would harm our business and could require us to seek additional financing or make such financing difficult to obtain on favorable terms, if at all.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other new products, product candidates and label expansion of existing products, and if our business development efforts are not successful, our ability to achieve profitability may be adversely impacted. </em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our current product development portfolio consists primarily of label expansion activities for Nabi-HB, BIVIGAM and ASCENIV. We have initiated small scale preclinical activities to potentially expand our current portfolio through new product development efforts or to in-license or acquire additional products and product candidates. If we are not successful in developing or acquiring additional products and product candidates, we will have to depend on our ability to raise capital for, and the successful commercialization of ASCENIV, as well as the revenue we may generate from the sale of Nabi-HB, BIVIGAM, contract manufacturing, and intermediates and plasma attributable to the operations of ADMA BioCenters, to support our operations.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">45</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Our ADMA BioCenters operations collect information from donors in the U.S. that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to meet their requirements.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Consumer privacy is highly protected by federal and state law.The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, impose, among other things, obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by covered entities and business associates. A &#8220;covered entity&#8221; is the primary type of HIPAA-regulated entity.Health plans/insurers, healthcare providers engaging in standard transactions (insurance/health plan claims and encounters, payment and remittance advice, claims status, eligibility, enrollment/disenrollment, referrals and authorizations, coordination of benefits and premium payments), and healthcare clearinghouses (switches that convert data between standard and non-standard data sets) are covered entities. A &#8220;business associate&#8221; provides services to covered entities (directly or as subcontractors to other business associates) involving arranging, creating, receiving, maintaining, or transmitting protected health information (&#8220;PHI&#8221;) on a covered entity&#8217;s behalf.In order to legally provide access to PHI to service providers, covered entities and business associates must enter into a &#8220;business associate agreement&#8221; (&#8220;BAA&#8221;) with the service provider PHI recipient. Among other things, HITECH made certain aspects of the HIPAA&#8217;s rules (notably the Security Rule) directly applicable to business associates &#8211; independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal court to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. The HHS Office of Civil Rights (&#8220;OCR&#8221;) has increased its focus on compliance and continues to train state attorneys general for enforcement purposes. OCR has recently increased both its efforts to audit HIPAA compliance and its level of enforcement, with one recent penalty exceeding $5.0 million. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">While we are not a covered entity or business associate subject to HIPAA, even when HIPAA does not apply, according to the U.S. Federal Trade Commission (the &#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule.In addition, states impose a variety of laws protecting consumer information, with certain sensitive information such as HIV/Sexually Transmitted Disease status subject to heightened standards.In addition, federal and state privacy, data security, and breach notification laws, rules and regulations, and other laws apply to the collection, use and security of personal information, including social security number, driver&#8217;s license numbers, government identifiers, credit card and financial account numbers.Some state privacy and security laws apply more broadly than HIPAA and associated regulations. For example, California recently enacted legislation &#8211; the California Consumer Privacy Act, or CCPA &#8211; which went into effect January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. It remains unclear what, if any, modifications will be made to this legislation or how it will be interpreted. We could be subject to enforcement action and litigation exposure if we fail to adhere to these data privacy and security laws.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We may neither be successful in integrating the Biotest Assets into our business nor realize the strategic and financial benefits currently anticipated from the Biotest Transaction.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On June 6, 2017, we completed Biotest Transaction, in which we acquired certain assets (the &#8220;Biotest Assets&#8221;) of the Therapy Business Unit (&#8220;BTBU&#8221;) of BPC, which included two FDA-licensed products, Nabi-HB and BIVIGAM, and the Boca Facility. The Biotest Transaction involves the integration of two businesses that previously have operated independently with principal offices in two distinct locations. We continue to expend significant management attention and resources to integrate the two companies following completion of the Biotest Transaction. The failure to integrate successfully and to manage successfully the challenges presented by the integration process may result in the combined company&#8217;s failure to achieve some or all of the anticipated benefits of the Biotest Transaction. There is also uncertainty as to whether the combined business will be able to operate at a profitable level in the future given the relatively small size of the Biotest Assets and the competitive environment in which we operate.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">46</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Potential difficulties that may be encountered in the integration process include, but are not limited to, the following:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">using our cash and other assets efficiently to develop the business on a post-Biotest Transaction basis; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">appropriately managing the liabilities of our Company on a post-Biotest Transaction basis; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">potential unknown or currently unquantifiable liabilities associated with the Biotest Transaction and the operations of our Company on a post-Biotest Transaction basis; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">potential unknown and unforeseen expenses, delays or regulatory conditions associated with the Biotest Transaction; and </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">performance shortfalls in one or both of the businesses as a result of the diversion of the applicable management&#8217;s attention caused by completing the Biotest Transaction and integrating the business. </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;">Delays in the integration process could adversely affect the combined company&#8217;s business, financial results, financial condition and stock price following the Biotest Transaction. Even if the combined company were able to integrate the business operations successfully, there can be no assurance that this integration will result in the realization of the full benefits of synergies, innovation and operational efficiencies that may be possible from this integration or that these benefits will be achieved within a reasonable period of time.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>The Biotest Transaction exposes us to liabilities, a release of claims and competition that could have a material adverse effect on our business, financial condition, results of operations and stock price.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As part of the consideration for the Biotest Transaction, we agreed to assume certain liabilities of BPC related to BTBU, which exposes us to liabilities that are not within our control and we cannot predict the extent to which these liabilities may arise in the future. Any liabilities that may arise could have a material adverse effect on our business, financial condition, results of operations and stock price. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Master Purchase and Sale Agreement, dated as of January 21, 2017 (the &#8220;Master Purchase Agreement&#8221;) contains indemnification undertakings by the parties thereto for certain losses, including, among other things, indemnification for any losses arising from breaches of its representations, warranties, covenants and agreements in the Master Purchase Agreement. In connection with the Share Transfer, Amendment and Release Agreement among us, BPC, Biotest AG, Biotest US Corporation and The Biotest Divestiture Trust (the &#8220;Biotest Trust&#8221;) (the &#8220;Biotest Transfer Agreement&#8221;), we granted a full release to Biotest from any and all past, present or future indemnification claims arising under or in connection with the Master Purchase Agreement. Significant indemnification claims by BPC or its affiliates or breaches by BPC or its affiliates of any indemnity obligations which would have been owed to us under the Master Purchase Agreement prior to the release granted in the Biotest Transfer Agreement could have a material adverse effect on our business, financial condition, results of operations and stock price.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As part of the consideration for the Biotest Transaction, the parties also agreed to a mutual release, pursuant to which the parties agreed not to bring any suit, action or claim for any breach or default under the existing manufacturing and supply agreement or master services agreement prior to the closing of the Biotest Transaction. This release remains effective from and after the closing of the Biotest Transaction. The inability to seek these remedies could have a material adverse effect on our business, financial condition, results of operations and stock price.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In addition, while the Master Purchase Agreement contains certain non-compete clauses, such clauses do not prohibit either the Biotest Guarantors (as defined therein) or their other affiliates from directly or indirectly (other than through BPC) competing with BTBU after the closing of the Biotest Transaction. Such competition could result in the loss of existing or new customers, price reductions, reduced operating margins and loss of market share, which could have a material adverse effect on our business, financial condition, results of operations and stock price.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">47</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>If our due diligence investigation for the Biotest Transaction was inadequate and/or the representations, warranties and indemnification given to us by BPC were inadequate, then it could result in a material adverse effect on our business.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Even though we believe that we conducted a reasonable and customary due diligence investigation of BTBU and we received market representations, warranties and indemnities from Biotest and BPC, we cannot be sure that our due diligence investigation uncovered all material or non-material issues that may be present. There also can be no assurances that we received access to or had the ability to diligence certain information, as well as appropriate representations and or warranties, that it would be possible to uncover all material issues through customary due diligence, or that issues outside of our control will not later arise or that all material issues which are or could have been discovered would otherwise be covered by the representations and warranties of Biotest and BPC and therefore indemnifiable. In connection with the Biotest Transfer Agreement, we granted a full release to Biotest from any and all past, present or future indemnification claims arising under or in connection with the Master Purchase Agreement. If we failed to identify any important issues, or if it were not possible to uncover all material issues, any such material issue could result in a material adverse effect on our business, financial condition, results of operations and stock price.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>The Perceptive Credit Facility is subject to acceleration in specified circumstances, which may result in Perceptive taking possession and disposing of any collateral.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On February 11, 2019 (the &#8220;Perceptive Closing Date&#8221;), we entered into the Perceptive Credit Agreement with Perceptive Credit Holdings II, LP, as the lender and administrative agent (&#8220;Perceptive&#8221;). The Perceptive Credit Agreement, as amended, provides for a senior secured term loan facility in a principal amount of up to $85.0 million (the &#8220;Perceptive Credit Facility&#8221;), comprised of (i) a term loan made on the Perceptive Closing Date in the principal amount of $45.0 million, as evidenced by our issuance of a promissory note in favor of Perceptive on the Perceptive Closing Date (the &#8220;Perceptive Tranche I Loan&#8221;), (ii) a term loan in the principal amount of $27.5 million evidenced by our of a promissory note in favor of Perceptive on May 3, 2019 (the &#8220;Perceptive Tranche II Loan&#8221;); and (iii) an additional commitment in the principal amount of up to $12.5 million (the &#8220;Perceptive Tranche III Loan,&#8221; and together with the Perceptive Tranche I Loan and the Perceptive Tranche II Loan, the &#8220;Perceptive Loans&#8221;) which we drew down on March 20, 2020. The Perceptive Loans each have a maturity date of March 1, 2022, subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default (as defined in the Perceptive Credit Agreement). The Perceptive Loans are secured by substantially all of our assets, including our intellectual property. Events of Default include, among others, non-payment of principal, interest, or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. In addition to an increase in the rate of interest on the Perceptive Loans of 4% per annum, the occurrence of an Event of Default could result in, among other things, the termination of commitments under the Perceptive Credit Facility, the declaration that all outstanding Loans are immediately due and payable in whole or in part, and Perceptive taking immediate possession of, and selling, any collateral securing the Perceptive Loans.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Developments by competitors may render our products or technologies obsolete or non-competitive.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our current products and any future product we may develop will have to compete with other marketed therapies. In addition, other companies may pursue the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from pharmaceutical and biotechnology companies in the U.S. and abroad. In addition, companies pursuing different but related fields represent substantial competition. Many of these organizations competing with us have substantially greater financial resources, larger research and development staffs and facilities, longer product development history in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do. These organizations also compete with us to attract qualified personnel and parties for acquisitions, joint ventures or other collaborations.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">48</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and business prospects may be materially damaged.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As we move forward in clinical development we are also uncovering novel aspects of our products and are drafting patents to cover our inventions. We rely on a combination of patent rights, trade secrets and nondisclosure and non-competition agreements to protect our proprietary intellectual property, and we will continue to do so. There can be no assurance that our patent, trade secret policies and practices or other agreements will adequately protect our intellectual property. Our issued patents may be challenged, found to be over-broad or otherwise invalidated in subsequent proceedings before courts or the U.S. Patent and Trademark Office. Even if enforceable, we cannot provide any assurances that they will provide significant protection from competition. The processes, systems, and/or security measures we use to preserve the integrity and confidentiality of our data and trade secrets may be breached, and we may not have adequate remedies as a result of any such breaches. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. There can be no assurance that the confidentiality, nondisclosure and non-competition agreements with employees, consultants and other parties with access to our proprietary information to protect our trade secrets, proprietary technology, processes and other proprietary rights, or any other security measures relating to such trade secrets, proprietary technology, processes and proprietary rights, will be adequate, will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We could lose market exclusivity of a product earlier than expected.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In the pharmaceutical and biotechnology industries, the majority of an innovative product&#8217;s commercial value is realized during its market exclusivity period. In the U.S. and in some other countries, when market exclusivity expires and generic versions are approved and marketed or when biosimilars are introduced (even if only for a competing product), there are usually very substantial and rapid declines in a product&#8217;s revenues.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Market exclusivity for our products is based upon patent rights and certain regulatory forms of exclusivity. The scope of our patent rights may vary from country to country and may also be dependent on the availability of meaningful legal remedies in a country. The failure to obtain patent and other intellectual property rights, or limitations on the use or loss of such rights, could be material to us. In some countries, basic patent protections for our products may not exist because certain countries did not historically offer the right to obtain specific types of patents and/or we (or our licensors) did not file in those markets. In addition, the patent environment can be unpredictable and the validity and enforceability of patents cannot be predicted with certainty. Absent relevant patent protection for a product, once the data exclusivity period expires, generic versions can be approved and marketed.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Patent rights covering our products may become subject to patent litigation. In some cases, manufacturers may seek regulatory approval by submitting their own clinical trial data to obtain marketing approval or choose to launch a generic product &#8220;at risk&#8221; before the expiration of our patent rights/or before the final resolution of related patent litigation. Enforcement of claims in patent litigation can be very costly, time-consuming and no assurance can be given that we will prevail. In addition, any such litigation may divert our management's attention from our core business and reduce the resources available for our clinical development, manufacturing and marketing activities, and consequently have a material and adverse effect on our business and prospects, regardless of the outcome.</p><p style="MARGIN: 0px; text-align:left;">There is no assurance that ASCENIV, or any other of our products for which we are issued a patent, will enjoy market exclusivity for the full time period of the respective patent. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">49</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Third parties could obtain patents that may require us to negotiate licenses to conduct our business, and there can be no assurance that the required licenses would be available on reasonable terms or at all.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We may not be able to operate our business without infringing third-party patents. Numerous U.S. and foreign patents and pending patent applications owned by third parties exist in fields that relate to the development and commercialization of IG. In addition, many companies have employed intellectual property litigation as a way to gain a competitive advantage. It is possible that infringement claims may occur as the number of products and competitors in our market increases. In addition, to the extent that we gain greater visibility and market exposure as a public company, we face a greater risk of being the subject of intellectual property infringement claims. We cannot be certain that the conduct of our business does not and will not infringe intellectual property or other proprietary rights of others in the U.S. and in foreign jurisdictions. If our products, methods, processes and other technologies are found to infringe third-party patent rights, we could be prohibited from manufacturing and commercializing the infringing technology, process or product unless we obtain a license under the applicable third-party patent and pay royalties or are able to design around such patent. We may be unable to obtain a license on terms acceptable to us, or at all, and we may not be able to redesign our products or processes to avoid infringement. Even if we are able to redesign our products or processes to avoid an infringement claim, our efforts to design around the patent could require significant time, effort and expense and ultimately may lead to an inferior or more costly product and/or process. Any claim of infringement by a third party, even those without merit, could cause us to incur substantial costs defending against the claim and could distract our management from our business. Furthermore, if any such claim is successful, a court could order us to pay substantial damages, including compensatory damages for any infringement, plus prejudgment interest and could, in certain circumstances, treble the compensatory damages and award attorney fees. These damages could be substantial and could harm our reputation, business, financial condition and operating results. A court also could enter orders that temporarily, preliminarily or permanently prohibit us, our licensees, if any, and our customers from making, using, selling, offering to sell or importing one or more of our products or practicing our proprietary technologies or processes, or could enter an order mandating that we undertake certain remedial activities. Any of these events could seriously harm our business, operating results and financial condition.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>If we are unable to successfully manage our growth, our business may be harmed.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our success will depend on the expansion of our commercial and manufacturing activities, supply of plasma and overall operations and the effective management of our growth, which will place a significant strain on our management and on our administrative, operational and financial resources. To manage this growth, we must expand our facilities, augment our operational, financial and management systems and hire and train additional qualified personnel. Our ability to accomplish each of these factors may be negatively impacted as a consequence of the COVID-19 pandemic. If we are unable to manage our growth effectively, our business could be harmed.</p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>The loss of one or more key members of our management team could adversely affect our business.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our performance is substantially dependent on the continued service and performance of our management team, who have extensive experience and specialized expertise in our business. In particular, the loss of Adam S. Grossman, our President and Chief Executive Officer, could adversely affect our business and operating results. We do not have &#8220;key person&#8221; life insurance policies for any members of our management team. We have employment agreements with each of our executive officers; however, the existence of an employment agreement does not guarantee retention of members of our management team and we may not be able to retain those individuals for the duration of or beyond the end of their respective terms. The loss of services of key personnel, or the inability to attract and retain additional qualified personnel, could result in delays in development or approval of our product candidates and diversion of management resources. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Cyberattacks and other security breaches could compromise our proprietary and confidential information, which could harm our business and reputation.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In the ordinary course of our business, we generate, collect and store proprietary information, including intellectual property and business information. The secure storage, maintenance, and transmission of and access to this information is important to our operations and reputation. Computer hackers may attempt to penetrate our computer systems and, if successful, misappropriate our proprietary and confidential information including e-mails and other electronic communications. Further, while many of our employees and certain suppliers with whom we do business operate in a remote working environment during the COVID-19 pandemic, the risk of cybersecurity attacks and data breaches, particularly through phishing attempts, may be increased as we and third-parties with whom we interact leverage our IT infrastructure in unanticipated ways during the ongoing COVID-19 pandemic. In addition, an employee, contractor, or other third party with whom we do business may attempt to obtain such information, and may purposefully or inadvertently cause a breach involving such information. While we have certain safeguards in place to reduce the risk of and detect cyberattacks, including a Company-wide cybersecurity policy, our information technology networks and infrastructure may be vulnerable to unpermitted access by hackers or other breaches, or employee error or malfeasance. Any such compromise of our data security and access to, or public disclosure or loss of, confidential business or proprietary information could disrupt our operations, damage our reputation, provide our competitors with valuable information and subject us to additional costs, which could adversely affect our business.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">50</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>If we are unable to hire and retain a substantial number of qualified personnel, our ability to sustain and grow our business may be harmed.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our success depends in part on our ability to attract, motivate, and retain a sufficient number of qualified employees across various areas of our operations, such as research and development, manufacturing operations, and sales, who understand and appreciate our strategy and culture and are able to contribute to our mission. We will need to hire additional qualified personnel with expertise in commercialization, sales, marketing, medical affairs, reimbursement, government regulation, formulation, quality control, manufacturing and finance and accounting. In particular, over the next 12-24 months, we expect to hire several new employees devoted to commercialization, sales, marketing, medical and scientific affairs, regulatory affairs, quality control, finance and general and operational management. Qualified individuals of the requisite caliber and number needed to fill these positions may be in short supply in some areas. We compete for qualified individuals with numerous biopharmaceutical companies, universities and other research institutions. Competition for such individuals is intense, and we cannot assure you that our search for such personnel will be successful, particularly if the COVID-19 pandemic causes significant changes in the competitive market for such personnel or travel restrictions related to COVID-19 prevent qualified personnel from applying for employment. If we are unable to hire and retain personnel capable of consistently performing at a high level, our business and operations could be materially adversely affected. Additionally, any material increases in existing employee turnover rates or increases in labor costs could have a material adverse effect on our business, financial condition or operating results.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We currently collect human blood plasma at our ADMA BioCenters facility, and if we cannot maintain FDA approval for this facility or obtain FDA approval for additional facilities that we create or acquire rights to, we may be adversely affected and may not be able to sell or use this human blood plasma for future commercial purposes.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We intend to maintain FDA approval of our ADMA BioCenters collection facility in Kennesaw, GA for the collection of human blood plasma and we may seek other governmental and regulatory approvals for this facility. We also plan to grow through the building and licensing of additional ADMA BioCenters facilities in various regions of the U.S. Collection facilities are subject to FDA and potentially other governmental and regulatory inspections and extensive regulation, including compliance with current cGMP, FDA and other government approvals, as applicable. Failure to comply with applicable governmental regulations or to receive applicable approvals for our future facilities may result in enforcement actions, such as adverse inspection reports, warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of regulatory authority approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses, any of which may significantly delay or suspend our operations for these locations, potentially having a materially adverse effect on our ability to manufacture our products or offer for sale plasma collected at the affected site(s).</p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We currently manufacture our current marketed products, pipeline products, and products for third parties in our manufacturing and testing facilities, and if we or our vendors cannot maintain appropriate FDA status for these facilities, we may be adversely affected, and may not be able to sell, manufacture or commercialize these products.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">There are no assurances we will be able to maintain compliance with all FDA or other regulations.Our third-party vendors may perform activities for themselves or other clients and we may not be privy to all regulatory findings or issues discovered by the FDA or other regulatory agencies. Such findings, which are out of our control, may adversely affect our ability to continue to work with these vendors, or our ability to release commercial drug product or perform necessary testing or other actions for us or our clients, which may be required in order to remain FDA compliant or to commercialize our products.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">51</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The testing and marketing of medical products entail an inherent risk of product liability. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of pharmaceutical products we develop, either alone or with collaborators.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Many of our business practices are subject to scrutiny by federal and state regulatory authorities, as well as to lawsuits brought by private citizens under federal and state laws. Failure to comply with applicable law or an adverse decision in lawsuits may result in adverse consequences to us.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The laws governing our conduct in the U.S. are enforceable on the federal and state levels by criminal, civil and administrative penalties. Violations of laws such as the Federal Food, Drug, and Cosmetic Act, the Social Security Act (including the Anti-Kickback Statute), the Public Health Service Act and the Federal False Claims Act, and any regulations promulgated under the authority of the preceding, may result in jail sentences, fines or exclusion from federal and state programs, as may be determined by Medicare, Medicaid and HHS and other regulatory authorities as well as by the courts. Similarly, the violation of applicable laws, rules and regulations of the State of Florida with respect to the manufacture of our products and product candidates may result in jail sentences, fines or exclusion from applicable state programs. There can be no assurance that our activities will not come under the scrutiny of federal and/or state regulators and other government authorities or that our practices will not be found to violate applicable laws, rules and regulations or prompt lawsuits by private citizen &#8220;relators&#8221; under federal or state false claims laws.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">For example, under the Anti-Kickback Statute and similar state laws and regulations, the offer or payment of anything of value for patient referrals, or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease, or ordering of any time or service reimbursable in whole or in part by a federal healthcare program is prohibited. This places constraints on the marketing and promotion of products and on common business arrangements, such as discounted terms and volume incentives for customers in a position to recommend or choose products for patients, such as physicians and hospitals, and these practices can result in substantial legal penalties, including, among others, exclusion from the Medicare and Medicaid programs. Arrangements with referral sources such as purchasers, group purchasing organizations, physicians and pharmacists must be structured with care to comply with applicable requirements. Legislators and regulators may seek to further restrict the scope of financial relationships that are considered appropriate. For example, HHS issued a proposed rule in February 2019, which aims to eliminate certain Anti-Kickback Statute safe harbor protection for drug rebates. Also, certain business practices, such as payments of consulting fees to healthcare providers, sponsorship of educational or research grants, charitable donations, interactions with healthcare providers that prescribe products for uses not approved by the FDA and financial support for continuing medical education programs, must be conducted within narrowly prescribed and controlled limits to avoid any possibility of wrongfully influencing healthcare providers to prescribe or purchase particular products or as a reward for past prescribing. Under the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) and the companion Health Care and Education Reconciliation Act, which together are referred to as the &#8220;Healthcare Reform Law,&#8221; payments and transfers of value by pharmaceutical manufacturers subject to this &#8220;Sunshine Act&#8221; and its implementing regulations to U.S.&#8211;licensed physicians and teaching hospitals, must be tracked and reported, and will be publicly disclosed. Such &#8220;applicable manufacturers&#8221; are also required to report certain ownership interests held by physicians and their immediate family members. In 2018, the Sunshine Act was extended to require tracking and reporting of payments and transfers of value to physician assistants, nurse practitioners, and other mid-level practitioners (with reporting requirements going into effect in 2022 for payments and transfers of value made in 2021). A number of states have similar laws in place. Additional and stricter prohibitions could be implemented by federal and state authorities. Where such practices have been found to be improper incentives to use such products, government investigations and assessments of penalties against manufacturers have resulted in substantial damages and fines. Many manufacturers have been required to enter into consent decrees or orders that prescribe allowable corporate conduct.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">52</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Failure to satisfy requirements under the Federal Food, Drug, and Cosmetic Act can also result in penalties, as well as requirements to enter into consent decrees or orders that prescribe allowable corporate conduct. In addition, while regulatory authorities generally do not regulate physicians&#8217; discretion in their choice of treatments for their patients, they do restrict communications by manufacturers on unapproved uses of approved products or on the potential safety and efficacy of unapproved products in development. Companies in the U.S., Canada and the European Union cannot promote approved products for other indications that are not specifically approved by the competent regulatory authorities such as the FDA in the U.S., nor can companies promote unapproved products. In limited circumstances, companies may disseminate to physicians information regarding unapproved uses of approved products or results of studies involving investigational products. If such activities fail to comply with applicable regulations and guidelines of the various regulatory authorities, we may be subject to warnings from, or enforcement action by, these authorities. Furthermore, if such activities are prohibited, it may harm demand for our products. Promotion of unapproved drugs or devices or unapproved indications for a drug or device is a violation of the Federal Food, Drug, and Cosmetic Act and subjects us to civil and criminal sanctions. Furthermore, sanctions under the Federal False Claims Act have recently been brought against companies accused of promoting off-label uses of drugs, because such promotion induces the use and subsequent claims for reimbursement under Medicare and other federal programs. Similar actions for off-label promotion have been initiated by several states for Medicaid fraud. The Healthcare Reform Law significantly strengthened provisions of the Federal False Claims Act, the Anti-Kickback Statute that applies to Medicare and Medicaid, and other healthcare fraud provisions, leading to the possibility of greatly increased qui tam suits by relators for perceived violations. Violations or allegations of violations of the foregoing restrictions could materially and adversely affect our business.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We are required to report detailed pricing information, net of included discounts, rebates and other concessions, to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) for the purpose of calculating national reimbursement levels, certain federal prices and certain federal and state rebate obligations. Inaccurate or incomplete reporting of pricing information could result in liability under the False Claims Act, the federal Anti-Kickback Statute and various other laws, rules and regulations.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We will need to establish systems for collecting and reporting this data accurately to CMS and institute a compliance program to assure that the information collected is complete in all respects. If we report pricing information that is not accurate to the federal government, we could be subject to fines and other sanctions that could adversely affect our business. If we choose to pursue clinical development and commercialization in the European Union or otherwise market and sell our products outside of the U.S., we must obtain and maintain regulatory approvals and comply with regulatory requirements in such jurisdictions. The approval procedures vary among countries in complexity and timing. We may not obtain approvals from regulatory authorities outside the U.S. on a timely basis, if at all, which would preclude us from commercializing products in those markets.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In addition, some countries, particularly the countries of the European Union, regulate the pricing of prescription pharmaceuticals. In these countries, pricing discussions with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. Such trials may be time-consuming and expensive, and may not show an advantage in efficacy for our products. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, in either the U.S. or the European Union, we could be adversely affected.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Also, under the U.S. Foreign Corrupt Practices Act, the U.S. has increasingly focused on regulating the conduct by U.S. businesses occurring outside of the U.S., generally prohibiting remuneration to foreign officials for the purpose of obtaining or retaining business. To enhance compliance with applicable healthcare laws, and mitigate potential liability in the event of noncompliance, regulatory authorities such as the HHS Office of Inspector General (the &#8220;OIG&#8221;) have recommended the adoption and implementation of a comprehensive healthcare compliance program that generally contains the elements of an effective compliance and ethics program described in Section 8B2.1 of the U.S. Sentencing Commission Guidelines Manual. Increasing numbers of U.S.-based pharmaceutical companies have such programs. We will need to adopt healthcare compliance and ethics programs that would incorporate the OIG&#8217;s recommendations and train our employees. Such a program may be expensive and may not provide assurance that we will avoid compliance issues.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">53</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We are also required to comply with the applicable laws, rules, regulations and permit requirements of the various states in which our business operates, including the State of Florida where our manufacturing facility is located. These regulations and permit requirements are not always in concert with applicable federal laws, rules and regulations regulating our business. Although compliant with applicable federal requirements, we may be required to comply with additional state laws, rules, regulations and permits. Failure to appropriately comply with such state requirements could result in temporary or long-term cessation of our manufacturing operations, as well as fines and other sanctions. Any such penalties may have a material adverse effect on our business and results of operations.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We are subject to extensive and rigorous governmental regulation, including the requirement of FDA and other federal, state and local business regulatory</em></strong><strong><em> </em></strong><strong><em>approval before our products and product candidates may be lawfully marketed, and our ability to obtain regulatory approval of our products and product candidates from the FDA in a timely manner, access the public markets and obtain necessary capital in order to properly capitalize and continue our operations may be hindered by inadequate funding for the FDA, the SEC and other state and local government agencies</em></strong><strong><em>.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Both before and after the approval of our products, our products, our operations, our facilities, our suppliers and our contract research organizations are subject to extensive regulation by federal, state and local governmental authorities in the U.S. and other countries, with regulations differing from country to country. In the U.S., the FDA regulates, among other things, the pre-clinical testing, clinical trials, manufacturing, safety, efficacy, potency, labeling, storage, record keeping, quality systems, advertising, promotion, sale and distribution of therapeutic products. Failure to comply with applicable requirements could result in, among other things, one or more of the following actions: notices of violation, untitled letters, warning letters, complete response letters, fines and other monetary penalties, unanticipated expenditures, delays in approval or refusal to approve a product or product candidate, product recall or seizure, interruption of manufacturing or clinical trials, operating restrictions, injunctions and criminal prosecution. Our products and product candidates cannot be lawfully marketed in the U.S. without FDA and other federal, state and local business regulatory approval. Any failure to receive the marketing approvals necessary to commercialize our product or product candidates could harm our business.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The regulatory review and approval process of governmental authorities is lengthy, expensive and uncertain. For example, in December 2016, BPC, the owner of BIVIGAM prior to the Biotest Transaction in June 2017, temporarily suspended the commercial production of BIVIGAM in order to focus on the completion of planned improvements to the manufacturing process. We resumed production of BIVIGAM utilizing our now FDA-approved IVIG manufacturing process with two conformance lots in the fourth quarter of 2017 and a third conformance lot in the first quarter of 2018. During the first half of 2018, we qualified and filled the BIVIGAM conformance batches and the product is on stability. In June 2018, we filed a drug substance PAS with the FDA for BIVIGAM to include the ADMA improvements for BIVIGAM and to seek FDA authorization which would enable us to resume commercial scale manufacturing and re-launch and commercialize this product. On December 19, 2018, we received the BIVIGAM CRL for our PAS submission for BIVIGAM drug substance. The BIVIGAM CRL requested certain additional information and clarifications relating to CMC matters contained in our PAS submission for drug substance, including complete resolution of certain manufacturing related deviations, information pertaining to how certain in-process manufacturing samples are taken, as well as updates on certain stability data previously submitted. As the information we believed necessary to address and respond to the matters raised in the BIVIGAM CRL was readily available in our files, on January 7, 2019 we announced that our responses to the BIVIGAM CRL were submitted to the FDA for further review. Subsequent to the January 7, 2019 resubmission to the FDA, we received an information request for a limited number of questions. On May 9, 2019, we received FDA approval for our PAS for BIVIGAM. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Additionally, the ability of the FDA and other federal, state and local business regulatory agencies to review and approve products and product candidates can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA and other federal, state and local business regulatory agencies have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for products and product candidate submissions to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including in December 2018 and January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown reoccurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions and other reporting requirements which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">54</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>The manufacturing processes for plasma-based biologics are complex and involve biological intermediates that are susceptible to contamination and impurities.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Plasma is a raw material that is susceptible to damage and contamination and may contain human pathogens, any of which would render the plasma unsuitable as raw material for further manufacturing. For instance, improper storage of plasma, by us or third-party suppliers, may require us to destroy some of our raw material. If unsuitable plasma is not identified and discarded prior to the release of the plasma to the manufacturing process, it may be necessary to discard intermediate or finished product made from that plasma or to recall any finished product released to the market, resulting in a charge to cost of product revenue. The manufacture of our plasma products is an extremely complex process of fractionation, purification, testing, filling and finishing. Our products can become non-releasable or otherwise fail to meet our stringent specifications or regulatory agencies&#8217; specifications through a failure in one or more of these process steps. We may detect instances in which an unreleased product was produced without adherence to our manufacturing procedures or plasma used in our production process was not collected or stored in a compliant manner consistent with our cGMP or other regulations. Such an event of noncompliance would likely result in our determination that the implicated products should not be released or maybe replaced or withdrawn from the market and therefore should be destroyed. Once manufactured, our plasma-derived products must be handled carefully and kept at appropriate temperatures. Our failure, or the failure of third parties that supply, test, ship or distribute our products to properly care for our products, may require that those products be destroyed. Even if handled properly, biologics may form or contain particulates or have other issues or problems after storage which may require products to be destroyed or recalled. While we expect to write off small amounts of work-in-progress in the ordinary course of business due to the complex nature of plasma, our processes and our products, unanticipated events may lead to write-offs and other costs materially in excess of our expectations and the reserves we have established for these purposes. Such write-offs and other costs could cause material fluctuations in our results of operations.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Furthermore, contamination of our products could cause investors, consumers, or other third parties with whom we conduct business to lose confidence in the reliability of our manufacturing procedures, which could adversely affect our revenues. In addition, faulty or contaminated products that are unknowingly distributed could result in patient harm, threaten the reputation of our products and expose us to product liability damages and claims from companies for whom we do contract manufacturing.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and manufacturing processes against transmittable diseases.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Despite overlapping safeguards, including the screening of donors and other steps to remove or inactivate viruses and other infectious disease causing agents, the risk of transmissible disease through blood plasma products cannot be entirely eliminated. For example, since plasma-derived therapeutics involves the use and purification of human plasma, there has been concern raised about the risk of transmitting HIV, prions, West Nile virus, H1N1 virus or &#8220;swine flu&#8221; and other blood-borne pathogens through plasma-derived products. There are also concerns about the future transmission of H5N1 virus, or &#8220;bird flu.&#8221; In the 1980s, thousands of hemophiliacs worldwide were infected with HIV through the use of contaminated Factor VIII. Other producers of Factor VIII, though not us, were defendants in numerous lawsuits resulting from these infections. New infectious diseases emerge in the human population from time to time. If a new infectious disease has a period during which time the causative agent is present in the bloodstream but symptoms are not present, it is possible that plasma donations could be contaminated by that infectious agent. Typically, early in an outbreak of a new disease, tests for the causative agent do not exist. During this early phase, we must rely on screening of donors for behavioral risk factors or physical symptoms to reduce the risk of plasma contamination. Screening methods are generally less sensitive and specific than a direct test as a means of identifying potentially contaminated plasma units. During the early phase of an outbreak of a new infectious disease, our ability to manufacture safe products would depend on the manufacturing process&#8217; capacity to inactivate or remove the infectious agent. To the extent that a product&#8217;s manufacturing process is inadequate to inactivate or remove an infectious agent, our ability to manufacture and distribute that product would be impaired. If a new infectious disease were to emerge in the human population, such as COVID-19, or if there were a reemergence of an infectious disease, the regulatory and public health authorities could impose precautions to limit the transmission of the disease that would impair our ability to procure plasma, manufacture our products or both. Such precautionary measures could be taken before there is conclusive medical or scientific evidence that a disease poses a risk for plasma-derived products. In recent years, new testing and viral inactivation methods have been developed that more effectively detect and inactivate infectious viruses in collected plasma. There can be no assurance, however, that such new testing and inactivation methods will adequately screen for, and inactivate, infectious agents in the plasma used in the production of our products.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">55</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source plasma with proper specifications or other necessary raw materials.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In order for plasma to be used in the manufacturing of our products, the individual centers at which the plasma is collected must be licensed by the FDA and approved by the regulatory authorities of any country in which we may wish to commercialize our products. When we open a new plasma center, and on an ongoing basis after licensure, it must be inspected by the FDA for compliance with cGMP and other regulatory requirements. Therefore, even if we are able to construct new plasma collection centers to complement our Kennesaw, GA plasma collection facility, an unsatisfactory inspection could prevent a new center from being licensed or risk the suspension or revocation of an existing license. We do not and will not have adequate plasma to manufacture our products. Therefore, we are reliant on the purchase of plasma from third parties to manufacture our products. We can give no assurances that appropriate plasma will be available to us on commercially reasonable terms, or at all, to manufacture our products. Further, the COVID-19 pandemic has resulted in, and may continue to result in, significant constraints in raw material supply across various different industries, including the supply of plasma. It is possible that in the future, the COVID-19 pandemic and government responses thereto will have an adverse effect on our ability to source plasma from donors in quantity and quality sufficient for our manufacturing processes. In order to maintain a plasma center&#8217;s license, its operations must continue to conform to cGMP and other regulatory requirements. In the event that we determine that plasma was not collected in compliance with cGMP, we may be unable to use and may ultimately destroy plasma collected from that center, which would be recorded as a charge to cost of product revenue. Additionally, if non-compliance in the plasma collection process is identified after the impacted plasma has been pooled with compliant plasma from other sources, entire plasma pools, in-process intermediate materials and final products could be impacted. Consequently, we could experience significant inventory impairment provisions and write-offs which could adversely affect our business and financial results. We plan to increase our supplies of plasma for use in the manufacturing processes through increased purchases of plasma from third-party suppliers as well as collections from our existing ADMA BioCenters plasma collection facility. This strategy is dependent upon our ability to maintain a cGMP compliant environment in our plasma facility and to expand production and attract donors to our facility. There is no assurance that the FDA will inspect and license any of our unlicensed plasma collection facilities which we may, in the future, construct, in a timely manner consistent with our production plans. If we misjudge the readiness of a center for an FDA inspection, we may lose credibility with the FDA and cause the FDA to more closely examine all of our operations. Such additional scrutiny could materially hamper our operations and our ability to increase plasma collections. Our ability to expand production and increase our plasma collection facility to more efficient production levels may be affected by changes in the economic environment and population in selected regions where ADMA BioCenters operates its current or future plasma facilities, by the entry of competitive plasma centers into regions where ADMA BioCenters operates such centers, by misjudging the demographic potential of individual regions where ADMA BioCenters expects to expand production and attract new donors, by unexpected facility related challenges, or by unexpected management challenges at selected plasma facilities held by us from time to time.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Our ability to commercialize our products, alone or with collaborators, will depend in part upon the extent to which reimbursement will be available from governmental agencies, health administration authorities, private health maintenance organizations and health insurers and other healthcare payers, and also depends upon the approval, timing and representations by the FDA or other governmental authorities for our product candidates. </em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our ability to generate product revenues will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of coverage. Significant uncertainty exists as to the reimbursement status of newly approved healthcare products, as well as to the timing, language, specifications and other details pertaining to the approval of such products. Healthcare payers, including Medicare, are challenging the prices charged for medical products and services. Government and other healthcare payers increasingly attempt to contain healthcare costs by limiting both coverage and the level of reimbursement for products. Even if one of our product candidates is approved by the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover such product. If government and other healthcare payers do not provide adequate coverage and reimbursement levels for one of our products, once approved, market acceptance of such product could be reduced. Prices in many countries, including many in Europe, are subject to local regulation and certain pharmaceutical products, such as plasma-derived products, are subject to price controls in several of the world&#8217;s principal markets, including many countries within the European Union. In the U.S., where pricing levels for our products are substantially established by third-party payers, including Medicare, if payers reduce the amount of reimbursement for a product, it may cause groups or individuals dispensing the product to discontinue administration of the product, to administer lower doses, to substitute lower cost products or to seek additional price-related concessions. These actions could have a negative effect on our financial results, particularly in cases where our products command a premium price in the marketplace, or where changes in reimbursement induce a shift in the site of treatment. The existence of direct and indirect price controls and pressures over our products could materially adversely affect our financial prospects and performance.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">56</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>The new biosimilar pathway established as part of healthcare reform may make it easier for competitors to market biosimilar products.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Healthcare Reform Law introduced an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to an FDA-licensed biological product. A biological product may be demonstrated to be &#8220;biosimilar&#8221; if data shows that, among other things, the product is &#8220;highly similar&#8221; to an already-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. The law provides that a biosimilar application may be submitted as soon as four years after the reference product is first licensed, and that the FDA may not make approval of an application effective until 12 years after the reference product was first licensed. Since the enactment of the law, the FDA has issued several guidance documents to assist sponsors of biosimilar products in preparing their approval applications. The FDA approved the first biosimilar product in 2015, and has since approved a number of biosimilars. As a result of the biosimilar pathway in the U.S., we expect in the future to face greater competition from biosimilar products, including a possible increase in patent challenges.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>The implementation of the Healthcare Reform Law in the U.S. may adversely affect our business.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Through the March 2010 adoption of the Healthcare Reform Law in the U.S., substantial changes are being made to the current system for paying for healthcare in the U.S., including programs to extend medical benefits to millions of individuals who currently lack insurance coverage. The changes contemplated by the Healthcare Reform Law are subject to rule-making and implementation timelines that extend for several years, and this uncertainty limits our ability to forecast changes that may occur in the future. However, implementation has already begun with respect to certain significant cost-saving measures under the Healthcare Reform Law, for example with respect to several government healthcare programs, including Medicaid and Medicare Parts B and D, that may cover the cost of our future products, and these efforts could have a material adverse impact on our future financial prospects and performance. For example, in order for a manufacturer&#8217;s products to be reimbursed by federal funding under Medicaid, the manufacturer must enter into a Medicaid rebate agreement with the Secretary of HHS and pay certain rebates to the states based on utilization data provided by each state to the manufacturer and to CMS and pricing data provided by the manufacturer to the federal government. The states share these savings with the federal government, and sometimes implement their own additional supplemental rebate programs. Under the Medicaid drug rebate program, the rebate amount for most branded drug products was previously equal to a minimum of 15.1% of the Average Manufacturer Price (&#8220;AMP&#8221;) or the AMP less Best Price, whichever is greater. Effective January 1, 2010, the Healthcare Reform Law generally increased the size of the Medicaid rebates paid by manufacturers for single source and innovator multiple source (brand name) drug products from a minimum of 15.1% to a minimum of 23.1% of AMP, subject to certain exceptions. For non-innovator multiple source (generic) products, the rebate percentage is increased from a minimum of 11.0% to a minimum of 13.0% of AMP. In 2010, the Healthcare Reform Law also newly extended this rebate obligation to prescription drugs covered by Medicaid managed care organizations. These increases in required rebates may adversely affect our future financial prospects and performance. In order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. As the 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">57</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Effective in 2011, the Healthcare Reform Law imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs. These fees may adversely affect our future financial prospects and performance. The Healthcare Reform Law established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation through 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Healthcare Reform Law also creates new rebate obligations for our products under Medicare Part D, a partial, voluntary prescription drug benefit created by the U.S. federal government primarily for persons 65 years old and over. The Part D drug program is administered through private insurers that contract with CMS. Beginning in 2011, the Healthcare Reform Law generally requires that in order for a drug manufacturer&#8217;s products to be reimbursed under Medicare Part D, the manufacturer must enter into a Medicare Coverage Gap Discount Program agreement with the Secretary of HHS, and reimburse each Medicare Part D plan sponsor an amount equal to 50% savings for the manufacturer&#8217;s brand name drugs and biologics which the Part D plan sponsor has provided to its Medicare Part D beneficiaries who are in the &#8220;donut hole&#8221; (or a gap in Medicare Part D coverage for beneficiaries who have expended certain amounts for drugs). The Part D plan sponsor is responsible for calculating and providing the discount directly to its beneficiaries and for reporting these amounts paid to CMS&#8217;s contractor, which notifies drug manufacturers of the rebate amounts it must pay to each Part D plan sponsor. The rebate requirement could adversely affect our future financial performance, particularly if contracts with Part D plans cannot be favorably renegotiated or the Part D plan sponsors fail to accurately calculate payments due in a manner that overstates our rebate obligation. Regarding access to our products, the Healthcare Reform Law established and provided significant funding for a Patient-Centered Outcomes Research Institute to coordinate and fund Comparative Effectiveness Research (&#8220;CER&#8221;). While the stated intent of CER is to develop information to guide providers to the most efficacious therapies, outcomes of CER could influence the reimbursement or coverage for therapies that are determined to be less cost-effective than others. Should any of our products be determined to be less cost effective than alternative therapies, the levels of reimbursement for these products, or the willingness to reimburse at all, could be impacted, which could materially impact our future financial prospects and results.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">There have been repeated attempts by Congress to repeal or change the Healthcare Reform Law. </p><p style="MARGIN: 0px; text-align:left;">Further, on January 20, 2017, the new administration signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the Healthcare Reform Law that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. More recently, the U.S. District Court for the Northern District of Texas struck down the Healthcare Reform Law, deeming it unconstitutional given that Congress repealed the individual mandate in 2017. This decision has been stayed pending outcome of an appeal to the U.S. Fifth Circuit Court of Appeals. Although there is no immediate impact on the ACA, we will continue to evaluate the effect that the Healthcare Reform Law and its possible repeal and replacement, or potential total revocation by the Supreme Court of the United States, has on our business. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">58</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong>Risks Relating to our Finances, Capital Requirements and Other Financial Matters</strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We require additional funding and may be unable to raise capital when needed, which would force us to delay, curtail or eliminate one or more of our research and development programs or commercialization efforts.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our operations have consumed substantial amounts of cash since inception. For the six months ended June 30, 2020 and 2019, we had negative cash flows from operations of $45.9 million and $32.9 million, respectively, and for the years ended December 31, 2019 and 2018, we had negative cash flows from operations of approximately $76.2 million and $62.7 million, respectively. We expect to continue to spend substantial amounts on procurement of raw material plasma and other raw materials necessary to scale up our manufacturing operations, commercial product launches, capacity expansion at the Boca Facility, building additional plasma collection facilities, product development, quality assurance, regulatory affairs and conducting clinical trials for our product candidates and purchasing clinical trial materials, some of which may be required by the FDA. In addition, our end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months, requiring substantial investments in raw material plasma and other manufacturing materials. We expect that we will not be able to generate a sufficient amount of product revenue to achieve profitability before 2021 and, as a result, we expect that we will need to finance our operations through additional equity or debt financings or corporate collaboration and licensing agreements. We currently anticipate, based upon our projected revenue and expenditures, as well as the additional funds we are able to draw down under the Perceptive Credit Facility, that our current cash, cash equivalents and accounts receivable will be sufficient to fund our operations, as currently conducted, into the second quarter of 2021. In order to have sufficient cash to fund our operations thereafter, we will need to raise additional equity or debt financing before the end of the second quarter of 2021. This time frame may change based upon how quickly we are able to execute on our operational initiatives and the various financing options that may be available to us in 2021. However, if the assumptions underlying our estimated expenses prove to be incorrect, we may have to raise additional capital sooner than we currently expect. Until such time, if ever, as we can generate a sufficient amount of product revenue to achieve profitability, we expect to continue to finance our operations through additional equity or debt financings or corporate collaboration and licensing arrangements. If we are unable to raise additional capital as needed, including due to widespread liquidity constraints or significant market instability that could result from the COVID-19 pandemic, we will have to delay, curtail or eliminate our commercialization efforts or our product development activities.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We may not have cash available to us in amounts sufficient to enable us to make interest or principal payments on our indebtedness when due.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Perceptive Credit Facility provides for term loans of up to an aggregate principal amount of $85.0 million, all of which has been drawn down and is currently outstanding. Borrowings under the Perceptive Credit Facility bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will automatically increase by an additional 400 basis points. We are required to make monthly payments of interest during the term of the Perceptive Credit Facility of approximately $0.8 million, with all principal and unpaid interest due at maturity. The Perceptive Credit Facility has a maturity date of March 1, 2022, subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default. All of our obligations under the Perceptive Credit Facility are secured by a first-priority lien and security interest in substantially all of our and our subsidiaries&#8217; tangible and intangible assets, including intellectual property, and all of the equity interests in our subsidiaries.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In addition, we have $15.0 million in principal amount of indebtedness outstanding under an unsecured subordinated note issued by ADMA BioManufacturing to Biotest on June 6, 2017, which note bears interest at a rate of 6.0% per annum and matures on June 6, 2022. We are obligated to make semi-annual interest payments to Biotest of approximately $0.5 million, with all principal and unpaid interest due at maturity.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our current cash, cash equivalents and accounts receivable will not be sufficient to repay all of our current outstanding debt obligations as they mature. If we are unable to obtain additional financing and are otherwise unable to become profitable and generate cash from operations in the amounts necessary to repay our outstanding debt obligations when due, including as a result of the impact of the COVID-19 pandemic, our creditors would be able to accelerate all of the amounts due and, in the case of the Perceptive Credit Facility, seek to enforce their security interests, which could lead to our creditors taking immediate possession of and selling substantially all of our assets with no return provided to our stockholders.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt financing may involve covenants that, among other restrictions, limit our ability to incur liens or additional debt, pay dividends, redeem or repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. In addition, if we raise additional funds through licensing arrangements or the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">59</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We regularly maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation insurance limit. While we monitor the cash balances in our operating accounts on a daily basis and adjust the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on our business, if one or more of the financial institutions with which we deposit cash fails or is subject to other adverse conditions in the financial or credit markets. To date, we have experienced no loss or lack of access to our invested cash or cash equivalents; however, we can provide no assurance that access to our invested cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors&#8217; views of us and, as a result, the value of our common stock.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;) and related rules, our management is required to report on the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we have been required to upgrade, and may need to implement further upgrades, to our financial, information and operating systems, implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) may be limited.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We have incurred substantial losses during our history. As of December 31, 2019, we had federal and state NOLs of $175.1 million and $116.2 million, respectively. These NOLs will begin to expire at various dates beginning in 2027, if not limited by triggering events prior to such time. Under the provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), changes in our ownership, in certain circumstances, will limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Code imposes limitations on a company&#8217;s ability to use NOLs upon certain changes in such ownership. If we are limited in our ability to use our NOLs in future years in which we have taxable income, we will pay more taxes than if we were able to fully utilize our NOLs. The Biotest Transaction on June 6, 2017 resulted in a change in ownership of ADMA under Section 382 and, as a result, we were required to write off $57.6 million of federal NOLs. We may experience ownership changes in the future as a result of subsequent changes in our stock ownership that we cannot predict or control that could result in further limitations being placed on our ability to utilize our federal NOLs.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>The Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;) could adversely affect our business and financial condition.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"><span style="mso-tab-count:1">The TCJA, among other things, reduced the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limited the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limited the deduction for net operating losses generated after December 31, 2017 to 80% of current year taxable income and eliminated net operating loss carrybacks, provided immediate deductions for certain new investments instead of deductions for depreciation expense over time and modified or repealed many business deductions and credits. Federal net operating losses arising in taxable years ending after December 31, 2017 will be carried forward indefinitely pursuant to the TCJA. We continue to examine the impact this tax reform legislation may have on our business. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the TCJA is uncertain and our business and financial condition could be adversely affected. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock.</span></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">60</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong>Risks Associated with our Common Stock</strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our stock price may experience substantial volatility as a result of a number of factors, including:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">sales or potential sales of substantial amounts of our common stock; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">our ability to successfully leverage the anticipated benefits and synergies from the Biotest Transaction, including optimization of the combined businesses, operations and products and services, including the nature, strategy and focus of the combined company and the management and governance structure of the combined company; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">uncertainties in the equity markets related to the effects of the COVID-19 pandemic; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">delay or failure in initiating or completing preclinical or clinical trials or unsatisfactory results of these trials; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">delay in a decision by federal, state or local business regulatory authority; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">the timing of acceptance, third-party reimbursement and sales of BIVIGAM and ASCENIV; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">announcements about us or about our competitors, including clinical trial results, regulatory approvals or new product introductions; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">developments concerning our licensors or third-party vendors; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">litigation and other developments relating to our patents or other proprietary rights or those of our competitors; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">conditions in the pharmaceutical or biotechnology industries; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">governmental regulation and legislation; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">variations in our anticipated or actual operating results; and </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">change in securities analysts&#8217; estimates of our performance, or our failure to meet analysts&#8217; expectations. </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;">Many of these factors are beyond our control. The stock markets in general, and the market for pharmaceutical and biotechnology companies in particular, have historically experienced extreme price and volume fluctuations. These fluctuations often have been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors could reduce the market price of our common stock, regardless of our actual operating performance.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely affect the market price of our common stock.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of August 3, 2020, most of our 86,349,981 outstanding shares of common stock, as well as a substantial number of shares of our common stock underlying outstanding warrants, were available for sale in the public market, subject to certain restrictions with respect to sales of our common stock by our affiliates, either pursuant to Rule 144 under the Securities Act, or under effective registration statements. Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, could cause the market price of our common stock to decline or adversely affect demand for our common stock.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">61</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Our affiliates control a substantial amount of our shares of common stock. Provisions in our Second Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;), our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;) and Delaware law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore, depress the trading price of our common stock.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of June 30, 2020, Perceptive, our directors and executive officers and their affiliates beneficially owned approximately 27% of the outstanding shares of our common stock. Additionally, on November 14, 2018, the standstill provisions contained in that certain Stockholders Agreement, dated as of June 6, 2017, by and between us and BPC, as amended by the Biotest Transfer Agreement, which prohibited the Biotest Trust from, among other things, acquiring more than (i) 50%, less one share, of our issued and outstanding shares of capital stock on an as-converted basis, or (ii) 30% of the issued and outstanding shares of common stock, terminated and are of no further force and effect. This event could result in the Biotest Trust acquiring additional shares of our common stock or taking other actions with the goal of acquiring additional shares of our common stock.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Provisions of our Certificate of Incorporation, our Bylaws and Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our Company or changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interests. These provisions include:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">the inability of stockholders to call special meetings; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">the ability of our Board of Directors (the &#8220;Board&#8221;)to institute a stockholder rights plan, also known as a poison pill, that would work to dilute our stock, </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">classification of our Board and limitation on filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our Company; and </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:3%;"></td><td style="width:3%;vertical-align:top;"><span style="font-family:symbol">&#183;</span> </td><td style="vertical-align:top;">authorization of the issuance of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board, without any need for action by stockholders. </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In addition, Section 203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years, has owned 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition. In addition, as a result of the concentration of ownership of our shares of common stock, our stockholders may, from time to time, observe instances where there may be less liquidity in the public markets for our securities. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We have never paid and do not intend to pay cash dividends in the foreseeable future. As a result, capital appreciation, if any, will be your sole source of gain.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">We have never paid cash dividends on any of our capital stock and we currently intend to retain future earnings, if any, to fund the development and growth of our business. In addition, the terms of existing and future debt agreements may preclude us from paying dividends. For example, the Perceptive Credit Agreement prohibits us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>If we fail to adhere to the strict listing requirements of the Nasdaq Global Market (&#8220;Nasdaq&#8221;), we may be subject to delisting. As a result, our stock price may decline and our common stock may be delisted. If our stock were no longer listed on Nasdaq, the liquidity of our securities likely would be impaired.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">62</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our Common Stock currently trades on the Nasdaq Global Market under the symbol &#8220;ADMA.&#8221; If we fail to adhere to Nasdaq&#8217;s strict listing criteria, including with respect to stock price, our market capitalization and stockholders&#8217; equity, our stock may be delisted. This could potentially impair the liquidity of our securities not only in the number of shares that could be bought and sold at a given price, which may be depressed by the relative illiquidity, but also through delays in the timing of transactions and the potential reduction in media coverage. As a result, an investor might find it more difficult to dispose of our common stock. We believe that current and prospective investors would view an investment in our common stock more favorably if it continues to be listed on Nasdaq. Any failure at any time to meet the Nasdaq continued listing requirements could have an adverse impact on the value and trading activity of our common stock. Although we currently satisfy the listing criteria for Nasdaq, if our stock price declines dramatically, we could be at risk of failing to meet the Nasdaq continued listing criteria.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Penny stock regulations may affect your ability to sell our common stock.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Because the price of our common stock currently trades below $5.00 per share, our common stock is subject to Rule 15g-9 under the Exchange Act, which imposes additional sales practice requirements on broker dealers which sell these securities to persons other than established customers and accredited investors. Under these rules, broker-dealers who recommend penny stocks to persons other than established customers and &#8220;accredited investors&#8221; must make a special written suitability determination for the purchaser and receive the purchaser&#8217;s written agreement to a transaction prior to sale, which includes an acknowledgement that the purchaser&#8217;s financial situation, investment experience and investment objectives forming the basis for the broker-dealer&#8217;s suitability determination are accurately stated in such written agreement. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the associated risks. The additional burdens imposed upon broker-dealers by these requirements could discourage broker-dealers from effecting transactions in our common stock and may make it more difficult for holders of our common stock to sell shares to third parties or to otherwise dispose of them.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>We will continue to incur increased costs now that we are no longer an &#8220;emerging growth company.&#8221;</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Effective January 1, 2019, we ceased to be an &#8220;emerging growth company&#8221; as defined by the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for qualifying public companies. As an &#8220;emerging growth company,&#8221; we took advantage of certain benefits afforded to &#8220;emerging growth companies&#8221; under Section 7(a)(2)(B) of the Securities Act, which included delaying the adoption of new or revised accounting standards applicable to public companies until such standards would otherwise apply to private companies. As an emerging growth company, we were also exempt from the requirement to have our independent registered public accounting firm provide an attestation report on our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Consequently, we have, and will continue to, incur increased costs related to our compliance with Section 404 of the Sarbanes-Oxley Act. For example, in 2018, our Audit Committee retained the services of BDO, a Sarbanes-Oxley advisor, to assist with our internal controls over financial reporting and information technology relating to Section 404. Moreover, if we are not able to comply with the requirements of Section 404 applicable to us in a timely manner, or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our common stock could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><em>Our Board may, without stockholder approval, issue and fix the terms of shares of preferred stock and issue additional shares of common stock adversely affecting the rights of holders of our common stock.</em></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Our Certificate of Incorporation authorizes the issuance of up to 10,000,000 shares of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board. Currently, our Certificate of Incorporation authorizes the issuance of up to 150,000,000 shares of common stock. As of June 30, 2020, there were 54,384,080 shares remaining available for issuance, after giving effect to 9,265,939 shares of our common stock that were subject to outstanding stock options, RSUs, warrants or other convertible securities as of June 30, 2020 that may be issued by us without stockholder approval. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">63</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><span class="atag" id="p22">Item 2.<span style="mso-tab-count:1"> Unregistered Sales of Equity Securities and Use of Proceeds.</span></span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0.5in; text-align:left;">None.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><span class="atag" id="p23">Item 3.<span style="mso-tab-count:1"> Defaults Upon Senior Securities.</span></span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">None.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><span class="atag" id="p24">Item 4.<span style="mso-tab-count:1"> Mine Safety Disclosures.</span></span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Not applicable.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><strong><span class="atag" id="p25">Item 5.<span style="mso-tab-count:1"> Other Information.</span></span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On August 5, 2020, the Company entered into an Open Market Sale Agreement<sup>SM</sup> (the &#8220;Sale Agreement&#8221;) with Jefferies LLC, as agent (&#8220;Agent&#8221;), pursuant to which the Company may offer and sell (the &#8220;Offering&#8221;), from time to time, at its option, through or to the Agent, up to an aggregate of $50,000,000 of shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;). Any Shares to be offered and sold under the Sale Agreement will be issued and sold pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-234107), filed with the SEC on October 4, 2019, and declared effective on October 15, 2019 (the &#8220;Registration Statement&#8221;) and the prospectus supplement relating to the Offering, dated August 5, 2020, that will be filed with the SEC, by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, (the &#8220;Securities Act&#8221;),&#160;or if specified by the Company, by any other method permitted by law, including, but not limited to, in negotiated and block transactions. </p><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the terms of the Sale Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company cannot provide any assurances that it will issue any Shares pursuant to the Sale Agreement. The Company will pay the Agent a commission of up to 3.0% of the gross proceeds from each sale of the Shares under the Sale Agreement. The Company will also reimburse the Agent for certain expenses incurred in connection with the Sale Agreement and agreed to provide the Agent with customary indemnification rights with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. </span></p><p style="margin:0px">&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Sale Agreement will terminate upon the earliest of (a) the sale of the maximum number or amount of the Shares permitted to be sold under the Sale Agreement, (b) the termination of the Sale Agreement by either of the parties thereto.</p><p style="margin:0px">&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company currently intends to use any net proceeds from the Offering for general corporate purposes, which may include (i) the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV; (ii) the ongoing commercial sales of its IVIG products; (iii) expanding the manufacturing capacity of its Boca Facility, including supply chain functions, and enhancing the robustness of its supply chain oversight; (iv) expanding its plasma collection facility network; and (v) research and development and business development opportunities.</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"><span style="mso-tab-count:1">The foregoing description of the Sale Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sale Agreement, which is included hereto as Exhibit 1.1 and incorporated by reference herein.</span></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">This Quarterly Report on Form 10-Q shall not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be any offer, solicitation or sale of the Shares in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><p style="MARGIN: 0px; text-align:left;"><strong><span class="atag" id="p26">Item 6.<span style="mso-tab-count:2"> Exhibits</span></span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">See the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">64</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;</p><p style="MARGIN: 0px; text-align:center;"><strong><span class="atag" id="sig">SIGNATURES</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160; </td><td colspan="3" style="vertical-align:top;"><strong>ADMA Biologics, Inc.</strong> </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td colspan="3">&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td style="vertical-align:top;">Date:<span style="mso-tab-count:1"> August 5, 2020</span> </td><td style="vertical-align:top;">By: </td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;" colspan="2">/s/ Adam S. Grossman </td><td>&#160; </td></tr><tr style="height:15px"><td style="width:45%;">&#160; </td><td style="width:3%;">&#160; </td><td style="width:5%;vertical-align:top;">Name: </td><td style="width:35%;vertical-align:top;">Adam S. Grossman </td><td style="width:12%;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td style="vertical-align:top;">Title: </td><td style="vertical-align:top;">President and Chief Executive Officer </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td>&#160; </td><td>&#160; </td><td>&#160; </td></tr><tr style="height:15px"><td style="vertical-align:top;">Date:<span style="mso-tab-count:1"> August 5, 2020</span> </td><td style="vertical-align:top;">By: </td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;" colspan="2">/s/ Brian Lenz </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td style="vertical-align:top;">Name: </td><td style="vertical-align:top;">Brian Lenz </td><td>&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td>&#160; </td><td style="vertical-align:top;">Title: </td><td style="vertical-align:top;">Executive Vice President and Chief Financial Officer </td><td>&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">65</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#toc11">Table of Contents</a></em></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:center;"><strong>EXHIBIT INDEX </strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:8%;vertical-align:top;" colspan="5"><strong>Exhibit Number </strong></td><td style="width:2%;">&#160; </td><td style="BORDER-BOTTOM: #000000 1px solid;width:90%;vertical-align:top;"><strong>Description</strong> </td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="5"><p style="margin:0px"><a href="adma_ex11.htm">1.1*</a></p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px"><a href="adma_ex11.htm">Open Market Sale Agreement<sup>SM</sup>, dated August 5, 2020, by and between ADMA Biologics, Inc. and Jefferies LLC.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="5"><p style="margin:0px"><a href="adma_ex51.htm">5.1*</a></p></td><td></td><td><p style="margin:0px"><a href="adma_ex51.htm">Opinion of Morgan, Lewis &amp; Bockius LLP.</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="5"><p style="margin:0px"><a href="adma_ex51.htm">23.1*</a></p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px"><a href="adma_ex51.htm">Consent of Morgan, Lewis &amp; Bockius LLP (included in Exhibit 5.1).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="5" style="vertical-align:top;"><a href="adma_ex311.htm">31.1* </a></td><td></td><td style="vertical-align:top;"><a href="adma_ex311.htm">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. </a></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="5" style="vertical-align:top;"><a href="adma_ex312.htm">31.2* </a></td><td></td><td style="vertical-align:top;"><a href="adma_ex312.htm">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. </a></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="5" style="vertical-align:top;"><a href="adma_ex321.htm">32.1** </a></td><td></td><td style="vertical-align:top;"><a href="adma_ex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. </a></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="5" style="vertical-align:top;"><a href="adma_ex322.htm">32.2** </a></td><td></td><td style="vertical-align:top;"><a href="adma_ex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. </a></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="5" style="vertical-align:top;">101* </td><td>&#160; </td><td style="vertical-align:top;">The following materials from ADMA Biologics, Inc.&#8217;s Form 10-Q for the quarter ended June 30, 2020, formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets as of June 30, 2020 (Unaudited) and December 31, 2019, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2020 and 2019, (iii) Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) for the three and six months ended June 30, 2020 and 2019, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2020 and 2019, and (v) Notes to (Unaudited) Condensed Consolidated Financial Statements. </td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="5" style="vertical-align:top;">104 </td><td>&#160; </td><td style="vertical-align:top;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">_______________________________</p><p style="MARGIN: 0px; text-align:left;">* Filed herewith. </p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:left;">** In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">66</td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>adma_ex11.htm
<TEXT>
<html><head><title>adma_ex11.htm</title><!--Document created using EDGARMaster--></head><body style="text-align:justify;font-size:10pt;font-family: Times New Roman"><P style="TEXT-ALIGN: right; MARGIN: 0px"><STRONG>EXHIBIT 1.1</STRONG></P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG><STRONG><U><FONT style='mso-bidi-font-family: "times new roman"'>OPEN MARKET SALE AGREEMENT</FONT></U></STRONG><SUP><FONT style='mso-bidi-font-family: "times new roman"'>SM</FONT></SUP></STRONG></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: right; MARGIN: 0px"><STRONG><STRONG><FONT style='FONT-WEIGHT: normal; mso-bidi-font-family: "times new roman"'>August 5, 2020</FONT></STRONG></STRONG></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">JEFFERIES LLC <BR>520 Madison Avenue</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">New York, New York 10022</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">Ladies and Gentlemen:</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">ADMA Biologics, Inc., a Delaware corporation (the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Company</FONT></STRONG>&#8221;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Agent</FONT></STRONG>&#8221;), shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Common Shares</FONT></STRONG>&#8221;), having an aggregate offering price of up to $50.0 million on the terms set forth in this agreement (this &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Agreement</FONT></STRONG>&#8221;).</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px"><STRONG><STRONG><FONT style="mso-list: ignore">Section 1.</FONT></STRONG><STRONG> DEFINITIONS</STRONG></STRONG></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Certain Definitions</U>. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the following respective meanings:</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Affiliate</FONT></STRONG>&#8221; of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first- mentioned Person. The term &#8220;control&#8221; (including the terms &#8220;controlling,&#8221; &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Agency Period</FONT></STRONG>&#8221; means the period commencing on the date of this Agreement and expiring on the earliest to occur of (x) the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y) the date this Agreement is terminated pursuant to <U>Section 7</U>.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Commission</FONT></STRONG>&#8221; means the U.S. Securities and Exchange Commission.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Exchange Act</FONT></STRONG>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Floor Price</FONT></STRONG>&#8221; means the minimum price set by the Company in the Issuance Notice below, which the Agent shall not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent and which in no event shall be less than $1.00 without the prior written consent of the Agent, which may be withheld in the Agent&#8217;s sole discretion.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">____________________</P>
<P style="MARGIN: 0px 0px 0px 0in"><SUP>SM</SUP> &#8220;Open Market Sale Agreement&#8221; is a service mark of Jefferies LLC</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px"></TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Issuance Amount</FONT></STRONG>&#8221; means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Issuance Notice</FONT></STRONG>&#8221; means a written notice delivered to the Agent by the Company in accordance with this Agreement in the form attached hereto as <U>Exhibit A</U> that is executed by its Chief Executive Officer, President or Chief Financial Officer. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Issuance Notice Date</FONT></STRONG>&#8221; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to <U>Section 3(b)(i)</U>. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Issuance Price</FONT></STRONG>&#8221; means the Sales Price less the Selling Commission.&nbsp;&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Maximum Program Amount</FONT></STRONG>&#8221; means Common Shares with an aggregate Sales Price of the lesser of (a) $50,000,000, (b) the number or dollar amount of Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (c) the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital stock), (d) the number or dollar amount of Common Shares permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable), or (e) the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below).&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Person</FONT></STRONG>&#8221; means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint venture, joint stock company, governmental authority or other entity of any kind.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Principal Market</FONT></STRONG>&#8221; means the Nasdaq Global Market or such other national securities exchange on which the Common Shares, including any Shares, are then listed.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Sales Price</FONT></STRONG>&#8221; means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Securities Act</FONT></STRONG>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Selling Commission</FONT></STRONG>&#8221; means up to three percent (3%) of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG>Settlement Date</STRONG>&#8221; means the second business day following each Trading Day during the period set forth in the Issuance Notice on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales. </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">2</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Shares</FONT></STRONG>&#8221; shall mean the Company&#8217;s Common Shares issued or issuable pursuant to this Agreement.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Trading Day</FONT></STRONG>&#8221; means any day on which the Principal Market is open for trading.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><STRONG><STRONG><FONT style="mso-list: ignore">Section 2.</FONT></STRONG> REPRESENTATIONS AND WARRANTIES OF THE COMPANY</STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">The Company represents and warrants to, and agrees with, the Agent that as of (1) the date of this Agreement, (2) each Issuance Notice Date, (3) each Settlement Date, (4) each Triggering Event Date and (5) as of each Time of Sale (as defined below) (each of the times referenced above is referred to herein as a &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Representation Date</FONT></STRONG>&#8221;), except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date: </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company has prepared and filed with the Commission a shelf registration statement on Form S-3 (File No. 333-234107) that contains <FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn">a base prospectus (the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Base Prospectus</FONT></STRONG>&#8221;). Such registration statement registers the issuance and sale by the Company of the Shares under the Securities Act. The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with respect to the Shares. Except where the context otherwise requires, <FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn">such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits and schedules thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities Act as from time to time amended or supplemented, is herein referred to as the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Registration Statement</FONT></STRONG>,&#8221; and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Securities Act relating to a particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities Act, in each case, as from time to time amended or supplemented, is referred to herein as the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Prospectus</FONT></STRONG>,&#8221; except that if any revised prospectus is provided to the Agent<FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"> by the Company for use in connection with the offering of the Shares that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Prospectus</FONT></STRONG>&#8221; shall refer to such revised prospectus from and after the time it is first provided to the Agent<FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"> for such use. The Registration Statement at the time it originally became effective is herein called the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Original Registration Statement</FONT></STRONG>.&#8221; As used in this Agreement, the terms &#8220;amendment&#8221; or &#8220;supplement&#8221; when applied to the Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference. </FONT></FONT></FONT></FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn">All references in this Agreement to financial statements and schedules and other information that is &#8220;contained,&#8221; &#8220;included&#8221; or &#8220;stated&#8221; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date; and all references in this Agreement to amendments or supplements to the Registration Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act that is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date</FONT>. The Company&#8217;s obligations under this Agreement to furnish, provide or deliver or make available (and all other references of like import) copies of any report or statement shall be deemed satisfied if the same is filed with the Commission through its Electronic Data Gathering, Analysis and Retrieval system (&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">EDGAR</FONT></STRONG>&#8221;).</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">3</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">At the time the Registration Statement was originally declared effective and at the time the Company&#8217;s most recent annual report on Form 10-K was filed with the Commission, if later, the Company met the then-applicable requirements for use of Form S-3 under the Securities Act. During the Agency Period, each time the Company files an annual report on Form 10-K the Company will meet the then-applicable requirements for use of Form S-3 under the Securities Act. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(b)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Original Registration Statement and any Rule 462(b) Registration Statement have been declared effective by the Commission under the Securities Act. The Company has complied, to the Commission&#8217;s satisfaction, with all requests of the Commission for additional or supplemental information. No stop order suspending the effectiveness of the Registration Statement or any Rule 462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission.<SUP> </SUP></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">The Prospectus when filed complied in all material respects with the Securities Act and, if filed with the Commission through EDGAR (except as may be permitted by Regulation S&#8209;T under the Securities Act), was identical to the copy thereof delivered to the Agent for use in connection with the issuance and sale of the Shares. Each of the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment thereto, at the time it became effective and at each Representation Date, complied and will comply, as the case may be, in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the date of this Agreement, the Prospectus and any Free Writing Prospectus (as defined below) considered together (collectively, the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Time of Sale Information</FONT></STRONG>&#8221;) did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus, as amended or supplemented, as of its date and at each Representation Date, did not and will not, as the case may be, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule 462(b) Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use therein, <FONT style="mso-font-width: 0%">it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in <U>Section 6</U> below.</FONT> There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. The Registration Statement and the offer and sale of the Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule. </P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">4</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(c)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company is not an &#8220;ineligible issuer&#8221; in connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Any Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act. Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or retention where required and legending, and each such Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted, conflicts with or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein. Except for the Free Writing Prospectuses, if any, and electronic road shows, if any, furnished to the Agent before first use, the Company has not prepared, used or referred to, and will not, without the Agent&#8217;s prior consent, prepare, use or refer to, any Free Writing Prospectus.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(d)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as applicable, and, when read together with the other information in the Prospectus, do not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(e)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><FONT style="mso-font-width: 0%">The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they were or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other information in the Prospectus, at the time the Registration Statement and any amendments thereto become effective and at each </FONT><FONT style="mso-bidi-font-weight: bold">Time of Sale</FONT><FONT style="mso-font-width: 0%"> (as defined below), as the case may be, will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(f)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement and the Prospectus (other than for subsequent issuances, if any, pursuant to employee benefit plans described in the Prospectus or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement and the Prospectus). All the outstanding Common Shares have been duly authorized and validly issued, are fully paid and nonassessable and are free of any preemptive or similar rights; except as set forth in the Time of Sale Information and the Prospectus, the Company is not a party to or bound by any outstanding options, warrants or similar rights to subscribe for, or contractual obligations to issue, sell, transfer or acquire, any of its capital stock or any securities convertible into or exchangeable for any of such capital stock; the Common Shares to be issued and sold by the Company hereunder have been duly authorized and, when issued and delivered against full payment therefor in accordance with the terms hereof will be validly issued, fully paid and nonassessable and free of any preemptive or similar rights; and the capital stock of the Company conforms to the description thereof in the Registration Statement, the Time of Sale Information and the Prospectus (or any amendment or supplement thereto).</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">5</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(g)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Each of the Company and its subsidiaries is duly organized and validly existing as a corporation, limited liability company or other organization in good standing under the laws of the jurisdiction of its incorporation or organization with full corporate or organizational power and authority to own, lease and operate its properties and to conduct its business as presently conducted and as described in the Registration Statement, the Time of Sale Information and the Prospectus (and any amendment or supplement thereto) and is duly registered and qualified to conduct its business and is in good standing in each jurisdiction or place where the nature of its properties or the conduct of its business requires such registration or qualification, except where the failure to so register or qualify would not have a material adverse effect on the condition (financial or other), business, properties, net worth, results of operations or prospects of the Company and its subsidiaries, taken as a whole (a &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Material Adverse Effect</FONT></STRONG>&#8221;). As used in this Agreement, &#8220;subsidiaries&#8221; shall mean the Company&#8217;s significant subsidiaries (as such term is defined in Rule 1-02 of Regulation S-X promulgated by the Commission), as set forth on Schedule A. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(h)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The issued and outstanding shares of capital stock of each of the Company&#8217;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company free and clear of any security interests, liens, encumbrances, equities or claims, other than liens granted in connection with the Company&#8217;s Credit Agreement, dated as of February 11, 2019, with Perceptive Credit Holdings II, LP, as amended on May 3, 2019 (the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Credit Agreement</FONT></STRONG>&#8221;). </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(i)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Except as would not have, individually or in the aggregate, a Material Adverse Effect, there are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened, against the Company or its subsidiaries or to which the Company or its subsidiaries or any of their properties are subject, that are required to be described in the Registration Statement, Time of Sale Information or the Prospectus (or any amendment or supplement thereto) but are not disclosed as required. Except as described in the Registration Statement, Time of Sale Information or Prospectus, there is no action, suit, inquiry, proceeding or investigation by or before any court or governmental or other regulatory or administrative agency or commission pending or, to the knowledge of the Company, threatened, against or involving the Company or its subsidiaries, which might individually or in the aggregate prevent or adversely affect the transactions contemplated by this Agreement or result in a Material Adverse Effect, nor to the Company&#8217;s knowledge, is there any basis for any such action, suit, inquiry, proceeding or investigation.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(j)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>There are no agreements, contracts, indentures, leases or other instruments that are required to be described in the Registration Statement, the Time of Sale Information or the Prospectus (or any amendment or supplement thereto) or to be filed as an exhibit to the Registration Statement that are not described, filed or incorporated by reference in the Registration Statement, the Time of Sale Information and the Prospectus as required by the Securities Act. Neither the Company nor the applicable subsidiary has received notice or been made aware of a breach or default by the Company under any of such contracts.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">6</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(k)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Neither the Company nor any of its subsidiaries is (i) in violation of (A) its certificate of incorporation or bylaws, or other organizational documents, each as amended to date, (B) any federal, state or foreign law, ordinance, administrative or governmental rule or regulation applicable to the Company or any of its subsidiaries, the violation of which would have a Material Adverse Effect or (C) any decree of any federal, state or foreign court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries, the violation of which would have a Material Adverse Effect; or (ii) in default in any material respect in the performance of any obligation, agreement or condition contained in (A) any bond, debenture, note or any other evidence of indebtedness or (B) any agreement, indenture, lease or other instrument (each of (A) and (B), an &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Existing Instrument</FONT></STRONG>&#8221;) to which the Company or any of its subsidiaries is a party or by which any of their properties may be bound, which default would have a Material Adverse Effect; and to the knowledge of the Company there does not exist any state of facts that constitutes an event of default on the part of the Company or any of its subsidiaries as defined in such Existing Instruments or that, with notice or lapse of time or both, would constitute such an event of default. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(l)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The Company&#8217;s execution and delivery of this Agreement and the performance by the Company of its obligations under this Agreement have been duly and validly authorized by the Company and this Agreement has been duly executed and delivered by the Company.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(m)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>None of the issuance and sale of the Shares by the Company, the execution, delivery or performance of this Agreement by the Company nor the consummation by the Company of the transactions contemplated hereby (i) requires any consent, approval, authorization or other order of or registration or filing with, any court, regulatory body, administrative agency or other governmental body, agency or official (except such as may be required for the registration of the Shares under the Securities Act, the listing of the Shares for trading on the Nasdaq Global Market and compliance with the securities or Blue Sky laws of various jurisdictions, all of which will be, or have been, effected in accordance with this Agreement and except as required under FINRA&#8217;s Rules of Fair Practice), (ii) conflicts with or will conflict with or constitutes or will constitute a breach of, or a default under, the Company&#8217;s certificate of incorporation, as amended to date, (iii) conflicts with or will conflict with or constitutes or will constitute a breach of, or a default under, the Company&#8217;s bylaws, as amended to date, or any agreement, indenture, lease or other instrument to which the Company or any of its subsidiaries is a party or by which any of its properties may be bound, (iv) violates any statute, law, regulation, ruling, filing, judgment, injunction, order or decree applicable to the Company or any of its subsidiaries or any of their properties, or (v) results in a breach of, or default under, or results in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or requires the consent of any other party to, any Existing Instrument, except, in the case of clauses (i), (iii), (iv) and (v), for such conflicts, breaches, defaults, liens, charges or encumbrances in that will not, individually or in the aggregate, result in a Material Adverse Effect.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(n)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Except as described in the Registration Statement, Time of Sale Information and the Prospectus, neither the Company nor any of its subsidiaries has outstanding any options to purchase, or any warrants to subscribe for, or any securities or obligations convertible into, or any contracts or commitments to issue or sell, any Common Shares or any such warrants or convertible securities or obligations. Except as described in the Registration Statement, Time of Sale Information and Prospectus, no holder of securities of the Company has rights to the registration of any securities of the Company as a result of or in connection with the filing of the Registration Statement or the consummation of the transactions contemplated hereby that have not been satisfied or heretofore waived in writing.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">7</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(o)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>CohnReznick LLP, the independent registered public accounting firm who has audited the financial statements of the Company (including the related notes thereto and supporting schedules) filed as part of the Registration Statement, Time of Sale Information and the Prospectus (or any amendment or supplement thereto), are independent public accountants as required by the Securities Act and the Exchange Act.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(p)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The financial statements, together with related schedules and notes, included in the Registration Statement, the Time of Sale Information and the Prospectus (and any amendment or supplement thereto), present fairly in all material respects the financial condition, results of operations, cash flows and changes in financial position of the Company on the basis stated in the Registration Statement at the respective dates or for the respective periods to which they apply; such statements and related schedules and notes have been prepared in accordance with generally accepted accounting principles consistently applied throughout the periods involved, except as disclosed therein; and the other financial and statistical information and data set forth in the Registration Statement and Prospectus (and any amendment or supplement thereto) is accurately presented and prepared on a basis consistent with such financial statements and the books and records of the Company. No other financial statements or schedules are required to be included in the Registration Statement.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(q)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Since the date of the last balance sheet included in or incorporated by reference into the Prospectus (i) neither the Company nor any of its subsidiaries has incurred any material liabilities or obligations, indirect, direct or contingent, or entered into any transaction that is not in the ordinary course of business, (ii) neither the Company nor any of its subsidiaries has sustained any material loss or interference with its business or properties from fire, flood, windstorm, accident or other calamity, whether or not covered by insurance, (iii) neither the Company nor any of its subsidiaries has paid or declared any dividends or other distributions with respect to its capital stock and the Company is not in default under the terms of any class of capital stock of the Company or any outstanding debt obligations, (iv) there has not been any change in the authorized or outstanding capital stock of the Company or any material change in the indebtedness of the Company (other than in the ordinary course of business) and (v) there has not been any material adverse change, or any development involving or that may reasonably be expected to result in a Material Adverse Effect, in the condition (financial or otherwise), business, properties, net worth, result of operations or prospects of the Company.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(r)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Common Shares are registered pursuant to Section 12(b) of the Exchange Act and listed on the Nasdaq Global Market, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Nasdaq Global Market, nor has the Company received any notification that the Commission or the Nasdaq is contemplating terminating such registration or listing.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">8</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(s)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Other than excepted activity pursuant to Regulation M under the Exchange Act, the Company has not taken and will not take, directly or indirectly, any action that constituted, or any action designed to, or that might reasonably be expected to cause or result in or constitute, under the Securities Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares or for any other purpose.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(t)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company and each of its subsidiaries have filed, or have applied for an extension of time to file, all tax returns required to be filed (other than certain state or local tax returns, as to which the failure to file, individually or in the aggregate, would not have a Material Adverse Effect), which filed returns are complete and correct, and neither the Company nor any subsidiary is in default in the payment of any taxes that were payable pursuant to said filed returns or any assessments with respect thereto; unless the same has been contested in good-faith. All deficiencies asserted as a result of any federal, state, local or foreign tax audits have been paid or finally settled and no issue has been raised in any such audit that, by application of the same or similar principles, reasonably could be expected to result in a proposed deficiency for any other period not so audited. There are no outstanding agreements or waivers extending the statutory period of limitation applicable to any federal, state, local or foreign tax return for any period. No stamp or other issuance or transfer taxes or duties and no capital gains, income, withholding or other taxes are payable by the Agent in the United States or any political subdivision or taxing authority thereof or therein in connection with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the Company of the Shares.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(u)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Except as set forth in the Registration Statement, Time of Sale Information and the Prospectus, there are no transactions with &#8220;affiliates&#8221; (as defined in Rule 405 under the Securities Act) or any officer, director or security holder of the Company (whether or not an affiliate) that are required by the Securities Act to be disclosed in the Registration Statement, Time of Sale Information and the Prospectus. Additionally, no relationship, direct or indirect, exists between the Company or any of its subsidiaries on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any subsidiary on the other hand that is required by the Securities Act to be disclosed in the Registration Statement, the Time of Sale Information and the Prospectus that is not so disclosed.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(v)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company is not an &#8220;investment company&#8221; or an &#8220;affiliated person&#8221; of, or &#8220;promoter&#8221; or &#8220;principal underwriter&#8221; for, an investment company within the meaning of the Investment Company Act of 1940, as amended.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(w)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Except as would not have, individually or in the aggregate, a Material Adverse Effect, or as otherwise disclosed in the Time of Sale Information and the Prospectus, each of the Company and its subsidiaries has good and marketable title to all property (real and personal) described in the Time of Sale Information and the Prospectus as being owned by it, free and clear of all liens, claims, security interests or other encumbrances except (i) as provided by the Credit Agreement, (ii) such as are described in the Time of Sale Information and the Prospectus or (iii) such as do not have or will not result in a Material Adverse Effect to the use of the property or the conduct of the business of the Company. All property (real and personal) held under lease by the Company and its subsidiaries is held by it under valid, subsisting and enforceable leases with only such exceptions as in the aggregate are not materially burdensome and do not have or result in a Material Adverse Effect to the use of the property or the conduct of the business of the Company.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">9</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(x)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Except as otherwise disclosed in the Time of Sale Information and the Prospectus, each of the Company and its subsidiaries has all permits, licenses, franchises, approvals, consents and authorizations of governmental or regulatory authorities (hereinafter &#8220;permit&#8221; or &#8220;permits&#8221;) as are necessary to own its properties and to conduct its business in the manner described in the Time of Sale Information and the Prospectus, subject to such qualifications as may be set forth in the Time of Sale Information and the Prospectus, except where the failure to have obtained any such permit has not had and will not have a Material Adverse Effect; each of the Company and its subsidiaries has operated and is operating its business in material compliance with and not in material violation of all of its obligations with respect to each such permit and no event has occurred that allows, or after notice or lapse of time would allow, revocation or termination of any such permit or result in any other material impairment of the rights of any such permit, subject in each case to such qualification as may be set forth in the Time of Sale Information and the Prospectus; and, except as described in the Time of Sale Information and the Prospectus, such permits contain no restrictions that are materially burdensome to the Company or any of its subsidiaries.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(y)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The consolidated financial statements of the Company, together with the related schedules and notes thereto, set forth or incorporated by reference in the Time of Sale Information and the Prospectus present fairly in all material respects (i) the financial condition of the Company and its consolidated subsidiaries as of the dates indicated and (ii) the consolidated results of operations, stockholders&#8217; equity and changes in cash flows of the Company and its consolidated subsidiaries for the periods therein specified; and such financial statements and related schedules and notes thereto have been prepared in conformity with United States generally accepted accounting principles, consistently applied throughout the periods involved (except as otherwise stated therein and subject, in the case of unaudited financial statements, to the absence of footnotes and normal year-end adjustments). There are no other financial statements (historical or pro forma) that are required to be included or incorporated by reference in the Time of Sale Information and the Prospectus; and the Company does not have any material liabilities or obligations, direct or contingent (including any off-balance sheet obligations), not disclosed in the Time of Sale Information and the Prospectus; and all disclosures contained in the Time of Sale Information and the Prospectus regarding &#8220;non-GAAP financial measures&#8221; (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10(e) of Regulation S-K under the Securities Act, to the extent applicable, and present fairly in all material respects the information shown therein and the Company&#8217;s basis for using such measures. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(z)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company and its subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorizations and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">10</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(aa)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company has established and maintains and evaluates &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rule 13a-15 and 15d-15 under the Exchange Act); such disclosure controls and procedures are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#8217;s Chief Executive Officer and its Chief Financial Officer by others within those entities, and such disclosure controls and procedures are effective to perform the functions for which they were established; the Company&#8217;s independent auditors and the Audit Committee of the Board of Directors of the Company have been advised of (i) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize, and report financial data and (ii) all fraud, whether or not material, known to the Company, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting; since the date of the most recent evaluation of such disclosure controls and procedures, except as described in the Registration Statement, the Time of Sale Information and the Prospectus, there have been no significant changes in internal control over financial reporting or in other factors that has materially affected or is reasonably likely to materially affect internal control over financial reporting, including any corrective actions with regard to significant deficiencies and material weaknesses; the principal executive officers (or their equivalents) and principal financial officers (or their equivalents) of the Company have made all certifications required by the Sarbanes-Oxley Act of 2002, as amended (the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Sarbanes-Oxley Act</FONT></STRONG>&#8221;) and any related rules and regulations promulgated by the Commission, and the statements contained in each such certification are complete and correct; the Company and its subsidiaries are, and the Company has taken all necessary actions to ensure that the Company&#8217;s directors and officers in their capacities as such are, each in compliance in all material respects with all applicable effective provisions of the Sarbanes-Oxley Act and the rules and regulations of the Commission and the Nasdaq Stock Market promulgated thereunder. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(bb)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The Company and, to the knowledge of the Company, the Company&#8217;s directors or officers, in their capacities as such, are each in compliance in all material respects with Section 402 of the Sarbanes-Oxley Act and the rules and regulations promulgated thereunder.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(cc)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company has not, prior to the date hereof, made any offer or sale of securities which could be &#8220;integrated&#8221; for purposes of the Securities Act with the offer and sale of the Common Shares pursuant to the Registration Statement, the Time of Sale Information and the Prospectus; and except as disclosed in the Registration Statement, Time of Sale Information and the Prospectus, the Company has not sold or issued any security during the 180-day period preceding the date of the Prospectus, including but not limited to any sales pursuant to Rule 144A or Regulations D or S under the Securities Act, other than Common Shares used pursuant to employee benefit plans, qualified stock option plans or the employee compensation plans or pursuant to outstanding options, rights or warrants as described in the Time of Sale Information and the Prospectus.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">11</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(dd)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>(i) None of the Company or any of its subsidiaries or affiliates, or any officer or employee thereof, or, to the Company&#8217;s knowledge, any director, agent or representative of the Company or of any of its subsidiaries or affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) (&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Government Official</FONT></STRONG>&#8221;) in order to influence official action, or to any person in violation of any applicable anti-corruption laws; (ii) the Company and each of its subsidiaries and affiliates have conducted their businesses in compliance with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; and (iii) neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(ee)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The operations of the Company and each of its subsidiaries are and have been conducted at all times in material compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and each of its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Anti-Money Laundering Laws</FONT></STRONG>&#8221;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(ff)<FONT style='FONT: 7pt "times new roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; </FONT></FONT>(i) None of the Company, any of its subsidiaries, or any officer or employee thereof, or, to the Company&#8217;s knowledge, any director, agent, affiliate or representative of the Company or any of its subsidiaries, is an individual or entity (&#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Person</FONT></STRONG>&#8221;) that is, or is owned or controlled by one or more Persons that are:</FONT></P>
<P style="MARGIN: 0px">&nbsp; </P>
<P style="MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px">(A) the subject of any sanctions administered or enforced by the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury, or other relevant sanctions authority (collectively, &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Sanctions</FONT></STRONG>&#8221;), or </P>
<P style="MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px">(B) located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Crimea, Cuba, Iran, North Korea and Syria).</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">12</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px; TEXT-INDENT: 90px">(ii) The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person:</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px">(A) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; or</P>
<P style="MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px">(B) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(gg)<FONT style='FONT: 7pt "times new roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT></FONT>(iii) For the past five years, the Company and each of its subsidiaries have not knowingly engaged in, are not now knowingly engaged in any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(hh)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>No labor problem or dispute with the employees of the Company or any of its subsidiaries exists, or, to the Company&#8217;s knowledge, is threatened or imminent, which would reasonably be expected to result in a Material Adverse Effect. The Company is not aware that any key employee or significant group of employees of the Company or any of its subsidiaries plans to terminate employment with the Company or any of its subsidiaries. Neither the Company nor any of its subsidiaries has engaged in any unfair labor practice, and except for matters which would not, individually or in the aggregate, result in a Material Adverse Effect, (i) there is (A) no unfair labor practice complaint pending or, to the Company&#8217;s knowledge, threatened against the Company or any of its subsidiaries before the National Labor Relations Board, and no grievance or arbitration proceeding arising out of or under collective bargaining agreements is pending or to the Company&#8217;s knowledge, threatened, (B) no strike, labor dispute, slowdown or stoppage pending or, to the Company&#8217;s knowledge, threatened against the Company or any of its subsidiaries and (C) no union representation dispute currently existing concerning the employees of the Company or any of its subsidiaries and (ii) to the Company&#8217;s knowledge, (A) no union organizing activities are currently taking place concerning the employees of the Company or any of its subsidiaries and (B) there has been no violation of any federal, state, local or foreign law relating to discrimination in the hiring, promotion or pay of employees, any applicable wage or hour laws or any provision of the Employee Retirement Income Security Act of 1974 (&#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">ERISA</FONT></STRONG>&#8221;) or the rules and regulations promulgated thereunder concerning the employees of the Company or any of its subsidiaries. </P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(ii)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The Company and its subsidiaries are (i) in compliance with any and all applicable federal, state, local and foreign laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Environmental Laws</FONT></STRONG>&#8221;), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or other approvals would not, individually or in the aggregate, have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has been named as a &#8220;potentially responsible party&#8221; under the Comprehensive Environmental Response Compensation and Liability Act of 1980, as amended. Neither the Company nor any of its subsidiaries owns, leases or occupies any property that appears on any list of hazardous sites compiled by any state or local governmental agency. There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, individually or in the aggregate, result in a Material Adverse Effect. </FONT></P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">13</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(jj)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Each of the Company and its subsidiaries owns and has full right, title and interest in and to, or has valid licenses to use, each material trade name, trademark, service mark, patent, copyright, approval, trade secret and other similar rights (collectively &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Intellectual Property</FONT></STRONG>&#8221;) under which the Company and its subsidiaries conduct all or any material part of its business, and the Company has not created any lien or encumbrance on, or granted any right or license with respect to, any such Intellectual Property except where the failure to own or obtain a license or right to use any such Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect; there is no material claim pending against the Company or its subsidiaries with respect to any Intellectual Property and the Company and its subsidiaries have not received notice or otherwise become aware that any Intellectual Property that it uses or has used in the conduct of its business infringes upon or conflicts with the rights of any third party. Neither the Company nor any of its subsidiaries has become aware that any material Intellectual Property that it uses or has used in the conduct of its business infringes upon or conflicts with the rights of any third party. </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(kk)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>To the Company&#8217;s knowledge, there are no affiliations or associations between (i) any member of FINRA and (ii) the Company or any of the Company&#8217;s officers, directors, 5% or greater security holders or any beneficial owner of the Company&#8217;s unregistered equity securities that were acquired at any time on or after the 180th day immediately preceding the date the Registration Statement was initially filed with the Commission.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(ll)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which it is engaged; and neither the Company nor any of its subsidiaries has reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a comparable cost.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(mm)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company and its subsidiaries and any &#8220;employee benefit plan&#8221; (as defined under ERISA) established or maintained by the Company, its subsidiaries or their &#8220;ERISA Affiliates&#8221; (as defined below) are in compliance in all material respects with ERISA and all other applicable state and federal laws. &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">ERISA Affiliate</FONT></STRONG>&#8221; means, with respect to the Company or a subsidiary, any member of any group or organization described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended (the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Code</FONT></STRONG>&#8221;) of which the Company or such subsidiary is a member. No &#8220;reportable event&#8221; (as defined in ERISA) has occurred or is reasonably expected to occur with respect to any &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates. No &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#8220;employee benefit plan&#8221; were terminated, would have any &#8220;amount of unfunded benefit liabilities&#8221; (as defined in ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any &#8220;employee benefit plan&#8221; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, that would cause the loss of such qualification. </P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">14</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(nn)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Information or the Prospectus that have not been described as required.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(oo)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Neither the Company nor any of its subsidiaries nor, to the Company&#8217;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement, the Time of Sale Information or the Prospectus.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(pp)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Except as pursuant to this Agreement, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#8217;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(qq)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Each financial or operational projection or other &#8220;forward-looking statement&#8221; (as defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Information or the Prospectus (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward&#8209;looking statement. No such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(rr)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company does not have any outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section 13(k) of the Exchange Act.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(ss)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">IT Systems</FONT></STRONG>&#8221;) are adequate within reasonable industry standards for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#8220;Personal Data,&#8221; used in connection with their businesses. &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Personal Data</FONT></STRONG>&#8221; means (i) a natural person&#8217;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&#8217;s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as &#8220;personally identifying information&#8221; under the Federal Trade Commission Act, as amended; (iii) &#8220;personal data&#8221; as defined by GDPR (as defined below); (iv) any information which would qualify as &#8220;protected health information&#8221; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">HIPAA</FONT></STRONG>&#8221;); and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#8217;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. </P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">15</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(tt)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The Company and its subsidiaries are, and at all times in the past three years have been, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in compliance with, the European Union General Data Protection Regulation (&#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">GDPR</FONT></STRONG>&#8221;) (EU 2016/679) (collectively, the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Privacy Laws</FONT></STRONG>&#8221;). To facilitate compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Policies</FONT></STRONG>&#8221;). The Company and its subsidiaries have at all times during the last three years made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(uu)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The clinical trials and other studies conducted by the Company, or, to the Company&#8217;s knowledge, by its collaborators or contractors on behalf of the Company (collectively, &#8220;studies&#8221;), that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Information or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with applicable Health Care Laws (as defined in Section 2(vv)), including relevant and applicable good clinical practices (GCPs), and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are materially inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Information or the Prospectus; the Company and its subsidiaries have made all such material filings and obtained all such material approvals in relation to the studies as may be required by United States Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Regulatory Agencies</FONT></STRONG>&#8221;); and neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Information or the Prospectus. </FONT></P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">16</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(vv)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Except as described in the Registration Statement, the Time of Sale Information and the Prospectus, the Company and its subsidiaries are, and at all times have been, in material compliance with all Health Care Laws applicable to their business and operations. For purposes of this Agreement, &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Health Care Laws</FONT></STRONG>&#8221; means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Public Health Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) (42 U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section 1320-7h), and applicable laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii) the directives and regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any of its subsidiaries has received written notice of any material claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&#8217;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(ww)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>All statistical, demographic and market related data included in the Registration Statement or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate. To the extent required, the Company has obtained the written consent for the use of such data from such sources.</FONT></P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">17</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(xx)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>The Company and its subsidiaries have been and are in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Effect.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(yy)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT>Except as disclosed in the Prospectus, no subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#8217;s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">Any certificate signed by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to <U>Section 4(o)</U> hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><STRONG><STRONG><FONT style="mso-list: ignore">Section 3.</FONT></STRONG> ISSUANCE AND SALE OF COMMON SHARES</STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Sale of Securities</U></FONT>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(b)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Mechanics of Issuances</U>. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">(i) <U>Issuance Notice</U>. Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on which the conditions set forth in <U>Section 5(a)</U> and <U>Section 5(b)</U> shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance Notice; <EM><FONT style="FONT-STYLE: italic">provided, however</FONT></EM>, that (A) in no event may the Company deliver an Issuance Notice to the extent that (I) the sum of (x) the aggregate Sales Price of the requested Issuance Amount, plus (y) the aggregate Sales Price of all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount; and (B) prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by e&#8209;mail to the persons set forth in Schedule B hereto, with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time. </P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">18</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">(ii)<FONT style="mso-tab-count: 1"> <U>Agent Efforts</U>. Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice, the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement. For the avoidance of doubt, the parties to this Agreement may modify an Issuance Notice at any time provided they both agree in writing to any such modification. </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">(iii)<FONT style="mso-tab-count: 1"> <U>Method of Offer and Sale</U>. The Shares may be offered and sold (A) in privately negotiated transactions with the consent of the Company; (B) as block transactions; or (C) by any other method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the Principal Market or sales made into any other existing trading market of the Common Shares. Nothing in this Agreement shall be deemed to require either party to agree to the method of offer and sale specified in the preceding sentence, and (except as specified in clauses (A) and (B) above) the method of placement of any Shares by the Agent shall be at the Agent&#8217;s discretion.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">(iv)<FONT style="mso-tab-count: 1"> <U>Confirmation to the Company</U>. If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no later than the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company in respect thereof. </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">(v)<FONT style="mso-tab-count: 1"> <U>Settlement</U>. Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of Shares and, subject to the provisions of <U>Section 5</U>, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Agent or its designee&#8217;s account at The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of immediately available funds, the related Issuance Price in same day funds delivered to an account designated by the Company prior to the Settlement Date. The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant time Shares are sold pursuant to this Agreement (each, a &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Time of Sale</FONT></STRONG>&#8221;). </FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">19</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">(vi)<FONT style="mso-tab-count: 1"> <U>Suspension or Termination of Sales</U>. Consistent with standard market settlement practices, the Company or the Agent may, upon notice to the other party hereto in writing or by telephone (confirmed immediately by verifiable email), suspend any sale of Shares, and the period set forth in an Issuance Notice shall immediately terminate; <EM><FONT style="FONT-STYLE: italic">provided, however</FONT></EM>, that (A) such suspension and termination shall not affect or impair either party&#8217;s obligations with respect to any Shares placed or sold hereunder prior to the receipt of such notice; (B) if the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with <U>Section 3(b)(v)</U> with respect to such Shares; and (C) if the Company defaults in its obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares from stock lenders in the event that the Company has not delivered Shares to settle sales as required by subsection (v) above, and may use the Shares to settle or close out such borrowings. The Company agrees that no such notice shall be effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to <U>Section 3(b)(i)</U>. </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">(vii)<FONT style="mso-tab-count: 1"> <U>No Guarantee of Placement, Etc.</U> The Company acknowledges and agrees that (A) there can be no assurance that the Agent will be successful in placing Shares; (B) the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares; and (C) the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">(viii)<FONT style="mso-tab-count: 1"> <U>Material Non-Public Information.</U> Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the Company is in possession of material non-public information.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%"><FONT style="mso-list: ignore">(c)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Fees</U></FONT><FONT style="mso-bookmark: _ref234639077">. As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to <U>Section 3(b)(vi))</U> by the Agent deducting the Selling Commission from the applicable Issuance Amount. </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%"><FONT style="mso-list: ignore">(d)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT></FONT></FONT><U>Expenses</U>. <FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-font-width: 0%">The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Shares; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Shares; (iv) all fees and expenses of the Company&#8217;s counsel, independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus (as defined below) prepared by or on behalf of, used by, or referred to by the Company, and all amendments and supplements thereto, and this Agreement; (vi) all filing fees, attorneys&#8217; fees and expenses incurred by the Company or the Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent, preparing and printing a &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Blue Sky Survey</FONT></STRONG>&#8221; or memorandum and a &#8220;Canadian wrapper&#8221; and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions; (vii) the reasonable fees and disbursements of the Agent&#8217;s counsel, including<FONT style="mso-font-width: 0%"> the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent&#8217;s participation in the offering and distribution of the Shares</FONT>;<FONT style="mso-font-width: 0%"> (viii) the filing fees incident to FINRA review, if any; (ix) the costs and expenses of the Company relating to investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such consultants, and the cost of any aircraft chartered in connection with the road show; and (x) the fees and expenses associated with listing the Shares on the </FONT>Principal Market. <FONT style="mso-font-width: 0%">The fees and disbursements of Agent&#8217;s counsel pursuant to subsections (vi) and (vii) above shall not exceed (A) $50,000 in connection with entering into this Agreement and filing of the program&nbsp;and (B) $15,000 in connection with each Triggering Event Date (as defined below) on which the Company is required to provide a certificate pursuant to <U>Section 4(o</U>).</FONT> </FONT></FONT></FONT></FONT></P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">20</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><STRONG><STRONG><FONT style="mso-list: ignore">Section 4.</FONT></STRONG><STRONG> ADDITIONAL COVENANTS</STRONG></STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this Agreement:</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U><FONT style="mso-bidi-font-style: italic">Exchange Act Compliance</FONT></U>. During the Agency Period, the Company shall (i) file, on a timely basis, with the Commission all reports and documents required to be filed under Section 13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act; and (ii) either (A) include in its quarterly reports on Form 10-Q and its annual reports on Form 10-K, a summary detailing, for the relevant reporting period, (1) the number of Shares sold through the Agent pursuant to this Agreement and (2) the net proceeds received by the Company from such sales or (B) prepare a prospectus supplement containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an &#8220;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Interim Prospectus Supplement</FONT></STRONG>&#8221;), such summary information and, at least once a quarter and subject to this Section 4, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the time periods required by Rule 424(b) and Rule 430B under the Securities Act)). </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(b)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Securities Act Compliance</U>. After the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii) of the time and date of any filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus, any Free Writing Prospectus; (iii) of the time and date that any post-effective amendment to the Registration Statement or any Rule 462(b) Registration Statement becomes effective; and (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its reasonable efforts to obtain the lifting of such order as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were received in a timely manner by the Commission. </FONT></P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">21</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(c)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Amendments and Supplements to the Prospectus and Other Securities Act Matters</U><FONT style="mso-bidi-font-style: italic">.</FONT> If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including the Securities Act, the Company agrees (subject to Section 4(d) and 4(f)) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law including the Securities Act. Neither the Agent&#8217;s consent to, or delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#8217;s obligations under Sections 4(d) and 4(f).</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(d)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Agent&#8217;s Review of Proposed Amendments and Supplements</U><FONT style="mso-bidi-font-style: italic">.</FONT><EM><FONT style="FONT-STYLE: italic; mso-bidi-font-style: normal"> </FONT></EM>Prior to amending or supplementing the Registration Statement (including any registration statement filed under Rule 462(b) under the Securities Act) or the Prospectus (excluding any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any such proposed amendment or supplement without the Agent&#8217;s prior consent, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(e)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Use of Free Writing Prospectus</U></FONT><FONT style="mso-bookmark: _ref234639148">. Neither the Company nor the Agent has prepared, used, referred to or distributed, or will prepare, use, refer to or distribute, without the other party&#8217;s prior written consent, any &#8220;written communication</FONT>&#8221; that constitutes <FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639148">a &#8220;free writing prospectus&#8221; as such terms are defined in Rule 405 </FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT>under the Securities Act with respect to the offering contemplated by this Agreement (any <FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639148">such free writing prospectus being referred to herein as a &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Free Writing Prospectus</FONT></STRONG>&#8221;). </FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">22</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(f)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Free Writing Prospectuses</U><FONT style="mso-bidi-font-style: italic">. </FONT>The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Agent&#8217;s consent, not to be unreasonably withheld. The Company shall furnish to the Agent, without charge, as many copies of any free writing prospectus prepared by or on behalf of, or used by the Company, as the Agent may reasonably request. If at any time when a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such subsequent time, not misleading, as the case may be; <EM><FONT style="FONT-STYLE: italic">provided, however</FONT></EM>, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Agent&#8217;s consent, not to be unreasonably withheld. </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(g)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Filing of Agent Free Writing Prospectuses</U><FONT style="mso-bidi-font-style: italic">. </FONT>The Company shall not to take any action that would result in the Agent or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of the Agent that the Agent otherwise would not have been required to file thereunder.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(h)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Copies of Registration Statement and Prospectus</U>. After the date of this Agreement through the last time that a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares, the Company agrees to furnish the Agent with copies (which may be electronic copies) of the Registration Statement and each amendment thereto, and with copies of the Prospectus and each amendment or supplement thereto in the form in which it is filed with the Commission pursuant to the Securities Act or Rule 424(b) under the Securities Act, both in such quantities as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is required under the Securities Act or under the blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus is delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such offers as soon as practicable); and if the Company decides to amend or supplement the Registration Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare and cause to be filed promptly with the Commission an amendment or supplement to the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance; provided, however, that if during such same period the Agent is required to deliver a prospectus in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">23</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(i)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Blue Sky Compliance</U>. The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its reasonable efforts to obtain the withdrawal thereof as soon as practicable.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(j)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Earnings Statement</U>. As soon as practicable, the Company will make generally available to its security holders and to the Agent an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(k)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Listing; Reservation of Shares</U>. (a) The Company will maintain the listing of the Shares on the Principal Market; and (b) the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling the Company to satisfy its obligations under this Agreement.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(l)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Transfer Agent</U>. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold; mso-fareast-language: zh-cn"><FONT style="mso-list: ignore">(m)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn">Due Diligence</FONT></U><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn">.</FONT><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"> </FONT>During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers, during normal business hours and at the Company&#8217;s principal offices, as the Agent may reasonably request from time to time.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(n)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Representations and Warranties</U>. The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement Date shall be deemed to be (i) an affirmation to the Agent that the representations and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto); and (ii) an undertaking that the Company will advise the Agent if any of such representations and warranties will not be true and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">24</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(o)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Deliverables at Triggering Event Dates; Certificates.</U> The Company agrees that on or prior to the date of the first Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon:</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 90px">(A)<FONT style="mso-tab-count: 1"> the filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to Section 4(a)(ii)(B)), by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into the Registration Statement or Prospectus; </FONT></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 90px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 90px">(B)<FONT style="mso-tab-count: 1"> the filing with the Commission of an annual report on Form 10-K or a quarterly report on Form 10-Q (including any Form 10-K/A or Form 10-Q/A containing amended financial information or a material amendment to the previously filed annual report on Form 10-K or quarterly report on Form 10-Q), in each case, of the Company; or</FONT></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 90px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 90px">(C)<FONT style="mso-tab-count: 1"> the filing with the Commission of a current report on Form 8-K of the Company containing amended financial information (other than information &#8220;furnished&#8221; pursuant to Item 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) that is material to the offering of securities of the Company in the Agent&#8217;s reasonable discretion; </FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">(any such event, a &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Triggering Event Date</FONT></STRONG>&#8221;), the Company shall furnish the Agent (but in the case of clause (C) above only if the Agent reasonably determines that the information contained in such current report on Form 8-K of the Company is material) with a certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented, (A) confirming that the representations and warranties of the Company contained in this Agreement are true and correct, (B) that the Company has performed all of its obligations hereunder to be performed on or prior to the date of such certificate and as to the matters set forth in <U>Section 5(a)(iii)</U> hereof, and (C) containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this <U>Section 4(o)</U> shall be waived for any Triggering Event Date occurring at a time when no Issuance Notice is pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event Date when a suspension was in effect and did not provide the Agent with a certificate under this Section 4(o), then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with this Section 4(o) dated as of the date that the instructions for the sale of Shares are issued. </P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">25</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(p)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Legal Opinions.</U> On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause to be furnished to the Agent, a negative assurances letter and the written legal opinion of Morgan, Lewis &amp; Bockius LLP, counsel to the Company, Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Agent, and Casimir Jones, S.C., intellectual property counsel to the Company, each dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented. In lieu of such opinions for subsequent periodic filings, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event Date <FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn">(except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of such Triggering Event Date)</FONT>. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(q)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Comfort Letter</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause CohnReznick LLP, the independent registered public accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel; provided, however, that any such comfort letter will only be required on the Triggering Event Date specified to the extent that it contains financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus. If requested by the Agent, the Company shall also cause a comfort letter to be furnished to the Agent within ten (10) Trading Days of the date of occurrence of any material transaction or event requiring the filing of a current report on Form 8-K containing material amended financial information of the Company, including the restatement of the Company&#8217;s financial statements. The Company shall be required to furnish no more than one comfort letter hereunder per calendar quarter. </P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">(r) <U>Secretary&#8217;s Certificate.</U> On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date, the Company shall furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery (i) certifying that attached thereto are true and complete copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the issuance of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of such certificate, (ii) certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person who executed this Agreement for or on behalf of the Company, and (iii) containing any other certification that the Agent shall reasonably request. </P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">26</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(s)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Agent&#8217;s Own Account; Clients&#8217; Account</U>. The Company consents to the Agent trading, in compliance with applicable law, in the Common Shares for the Agent&#8217;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement.</FONT></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(t)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Investment Limitation</U><FONT style="mso-font-width: 0%">. The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(u)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Market Activities</U>. The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall use commercially reasonable efforts to cause each of its affiliates to, comply with all applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Rule 102</FONT></STRONG>&#8221;) do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in Section (d) of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall use commercial reasonable efforts to cause each of its affiliates to, comply with Rule 102 as though such exception were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply<FONT style="mso-font-width: 0%">. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section (d) of Rule 102. </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(v)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Notice of Other Sale</U>. Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common Shares, during the period beginning on the third Trading Day immediately prior to the date on which any Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice; and will not directly or indirectly enter into any other &#8220;at the market&#8221; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement; provided, however, that such restrictions will not be required in connection with the Company&#8217;s (i) issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise of options or other equity awards pursuant to any employee or director share option, incentive or benefit plan, share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under Nasdaq rules or other compensation plan of the Company or its subsidiaries, as in effect on the date of this Agreement, (ii) issuance or sale of Common Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting of warrants, options or other equity awards outstanding at the date of this Agreement, (iii) issuance or sale of Common Shares or securities convertible into or exchangeable for Common Shares as consideration for mergers, acquisitions, other business combinations, joint ventures or strategic alliances occurring after the date of this Agreement that are not used for capital raising purposes provided that the aggregate number of shares issued pursuant to this clause (iii) shall not exceed 7.5% of the total number of outstanding Common Shares at such time, and (iv) modification of any outstanding options, warrants of any rights to purchase or acquire Common Shares. </FONT></P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">27</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><STRONG><STRONG><FONT style="mso-list: ignore">Section 5.</FONT></STRONG> CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT</STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Conditions Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares</U>. The right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance, of each of the following conditions:</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: justify; MARGIN-LEFT: auto; BORDER-SPACING: 0; LINE-HEIGHT: normal; MARGIN-RIGHT: auto" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 4%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(i) </P></TD>
<TD style="VERTICAL-ALIGN: top"><FONT style="mso-tab-count: 1"><U>Accuracy of the Company&#8217;s Representations and Warranties; Performance by the Company</U>. The Company shall have delivered the certificate required to be delivered pursuant to <U>Section 4(o)</U> on or before the date on which delivery of such certificate is required pursuant to <U>Section 4(o)</U>. The Company shall have performed, satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants contained in <U>Section 4(m)</U>, <U>Section 4(q)</U> and <U>Section 4(r)</U>.</FONT></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(ii) </P></TD>
<TD style="VERTICAL-ALIGN: top"><FONT style="mso-tab-count: 1"><U>No Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by this Agreement.</FONT></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(iii) </P></TD>
<TD style="VERTICAL-ALIGN: top"><FONT style="mso-tab-count: 1"><U>Material Adverse Changes</U>. <FONT style="mso-font-width: 0%">Except as disclosed in the Prospectus and the Time of Sale Information, (a) <FONT style="mso-font-width: 0%">in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#8220;nationally recognized statistical rating organization&#8221; as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.</FONT></FONT></FONT></TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">28</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: justify; MARGIN-LEFT: auto; BORDER-SPACING: 0; LINE-HEIGHT: normal; MARGIN-RIGHT: auto" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 4%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(iv) </P></TD>
<TD style="VERTICAL-ALIGN: top"><U>No Suspension of Trading in or Delisting of Common Shares; Other Events</U>. The trading of the Common Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without limitation the Shares) shall have been approved for listing or quotation on and shall not have been delisted from the Nasdaq Stock Market, the New York Stock Exchange or any of their constituent markets. There shall not have occurred (and be continuing in the case of occurrences under clauses (i) and (ii) below) any of the following: (<FONT style="mso-font-width: 0%">i) trading or quotation in any of the Company&#8217;s securities shall have been suspended or limited by the Commission or by the Principal Market <FONT style="mso-font-width: 0%">or trading in securities generally on either the Principal Market <FONT style="mso-font-width: 0%">shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or the FINRA; (ii) a general banking moratorium shall have been declared by any of federal or New York, authorities; or (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#8217; or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities.</FONT></FONT></FONT></TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(b)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Documents Required to be Delivered on each Issuance Notice Date</U>. The Agent&#8217;s obligation to use its commercially reasonable efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the <FONT style="mso-font-width: 0%">Chief Executive <FONT style="mso-font-width: 0%">Officer</FONT></FONT>, President or Chief Financial Officer of<FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"> the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of such certificate (which certificate shall not be required if the foregoing representations shall be set forth in the Issuance Notice). </FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></P><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%">
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(c)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>No Misstatement or Material Omission</U>. Agent shall not have advised the Company that the Registration Statement, the Prospectus or the Times of Sales Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#8217;s reasonable opinion is material, or omits to state a fact that in the Agent&#8217;s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.</FONT></P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">29</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><STRONG><STRONG><FONT style="mso-list: ignore">Section 6.</FONT></STRONG> INDEMNIFICATION AND CONTRIBUTION</STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%"><FONT style="mso-list: ignore">(a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Indemnification of the Agent</U></FONT><FONT style="mso-bookmark: _ref234653909">. <FONT style="mso-font-width: 0%">The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Agent or such officer, employee or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold<FONT style="mso-font-width: 0%"> or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, <FONT style="mso-font-width: 0%">and to reimburse the Agent and each such <FONT style="mso-bookmark: ole_link2">officer, employee and controlling person for any and all expenses (including the fees and disbursements of counsel chosen by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the Agent&#8217;s name in the Prospectus. The indemnity agreement set forth in this <U>Section 6(a)</U> shall be in addition to any liabilities that the Company may otherwise have.</FONT></FONT></FONT></FONT></FONT></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(b)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Indemnification of the Company, its directors and officers</U></FONT><FONT style="mso-bookmark: _ref234642211">. The Agent agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; but, for each of (i) and (ii) above, only to the extent arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the name in the Prospectus, and to reimburse the Company and each such director, officer and controlling person for any and all documented expenses (including the fees and disbursements of one counsel chosen by the Company) as such expenses are reasonably incurred by the Company or such officer, director or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this <U>Section 6(b)</U> shall be in addition to any liabilities that the Agent or the Company may otherwise have.</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">30</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bookmark: _ref234642211"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(c)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Notifications and Other Indemnification Procedures</U></FONT><FONT style="mso-bookmark: _ref234642211">. <FONT style="mso-font-width: 0%">Promptly after receipt by an indemnified party under this <U>Section 6</U><FONT style="mso-font-width: 0%"> of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section 6</U>, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution or otherwise than under the indemnity agreement contained in this <U>Section 6</U> or to the extent it is not prejudiced as a proximate result of such failure. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#8217;s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this <U>Section 6</U><FONT style="mso-font-width: 0%"> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Agent (in the case of counsel for the indemnified parties referred to in <U>Section 6(a)</U><STRONG><FONT style="FONT-WEIGHT: bold"> </FONT></STRONG>above), <FONT style="mso-font-width: 0%">(ii) the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or </FONT>(iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party<FONT style="mso-font-width: 0%">, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</FONT></FONT></FONT></FONT></FONT></FONT></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(d)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Settlements</U>. <FONT style="mso-font-width: 0%">The indemnifying party under this <U>Section 6</U> shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by <U>Section 6(b)</U> hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request; and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding.</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px">
<P style="TEXT-ALIGN: center; MARGIN: 0px">31</P></TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(e)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U>Contribution</U></FONT><FONT style="mso-bookmark: _ref234642115">. <FONT style="mso-font-width: 0%">If the indemnification provided for in this <U>Section 6</U> is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this Agreement; or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from the offering of the Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent. The relative fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Agent, on the other hand, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</FONT></FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-tab-count: 1"><FONT style="mso-font-width: 0%">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in <U>Section 6(b)</U>, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in <U>Section 6(b)</U> with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this <U>Section 6(d)</U>; <EM><FONT style="FONT-STYLE: italic; mso-bidi-font-style: normal">provided, however,</FONT></EM> that no additional notice shall be required with respect to any action for which notice has been given under <U>Section 6(b)</U> for purposes of indemnification. </FONT></FONT></P>
<P style="MARGIN: 0px">&nbsp; </P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">32</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-font-width: 0%"><FONT style="mso-tab-count: 1">The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this <U>Section 6(d)</U> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this <U>Section 6(d)</U>.</FONT></FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-font-width: 0%"><FONT style="mso-tab-count: 1">Notwithstanding the provisions of this <U>Section 6(d)</U>, the Agent shall not be required to contribute any amount in excess of the agent fees received by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this <U>Section 6(d)</U>, each officer and employee of the Agent and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company with the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.</FONT></FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><STRONG><STRONG><FONT style="mso-list: ignore">Section 7.</FONT></STRONG> TERMINATION &amp; SURVIVAL</STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Term</U>. Subject to the provisions of this <U>Section 7</U>, the term of this Agreement shall continue from the date of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this <U>Section 7</U>.</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 4%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 4%">
<P style="MARGIN: 0px">&nbsp; </P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(b) </P></TD>
<TD style="VERTICAL-ALIGN: top"><U>Termination; Survival Following Termination</U><FONT style="mso-bookmark: _ref234912826">. </FONT></TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp; </P><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%">
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: justify; MARGIN-LEFT: auto; BORDER-SPACING: 0; LINE-HEIGHT: normal; MARGIN-RIGHT: auto" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 8%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(i) </P></TD>
<TD style="VERTICAL-ALIGN: top"><FONT style="mso-tab-count: 1">Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement, upon ten (10) Trading Days&#8217; notice to the other party; provided that, (A) if the Company terminates this Agreement after the Agent confirms to <FONT style="mso-bidi-font-weight: bold">the Company any sale of Shares, the Company shall remain obligated to <FONT style="mso-bidi-font-weight: bold">comply with <U style="text-underline: black">Section 3(b)(v)</U> with respect to such Shares and (B) <U>Section 2</U>, <U>Section 6</U>, <U>Section 7</U> and <U>Section 8</U> shall survive termination of this Agreement. If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement.</FONT></FONT></FONT></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">(ii) </P></TD>
<TD style="VERTICAL-ALIGN: top"><FONT style="mso-font-width: 0%">In addition to the survival provision of <U>Section 7(b)(i)</U>, the respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any termination of this Agreement.</FONT></TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-tab-count: 1">
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">33</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><STRONG><STRONG><FONT style="mso-list: ignore">Section 8.</FONT></STRONG> MISCELLANEOUS</STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U>Press Releases and Disclosure</U>. The Company may issue a press release describing the material terms of the transactions contemplated hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form 8&#8209;K, with this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosures that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (including, without limitation, any disclosure required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto.</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(b)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%">No Advisory or Fiduciary Relationship</FONT></U><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%">.</FONT><STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal; mso-font-width: 0%"> </FONT></STRONG>The Company acknowledges and agrees that (i) the transactions contemplated by this Agreement, including the determination of any fees, are arm&#8217;s-length commercial transactions between the Company and the Agent, (ii) when acting as a principal under this Agreement, the Agent is and has been acting solely as a principal is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii) the Agent has not assumed nor will assume an advisory or fiduciary responsibility in favor of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not have any obligation to the Company with respect to the transactions contemplated hereby except the obligations expressly set forth in this Agreement, (iv) the Agent and its respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (v) the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.<FONT style="mso-font-width: 0%"> </FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(c)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U><FONT style="mso-font-width: 0%">Research Analyst Independence</FONT></U><FONT style="mso-font-width: 0%">. The Company acknowledges that the Agent&#8217;s research analysts and research departments are required to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and as such the Agent&#8217;s research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company or the offering that differ from the views of their respective investment banking divisions. The Company understands that the Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">34</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(d)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%">Notices</FONT></U></FONT><FONT style="mso-bookmark: _ref234913214"><FONT style="mso-font-width: 0%">. </FONT></FONT><FONT style="mso-font-width: 0%">All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows:</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px 0px 0px 30px"><FONT style="mso-font-width: 0%">If to the </FONT>Agent<FONT style="mso-font-width: 0%">:</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px 0px 0px 75px">Jefferies LLC<BR>520 Madison Avenue<BR>New York, NY 10022<BR>Facsimile: (646) 619-4437 <BR>Attention: General Counsel</P><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%">
<P style="MARGIN: 0px">&nbsp; </P>
<P style="MARGIN: 0px 0px 0px 30px"><FONT style="mso-font-width: 0%">with a copy (which shall not constitute notice) to:</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT>
<P style="MARGIN: 0px 0px 0px 75px">Wilmer Cutler Pickering Hale and Dorr LLP<BR>7 World Trade Center</P>
<P style="MARGIN: 0px 0px 0px 75px">250 Greenwich Street</P>
<P style="MARGIN: 0px 0px 0px 75px">New York, NY 10007 Facsimile: (212) 230-8888 Attention: Lisa Firenze</P><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%">
<P style="MARGIN: 0px">&nbsp; </P>
<P style="MARGIN: 0px 0px 0px 30px"><FONT style="mso-font-width: 0%">If to the Company:<BR style="mso-special-character: line-break"></FONT></P>
<P style="MARGIN: 0px">&nbsp;</P></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT>
<P style="MARGIN: 0px 0px 0px 75px">ADMA Biologics, Inc. 465 State Route 17</P>
<P style="MARGIN: 0px 0px 0px 75px">Ramsey, New Jersey 07466</P>
<P style="MARGIN: 0px 0px 0px 75px">Attention: Adam S. Grossman</P><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%">
<P style="MARGIN: 0px">&nbsp; </P>
<P style="MARGIN: 0px 0px 0px 30px"><FONT style="mso-font-width: 0%">with a copy (which shall not constitute notice) to:</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT>
<P style="MARGIN: 0px 0px 0px 75px">Morgan, Lewis &amp; Bockius LLP 502 Carnegie Center</P>
<P style="MARGIN: 0px 0px 0px 75px">Princeton, NJ 08540-0621</P>
<P style="MARGIN: 0px 0px 0px 75px">Attention: David C. Schwartz</P><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-fareast-font-family: simsun; mso-fareast-language: zh-cn"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639077"><FONT style="mso-bookmark: _ref235956450"><FONT style="mso-font-width: 0%"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-bookmark: _ref234639148"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%"><FONT style="mso-font-width: 0%">
<P style="MARGIN: 0px">&nbsp; </P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px"><FONT style="mso-font-width: 0%">Any party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this <U>Section 8(d)</U>.</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(e)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%">Successors</FONT></U><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%; mso-bidi-font-style: italic">.</FONT><FONT style="mso-font-width: 0%; mso-bidi-font-style: italic"> </FONT><FONT style="mso-font-width: 0%">This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in </FONT><U>Section 6</U><FONT style="mso-font-width: 0%">, and in each case their respective successors, and no other person will have any right or obligation hereunder. The term &#8220;<FONT style="mso-bidi-font-weight: bold">successors&#8221; shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase.</FONT></FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(f)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%">Partial Unenforceability</FONT></U><FONT style="mso-font-width: 0%">. The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">35</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(g)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT><U><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%">Governing Law Provisions</FONT></U></FONT><FONT style="mso-bookmark: _ref234926135"><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%; mso-bidi-font-style: italic">.</FONT></FONT><FONT style="mso-bookmark: _ref234926135"><FONT style="mso-font-width: 0%"> This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (&#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Related Proceedings</FONT></STRONG>&#8221;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Specified Courts</FONT></STRONG>&#8221;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Related Judgment</FONT></STRONG>&#8221;), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&#8217;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. </FONT></FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%"><FONT style="mso-list: ignore">(h)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%">General Provisions</FONT></U><FONT style="mso-bidi-font-weight: bold; mso-font-width: 0%">.</FONT><FONT style="mso-font-width: 0%"> This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a </FONT>portable document format <FONT style="mso-font-width: 0%">(PDF) file. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The Article and Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.</FONT></P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px"><FONT style="mso-bidi-font-weight: bold"><FONT style="mso-list: ignore">(i)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT></FONT><U><FONT style="mso-font-width: 0%">Counterparts; Electronic Signatures.</FONT></U><FONT style="mso-font-width: 0%"> </FONT>This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same Agreement. Delivery of an executed Agreement by one party to the other may be made by facsimile, electronic mail or other transmission method as permitted by applicable law, and the parties hereto agree that any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. A party&#8217;s electronic signature (complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. &#167;&#167; 301-309), as amended from time to time, or other applicable law) of this Agreement shall have the same validity and effect as a signature affixed by the party&#8217;s hand.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><EM><FONT style="FONT-STYLE: italic">[Signature Page Immediately Follows]</FONT></EM></P><FONT style='FONT-STYLE: italic; mso-fareast-font-family: "times new roman"; mso-fareast-language: en-us; mso-ansi-language: en-us; mso-bidi-language: ar-sa'>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">36</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"></P></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT>
<P style="TEXT-ALIGN: justify; MARGIN: 0px; TEXT-INDENT: 45px">If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD>
<TD colSpan=2>Very truly yours,
<P style="MARGIN: 0px"><STRONG><FONT style="FONT-WEIGHT: bold">&nbsp;&nbsp;&nbsp; </FONT></STRONG></P>
<P style="MARGIN: 0px"><STRONG><FONT style="FONT-WEIGHT: bold">ADMA BIOLOGICS, INC.</FONT></STRONG></P></TD>
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD style="WIDTH: 50%">&nbsp;</TD>
<TD style="WIDTH: 3%">&nbsp;&nbsp; </TD>
<TD style="WIDTH: 35%">&nbsp;</TD>
<TD style="WIDTH: 12%">&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD></TD>
<TD>By:</TD>
<TD style="BORDER-BOTTOM: black 1px solid">/s/ Adam Grossman<FONT style="mso-tab-count: 3"> </FONT></TD>
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD>Name: Adam Grossman </TD>
<TD>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Title: President and Chief Executive Officer</TD>
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the date first above written.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><STRONG><FONT style="FONT-WEIGHT: bold">JEFFERIES LLC </FONT></STRONG></P>
<P style="MARGIN: 0px">&nbsp;&nbsp; </P>
<P style="MARGIN: 0px">By: <U>/s/ Kevin Sheridan&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P>
<P style="MARGIN: 0px 0px 0px 30px">Name: Kevin Sheridan </P>
<P style="MARGIN: 0px 0px 0px 30px">Title: Managing Director</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG><FONT style="FONT-WEIGHT: bold">&nbsp;</FONT></STRONG></P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px"></TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG><FONT style="FONT-WEIGHT: bold">EXHIBIT A</FONT></STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px">ISSUANCE NOTICE</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">[Date]</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Jefferies LLC</P>
<P style="MARGIN: 0px">520 Madison Avenue</P>
<P style="MARGIN: 0px">New York, New York 10022</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Attn: [__________]</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">Reference is made to the Open Market Sale Agreement between __________ (the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Company</FONT></STRONG>&#8221;) and Jefferies LLC (the &#8220;<STRONG><FONT style="FONT-WEIGHT: bold">Agent</FONT></STRONG>&#8221;) dated as of ________ ___, 20__. The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof. </P>
<P style="MARGIN: 0px">&nbsp; </P>
<P style="MARGIN: 0px">Date of Delivery of Issuance Notice (determined pursuant to <U>Section 3(b)(i)</U>): </P>
<P style="MARGIN: 0px">_______________________</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Issuance Amount (equal to the total Sales Price for such Shares):</P></FONT></FONT>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px 0px 0px 210px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $_______________________</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Number of days in selling period:<FONT style="mso-tab-count: 1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ________________________</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">First date of selling period:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; <FONT style="mso-tab-count: 1">&nbsp;_______________________</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Last date of selling period:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="mso-tab-count: 1">&nbsp;_______________________</FONT></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Settlement Date(s) if other than standard T+2 settlement:</P>
<P style="MARGIN: 0px 0px 0px 210px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; _______________________</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">Floor Price Limitation (in no event less than $1.00 without the prior written consent of the Agent, which consent may be withheld in the Agent&#8217;s sole discretion): $ ____ per share</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Comments: __________________________________________________________________</P>
<P style="MARGIN: 0px">&nbsp;&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD>
<TD colSpan=2><STRONG>______________________________</STRONG></TD>
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD style="WIDTH: 47%">&nbsp;</TD>
<TD style="WIDTH: 3%">&nbsp;</TD>
<TD style="WIDTH: 30%">&nbsp;</TD>
<TD style="WIDTH: 15%">&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD></TD>
<TD>By:</TD>
<TD style="BORDER-BOTTOM: black 1px solid"></TD>
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Name:</TD>
<TD>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Title: </TD>
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">&nbsp;<STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">&nbsp;</FONT></STRONG></P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px">A-1</TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Schedule A</FONT></STRONG></P>
<P style="TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Subsidiaries</FONT></STRONG></P>
<P style="TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px; TEXT-INDENT: 45px">The entities listed on Exhibit 21.1 to the company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px"></TD></TR>
<TR style="HEIGHT: 15px; PAGE-BREAK-AFTER: always">
<TD></TD></TR>
<TR style="HEIGHT: 15px">
<TD>&nbsp;</TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Schedule B</FONT></STRONG></P>
<P style="TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG><FONT style="FONT-WEIGHT: bold; mso-bidi-font-weight: normal">Notice Parties</FONT></STRONG></P>
<P style="TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><U>The Company</U></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Adam Grossman</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Brian Lenz</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><U>The Agent</U></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Michael Magarro</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Donald Lynaugh</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT: 10pt times new roman; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD class=hpbhr>&nbsp;</TD></TR>
<TR style="HEIGHT: 15px">
<TD style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px"></TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;</P></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>adma_ex51.htm
<TEXT>
<html><head><title>adma_ex51.htm</title><!--Document created using EDGARMaster--></head><body style="text-align:left;font-size:10pt;font-family: Times New Roman"><P style="TEXT-ALIGN: right; MARGIN: 0px"><STRONG>&nbsp; EXHIBIT 5.1</STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px"><IMG src="adma_ex51img2.jpg"></P>
<P style="MARGIN: 0px">August 5, 2020</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">ADMA Biologics, Inc.</P>
<P style="MARGIN: 0px">465 Route 17</P>
<P style="MARGIN: 0px">Ramsey, NJ 07446</P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; WIDTH: 100%; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Re:</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px"><U>ADMA Biologics, Inc., Registration Statement on Form S-3 (File No.&nbsp;333-234107)</U> </P></TD></TR></TABLE>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">Ladies and Gentlemen:</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">We have acted as counsel to ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;), in connection with the filing of a prospectus supplement, dated August 5, 2020 (the &#8220;Prospectus&#8221;), by the Company with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on August 5, 2020 pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended (the &#8220;Act&#8221;), relating to the offer and sale by the Company of up to $50,000,000 aggregate offering price of shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), in an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Act in accordance with the Open Market Sale Agreement<SUP>SM</SUP>, dated August 5, 2020, by and between the Company and Jefferies LLC (the &#8220;Sale Agreement&#8221;), pursuant to the referenced Registration Statement on Form S-3 (No. 333-234107) (the &#8220;Registration Statement&#8221;) filed with the Commission on October 4, 2019 and declared effective on October 15, 2019.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">As to all matters of fact (including factual conclusions and characterizations and descriptions of purpose, intention or other state of mind), we have relied, with your permission, entirely upon written actions by the Board of Directors of the Company and certificates of certain officers of the Company and have assumed, without independent inquiry, the accuracy of those certificates and written actions by the Board of Directors of the Company.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">As counsel to the Company, in rendering the opinions hereinafter expressed, we have examined and relied upon originals or copies of such corporate records, agreements, documents and instruments as we have deemed necessary or advisable for purposes of this opinion, including (i) the certificate of incorporation and bylaws of the Company, (ii) the Registration Statement and the exhibits thereto filed with the Commission, (iii) the Prospectus, (iv) the Sale Agreement, and (v) the written actions of the Board of Directors of the Company referenced above.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">This opinion is limited solely to the Delaware General Corporation Law without regard to choice of law, to the extent that the same may apply to or govern the transactions contemplated by the Registration Statement. We express no opinion as to the effect of events occurring, circumstances arising, or changes of law becoming effective or occurring, after the date hereof on the matters addressed in this opinion.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">Based on such examination and subject to the foregoing, we are of the opinion that the Shares, when issued by the Company and delivered by the Company against payment therefor as contemplated by the Sales Agreement and an Issuance Notice (as defined in the Sales Agreement), will be validly issued, fully paid and non-assessable.</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">&nbsp;&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px">We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the reference to us under the caption &#8220;Legal Matters&#8221; in the Prospectus. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Commission thereunder. In rendering this opinion, we are opining only as to the specific legal issues expressly set forth herein, and no opinion shall be inferred as to any other matter or matters. This opinion is intended solely for use in connection with the issuance and sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose.</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">Very truly yours,</P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="MARGIN: 0px">/s/ Morgan, Lewis &amp; Bockius LLP</P>
<P style="TEXT-ALIGN: right; MARGIN: 0px"><IMG src="adma_ex51img5.jpg"></P></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>adma_ex311.htm
<TEXT>
<html><head><title>adma_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="text-align:left;font-size:10pt;font-family: Times New Roman"><P style="TEXT-ALIGN: right; MARGIN: 0px"><STRONG>EXHIBIT 31.1</STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in"><STRONG>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER<BR>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002<STRIKE></STRIKE></STRONG></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in">I, Adam S. Grossman, certify that:<STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.5in"><FONT style="mso-list: ignore">1.<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>I have reviewed this Quarterly Report on Form 10-Q of ADMA Biologics, Inc.;<STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.5in"><FONT style="mso-list: ignore">2.<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;<STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.5in"><FONT style="mso-list: ignore">3.<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;<STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.5in"><FONT style="mso-list: ignore">4.<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:<STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; <STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">b)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;<STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">c)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and<STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">d)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and<STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.5in"><FONT style="mso-list: ignore">5.<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):<STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and<STRIKE></STRIKE></P>
<P style="MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">b)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </P>
<P style="MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; WIDTH: 100%; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 48%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Date: August 5, 2020</P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">By:</P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<P style="MARGIN: 0px">/s/ Adam S. Grossman</P></TD>
<TD style="WIDTH: 12%">
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Name:</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Adam S. Grossman</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Title:</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">President and Chief Executive Officer<BR>(Principal Executive Officer)</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR></TABLE></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>adma_ex312.htm
<TEXT>
<html><head><title>adma_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="text-align:left;font-size:10pt;font-family: Times New Roman"><P style="TEXT-ALIGN: right; MARGIN: 0px"><STRONG>EXHIBIT 31.2<STRIKE></STRIKE></STRONG></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in"><STRONG>CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER<BR>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002<STRIKE></STRIKE></STRONG></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in">I, Brian Lenz, certify that:<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 0.5in"><FONT style="mso-list: ignore">1.<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>I have reviewed this Quarterly Report on Form 10-Q of ADMA Biologics, Inc.;<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 0.5in"><FONT style="mso-list: ignore">2.<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 0.5in"><FONT style="mso-list: ignore">3.<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 0.5in"><FONT style="mso-list: ignore">4.<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; <STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">b)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">c)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">d)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 0.5in"><FONT style="mso-list: ignore">5.<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">a)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 63pt"><FONT style="mso-list: ignore">b)<FONT style='FONT: 7pt "times new roman"'> </FONT></FONT>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.<STRIKE></STRIKE></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; WIDTH: 100%; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 48%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Date: August 5, 2020</P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">By:</P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<P style="MARGIN: 0px">/s/ Brian Lenz </P></TD>
<TD style="WIDTH: 12%">
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Name:</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Brian Lenz</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Title:</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>adma_ex321.htm
<TEXT>
<html><head><title>adma_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="text-align:left;font-size:10pt;font-family: Times New Roman"><P style="TEXT-ALIGN: right; MARGIN: 0px"><STRONG>EXHIBIT 32.1</STRONG></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</STRONG></P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</STRONG></P>
<P style="TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Adam S. Grossman, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp; </P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 1%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">1. </P></TD>
<TD style="VERTICAL-ALIGN: top">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD style="WIDTH: 1%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">2. </P></TD>
<TD style="VERTICAL-ALIGN: top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; WIDTH: 100%; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 48%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Date: August 5, 2020</P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">By:</P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<P style="MARGIN: 0px">/s/ Adam S. Grossman</P></TD>
<TD style="WIDTH: 12%">
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Name:</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Adam S. Grossman</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Title:</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">President and Chief Executive Officer<BR>(Principal Executive Officer)</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>adma_ex322.htm
<TEXT>
<html><head><title>adma_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="text-align:left;font-size:10pt;font-family: Times New Roman"><P style="TEXT-ALIGN: right; MARGIN: 0px"><STRONG>EXHIBIT 32.2</STRONG></P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG>CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</STRONG></P>
<P style="TEXT-ALIGN: center; MARGIN: 0px"><STRONG>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</STRONG></P>
<P style="TEXT-ALIGN: center; MARGIN: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian Lenz, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; FONT-VARIANT: normal; WIDTH: 100%; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; BORDER-SPACING: 0; LINE-HEIGHT: normal" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 1%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">1. </P></TD>
<TD style="VERTICAL-ALIGN: top">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px; TEXT-INDENT: 30px">&nbsp;</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD style="WIDTH: 1%">
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">2. </P></TD>
<TD style="VERTICAL-ALIGN: top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P style="MARGIN: 0px">&nbsp;&nbsp;</P>
<TABLE style="FONT-SIZE: 10pt; WIDTH: 100%; BORDER-SPACING: 0" cellPadding=0>

<TR style="HEIGHT: 15px">
<TD style="WIDTH: 48%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Date: August 5, 2020</P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">By:</P></TD>
<TD style="WIDTH: 35%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<P style="MARGIN: 0px">/s/ Brian Lenz</P></TD>
<TD style="WIDTH: 12%">
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Name:</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Brian Lenz</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR>
<TR style="HEIGHT: 15px">
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Title:</P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="MARGIN: 0px">Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)</P></TD>
<TD>
<P style="MARGIN: 0px">&nbsp;</P></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; MARGIN: 0px">&nbsp;</P></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>adma-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 1.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/05/2020-->
<!--Copyright (c) 2020 NTDAS Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:adma="http://admabiologics.com/20200630" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://admabiologics.com/20200630">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://admabiologics.com/role/Cover" id="Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" id="CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" id="CondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited" id="CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
        <link:definition>0000007 - Disclosure - ORGANIZATION AND BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/INVENTORIES" id="INVENTORIES">
        <link:definition>0000009 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>000010 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>000011 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DEBT" id="DEBT">
        <link:definition>000012 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>000013 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>000014 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CommitmentAndContingencies" id="CommitmentAndContingencies">
        <link:definition>000015 - Disclosure - COMMITMENT AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SEGMENTS" id="SEGMENTS">
        <link:definition>000016 - Disclosure - SEGMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/TransferOfPlasmaCenterAssets" id="TransferOfPlasmaCenterAssets">
        <link:definition>000017 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligations" id="LeaseObligations">
        <link:definition>000018 - Disclosure - LEASE OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" id="SupplementalDisclosureOfCashFlowInformation">
        <link:definition>000019 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000020 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InventoriesTables" id="InventoriesTables">
        <link:definition>000023 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <link:definition>000024 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <link:definition>000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DebtTables" id="DebtTables">
        <link:definition>000026 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsTables" id="SegmentsTables">
        <link:definition>000028 - Disclosure - SEGMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsTables" id="LeaseObligationsTables">
        <link:definition>000029 - Disclosure - LEASE OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" id="SupplementalDisclosureOfCashFlowInformationTables">
        <link:definition>000030 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative" id="OrganizationAndBusinessDetailsNarrative">
        <link:definition>000031 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InventoriesDetails" id="InventoriesDetails">
        <link:definition>000034 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
        <link:definition>000035 - Disclosure - INTANGIBLE ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
        <link:definition>000036 - Disclosure - INTANGIBLE ASSETS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
        <link:definition>000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <link:definition>000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
        <link:definition>000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DebtDetails" id="DebtDetails">
        <link:definition>000040 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DebtDetails1" id="DebtDetails1">
        <link:definition>000041 - Disclosure - DEBT (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
        <link:definition>000042 - Disclosure - DEBT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>000043 - Disclosure - STOCKHOLDERS EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>000044 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
        <link:definition>000045 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
        <link:definition>000046 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>000047 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsDetails" id="SegmentsDetails">
        <link:definition>000050 - Disclosure - SEGMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative" id="TransferOfPlasmaCenterAssetsDetailsNarrative">
        <link:definition>000051 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsDetails" id="LeaseObligationsDetails">
        <link:definition>000052 - Disclosure - LEASE OBLIGATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsDetailsNarrative" id="LeaseObligationsDetailsNarrative">
        <link:definition>000053 - Disclosure - LEASE OBLIGATIONS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" id="SupplementalDisclosureOfCashFlowInformationDetails">
        <link:definition>000054 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000055 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <import namespace="http://fasb.org/srt-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" />
  <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <element id="adma_ProductRevenue" name="ProductRevenue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_LicenseRevenue" name="LicenseRevenue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_AmortizationOfLicenseRevenue" name="AmortizationOfLicenseRevenue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_PaymentOfDebtRefinancingFees" name="PaymentOfDebtRefinancingFees" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock" name="TransferOfPlasmaCenterAssetsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="adma_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_AmortizationExpense" name="AmortizationExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_SubordinatedDebtCarryingValue" name="SubordinatedDebtCarryingValue" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_SubordinatedDebtInstrumentUnamortizedDiscount" name="SubordinatedDebtInstrumentUnamortizedDiscount" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" name="PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_DescriptionOfPrepaidPrincipalAmount" name="DescriptionOfPrepaidPrincipalAmount" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="adma_AdditionlalDescription" name="AdditionlalDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="adma_InterestRateDescription" name="InterestRateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="adma_ExpirationDate" name="ExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="adma_DeferredFacilityFee" name="DeferredFacilityFee" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_PrepaymentPenalty" name="PrepaymentPenalty" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_UnamortizedDebtDiscount" name="UnamortizedDebtDiscount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_AdditionalFacilityFee" name="AdditionalFacilityFee" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_DebtServiceReserve" name="DebtServiceReserve" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="adma_UnderwrittenPublicOffering" name="UnderwrittenPublicOffering" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="adma_CommonStockReservedForOutstanding" name="CommonStockReservedForOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="adma_CompensationExpense" name="CompensationExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_CommonStockGranted" name="CommonStockGranted" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="adma_CreditFacilityPercentage" name="CreditFacilityPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="adma_PublicOfferingDescription" name="PublicOfferingDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="adma_PurchasePercentageFromInventory" name="PurchasePercentageFromInventory" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="adma_PurchaseOfRawMaterial" name="PurchaseOfRawMaterial" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_PlasmaSupplyAgreementTerm" name="PlasmaSupplyAgreementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="adma_CapitalExpenditure" name="CapitalExpenditure" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_TotalAssets" name="TotalAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_GainUponTransferFacilities" name="GainUponTransferFacilities" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_NetCarryingValueOfAssets" name="NetCarryingValueOfAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_InterestPortionOfMinimumLeasePayments" name="InterestPortionOfMinimumLeasePayments" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_OperatingLeaseLiabilityTotal" name="OperatingLeaseLiabilityTotal" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_LeaseDescription" name="LeaseDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="adma_IncrementalBorrowingRate" name="IncrementalBorrowingRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" name="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_WarrantsIssuedInConnectionWithNotePayable" name="WarrantsIssuedInConnectionWithNotePayable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="adma_CommonStockOffering" name="CommonStockOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="adma_CommissionDescription" name="CommissionDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="BiotestMember" id="adma_BiotestMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CustomerTwoMember" id="adma_CustomerTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CustomerThreeMember" id="adma_CustomerThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PropertyAndEquipmentMember" id="adma_PropertyAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityIncentivePlanMember" id="adma_EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RightToIntermediatesMember" id="adma_RightToIntermediatesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PlasmaCentersMember" id="adma_PlasmaCentersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PlasmaCollectionCenterMember" id="adma_PlasmaCollectionCenterMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AdmaBiomanufacturingMember" id="adma_AdmaBiomanufacturingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PerceptiveCreditAgreementMember" id="adma_PerceptiveCreditAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PerceptiveTrancheILoanMember" id="adma_PerceptiveTrancheILoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PerceptiveTrancheIILoanMember" id="adma_PerceptiveTrancheIILoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PerceptiveTrancheIIILoanMember" id="adma_PerceptiveTrancheIIILoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MarathonHealthcareFinanceFundLPMember" id="adma_MarathonHealthcareFinanceFundLPMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PerceptiveTrancheIIIWarrantMember" id="adma_PerceptiveTrancheIIIWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BPCMember" id="adma_BPCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsolidatedMember" id="adma_ConsolidatedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryOneTwoThousandNineteenMember" id="adma_JanuaryOneTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ArethLLCMember" id="adma_ArethLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SaleAgreementMember" id="adma_SaleAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JefferiesLLCMember" id="adma_JefferiesLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>adma-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 1.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/05/2020-->
<!--Copyright (c) 2020 NTDAS Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://admabiologics.com/role/Cover" xlink:href="adma-20200630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="adma-20200630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:href="adma-20200630.xsd#OrganizationAndBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/INVENTORIES" xlink:href="adma-20200630.xsd#INVENTORIES" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:href="adma-20200630.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:href="adma-20200630.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DEBT" xlink:href="adma-20200630.xsd#DEBT" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:href="adma-20200630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:href="adma-20200630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentAndContingencies" xlink:href="adma-20200630.xsd#CommitmentAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SEGMENTS" xlink:href="adma-20200630.xsd#SEGMENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/TransferOfPlasmaCenterAssets" xlink:href="adma-20200630.xsd#TransferOfPlasmaCenterAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:href="adma-20200630.xsd#LeaseObligations" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:href="adma-20200630.xsd#SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEvents" xlink:href="adma-20200630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:href="adma-20200630.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:href="adma-20200630.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:href="adma-20200630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtTables" xlink:href="adma-20200630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:href="adma-20200630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:href="adma-20200630.xsd#SegmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:href="adma-20200630.xsd#LeaseObligationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:href="adma-20200630.xsd#SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative" xlink:href="adma-20200630.xsd#OrganizationAndBusinessDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:href="adma-20200630.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetails" xlink:href="adma-20200630.xsd#IntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetails1" xlink:href="adma-20200630.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetailsNarrative" xlink:href="adma-20200630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:href="adma-20200630.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="adma-20200630.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:href="adma-20200630.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails1" xlink:href="adma-20200630.xsd#DebtDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetailsNarrative" xlink:href="adma-20200630.xsd#DebtDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails" xlink:href="adma-20200630.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails1" xlink:href="adma-20200630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails2" xlink:href="adma-20200630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails3" xlink:href="adma-20200630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetailsNarrative" xlink:href="adma-20200630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="adma-20200630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="adma-20200630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsDetails" xlink:href="adma-20200630.xsd#SegmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative" xlink:href="adma-20200630.xsd#TransferOfPlasmaCenterAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:href="adma-20200630.xsd#LeaseObligationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsNarrative" xlink:href="adma-20200630.xsd#LeaseObligationsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:href="adma-20200630.xsd#SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEventsDetailsNarrative" xlink:href="adma-20200630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:title="0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNet" xlink:label="loc_us-gaapAssetsNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNet" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNet" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNet" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNet" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubordinatedLongTermDebt" xlink:label="loc_us-gaapSubordinatedLongTermDebt" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapSubordinatedLongTermDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:title="0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ProductRevenue" xlink:label="loc_admaProductRevenue" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_admaProductRevenue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_LicenseRevenue" xlink:label="loc_admaLicenseRevenue" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_admaLicenseRevenue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited" xlink:title="0000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="loc_admaAmortizationOfLicenseRevenue" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_admaAmortizationOfLicenseRevenue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="loc_us-gaapPaymentsForLeasingCosts" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForLeasingCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PaymentOfDebtRefinancingFees" xlink:label="loc_admaPaymentOfDebtRefinancingFees" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_admaPaymentOfDebtRefinancingFees" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness" xlink:title="0000007 - Disclosure - ORGANIZATION AND BUSINESS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/INVENTORIES" xlink:title="0000009 - Disclosure - INVENTORIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets" xlink:title="000010 - Disclosure - INTANGIBLE ASSETS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DEBT" xlink:title="000012 - Disclosure - DEBT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity" xlink:title="000013 - Disclosure - STOCKHOLDERS' EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions" xlink:title="000014 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentAndContingencies" xlink:title="000015 - Disclosure - COMMITMENT AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SEGMENTS" xlink:title="000016 - Disclosure - SEGMENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/TransferOfPlasmaCenterAssets" xlink:title="000017 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations" xlink:title="000018 - Disclosure - LEASE OBLIGATIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:title="000019 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEvents" xlink:title="000020 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables" xlink:title="000023 - Disclosure - INVENTORIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables" xlink:title="000024 - Disclosure - INTANGIBLE ASSETS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:title="000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtTables" xlink:title="000026 - Disclosure - DEBT (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables" xlink:title="000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables" xlink:title="000028 - Disclosure - SEGMENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables" xlink:title="000029 - Disclosure - LEASE OBLIGATIONS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:title="000030 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative" xlink:title="000031 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails" xlink:title="000034 - Disclosure - INVENTORIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetails" xlink:title="000035 - Disclosure - INTANGIBLE ASSETS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetails1" xlink:title="000036 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetailsNarrative" xlink:title="000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:title="000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails" xlink:title="000040 - Disclosure - DEBT (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails1" xlink:title="000041 - Disclosure - DEBT (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetailsNarrative" xlink:title="000042 - Disclosure - DEBT (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails" xlink:title="000043 - Disclosure - STOCKHOLDERS EQUITY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails1" xlink:title="000044 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails2" xlink:title="000045 - Disclosure - STOCKHOLDERS EQUITY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails3" xlink:title="000046 - Disclosure - STOCKHOLDERS EQUITY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetailsNarrative" xlink:title="000047 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsDetails" xlink:title="000050 - Disclosure - SEGMENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative" xlink:title="000051 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails" xlink:title="000052 - Disclosure - LEASE OBLIGATIONS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsNarrative" xlink:title="000053 - Disclosure - LEASE OBLIGATIONS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:title="000054 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEventsDetailsNarrative" xlink:title="000055 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>adma-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 1.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/05/2020-->
<!--Copyright (c) 2020 NTDAS Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://admabiologics.com/role/Cover" xlink:href="adma-20200630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="adma-20200630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:href="adma-20200630.xsd#OrganizationAndBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/INVENTORIES" xlink:href="adma-20200630.xsd#INVENTORIES" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:href="adma-20200630.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:href="adma-20200630.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DEBT" xlink:href="adma-20200630.xsd#DEBT" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:href="adma-20200630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:href="adma-20200630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentAndContingencies" xlink:href="adma-20200630.xsd#CommitmentAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SEGMENTS" xlink:href="adma-20200630.xsd#SEGMENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/TransferOfPlasmaCenterAssets" xlink:href="adma-20200630.xsd#TransferOfPlasmaCenterAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:href="adma-20200630.xsd#LeaseObligations" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:href="adma-20200630.xsd#SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEvents" xlink:href="adma-20200630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:href="adma-20200630.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:href="adma-20200630.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:href="adma-20200630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtTables" xlink:href="adma-20200630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:href="adma-20200630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:href="adma-20200630.xsd#SegmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:href="adma-20200630.xsd#LeaseObligationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:href="adma-20200630.xsd#SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative" xlink:href="adma-20200630.xsd#OrganizationAndBusinessDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:href="adma-20200630.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetails" xlink:href="adma-20200630.xsd#IntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetails1" xlink:href="adma-20200630.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetailsNarrative" xlink:href="adma-20200630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:href="adma-20200630.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="adma-20200630.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:href="adma-20200630.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails1" xlink:href="adma-20200630.xsd#DebtDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetailsNarrative" xlink:href="adma-20200630.xsd#DebtDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails" xlink:href="adma-20200630.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails1" xlink:href="adma-20200630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails2" xlink:href="adma-20200630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails3" xlink:href="adma-20200630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetailsNarrative" xlink:href="adma-20200630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="adma-20200630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="adma-20200630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsDetails" xlink:href="adma-20200630.xsd#SegmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative" xlink:href="adma-20200630.xsd#TransferOfPlasmaCenterAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:href="adma-20200630.xsd#LeaseObligationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsNarrative" xlink:href="adma-20200630.xsd#LeaseObligationsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:href="adma-20200630.xsd#SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEventsDetailsNarrative" xlink:href="adma-20200630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:title="0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:title="0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited" xlink:title="0000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" order="9" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness" xlink:title="0000007 - Disclosure - ORGANIZATION AND BUSINESS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/INVENTORIES" xlink:title="0000009 - Disclosure - INVENTORIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets" xlink:title="000010 - Disclosure - INTANGIBLE ASSETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DEBT" xlink:title="000012 - Disclosure - DEBT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity" xlink:title="000013 - Disclosure - STOCKHOLDERS' EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions" xlink:title="000014 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentAndContingencies" xlink:title="000015 - Disclosure - COMMITMENT AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SEGMENTS" xlink:title="000016 - Disclosure - SEGMENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/TransferOfPlasmaCenterAssets" xlink:title="000017 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations" xlink:title="000018 - Disclosure - LEASE OBLIGATIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:title="000019 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEvents" xlink:title="000020 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables" xlink:title="000023 - Disclosure - INVENTORIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables" xlink:title="000024 - Disclosure - INTANGIBLE ASSETS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:title="000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtTables" xlink:title="000026 - Disclosure - DEBT (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables" xlink:title="000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables" xlink:title="000028 - Disclosure - SEGMENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables" xlink:title="000029 - Disclosure - LEASE OBLIGATIONS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:title="000030 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative" xlink:title="000031 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="80" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="90" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" order="100" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_JanuaryOneTwoThousandNineteenMember" xlink:label="loc_admaJanuaryOneTwoThousandNineteenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_admaJanuaryOneTwoThousandNineteenMember" order="81" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_BiotestMember" xlink:label="loc_admaBiotestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_admaBiotestMember" order="82" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CustomerThreeMember" xlink:label="loc_admaCustomerThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_admaCustomerThreeMember" order="83" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" order="84" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CustomerTwoMember" xlink:label="loc_admaCustomerTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_admaCustomerTwoMember" order="85" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwill" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails" xlink:title="000034 - Disclosure - INVENTORIES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetails" xlink:title="000035 - Disclosure - INTANGIBLE ASSETS (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_RightToIntermediatesMember" xlink:label="loc_admaRightToIntermediatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_admaRightToIntermediatesMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="loc_us-gaapCustomerContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerContractsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetails1" xlink:title="000036 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetailsNarrative" xlink:title="000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:title="000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaapLandMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember" order="26" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember" order="27" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PropertyAndEquipmentMember" xlink:label="loc_admaPropertyAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_admaPropertyAndEquipmentMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails" xlink:title="000040 - Disclosure - DEBT (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails1" xlink:title="000041 - Disclosure - DEBT (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetailsNarrative" xlink:title="000042 - Disclosure - DEBT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveCreditAgreementMember" xlink:label="loc_admaPerceptiveCreditAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_admaPerceptiveCreditAgreementMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_BPCMember" xlink:label="loc_admaBPCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_admaBPCMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheIIIWarrantMember" xlink:label="loc_admaPerceptiveTrancheIIIWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_admaPerceptiveTrancheIIIWarrantMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_MarathonHealthcareFinanceFundLPMember" xlink:label="loc_admaMarathonHealthcareFinanceFundLPMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_admaMarathonHealthcareFinanceFundLPMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheIIILoanMember" xlink:label="loc_admaPerceptiveTrancheIIILoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_admaPerceptiveTrancheIIILoanMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheIILoanMember" xlink:label="loc_admaPerceptiveTrancheIILoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_admaPerceptiveTrancheIILoanMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheILoanMember" xlink:label="loc_admaPerceptiveTrancheILoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_admaPerceptiveTrancheILoanMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" xlink:label="loc_admaPerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaPerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate" order="2" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_DescriptionOfPrepaidPrincipalAmount" xlink:label="loc_admaDescriptionOfPrepaidPrincipalAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaDescriptionOfPrepaidPrincipalAmount" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" order="4" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AdditionlalDescription" xlink:label="loc_admaAdditionlalDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaAdditionlalDescription" order="5" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_InterestRateDescription" xlink:label="loc_admaInterestRateDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaInterestRateDescription" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" order="8" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ExpirationDate" xlink:label="loc_admaExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaExpirationDate" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" order="11" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_DeferredFacilityFee" xlink:label="loc_admaDeferredFacilityFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaDeferredFacilityFee" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" order="13" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PrepaymentPenalty" xlink:label="loc_admaPrepaymentPenalty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaPrepaymentPenalty" order="14" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_UnamortizedDebtDiscount" xlink:label="loc_admaUnamortizedDebtDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaUnamortizedDebtDiscount" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees" order="16" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AdditionalFacilityFee" xlink:label="loc_admaAdditionalFacilityFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaAdditionalFacilityFee" order="17" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_DebtServiceReserve" xlink:label="loc_admaDebtServiceReserve" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaDebtServiceReserve" order="18" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" order="19" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails" xlink:title="000043 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails1" xlink:title="000044 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails2" xlink:title="000045 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails3" xlink:title="000046 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PlasmaCentersMember" xlink:label="loc_admaPlasmaCentersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_admaPlasmaCentersMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="loc_us-gaapCostOfGoodsTotalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfGoodsTotalMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetailsNarrative" xlink:title="000047 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_EquityIncentivePlanMember" xlink:label="loc_admaEquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_admaEquityIncentivePlanMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="5" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_UnderwrittenPublicOffering" xlink:label="loc_admaUnderwrittenPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaUnderwrittenPublicOffering" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" order="9" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommonStockReservedForOutstanding" xlink:label="loc_admaCommonStockReservedForOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaCommonStockReservedForOutstanding" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaapCommonStockSharesSubscribedButUnissued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscribedButUnissued" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="18" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CompensationExpense" xlink:label="loc_admaCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaCompensationExpense" order="19" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommonStockGranted" xlink:label="loc_admaCommonStockGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaCommonStockGranted" order="20" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ArethLLCMember" xlink:label="loc_admaArethLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_admaArethLLCMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CreditFacilityPercentage" xlink:label="loc_admaCreditFacilityPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaCreditFacilityPercentage" order="1" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PublicOfferingDescription" xlink:label="loc_admaPublicOfferingDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaPublicOfferingDescription" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsDetails" xlink:title="000050 - Disclosure - SEGMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ConsolidatedMember" xlink:label="loc_admaConsolidatedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_admaConsolidatedMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PlasmaCollectionCenterMember" xlink:label="loc_admaPlasmaCollectionCenterMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_admaPlasmaCollectionCenterMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaapCorporateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AdmaBiomanufacturingMember" xlink:label="loc_admaAdmaBiomanufacturingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_admaAdmaBiomanufacturingMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfRevenue" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="7" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CapitalExpenditure" xlink:label="loc_admaCapitalExpenditure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaCapitalExpenditure" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" order="9" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_TotalAssets" xlink:label="loc_admaTotalAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaTotalAssets" order="10" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative" xlink:title="000051 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails" xlink:title="000052 - Disclosure - LEASE OBLIGATIONS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsNarrative" xlink:title="000053 - Disclosure - LEASE OBLIGATIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_JanuaryOneTwoThousandNineteenMember" xlink:label="loc_admaJanuaryOneTwoThousandNineteenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_admaJanuaryOneTwoThousandNineteenMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" order="1" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_LeaseDescription" xlink:label="loc_admaLeaseDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaLeaseDescription" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="5" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_IncrementalBorrowingRate" xlink:label="loc_admaIncrementalBorrowingRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaIncrementalBorrowingRate" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:title="000054 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEventsDetailsNarrative" xlink:title="000055 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_SaleAgreementMember" xlink:label="loc_admaSaleAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_admaSaleAgreementMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_JefferiesLLCMember" xlink:label="loc_admaJefferiesLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_admaJefferiesLLCMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="1" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommonStockOffering" xlink:label="loc_admaCommonStockOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaCommonStockOffering" order="2" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommissionDescription" xlink:label="loc_admaCommissionDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_admaCommissionDescription" order="3" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>adma-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 1.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/05/2020-->
<!--Copyright (c) 2020 NTDAS Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_38d02b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_38d02b" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_1b7bb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_1b7bb4" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_39bf14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_39bf14" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_640967" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_640967" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl_c62edb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl_c62edb" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_c7e6ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl_c7e6ed" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_574837" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_574837" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_0462be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_0462be" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_8" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_e88d7b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_e88d7b" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl_2f139b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl_2f139b" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl_7dc32e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl_7dc32e" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_defb1d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_defb1d" xml:lang="en-US">Deposits and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_AssetsNet_lbl_e00035" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNet_lbl_e00035" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNet" xlink:label="us-gaap_AssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_AssetsNet_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNet_lbl_13" xml:lang="en-US">[Net Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_a08a83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_a08a83" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_bb5aeb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_bb5aeb" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_0df69f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_0df69f" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_b96a36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_b96a36" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl_f3ca89" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl_f3ca89" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl_16e379" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl_16e379" xml:lang="en-US">Current portion of lease obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_58b853" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_58b853" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_20" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl_850e3c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl_850e3c" xml:lang="en-US">Senior notes payable, net of discount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl_8458bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl_8458bf" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubordinatedLongTermDebt" xlink:label="us-gaap_SubordinatedLongTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedLongTermDebt" xlink:to="us-gaap_SubordinatedLongTermDebt_lbl_e91f62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubordinatedLongTermDebt_lbl_e91f62" xml:lang="en-US">Subordinated note payable, net of discount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl_155b14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl_155b14" xml:lang="en-US">Lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_316c09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_316c09" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_0b6c27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_0b6c27" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_26" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl_d17251" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl_d17251" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_a830bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_a830bc" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_28" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_c48b5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_c48b5d" xml:lang="en-US">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_36de2a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_36de2a" xml:lang="en-US">Common Stock, $0.0001 par value, 150,000,000 shares authorized, 86,349,981 and 59,318,355 shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_710d69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_710d69" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_f28879" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_f28879" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_3bba63" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_3bba63" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_33" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_cfb59f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_cfb59f" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_34" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_822da1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_822da1" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_92cd08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_92cd08" xml:lang="en-US">Preferred stock, shares par value</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_cca44e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_cca44e" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_f04512" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_f04512" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_361ee3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_361ee3" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_6dd036" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_6dd036" xml:lang="en-US">Common stock, shares par value</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_45d9f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_45d9f3" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_5fb467" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_5fb467" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_102611" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_102611" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_1f8abb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_1f8abb" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl_76c9ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl_76c9ab" xml:lang="en-US">REVENUES:</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ProductRevenue" xlink:label="adma_ProductRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ProductRevenue" xlink:to="adma_ProductRevenue_lbl_397fe3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ProductRevenue_lbl_397fe3" xml:lang="en-US">Product revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_LicenseRevenue" xlink:label="adma_LicenseRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_LicenseRevenue" xlink:to="adma_LicenseRevenue_lbl_e0b9a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_LicenseRevenue_lbl_e0b9a4" xml:lang="en-US">License revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_d20521" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl_d20521" xml:lang="en-US">Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl_5" xml:lang="en-US">[Revenues]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl_491a93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl_491a93" xml:lang="en-US">OPERATING EXPENSES:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl_73c767" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl_73c767" xml:lang="en-US">Cost of product revenue (exclusive of amortization expense shown below)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_b4d189" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_b4d189" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl_141b88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl_141b88" xml:lang="en-US">Plasma center operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_b72e62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_b72e62" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_7d9c9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_7d9c9a" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_6e9709" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_6e9709" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_12" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_01fbf8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_01fbf8" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_13" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl_ac5d00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl_ac5d00" xml:lang="en-US">OTHER INCOME (EXPENSE):</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl_fc0704" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl_fc0704" xml:lang="en-US">Interest and other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_c9ee58" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl_c9ee58" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl_16" xml:lang="en-US">[Interest Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_712cc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_712cc5" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_17" xml:lang="en-US">[Gain (Loss) on Extinguishment of Debt]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl_52bb60" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl_52bb60" xml:lang="en-US">Gain on transfer of plasma center assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl_46968a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl_46968a" xml:lang="en-US">Other expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl_a26932" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl_a26932" xml:lang="en-US">Other expense, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl_20" xml:lang="en-US">[Nonoperating Income (Expense)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_5cf525" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_5cf525" xml:lang="en-US">NET LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_21" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl_15a79f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl_15a79f" xml:lang="en-US">BASIC AND DILUTED LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_a30ef2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_a30ef2" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_1e2c5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_1e2c5a" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_928410" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_928410" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_e24111" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_e24111" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_6501cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_6501cd" xml:lang="en-US">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_00f907" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_00f907" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_f3d91b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_f3d91b" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_b813e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_b813e9" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_821ba6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_821ba6" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_9d0c2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_9d0c2f" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl_2197b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl_2197b2" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_c447f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_c447f3" xml:lang="en-US">Issuance of common stock, net of offering expenses, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl_04d618" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl_04d618" xml:lang="en-US">Warrants issued in connection with note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl_d4155f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl_d4155f" xml:lang="en-US">Issuance of common stock, net of offering expenses, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_9f5658" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_9f5658" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_a1173b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_a1173b" xml:lang="en-US">Exercise of stock options, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_043ec7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_043ec7" xml:lang="en-US">Exercise of stock options, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_e2262f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_e2262f" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_92ce29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_92ce29" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_cc55d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_cc55d9" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_3ade6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_3ade6b" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_9f1a6e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_9f1a6e" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_7df5d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_7df5d3" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_975927" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_975927" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl_a1358a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl_a1358a" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_e30551" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_e30551" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_7" xml:lang="en-US">[Share-based Payment Arrangement, Noncash Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl_6de89b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl_6de89b" xml:lang="en-US">Gain on transfer of plasma center assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl_749b7b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl_749b7b" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_a99f6a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_a99f6a" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="adma_AmortizationOfLicenseRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl_d91eb8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AmortizationOfLicenseRevenue_lbl_d91eb8" xml:lang="en-US">Amortization of license revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_be2aee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_be2aee" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisition:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_2ee58c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_2ee58c" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_f41c9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_f41c9b" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_14" xml:lang="en-US">[Increase (Decrease) in Inventories]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_30fe62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_30fe62" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_15" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl_22507a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl_22507a" xml:lang="en-US">Deposits and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl_16" xml:lang="en-US">[Increase (Decrease) in Other Operating Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_cbd243" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_cbd243" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_17" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_3c8805" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_3c8805" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl_a85ade" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl_a85ade" xml:lang="en-US">Other current and non-current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_a3b66b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_a3b66b" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_20" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_8a5a61" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_8a5a61" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_728607" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_728607" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl_8f3451" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl_8f3451" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_3c6fa3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_3c6fa3" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_ab07ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_ab07ae" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl_ff10e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl_ff10e5" xml:lang="en-US">Principal payments on notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl_2f9e6d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForFees_lbl_2f9e6d" xml:lang="en-US">Payment of end of term fee</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl_27" xml:lang="en-US">[Payments for Other Fees]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PaymentOfDebtRefinancingFees" xlink:to="adma_PaymentOfDebtRefinancingFees_lbl_8390df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adma_PaymentOfDebtRefinancingFees_lbl_8390df" xml:lang="en-US">Payment of debt refinancing fees</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PaymentOfDebtRefinancingFees" xlink:label="adma_PaymentOfDebtRefinancingFees" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PaymentOfDebtRefinancingFees" xlink:to="adma_PaymentOfDebtRefinancingFees_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PaymentOfDebtRefinancingFees_lbl_28" xml:lang="en-US">[Payment of debt refinancing fees]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl_f4cecd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl_f4cecd" xml:lang="en-US">Proceeds from issuance of note payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl_2bf9ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl_2bf9ed" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl_30" xml:lang="en-US">[Payments of Debt Issuance Costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_4ff639" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_4ff639" xml:lang="en-US">Proceeds from the issuance of common stock, net of offering expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl_a3342c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl_a3342c" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLeasingCosts" xlink:to="us-gaap_PaymentsForLeasingCosts_lbl_851d3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForLeasingCosts_lbl_851d3f" xml:lang="en-US">Payments on finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="us-gaap_PaymentsForLeasingCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLeasingCosts" xlink:to="us-gaap_PaymentsForLeasingCosts_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLeasingCosts_lbl_33" xml:lang="en-US">[Payments for Leasing Costs]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_558c33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_558c33" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_34" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_577d26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_577d26" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_35" xml:lang="en-US">[Cash and Cash Equivalents, Period Increase (Decrease)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_b7b6c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_b7b6c1" xml:lang="en-US">Cash and cash equivalents, including restricted cash - beginning of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_ab5152" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_ab5152" xml:lang="en-US">Cash and cash equivalents - end of period</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_b5e5bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_b5e5bc" xml:lang="en-US">ORGANIZATION AND BUSINESS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl_5279f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl_5279f1" xml:lang="en-US">1. ORGANIZATION AND BUSINESS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_ee4d6f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_ee4d6f" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_3dd6cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_3dd6cb" xml:lang="en-US">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl_a2922f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl_a2922f" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl_a6f705" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl_a6f705" xml:lang="en-US">3. INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl_28288d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl_28288d" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_92b72e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_92b72e" xml:lang="en-US">4. INTANGIBLE ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_57aa2c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_57aa2c" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_a2bce7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_a2bce7" xml:lang="en-US">5. PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl_779f2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl_779f2f" xml:lang="en-US">DEBT</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl_50f668" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl_50f668" xml:lang="en-US">6. DEBT</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_c090f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_c090f0" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_a0b36f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_a0b36f" xml:lang="en-US">7. STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_045f87" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_045f87" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_5abef7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_5abef7" xml:lang="en-US">8. RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_7696f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_7696f7" xml:lang="en-US">COMMITMENT AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_09847c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_09847c" xml:lang="en-US">9. COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl_a48be3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl_a48be3" xml:lang="en-US">SEGMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl_ff03e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl_ff03e4" xml:lang="en-US">10. SEGMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl_a564f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl_a564f2" xml:lang="en-US">TRANSFER OF PLASMA CENTER ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock" xlink:label="adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock" xlink:to="adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock_lbl_1da3a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock_lbl_1da3a5" xml:lang="en-US">11. TRANSFER OF PLASMA CENTER ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl_005e19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl_005e19" xml:lang="en-US">LEASE OBLIGATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl_ad873c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl_ad873c" xml:lang="en-US">12. LEASE OBLIGATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_cf2931" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_cf2931" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl_aae2af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl_aae2af" xml:lang="en-US">13. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_4d34f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_4d34f8" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_5d05cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_5d05cd" xml:lang="en-US">14. SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl_102559" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl_102559" xml:lang="en-US">Basis of presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_ac8259" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_ac8259" xml:lang="en-US">Use of estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl_921a77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl_921a77" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl_6199e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl_6199e1" xml:lang="en-US">Accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl_5" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_22559b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_22559b" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_6" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl_c6cacf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl_c6cacf" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl_7" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl_8335d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl_8335d3" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_985ad7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_985ad7" xml:lang="en-US">Revenue recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl_ca411a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl_ca411a" xml:lang="en-US">Cost of product revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_d2a071" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_d2a071" xml:lang="en-US">Loss per common share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl_303798" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl_303798" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl_12" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_f2343c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_f2343c" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_f6c9fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_f6c9fe" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_352888" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_352888" xml:lang="en-US">Schedule of dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl_fef5b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl_fef5b7" xml:lang="en-US">Schedule of inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_cc4c93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_cc4c93" xml:lang="en-US">Intangible asset future aggregate amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl_712be8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl_712be8" xml:lang="en-US">Schedule of Intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_45de22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_45de22" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSubordinatedBorrowingTextBlock" xlink:label="us-gaap_ScheduleOfSubordinatedBorrowingTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubordinatedBorrowingTextBlock" xlink:to="us-gaap_ScheduleOfSubordinatedBorrowingTextBlock_lbl_6cd3e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubordinatedBorrowingTextBlock_lbl_6cd3e1" xml:lang="en-US">Summary of subordinated note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl_ee432a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl_ee432a" xml:lang="en-US">Summary of notes payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl_c3f627" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl_c3f627" xml:lang="en-US">Schedule of assumptions</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_54c1f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_54c1f8" xml:lang="en-US">Schedule of compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl_ae4366" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl_ae4366" xml:lang="en-US">Schedule of option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl_9e7b8e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl_9e7b8e" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl_4fca09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl_4fca09" xml:lang="en-US">Summarized segment financial information</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl_b3c338" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl_b3c338" xml:lang="en-US">Schedule of future minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl_7c298f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl_7c298f" xml:lang="en-US">Schedule of supplemental cash flow information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_a122bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_a122bf" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_WorkingCapital" xlink:label="adma_WorkingCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_WorkingCapital" xlink:to="adma_WorkingCapital_lbl_abee10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_WorkingCapital_lbl_abee10" xml:lang="en-US">Working capital</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_36bf1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_36bf1c" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl_cdf05b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl_cdf05b" xml:lang="en-US">Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl_5a7274" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl_5a7274" xml:lang="en-US">Restricted stock units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl_491641" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl_491641" xml:lang="en-US">Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_366e65" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_366e65" xml:lang="en-US">Potentially dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_5f829d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_5f829d" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl_bfc21b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl_bfc21b" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl_914ee9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl_914ee9" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl_9b6911" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl_9b6911" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_JanuaryOneTwoThousandNineteenMember" xlink:label="adma_JanuaryOneTwoThousandNineteenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_JanuaryOneTwoThousandNineteenMember" xlink:to="adma_JanuaryOneTwoThousandNineteenMember_lbl_d304c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_JanuaryOneTwoThousandNineteenMember_lbl_d304c5" xml:lang="en-US">January 1, 2019 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_BiotestMember" xlink:label="adma_BiotestMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_BiotestMember" xlink:to="adma_BiotestMember_lbl_29ffad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_BiotestMember_lbl_29ffad" xml:lang="en-US">Biotest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CustomerThreeMember" xlink:label="adma_CustomerThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_CustomerThreeMember" xlink:to="adma_CustomerThreeMember_lbl_75b906" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_CustomerThreeMember_lbl_75b906" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl_cb994a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl_cb994a" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CustomerTwoMember" xlink:label="adma_CustomerTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_CustomerTwoMember" xlink:to="adma_CustomerTwoMember_lbl_f04347" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_CustomerTwoMember_lbl_f04347" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl_023623" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Goodwill_lbl_023623" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl_27f913" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl_27f913" xml:lang="en-US">Vesting term</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_a6071d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_a6071d" xml:lang="en-US">Right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_ccab14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_ccab14" xml:lang="en-US">Lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl_789808" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl_789808" xml:lang="en-US">Note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl_a331a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl_a331a6" xml:lang="en-US">Risk concentration</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl_3f254a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl_3f254a" xml:lang="en-US">Raw materials</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl_fbb7a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl_fbb7a4" xml:lang="en-US">Work-in-process</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl_c06dfe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl_c06dfe" xml:lang="en-US">Finished goods</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_ebeef7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_lbl_ebeef7" xml:lang="en-US">Total inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_ef49cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_ef49cc" xml:lang="en-US">Finite Lived Intangible Assets By Major Class Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl_9296ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl_9296ac" xml:lang="en-US">Trademark and other intangible rights related to Nabi-HB [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_RightToIntermediatesMember" xlink:label="adma_RightToIntermediatesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl_cab472" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_RightToIntermediatesMember_lbl_cab472" xml:lang="en-US">Right to intermediates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="us-gaap_CustomerContractsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerContractsMember" xlink:to="us-gaap_CustomerContractsMember_lbl_70bfbd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerContractsMember_lbl_70bfbd" xml:lang="en-US">Customer contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl_8e0025" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl_8e0025" xml:lang="en-US">Cost</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl_a90b2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl_a90b2e" xml:lang="en-US">Accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_17f570" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_17f570" xml:lang="en-US">Net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_c5c1f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_c5c1f3" xml:lang="en-US">Remainder of 2020</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_cd22af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_cd22af" xml:lang="en-US">2021</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_1fe697" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_1fe697" xml:lang="en-US">2022</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_ce4e2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_ce4e2d" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_03278b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_03278b" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AmortizationExpense" xlink:label="adma_AmortizationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AmortizationExpense" xlink:to="adma_AmortizationExpense_lbl_77fa7e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AmortizationExpense_lbl_77fa7e" xml:lang="en-US">Amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl_363972" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl_363972" xml:lang="en-US">Property Plant And Equipment By Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl_613744" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl_613744" xml:lang="en-US">Manufacturing and laboratory equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl_d548f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl_d548f5" xml:lang="en-US">Office equipment and computer software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl_2baeeb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl_2baeeb" xml:lang="en-US">Furniture and fixtures [member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl_06e291" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl_06e291" xml:lang="en-US">Leasehold improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl_8c66b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl_8c66b5" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl_7ddbfc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl_7ddbfc" xml:lang="en-US">Buildings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl_559b2c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl_559b2c" xml:lang="en-US">Construction in process [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl_b75b0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl_b75b0f" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_88f9ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_88f9ff" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_3" xml:lang="en-US">[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_8e0f1d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_8e0f1d" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_109ffd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_109ffd" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PropertyAndEquipmentMember" xlink:label="adma_PropertyAndEquipmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PropertyAndEquipmentMember" xlink:to="adma_PropertyAndEquipmentMember_lbl_fa1f83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PropertyAndEquipmentMember_lbl_fa1f83" xml:lang="en-US">Property and equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_c3a82e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_c3a82e" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl_422a26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl_422a26" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl_3e848a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl_3e848a" xml:lang="en-US">Useful life</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl_3945eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl_3945eb" xml:lang="en-US">Notes payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract_lbl_10a8f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract_lbl_10a8f9" xml:lang="en-US">Less:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl_8dd74d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl_8dd74d" xml:lang="en-US">Debt discount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl_a26ea9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl_a26ea9" xml:lang="en-US">Senior notes payable</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_SubordinatedDebtCarryingValue" xlink:label="adma_SubordinatedDebtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SubordinatedDebtCarryingValue" xlink:to="adma_SubordinatedDebtCarryingValue_lbl_7db198" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_SubordinatedDebtCarryingValue_lbl_7db198" xml:lang="en-US">Subordinated note payable to Biotest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract_lbl_79b72f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract_lbl_79b72f" xml:lang="en-US">Less:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SubordinatedDebtInstrumentUnamortizedDiscount" xlink:to="adma_SubordinatedDebtInstrumentUnamortizedDiscount_lbl_27277a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adma_SubordinatedDebtInstrumentUnamortizedDiscount_lbl_27277a" xml:lang="en-US">Debt discount</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_SubordinatedDebtInstrumentUnamortizedDiscount" xlink:label="adma_SubordinatedDebtInstrumentUnamortizedDiscount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SubordinatedDebtInstrumentUnamortizedDiscount" xlink:to="adma_SubordinatedDebtInstrumentUnamortizedDiscount_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_SubordinatedDebtInstrumentUnamortizedDiscount_lbl_4" xml:lang="en-US">[Debt discount]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubordinatedDebt" xlink:label="us-gaap_SubordinatedDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubordinatedDebt" xlink:to="us-gaap_SubordinatedDebt_lbl_e1d277" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubordinatedDebt_lbl_e1d277" xml:lang="en-US">Subordinated note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_04a1ca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_04a1ca" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_cd53bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_cd53bb" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl_24b379" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl_24b379" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveCreditAgreementMember" xlink:label="adma_PerceptiveCreditAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PerceptiveCreditAgreementMember" xlink:to="adma_PerceptiveCreditAgreementMember_lbl_51d604" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PerceptiveCreditAgreementMember_lbl_51d604" xml:lang="en-US">Perceptive Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_BPCMember" xlink:label="adma_BPCMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_BPCMember" xlink:to="adma_BPCMember_lbl_4260ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_BPCMember_lbl_4260ea" xml:lang="en-US">BPC (Member)</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheIIIWarrantMember" xlink:label="adma_PerceptiveTrancheIIIWarrantMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PerceptiveTrancheIIIWarrantMember" xlink:to="adma_PerceptiveTrancheIIIWarrantMember_lbl_bc18e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PerceptiveTrancheIIIWarrantMember_lbl_bc18e3" xml:lang="en-US">Perceptive Tranche III Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_MarathonHealthcareFinanceFundLPMember" xlink:label="adma_MarathonHealthcareFinanceFundLPMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_MarathonHealthcareFinanceFundLPMember" xlink:to="adma_MarathonHealthcareFinanceFundLPMember_lbl_b0806d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_MarathonHealthcareFinanceFundLPMember_lbl_b0806d" xml:lang="en-US">Marathon Healthcare Finance Fund, L.P. (Member)</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheIIILoanMember" xlink:label="adma_PerceptiveTrancheIIILoanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PerceptiveTrancheIIILoanMember" xlink:to="adma_PerceptiveTrancheIIILoanMember_lbl_e5df5f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PerceptiveTrancheIIILoanMember_lbl_e5df5f" xml:lang="en-US">Perceptive Tranche III Loan (Member)</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheIILoanMember" xlink:label="adma_PerceptiveTrancheIILoanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PerceptiveTrancheIILoanMember" xlink:to="adma_PerceptiveTrancheIILoanMember_lbl_38e504" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PerceptiveTrancheIILoanMember_lbl_38e504" xml:lang="en-US">Perceptive Tranche II Loan (Member)</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheILoanMember" xlink:label="adma_PerceptiveTrancheILoanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PerceptiveTrancheILoanMember" xlink:to="adma_PerceptiveTrancheILoanMember_lbl_9ab8dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PerceptiveTrancheILoanMember_lbl_9ab8dc" xml:lang="en-US">Perceptive Tranche I Loan (Member)</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" xlink:label="adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" xlink:to="adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid_lbl_144726" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid_lbl_144726" xml:lang="en-US">Perceptive Tranche I Note and Perceptive Tranche II fees paid</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl_06abbf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl_06abbf" xml:lang="en-US">Interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_DescriptionOfPrepaidPrincipalAmount" xlink:label="adma_DescriptionOfPrepaidPrincipalAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DescriptionOfPrepaidPrincipalAmount" xlink:to="adma_DescriptionOfPrepaidPrincipalAmount_lbl_d4bd77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_DescriptionOfPrepaidPrincipalAmount_lbl_d4bd77" xml:lang="en-US">Description of prepaid principal amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl_924b79" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl_924b79" xml:lang="en-US">Principal amount of term loan</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AdditionlalDescription" xlink:label="adma_AdditionlalDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AdditionlalDescription" xlink:to="adma_AdditionlalDescription_lbl_8feec0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AdditionlalDescription_lbl_8feec0" xml:lang="en-US">Additionlal description</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_InterestRateDescription" xlink:label="adma_InterestRateDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_InterestRateDescription" xlink:to="adma_InterestRateDescription_lbl_560c21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_InterestRateDescription_lbl_560c21" xml:lang="en-US">Interest rate description</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl_5adac7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl_5adac7" xml:lang="en-US">Warrant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_b8e893" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl_b8e893" xml:lang="en-US">Warrant, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ExpirationDate" xlink:label="adma_ExpirationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ExpirationDate" xlink:to="adma_ExpirationDate_lbl_94b139" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ExpirationDate_lbl_94b139" xml:lang="en-US">Expiration date</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_022e93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_022e93" xml:lang="en-US">Warrant exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl_7309d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl_7309d4" xml:lang="en-US">Net Cash proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_DeferredFacilityFee" xlink:label="adma_DeferredFacilityFee" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DeferredFacilityFee" xlink:to="adma_DeferredFacilityFee_lbl_eff622" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_DeferredFacilityFee_lbl_eff622" xml:lang="en-US">Deferred facility fee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_9d40fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_9d40fa" xml:lang="en-US">Loss on the extinguishment of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PrepaymentPenalty" xlink:label="adma_PrepaymentPenalty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PrepaymentPenalty" xlink:to="adma_PrepaymentPenalty_lbl_9dd3e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PrepaymentPenalty_lbl_9dd3e4" xml:lang="en-US">Prepayment Penalty</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_UnamortizedDebtDiscount" xlink:label="adma_UnamortizedDebtDiscount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnamortizedDebtDiscount" xlink:to="adma_UnamortizedDebtDiscount_lbl_6aacc7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_UnamortizedDebtDiscount_lbl_6aacc7" xml:lang="en-US">Unamortized debt discount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl_b67891" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl_b67891" xml:lang="en-US">Fees and expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AdditionalFacilityFee" xlink:label="adma_AdditionalFacilityFee" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AdditionalFacilityFee" xlink:to="adma_AdditionalFacilityFee_lbl_42b647" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AdditionalFacilityFee_lbl_42b647" xml:lang="en-US">Additional facility fee</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_DebtServiceReserve" xlink:label="adma_DebtServiceReserve" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_DebtServiceReserve" xlink:to="adma_DebtServiceReserve_lbl_b0542f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_DebtServiceReserve_lbl_b0542f" xml:lang="en-US">Debt service reserve</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_944f87" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_944f87" xml:lang="en-US">Accrued interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_e010b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MaximumMember_lbl_e010b7" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_f671fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_f671fd" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_8fb586" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_8fb586" xml:lang="en-US">Dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_10c80b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl_10c80b" xml:lang="en-US">Expected term</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl_bdaa29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl_bdaa29" xml:lang="en-US">Volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_e5e4e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl_e5e4e9" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl_609d60" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl_609d60" xml:lang="en-US">Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_f6d12a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_f6d12a" xml:lang="en-US">Outstanding at beginning of period</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_3" xml:lang="en-US">[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_7bb2ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_7bb2ab" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_47676e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_47676e" xml:lang="en-US">Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_fca2e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_fca2e8" xml:lang="en-US">Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod_lbl_8b6a93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod_lbl_8b6a93" xml:lang="en-US">Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_ad7574" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_ad7574" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod_lbl_68bb9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod_lbl_68bb9c" xml:lang="en-US">Options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl_b5d7e2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl_b5d7e2" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_97980b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_97980b" xml:lang="en-US">Outstanding at beginning of period</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_11" xml:lang="en-US">[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_ca09af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_ca09af" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_12" xml:lang="en-US">[Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_645100" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_645100" xml:lang="en-US">Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_13" xml:lang="en-US">[Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_f50973" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_f50973" xml:lang="en-US">Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_e40af1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_e40af1" xml:lang="en-US">Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_15" xml:lang="en-US">[Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_a1fe89" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_a1fe89" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice_lbl_75a6b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice_lbl_75a6b5" xml:lang="en-US">Options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice_lbl_17" xml:lang="en-US">[Options exercisable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl_d3f837" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl_d3f837" xml:lang="en-US">Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_166659" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_166659" xml:lang="en-US">Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl_779125" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl_779125" xml:lang="en-US">Vested</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_d3c051" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_d3c051" xml:lang="en-US">Forfeited</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl_38bde2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl_38bde2" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl_8" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_faf620" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_faf620" xml:lang="en-US">Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl_2b84b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl_2b84b2" xml:lang="en-US">Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl_11" xml:lang="en-US">[Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_72820c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_72820c" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl_645e2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl_645e2b" xml:lang="en-US">Income Statement Location Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl_06d0cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl_06d0cc" xml:lang="en-US">Research and development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PlasmaCentersMember" xlink:label="adma_PlasmaCentersMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaCentersMember" xlink:to="adma_PlasmaCentersMember_lbl_9e874c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PlasmaCentersMember_lbl_9e874c" xml:lang="en-US">Plasma centers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl_a0bfc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl_a0bfc4" xml:lang="en-US">Selling, general and administrative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="us-gaap_CostOfGoodsTotalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsTotalMember" xlink:to="us-gaap_CostOfGoodsTotalMember_lbl_dc6854" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsTotalMember_lbl_dc6854" xml:lang="en-US">Cost of product revenue [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_a35400" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_a35400" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_EquityIncentivePlanMember" xlink:label="adma_EquityIncentivePlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl_a41d11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_EquityIncentivePlanMember_lbl_a41d11" xml:lang="en-US">Equity Incentive Plans [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_83e044" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_83e044" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_da2f9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_da2f9a" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_e66728" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_e66728" xml:lang="en-US">Preferred stock, outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_91ff08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_91ff08" xml:lang="en-US">Common stock, par value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_122c3c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_122c3c" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_UnderwrittenPublicOffering" xlink:label="adma_UnderwrittenPublicOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_UnderwrittenPublicOffering" xlink:to="adma_UnderwrittenPublicOffering_lbl_f59c26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_UnderwrittenPublicOffering_lbl_f59c26" xml:lang="en-US">Underwritten public offering</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_ce2cdf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_ce2cdf" xml:lang="en-US">Common stock shares, issued</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_cdb98f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_cdb98f" xml:lang="en-US">Gross proceeds from public offering</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_3566a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_3566a7" xml:lang="en-US">Common stock, outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommonStockReservedForOutstanding" xlink:label="adma_CommonStockReservedForOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_CommonStockReservedForOutstanding" xlink:to="adma_CommonStockReservedForOutstanding_lbl_fbe07c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_CommonStockReservedForOutstanding_lbl_fbe07c" xml:lang="en-US">Common stock reserved for outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl_0db9fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl_0db9fd" xml:lang="en-US">Common stock issuable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl_1e1218" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl_1e1218" xml:lang="en-US">Warrants outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl_0e266a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl_0e266a" xml:lang="en-US">Weighted average exercise price of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl_11b103" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl_11b103" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl_116387" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl_116387" xml:lang="en-US">Options granted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_efef5f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_efef5f" xml:lang="en-US">Weighted average remaining contractual life of stock options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_984e42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_984e42" xml:lang="en-US">Weighted average remaining contractual life of stock options outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl_dfbbf3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl_dfbbf3" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CompensationExpense" xlink:label="adma_CompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_CompensationExpense" xlink:to="adma_CompensationExpense_lbl_212a7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_CompensationExpense_lbl_212a7f" xml:lang="en-US">Compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommonStockGranted" xlink:label="adma_CommonStockGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_CommonStockGranted" xlink:to="adma_CommonStockGranted_lbl_ad403a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_CommonStockGranted_lbl_ad403a" xml:lang="en-US">Common stock granted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_039377" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_039377" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ArethLLCMember" xlink:label="adma_ArethLLCMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl_2ba2aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ArethLLCMember_lbl_2ba2aa" xml:lang="en-US">Areth, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CreditFacilityPercentage" xlink:label="adma_CreditFacilityPercentage" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_CreditFacilityPercentage" xlink:to="adma_CreditFacilityPercentage_lbl_907b33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_CreditFacilityPercentage_lbl_907b33" xml:lang="en-US">Credit facility</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PublicOfferingDescription" xlink:label="adma_PublicOfferingDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PublicOfferingDescription" xlink:to="adma_PublicOfferingDescription_lbl_2825e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PublicOfferingDescription_lbl_2825e8" xml:lang="en-US">Public offering description</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl_7890d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl_7890d7" xml:lang="en-US">Rent expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:to="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl_5950a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl_5950a3" xml:lang="en-US">Monthly Rent</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl_c537b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl_c537b9" xml:lang="en-US">Debt instrument, frequency of periodic payment</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PurchasePercentageFromInventory" xlink:label="adma_PurchasePercentageFromInventory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PurchasePercentageFromInventory" xlink:to="adma_PurchasePercentageFromInventory_lbl_66aa97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PurchasePercentageFromInventory_lbl_66aa97" xml:lang="en-US">Purchase percentage from inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PurchaseOfRawMaterial" xlink:label="adma_PurchaseOfRawMaterial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PurchaseOfRawMaterial" xlink:to="adma_PurchaseOfRawMaterial_lbl_ae7edf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PurchaseOfRawMaterial_lbl_ae7edf" xml:lang="en-US">Purchase of raw material</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="adma_PlasmaSupplyAgreementTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl_88c675" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl_88c675" xml:lang="en-US">Plasma supply agreement term</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl_7b084b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl_7b084b" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ConsolidatedMember" xlink:label="adma_ConsolidatedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_ConsolidatedMember" xlink:to="adma_ConsolidatedMember_lbl_f225fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_ConsolidatedMember_lbl_f225fa" xml:lang="en-US">Consolidated (member)</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PlasmaCollectionCenterMember" xlink:label="adma_PlasmaCollectionCenterMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_PlasmaCollectionCenterMember" xlink:to="adma_PlasmaCollectionCenterMember_lbl_fb5a9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_PlasmaCollectionCenterMember_lbl_fb5a9a" xml:lang="en-US">Plasma Collection Centers</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateMember" xlink:label="us-gaap_CorporateMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateMember" xlink:to="us-gaap_CorporateMember_lbl_d54c18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateMember_lbl_d54c18" xml:lang="en-US">Corporate</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AdmaBiomanufacturingMember" xlink:label="adma_AdmaBiomanufacturingMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_AdmaBiomanufacturingMember" xlink:to="adma_AdmaBiomanufacturingMember_lbl_3885eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_AdmaBiomanufacturingMember_lbl_3885eb" xml:lang="en-US">ADMA BioManufacturing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_ed69f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl_ed69f4" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl_9857a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfRevenue_lbl_9857a3" xml:lang="en-US">Cost of product revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_958fd4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_958fd4" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_3dd3ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_3dd3ee" xml:lang="en-US">Interest and other expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl_d87483" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl_d87483" xml:lang="en-US">Gain on transfer of plasma center assets</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CapitalExpenditure" xlink:label="adma_CapitalExpenditure" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_CapitalExpenditure" xlink:to="adma_CapitalExpenditure_lbl_4f50d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_CapitalExpenditure_lbl_4f50d0" xml:lang="en-US">Capital expenditure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_f9aaf9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl_f9aaf9" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TotalAssets" xlink:to="adma_TotalAssets_lbl_37d347" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adma_TotalAssets_lbl_37d347" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_TotalAssets" xlink:label="adma_TotalAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_TotalAssets" xlink:to="adma_TotalAssets_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_TotalAssets_lbl_11" xml:lang="en-US">[TOTAL ASSETS]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_GainUponTransferFacilities" xlink:label="adma_GainUponTransferFacilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_GainUponTransferFacilities" xlink:to="adma_GainUponTransferFacilities_lbl_a52b86" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_GainUponTransferFacilities_lbl_a52b86" xml:lang="en-US">Gain upon transfer facilities</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_NetCarryingValueOfAssets" xlink:label="adma_NetCarryingValueOfAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_NetCarryingValueOfAssets" xlink:to="adma_NetCarryingValueOfAssets_lbl_23ec57" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_NetCarryingValueOfAssets_lbl_23ec57" xml:lang="en-US">Net carrying value of assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" xlink:to="us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized_lbl_59f349" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized_lbl_59f349" xml:lang="en-US">Combined fair value of obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl_78cf32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl_78cf32" xml:lang="en-US">Remainder of 2020</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Operating Leases, Future Minimum Payments, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl_c3b557" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl_c3b557" xml:lang="en-US">2021</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl_3" xml:lang="en-US">[Operating Leases, Future Minimum Payments, Due in Two Years]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl_c4c163" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl_c4c163" xml:lang="en-US">2022</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl_4" xml:lang="en-US">[Operating Leases, Future Minimum Payments, Due in Three Years]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl_baa6f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl_baa6f5" xml:lang="en-US">2023</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl_5" xml:lang="en-US">[Operating Leases, Future Minimum Payments, Due in Four Years]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl_d44da9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl_d44da9" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl_6" xml:lang="en-US">[Operating Leases, Future Minimum Payments, Due in Five Years]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl_7a7194" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl_7a7194" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl_e963f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl_e963f6" xml:lang="en-US">Total payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_InterestPortionOfMinimumLeasePayments" xlink:to="adma_InterestPortionOfMinimumLeasePayments_lbl_041fee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adma_InterestPortionOfMinimumLeasePayments_lbl_041fee" xml:lang="en-US">Less: imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_InterestPortionOfMinimumLeasePayments" xlink:label="adma_InterestPortionOfMinimumLeasePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_InterestPortionOfMinimumLeasePayments" xlink:to="adma_InterestPortionOfMinimumLeasePayments_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_InterestPortionOfMinimumLeasePayments_lbl_9" xml:lang="en-US">[Less: imputed interest]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_b8bd59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_b8bd59" xml:lang="en-US">Current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_10" xml:lang="en-US">[Operating Lease, Liability, Current]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_OperatingLeaseLiabilityTotal" xlink:to="adma_OperatingLeaseLiabilityTotal_lbl_9c00ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adma_OperatingLeaseLiabilityTotal_lbl_9c00ce" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_OperatingLeaseLiabilityTotal" xlink:label="adma_OperatingLeaseLiabilityTotal" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_OperatingLeaseLiabilityTotal" xlink:to="adma_OperatingLeaseLiabilityTotal_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_OperatingLeaseLiabilityTotal_lbl_11" xml:lang="en-US">[Total]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl_e4c991" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl_e4c991" xml:lang="en-US">Lease and rent expense</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_LeaseDescription" xlink:label="adma_LeaseDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_LeaseDescription" xlink:to="adma_LeaseDescription_lbl_b95f19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_LeaseDescription_lbl_b95f19" xml:lang="en-US">Lease description</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_a44b0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl_a44b0e" xml:lang="en-US">Operating Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl_213bc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl_213bc6" xml:lang="en-US">Weighted average remaining term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_f295d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_f295d9" xml:lang="en-US">Right of use asstes</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_IncrementalBorrowingRate" xlink:label="adma_IncrementalBorrowingRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_IncrementalBorrowingRate" xlink:to="adma_IncrementalBorrowingRate_lbl_c19f11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_IncrementalBorrowingRate_lbl_c19f11" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalCashFlowElementsAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAbstract_lbl_112ee4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAbstract_lbl_112ee4" xml:lang="en-US">SUPPLEMENTAL INFORMATION:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_be0cf6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_be0cf6" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_28a76a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_28a76a" xml:lang="en-US">Noncash Financing and Inesting Activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl_aa564f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl_aa564f" xml:lang="en-US">Equipment acquired reflected in accounts payable and accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl_5f2e6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl_5f2e6b" xml:lang="en-US">Right-to-use assets obtained in exchange for lease obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_WarrantsIssuedInConnectionWithNotePayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotePayable_lbl_76f663" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adma_WarrantsIssuedInConnectionWithNotePayable_lbl_76f663" xml:lang="en-US">Warrants issued in connection with note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_WarrantsIssuedInConnectionWithNotePayable" xlink:label="adma_WarrantsIssuedInConnectionWithNotePayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_WarrantsIssuedInConnectionWithNotePayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotePayable_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_WarrantsIssuedInConnectionWithNotePayable_lbl_7" xml:lang="en-US">[Warrants issued in connection with note payable]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_735990" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_735990" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl_893de8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl_893de8" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_8b5a4f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_8b5a4f" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_SaleAgreementMember" xlink:label="adma_SaleAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_SaleAgreementMember" xlink:to="adma_SaleAgreementMember_lbl_8eae2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_SaleAgreementMember_lbl_8eae2f" xml:lang="en-US">Sale Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_JefferiesLLCMember" xlink:label="adma_JefferiesLLCMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_JefferiesLLCMember" xlink:to="adma_JefferiesLLCMember_lbl_e9e0ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_JefferiesLLCMember_lbl_e9e0ae" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_e26727" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_e26727" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommonStockOffering" xlink:label="adma_CommonStockOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_CommonStockOffering" xlink:to="adma_CommonStockOffering_lbl_beeefe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_CommonStockOffering_lbl_beeefe" xml:lang="en-US">Common stock offering</link:label>
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommissionDescription" xlink:label="adma_CommissionDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adma_CommissionDescription" xlink:to="adma_CommissionDescription_lbl_02ee43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adma_CommissionDescription_lbl_02ee43" xml:lang="en-US">Commission description</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>adma-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 1.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 08/05/2020-->
<!--Copyright (c) 2020 NTDAS Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://admabiologics.com/role/Cover" xlink:href="adma-20200630.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="adma-20200630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="adma-20200630.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:href="adma-20200630.xsd#OrganizationAndBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/INVENTORIES" xlink:href="adma-20200630.xsd#INVENTORIES" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:href="adma-20200630.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:href="adma-20200630.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DEBT" xlink:href="adma-20200630.xsd#DEBT" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:href="adma-20200630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:href="adma-20200630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentAndContingencies" xlink:href="adma-20200630.xsd#CommitmentAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SEGMENTS" xlink:href="adma-20200630.xsd#SEGMENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/TransferOfPlasmaCenterAssets" xlink:href="adma-20200630.xsd#TransferOfPlasmaCenterAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:href="adma-20200630.xsd#LeaseObligations" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:href="adma-20200630.xsd#SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEvents" xlink:href="adma-20200630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:href="adma-20200630.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:href="adma-20200630.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:href="adma-20200630.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtTables" xlink:href="adma-20200630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:href="adma-20200630.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:href="adma-20200630.xsd#SegmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:href="adma-20200630.xsd#LeaseObligationsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:href="adma-20200630.xsd#SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative" xlink:href="adma-20200630.xsd#OrganizationAndBusinessDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="adma-20200630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:href="adma-20200630.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetails" xlink:href="adma-20200630.xsd#IntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetails1" xlink:href="adma-20200630.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsDetailsNarrative" xlink:href="adma-20200630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:href="adma-20200630.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="adma-20200630.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:href="adma-20200630.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails1" xlink:href="adma-20200630.xsd#DebtDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetailsNarrative" xlink:href="adma-20200630.xsd#DebtDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails" xlink:href="adma-20200630.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails1" xlink:href="adma-20200630.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails2" xlink:href="adma-20200630.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetails3" xlink:href="adma-20200630.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityDetailsNarrative" xlink:href="adma-20200630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="adma-20200630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="adma-20200630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsDetails" xlink:href="adma-20200630.xsd#SegmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative" xlink:href="adma-20200630.xsd#TransferOfPlasmaCenterAssetsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:href="adma-20200630.xsd#LeaseObligationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsNarrative" xlink:href="adma-20200630.xsd#LeaseObligationsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:href="adma-20200630.xsd#SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEventsDetailsNarrative" xlink:href="adma-20200630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:title="0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_6f0141" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_a1bb31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_6f0141" xlink:to="loc_us-gaapAssetsAbstract_a1bb31" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_398bea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_a1bb31" xlink:to="loc_us-gaapAssetsCurrentAbstract_398bea" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_043f16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_043f16" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_ede888" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_ede888" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_07cd76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapInventoryNet_07cd76" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_9b9c18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_9b9c18" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_5b9d6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapAssetsCurrent_5b9d6a" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_40c21c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_40c21c" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_0cd744" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_0cd744" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_c15ad2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapGoodwill_c15ad2" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_fe65e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_fe65e4" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNet" xlink:label="loc_us-gaapAssetsNet_4a8726" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapAssetsNet_4a8726" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_caf4d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_398bea" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_caf4d6" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_caf4d6" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_74c50e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapAccountsPayableCurrent_74c50e" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_25195e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_25195e" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent_7a9945" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapDeferredRevenueCurrent_7a9945" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent_1ccaaf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent_1ccaaf" order="18" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_7c7a3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapLiabilitiesCurrent_7c7a3f" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_272819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapLongTermNotesPayable_272819" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent_f4dddd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapDeferredRevenueNoncurrent_f4dddd" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubordinatedLongTermDebt" xlink:label="loc_us-gaapSubordinatedLongTermDebt_bf0c73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapSubordinatedLongTermDebt_bf0c73" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent_18b7e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent_18b7e4" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_2bf435" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_2bf435" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_486b76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapLiabilities_486b76" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_d6689c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapCommitmentsAndContingencies_d6689c" order="26" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_ba341e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_e9fefa" xlink:to="loc_us-gaapStockholdersEquityAbstract_ba341e" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_b68c49" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ba341e" xlink:to="loc_us-gaapPreferredStockValue_b68c49" order="28" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_ebe665" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ba341e" xlink:to="loc_us-gaapCommonStockValue_ebe665" order="29" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_0a5485" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ba341e" xlink:to="loc_us-gaapAdditionalPaidInCapital_0a5485" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_5f74f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ba341e" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_5f74f2" order="31" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_bfcbe1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ba341e" xlink:to="loc_us-gaapStockholdersEquity_bfcbe1" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_023b79" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_ba341e" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_023b79" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_093611" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_759892" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_093611" xlink:to="loc_us-gaapStockholdersEquityAbstract_759892" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_5a9147" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_759892" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_5a9147" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_7256b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_759892" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_7256b5" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_d72d04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_759892" xlink:to="loc_us-gaapPreferredStockSharesIssued_d72d04" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_b73848" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_759892" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_b73848" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_4fbf71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_759892" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_4fbf71" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_e4475a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_759892" xlink:to="loc_us-gaapCommonStockSharesAuthorized_e4475a" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_4ddb1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_759892" xlink:to="loc_us-gaapCommonStockSharesIssued_4ddb1d" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_138887" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_759892" xlink:to="loc_us-gaapCommonStockSharesOutstanding_138887" order="9" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:title="0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_6fbdb4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_8ccf80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_6fbdb4" xlink:to="loc_us-gaapRevenuesAbstract_8ccf80" order="1" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ProductRevenue" xlink:label="loc_admaProductRevenue_0d82e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_8ccf80" xlink:to="loc_admaProductRevenue_0d82e8" order="2" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_LicenseRevenue" xlink:label="loc_admaLicenseRevenue_356e93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_8ccf80" xlink:to="loc_admaLicenseRevenue_356e93" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_86bf83" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_8ccf80" xlink:to="loc_us-gaapRevenues_86bf83" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract_097c3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_8ccf80" xlink:to="loc_us-gaapCostsAndExpensesAbstract_097c3a" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_697a5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract_097c3a" xlink:to="loc_us-gaapCostOfRevenue_697a5d" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_9677d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract_097c3a" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_9677d4" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_0ad5c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract_097c3a" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_0ad5c6" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_76a3bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract_097c3a" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_76a3bc" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_376132" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract_097c3a" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_376132" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_a64f06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract_097c3a" xlink:to="loc_us-gaapOperatingExpenses_a64f06" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_005b12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract_097c3a" xlink:to="loc_us-gaapOperatingIncomeLoss_005b12" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract_097c3a" xlink:to="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther_2e7213" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" xlink:to="loc_us-gaapInterestIncomeOther_2e7213" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_e9b91e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" xlink:to="loc_us-gaapInterestExpense_e9b91e" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_db8589" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_db8589" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets_15e39f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets_15e39f" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome_22aa27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" xlink:to="loc_us-gaapOtherIncome_22aa27" order="18" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_2ccbe3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" xlink:to="loc_us-gaapNonoperatingIncomeExpense_2ccbe3" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_10de1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" xlink:to="loc_us-gaapNetIncomeLoss_10de1d" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_032bbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_032bbe" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_9c3757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract_f61efe" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_9c3757" order="22" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited" xlink:title="0000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_073259" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ab0deb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_073259" xlink:to="loc_us-gaapStatementTable_ab0deb" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f60db3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ab0deb" xlink:to="loc_us-gaapStatementLineItems_f60db3" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_3dae68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ab0deb" xlink:to="loc_us-gaapStatementEquityComponentsAxis_3dae68" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_01b19e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_3dae68" xlink:to="loc_us-gaapEquityComponentDomain_01b19e" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_aa8fa1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_01b19e" xlink:to="loc_us-gaapCommonStockMember_aa8fa1" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_ce0307" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_01b19e" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_ce0307" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_035693" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_01b19e" xlink:to="loc_us-gaapRetainedEarningsMember_035693" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_820cc8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapSharesIssued_820cc8" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_acfa04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapStockholdersEquity_acfa04" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_890045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_890045" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_e0b68a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_e0b68a" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_ccc7a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_ccc7a3" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_ae2e57" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_ae2e57" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_538bd6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapNetIncomeLoss_538bd6" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_202332" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_202332" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_a7824f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_a7824f" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_e5228a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapSharesIssued_e5228a" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_9fd3a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f60db3" xlink:to="loc_us-gaapStockholdersEquity_9fd3a7" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_e3d810" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_93b66a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d810" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_93b66a" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_804f96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_93b66a" xlink:to="loc_us-gaapNetIncomeLoss_804f96" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a89b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_93b66a" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a89b6" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_f397bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a89b6" xlink:to="loc_us-gaapDepreciationAndAmortization_f397bc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets_1b8884" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a89b6" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets_1b8884" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_72f9e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a89b6" xlink:to="loc_us-gaapShareBasedCompensation_72f9e8" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets_1fd985" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a89b6" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets_1fd985" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_61394f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a89b6" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_61394f" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_3f140d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a89b6" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_3f140d" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="loc_admaAmortizationOfLicenseRevenue_84fb5e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a89b6" xlink:to="loc_admaAmortizationOfLicenseRevenue_84fb5e" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a89b6" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_03b5ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_03b5ce" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_cf95ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_cf95ec" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_20bc3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_20bc3f" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets_961142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets_961142" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_b2b20f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_b2b20f" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_ce232e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_ce232e" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities_8a3af4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities_8a3af4" order="18" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_b860f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_b860f4" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_6828f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_f87db6" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_6828f4" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_d6a95d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_6828f4" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_d6a95d" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment_b3d37e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_6828f4" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment_b3d37e" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_8fa7f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_6828f4" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_8fa7f2" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_6828f4" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt_aba8cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapProceedsFromShortTermDebt_aba8cb" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_d21d93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapPaymentsForFees_d21d93" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PaymentOfDebtRefinancingFees" xlink:label="loc_admaPaymentOfDebtRefinancingFees_b6811e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_admaPaymentOfDebtRefinancingFees_b6811e" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfLongTermDebt_e8d0d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapProceedsFromIssuanceOfLongTermDebt_e8d0d9" order="28" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_7cd648" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_7cd648" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_6e7c6c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_6e7c6c" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_402666" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_402666" order="31" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:label="loc_us-gaapPaymentsForLeasingCosts_b5f0e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapPaymentsForLeasingCosts_b5f0e4" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_2aba94" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_2aba94" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_0b70db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_0b70db" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_ca70e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_ca70e6" order="35" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_c62214" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_28986d" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_c62214" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness" xlink:title="0000007 - Disclosure - ORGANIZATION AND BUSINESS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50f4d8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock_bc910f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50f4d8" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock_bc910f" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_105c23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_847200" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_105c23" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_847200" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/INVENTORIES" xlink:title="0000009 - Disclosure - INVENTORIES">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract_7478b5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock_a7f7f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract_7478b5" xlink:to="loc_us-gaapInventoryDisclosureTextBlock_a7f7f6" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets" xlink:title="000010 - Disclosure - INTANGIBLE ASSETS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_1c8e6c" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_01e05b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_1c8e6c" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_01e05b" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_a2c995" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_ea4bb7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_a2c995" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_ea4bb7" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DEBT" xlink:title="000012 - Disclosure - DEBT">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_c67580" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock_60c7d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_c67580" xlink:to="loc_us-gaapLongTermDebtTextBlock_60c7d0" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity" xlink:title="000013 - Disclosure - STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_5919e7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_44ab0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_5919e7" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_44ab0f" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions" xlink:title="000014 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_ff76e7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_e5c073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_ff76e7" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_e5c073" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentAndContingencies" xlink:title="000015 - Disclosure - COMMITMENT AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e69860" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_66c436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_e69860" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_66c436" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SEGMENTS" xlink:title="000016 - Disclosure - SEGMENTS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract_2dba91" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock_10abb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_2dba91" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock_10abb9" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/TransferOfPlasmaCenterAssets" xlink:title="000017 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract_31d3bc" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock" xlink:label="loc_admaTransferOfPlasmaCenterAssetsDisclosureTextBlock_092bb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_31d3bc" xlink:to="loc_admaTransferOfPlasmaCenterAssetsDisclosureTextBlock_092bb8" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations" xlink:title="000018 - Disclosure - LEASE OBLIGATIONS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_b0de92" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock_0771d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_b0de92" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock_0771d2" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:title="000019 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_75dd0a" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="loc_us-gaapCashFlowSupplementalDisclosuresTextBlock_83de9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_75dd0a" xlink:to="loc_us-gaapCashFlowSupplementalDisclosuresTextBlock_83de9b" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEvents" xlink:title="000020 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_45ecbd" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_6bdccb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_45ecbd" xlink:to="loc_us-gaapSubsequentEventsTextBlock_6bdccb" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_f91e97" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_fd49a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_fd49a9" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_73d88a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapUseOfEstimates_73d88a" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_9e0083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_9e0083" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock_2cd6b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapReceivablesPolicyTextBlock_2cd6b0" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock_88dc89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapInventoryPolicyTextBlock_88dc89" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy_02fb7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy_02fb7a" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_7fe9b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_7fe9b6" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock_579e66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock_579e66" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock_cd5524" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock_cd5524" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_ea3fe6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_ea3fe6" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock_5542da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock_5542da" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_10787d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_10787d" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_7ba932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_f91e97" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_7ba932" order="13" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_4ffa66" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f3fd53" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_4ffa66" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f3fd53" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables" xlink:title="000023 - Disclosure - INVENTORIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract_06fa18" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock_4db08e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract_06fa18" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock_4db08e" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables" xlink:title="000024 - Disclosure - INTANGIBLE ASSETS (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_a37ec8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f1b087" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_a37ec8" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f1b087" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_720860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_a37ec8" xlink:to="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_720860" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:title="000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_efdf07" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock_b3b30e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_efdf07" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock_b3b30e" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtTables" xlink:title="000026 - Disclosure - DEBT (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_850980" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSubordinatedBorrowingTextBlock" xlink:label="loc_us-gaapScheduleOfSubordinatedBorrowingTextBlock_c60929" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_850980" xlink:to="loc_us-gaapScheduleOfSubordinatedBorrowingTextBlock_c60929" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock_f45df5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_850980" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock_f45df5" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables" xlink:title="000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_8a660c" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f2e7ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_8a660c" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f2e7ec" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_150616" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_8a660c" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_150616" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock_be176c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_8a660c" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock_be176c" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_9a5626" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_8a660c" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_9a5626" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables" xlink:title="000028 - Disclosure - SEGMENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract_bcd6e1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock_689fdd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_bcd6e1" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock_689fdd" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables" xlink:title="000029 - Disclosure - LEASE OBLIGATIONS (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_1b5f97" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_ed630c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_1b5f97" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_ed630c" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:title="000030 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_4431a2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_d354d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_4431a2" xlink:to="loc_us-gaapScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_d354d5" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative" xlink:title="000031 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_529e20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_04624f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_529e20" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_04624f" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_c17531" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_529e20" xlink:to="loc_us-gaapNetIncomeLoss_c17531" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_WorkingCapital" xlink:label="loc_admaWorkingCapital_e12cd0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_529e20" xlink:to="loc_admaWorkingCapital_e12cd0" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_283452" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_58970b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_283452" xlink:to="loc_us-gaapStatementTable_58970b" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_c0f5c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_58970b" xlink:to="loc_us-gaapStatementLineItems_c0f5c7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_10c9d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_58970b" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_10c9d8" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_edde57" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_10c9d8" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_edde57" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_b49408" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_edde57" xlink:to="loc_us-gaapStockOptionMember_b49408" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_9a0ec0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_edde57" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_9a0ec0" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_1524b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_edde57" xlink:to="loc_us-gaapWarrantMember_1524b7" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5a1874" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c0f5c7" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5a1874" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_16ad77" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_eebc8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_16ad77" xlink:to="loc_us-gaapStatementTable_eebc8f" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_27edda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eebc8f" xlink:to="loc_us-gaapStatementLineItems_27edda" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_84ee69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eebc8f" xlink:to="loc_us-gaapAwardDateAxis_84ee69" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_1eaf3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_84ee69" xlink:to="loc_us-gaapAwardDateDomain_1eaf3f" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_92f17c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eebc8f" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_92f17c" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_6fa998" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_92f17c" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_6fa998" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis_ead0e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eebc8f" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis_ead0e4" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_f02f10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis_ead0e4" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_f02f10" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis_3d1777" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eebc8f" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis_3d1777" order="80" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_437ddf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis_3d1777" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_437ddf" order="80" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_JanuaryOneTwoThousandNineteenMember" xlink:label="loc_admaJanuaryOneTwoThousandNineteenMember_c87bf6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_1eaf3f" xlink:to="loc_admaJanuaryOneTwoThousandNineteenMember_c87bf6" order="81" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_BiotestMember" xlink:label="loc_admaBiotestMember_3364c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_6fa998" xlink:to="loc_admaBiotestMember_3364c2" order="82" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CustomerThreeMember" xlink:label="loc_admaCustomerThreeMember_8baa89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain_f02f10" xlink:to="loc_admaCustomerThreeMember_8baa89" order="83" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_8fad33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain_437ddf" xlink:to="loc_us-gaapAccountsReceivableMember_8fad33" order="84" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CustomerTwoMember" xlink:label="loc_admaCustomerTwoMember_6d685f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain_f02f10" xlink:to="loc_admaCustomerTwoMember_6d685f" order="85" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_203f48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_27edda" xlink:to="loc_us-gaapGoodwill_203f48" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1b5909" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_27edda" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_1b5909" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_df1a33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_27edda" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_df1a33" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_5f0952" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_27edda" xlink:to="loc_us-gaapOperatingLeaseLiability_5f0952" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_a3fd69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_27edda" xlink:to="loc_us-gaapDebtInstrumentFairValue_a3fd69" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_b09dd0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_27edda" xlink:to="loc_us-gaapConcentrationRiskPercentage1_b09dd0" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails" xlink:title="000034 - Disclosure - INVENTORIES (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract_bff3f2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials_b21fda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract_bff3f2" xlink:to="loc_us-gaapInventoryRawMaterials_b21fda" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess_99ba6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract_bff3f2" xlink:to="loc_us-gaapInventoryWorkInProcess_99ba6a" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods_51d318" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract_bff3f2" xlink:to="loc_us-gaapInventoryFinishedGoods_51d318" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_6b45cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract_bff3f2" xlink:to="loc_us-gaapInventoryNet_6b45cf" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetails" xlink:title="000035 - Disclosure - INTANGIBLE ASSETS (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_482974" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_1f92d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_482974" xlink:to="loc_us-gaapStatementTable_1f92d6" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_30f83b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1f92d6" xlink:to="loc_us-gaapStatementLineItems_30f83b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_5e7318" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1f92d6" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_5e7318" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_856296" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_5e7318" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_856296" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_a10770" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_856296" xlink:to="loc_us-gaapTrademarksMember_a10770" order="21" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_RightToIntermediatesMember" xlink:label="loc_admaRightToIntermediatesMember_20788d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_856296" xlink:to="loc_admaRightToIntermediatesMember_20788d" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="loc_us-gaapCustomerContractsMember_58d6c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_856296" xlink:to="loc_us-gaapCustomerContractsMember_58d6c2" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_3539fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_30f83b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_3539fc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_81c03b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_30f83b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_81c03b" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_c2969e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_30f83b" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_c2969e" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetails1" xlink:title="000036 - Disclosure - INTANGIBLE ASSETS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_f45267" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d216d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_f45267" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d216d0" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_16f98c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_f45267" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_16f98c" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a32f37" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_f45267" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a32f37" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2cb2a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_f45267" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2cb2a1" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5eb97e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_f45267" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5eb97e" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsDetailsNarrative" xlink:title="000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_dae4f0" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AmortizationExpense" xlink:label="loc_admaAmortizationExpense_3d30e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract_dae4f0" xlink:to="loc_admaAmortizationExpense_3d30e3" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:title="000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_f506f8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_df3eae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_f506f8" xlink:to="loc_us-gaapStatementTable_df3eae" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_c02e0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_df3eae" xlink:to="loc_us-gaapStatementLineItems_c02e0c" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_cbaaf0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_df3eae" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_cbaaf0" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_c87a00" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_cbaaf0" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_c87a00" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_45fdce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_c87a00" xlink:to="loc_us-gaapEquipmentMember_45fdce" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_9ec378" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_c87a00" xlink:to="loc_us-gaapOfficeEquipmentMember_9ec378" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_28a55b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_c87a00" xlink:to="loc_us-gaapFurnitureAndFixturesMember_28a55b" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_1ac938" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_c87a00" xlink:to="loc_us-gaapLeaseholdImprovementsMember_1ac938" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaapLandMember_7cb6a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_c87a00" xlink:to="loc_us-gaapLandMember_7cb6a9" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember_27acaa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_c87a00" xlink:to="loc_us-gaapBuildingMember_27acaa" order="26" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember_4cd1b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_c87a00" xlink:to="loc_us-gaapConstructionInProgressMember_4cd1b3" order="27" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_54037c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c02e0c" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_54037c" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2087ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c02e0c" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2087ba" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_e003a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c02e0c" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_e003a8" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_886eda" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_1eb85b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_886eda" xlink:to="loc_us-gaapStatementTable_1eb85b" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_a31089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1eb85b" xlink:to="loc_us-gaapStatementLineItems_a31089" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_4c3ca2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1eb85b" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_4c3ca2" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_293653" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_4c3ca2" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_293653" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_f6fce0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1eb85b" xlink:to="loc_srtRangeAxis_f6fce0" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_54c48c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_f6fce0" xlink:to="loc_srtRangeMember_54c48c" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember_885c66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_293653" xlink:to="loc_us-gaapBuildingMember_885c66" order="31" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PropertyAndEquipmentMember" xlink:label="loc_admaPropertyAndEquipmentMember_256c07" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_293653" xlink:to="loc_admaPropertyAndEquipmentMember_256c07" order="32" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_4d6f9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_54c48c" xlink:to="loc_srtMaximumMember_4d6f9a" order="33" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_443629" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a31089" xlink:to="loc_us-gaapDepreciation_443629" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_963f6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a31089" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_963f6b" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails" xlink:title="000040 - Disclosure - DEBT (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_b60400" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_84a7dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_b60400" xlink:to="loc_us-gaapNotesPayable_84a7dc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNetAbstract_6ec4d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_b60400" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNetAbstract_6ec4d1" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_2ce814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNetAbstract_6ec4d1" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_2ce814" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_992392" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNetAbstract_6ec4d1" xlink:to="loc_us-gaapLongTermNotesPayable_992392" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails1" xlink:title="000041 - Disclosure - DEBT (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_2483ef" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_SubordinatedDebtCarryingValue" xlink:label="loc_admaSubordinatedDebtCarryingValue_e97af4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_2483ef" xlink:to="loc_admaSubordinatedDebtCarryingValue_e97af4" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNetAbstract_52560d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_2483ef" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNetAbstract_52560d" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_SubordinatedDebtInstrumentUnamortizedDiscount" xlink:label="loc_admaSubordinatedDebtInstrumentUnamortizedDiscount_974185" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNetAbstract_52560d" xlink:to="loc_admaSubordinatedDebtInstrumentUnamortizedDiscount_974185" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubordinatedDebt" xlink:label="loc_us-gaapSubordinatedDebt_0982ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNetAbstract_52560d" xlink:to="loc_us-gaapSubordinatedDebt_0982ef" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetailsNarrative" xlink:title="000042 - Disclosure - DEBT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_6d56d7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0e461f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_6d56d7" xlink:to="loc_us-gaapStatementTable_0e461f" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ef57c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0e461f" xlink:to="loc_us-gaapStatementLineItems_ef57c3" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_8fe1d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0e461f" xlink:to="loc_us-gaapPlanNameAxis_8fe1d4" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_f339c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_8fe1d4" xlink:to="loc_us-gaapPlanNameDomain_f339c9" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_4f509e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0e461f" xlink:to="loc_srtTitleOfIndividualAxis_4f509e" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_692034" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_4f509e" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_692034" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis_0834b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0e461f" xlink:to="loc_us-gaapShortTermDebtTypeAxis_0834b7" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_d2c966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis_0834b7" xlink:to="loc_us-gaapShortTermDebtTypeDomain_d2c966" order="60" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveCreditAgreementMember" xlink:label="loc_admaPerceptiveCreditAgreementMember_74b2ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_f339c9" xlink:to="loc_admaPerceptiveCreditAgreementMember_74b2ec" order="61" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_BPCMember" xlink:label="loc_admaBPCMember_72bf49" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_692034" xlink:to="loc_admaBPCMember_72bf49" order="62" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheIIIWarrantMember" xlink:label="loc_admaPerceptiveTrancheIIIWarrantMember_1638c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain_d2c966" xlink:to="loc_admaPerceptiveTrancheIIIWarrantMember_1638c4" order="63" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_MarathonHealthcareFinanceFundLPMember" xlink:label="loc_admaMarathonHealthcareFinanceFundLPMember_734bf7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_692034" xlink:to="loc_admaMarathonHealthcareFinanceFundLPMember_734bf7" order="64" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheIIILoanMember" xlink:label="loc_admaPerceptiveTrancheIIILoanMember_9b8076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain_d2c966" xlink:to="loc_admaPerceptiveTrancheIIILoanMember_9b8076" order="65" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheIILoanMember" xlink:label="loc_admaPerceptiveTrancheIILoanMember_17da13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain_d2c966" xlink:to="loc_admaPerceptiveTrancheIILoanMember_17da13" order="66" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheILoanMember" xlink:label="loc_admaPerceptiveTrancheILoanMember_c1a167" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain_d2c966" xlink:to="loc_admaPerceptiveTrancheILoanMember_c1a167" order="67" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid" xlink:label="loc_admaPerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid_db0733" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_admaPerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid_db0733" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentRate_182a04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentRate_182a04" order="2" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_DescriptionOfPrepaidPrincipalAmount" xlink:label="loc_admaDescriptionOfPrepaidPrincipalAmount_ad64e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_admaDescriptionOfPrepaidPrincipalAmount_ad64e6" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_cb7958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_cb7958" order="4" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AdditionlalDescription" xlink:label="loc_admaAdditionlalDescription_0f08d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_admaAdditionlalDescription_0f08d1" order="5" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_InterestRateDescription" xlink:label="loc_admaInterestRateDescription_8ee080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_admaInterestRateDescription_8ee080" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_20c43b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_20c43b" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_37e70b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_37e70b" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ExpirationDate" xlink:label="loc_admaExpirationDate_89ae18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_admaExpirationDate_89ae18" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ca5a55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ca5a55" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_c2073f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_c2073f" order="11" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_DeferredFacilityFee" xlink:label="loc_admaDeferredFacilityFee_bc0880" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_admaDeferredFacilityFee_bc0880" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_d6fbe9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_d6fbe9" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PrepaymentPenalty" xlink:label="loc_admaPrepaymentPenalty_f58f8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_admaPrepaymentPenalty_f58f8b" order="14" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_UnamortizedDebtDiscount" xlink:label="loc_admaUnamortizedDebtDiscount_26b37c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_admaUnamortizedDebtDiscount_26b37c" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_16b479" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_us-gaapLegalFees_16b479" order="16" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AdditionalFacilityFee" xlink:label="loc_admaAdditionalFacilityFee_ba268a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_admaAdditionalFacilityFee_ba268a" order="17" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_DebtServiceReserve" xlink:label="loc_admaDebtServiceReserve_6f87de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_admaDebtServiceReserve_6f87de" order="18" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent_20b8ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ef57c3" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent_20b8ef" order="19" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails" xlink:title="000043 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_aabd78" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_4c897c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_aabd78" xlink:to="loc_us-gaapStatementTable_4c897c" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_2b06f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_4c897c" xlink:to="loc_us-gaapStatementLineItems_2b06f5" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_5fcd89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_4c897c" xlink:to="loc_srtRangeAxis_5fcd89" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_db4f97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_5fcd89" xlink:to="loc_srtRangeMember_db4f97" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_a3946a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_db4f97" xlink:to="loc_srtMaximumMember_a3946a" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_74d780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_db4f97" xlink:to="loc_srtMinimumMember_74d780" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3be736" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2b06f5" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3be736" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50790d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2b06f5" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50790d" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_090d6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2b06f5" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_090d6d" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b7629e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2b06f5" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b7629e" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails1" xlink:title="000044 - Disclosure - STOCKHOLDERS EQUITY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_06c90d" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_4fd1b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_06c90d" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_4fd1b3" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3e2c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_4fd1b3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3e2c3" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b3c629" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_4fd1b3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b3c629" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ab7d0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_4fd1b3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ab7d0f" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd1ad5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_4fd1b3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd1ad5" order="5" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod" xlink:label="loc_admaShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod_e219d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_4fd1b3" xlink:to="loc_admaShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod_e219d6" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_968c3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_4fd1b3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_968c3c" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" xlink:label="loc_admaShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod_ba237f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_4fd1b3" xlink:to="loc_admaShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod_ba237f" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_b0e919" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_4fd1b3" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_b0e919" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8023cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_b0e919" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8023cf" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_453cb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_b0e919" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_453cb9" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c21f6f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_b0e919" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c21f6f" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97054c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_b0e919" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_97054c" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6011e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_b0e919" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6011e6" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_33fe5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_b0e919" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_33fe5f" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice" xlink:label="loc_admaShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice_cee344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_b0e919" xlink:to="loc_admaShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice_cee344" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails2" xlink:title="000045 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_3e75e2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_afd440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_3e75e2" xlink:to="loc_us-gaapStatementTable_afd440" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_00d952" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_afd440" xlink:to="loc_us-gaapStatementLineItems_00d952" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_003778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_afd440" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_003778" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_0b313e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_003778" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_0b313e" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_8375e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_0b313e" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_8375e0" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_87102f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_00d952" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_87102f" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82abe1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_87102f" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82abe1" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_34c463" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_87102f" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_34c463" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_28d77a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_87102f" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_28d77a" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_505759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_87102f" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_505759" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9a32e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_87102f" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a9a32e" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b1d371" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_87102f" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b1d371" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bb6de2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b1d371" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bb6de2" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3f8e32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b1d371" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3f8e32" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_04f050" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b1d371" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_04f050" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1d5c2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b1d371" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1d5c2f" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e1e66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_b1d371" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e1e66" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetails3" xlink:title="000046 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_d836f1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_081637" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_d836f1" xlink:to="loc_us-gaapStatementTable_081637" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_2bed65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_081637" xlink:to="loc_us-gaapStatementLineItems_2bed65" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis_38f575" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_081637" xlink:to="loc_us-gaapIncomeStatementLocationAxis_38f575" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_e2aafe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis_38f575" xlink:to="loc_us-gaapIncomeStatementLocationDomain_e2aafe" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_fdb4a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_e2aafe" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_fdb4a2" order="21" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PlasmaCentersMember" xlink:label="loc_admaPlasmaCentersMember_cdaed8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_e2aafe" xlink:to="loc_admaPlasmaCentersMember_cdaed8" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_a9ce7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_e2aafe" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_a9ce7a" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="loc_us-gaapCostOfGoodsTotalMember_36a052" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_e2aafe" xlink:to="loc_us-gaapCostOfGoodsTotalMember_36a052" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_b7e14a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_2bed65" xlink:to="loc_us-gaapShareBasedCompensation_b7e14a" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityDetailsNarrative" xlink:title="000047 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_f85794" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_769e70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_f85794" xlink:to="loc_us-gaapStatementTable_769e70" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_8e7c5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_769e70" xlink:to="loc_us-gaapStatementLineItems_8e7c5f" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_5aac7d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_769e70" xlink:to="loc_us-gaapPlanNameAxis_5aac7d" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_b9b1ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_5aac7d" xlink:to="loc_us-gaapPlanNameDomain_b9b1ee" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_836399" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_769e70" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_836399" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_5c69df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_836399" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_5c69df" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_c16283" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_5c69df" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_c16283" order="21" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_EquityIncentivePlanMember" xlink:label="loc_admaEquityIncentivePlanMember_f23484" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_b9b1ee" xlink:to="loc_admaEquityIncentivePlanMember_f23484" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_9014c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_9014c3" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_e3197e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_e3197e" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_ba3086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_ba3086" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_b535ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_b535ae" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_402312" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapCommonStockSharesAuthorized_402312" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_UnderwrittenPublicOffering" xlink:label="loc_admaUnderwrittenPublicOffering_151abe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_admaUnderwrittenPublicOffering_151abe" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_a02257" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapCommonStockSharesIssued_a02257" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_728717" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_728717" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_03ec08" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapCommonStockSharesOutstanding_03ec08" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommonStockReservedForOutstanding" xlink:label="loc_admaCommonStockReservedForOutstanding_2426e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_admaCommonStockReservedForOutstanding_2426e5" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaapCommonStockSharesSubscribedButUnissued_1b358e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapCommonStockSharesSubscribedButUnissued_1b358e" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_35267d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_35267d" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c93b8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c93b8b" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8d1b8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8d1b8a" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ccd904" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ccd904" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e32c65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e32c65" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2f0023" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2f0023" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3a2034" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3a2034" order="18" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CompensationExpense" xlink:label="loc_admaCompensationExpense_7be2cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_admaCompensationExpense_7be2cf" order="19" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommonStockGranted" xlink:label="loc_admaCommonStockGranted_454900" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8e7c5f" xlink:to="loc_admaCommonStockGranted_454900" order="20" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_bdaf20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_526e3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_bdaf20" xlink:to="loc_us-gaapStatementTable_526e3a" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ba4808" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_526e3a" xlink:to="loc_us-gaapStatementLineItems_ba4808" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_97e958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_526e3a" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_97e958" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_c7c5dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_97e958" xlink:to="loc_us-gaapRelatedPartyDomain_c7c5dc" order="20" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ArethLLCMember" xlink:label="loc_admaArethLLCMember_bcc125" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_c7c5dc" xlink:to="loc_admaArethLLCMember_bcc125" order="21" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CreditFacilityPercentage" xlink:label="loc_admaCreditFacilityPercentage_c77559" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ba4808" xlink:to="loc_admaCreditFacilityPercentage_c77559" order="1" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PublicOfferingDescription" xlink:label="loc_admaPublicOfferingDescription_446114" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ba4808" xlink:to="loc_admaPublicOfferingDescription_446114" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_e56126" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ba4808" xlink:to="loc_us-gaapLeaseAndRentalExpense_e56126" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments_86c722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ba4808" xlink:to="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments_86c722" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment_ed10e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ba4808" xlink:to="loc_us-gaapDebtInstrumentFrequencyOfPeriodicPayment_ed10e6" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_1a62b0" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PurchasePercentageFromInventory" xlink:label="loc_admaPurchasePercentageFromInventory_bea23d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_1a62b0" xlink:to="loc_admaPurchasePercentageFromInventory_bea23d" order="1" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PurchaseOfRawMaterial" xlink:label="loc_admaPurchaseOfRawMaterial_15766a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_1a62b0" xlink:to="loc_admaPurchaseOfRawMaterial_15766a" order="2" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="loc_admaPlasmaSupplyAgreementTerm_20a2a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_1a62b0" xlink:to="loc_admaPlasmaSupplyAgreementTerm_20a2a1" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsDetails" xlink:title="000050 - Disclosure - SEGMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract_65665c" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_82296a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_65665c" xlink:to="loc_us-gaapStatementTable_82296a" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_4fa5aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_82296a" xlink:to="loc_us-gaapStatementLineItems_4fa5aa" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis_ea502e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_82296a" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis_ea502e" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_9b9124" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis_ea502e" xlink:to="loc_us-gaapSegmentDomain_9b9124" order="20" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_ConsolidatedMember" xlink:label="loc_admaConsolidatedMember_4abd79" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_9b9124" xlink:to="loc_admaConsolidatedMember_4abd79" order="21" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_PlasmaCollectionCenterMember" xlink:label="loc_admaPlasmaCollectionCenterMember_912a6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_9b9124" xlink:to="loc_admaPlasmaCollectionCenterMember_912a6a" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateMember" xlink:label="loc_us-gaapCorporateMember_eeb229" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_9b9124" xlink:to="loc_us-gaapCorporateMember_eeb229" order="23" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_AdmaBiomanufacturingMember" xlink:label="loc_admaAdmaBiomanufacturingMember_ea6cb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_9b9124" xlink:to="loc_admaAdmaBiomanufacturingMember_ea6cb2" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_f3ef10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4fa5aa" xlink:to="loc_us-gaapRevenues_f3ef10" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_af6aa0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4fa5aa" xlink:to="loc_us-gaapCostOfRevenue_af6aa0" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_a84140" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4fa5aa" xlink:to="loc_us-gaapOperatingIncomeLoss_a84140" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_c3428f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4fa5aa" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_c3428f" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets_0cf001" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4fa5aa" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets_0cf001" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_5e92f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4fa5aa" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_5e92f5" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_5c73ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4fa5aa" xlink:to="loc_us-gaapNetIncomeLoss_5c73ce" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CapitalExpenditure" xlink:label="loc_admaCapitalExpenditure_f9cad0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4fa5aa" xlink:to="loc_admaCapitalExpenditure_f9cad0" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_bf785d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4fa5aa" xlink:to="loc_us-gaapDepreciationAndAmortization_bf785d" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_TotalAssets" xlink:label="loc_admaTotalAssets_8bdea2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_4fa5aa" xlink:to="loc_admaTotalAssets_8bdea2" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative" xlink:title="000051 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract_cd3d4a" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_GainUponTransferFacilities" xlink:label="loc_admaGainUponTransferFacilities_b10ff0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_cd3d4a" xlink:to="loc_admaGainUponTransferFacilities_b10ff0" order="1" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_NetCarryingValueOfAssets" xlink:label="loc_admaNetCarryingValueOfAssets_2b620e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_cd3d4a" xlink:to="loc_admaNetCarryingValueOfAssets_2b620e" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="loc_us-gaapBusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized_2ef0a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract_cd3d4a" xlink:to="loc_us-gaapBusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized_2ef0a6" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails" xlink:title="000052 - Disclosure - LEASE OBLIGATIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_ae87ad" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8d490b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_ae87ad" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8d490b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears_b8e8df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_ae87ad" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears_b8e8df" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears_3c8db9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_ae87ad" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears_3c8db9" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears_8cceb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_ae87ad" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears_8cceb9" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears_454aae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_ae87ad" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears_454aae" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter_b9a711" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_ae87ad" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter_b9a711" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_1ddb2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_ae87ad" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_1ddb2b" order="7" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_InterestPortionOfMinimumLeasePayments" xlink:label="loc_admaInterestPortionOfMinimumLeasePayments_bf505a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_ae87ad" xlink:to="loc_admaInterestPortionOfMinimumLeasePayments_bf505a" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_d0bb8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_ae87ad" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_d0bb8e" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_OperatingLeaseLiabilityTotal" xlink:label="loc_admaOperatingLeaseLiabilityTotal_7f0c43" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_ae87ad" xlink:to="loc_admaOperatingLeaseLiabilityTotal_7f0c43" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsNarrative" xlink:title="000053 - Disclosure - LEASE OBLIGATIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_4b786e" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_31cc9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_4b786e" xlink:to="loc_us-gaapStatementTable_31cc9a" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_b1fb1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_31cc9a" xlink:to="loc_us-gaapStatementLineItems_b1fb1d" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_522742" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_31cc9a" xlink:to="loc_us-gaapAwardDateAxis_522742" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_bec2f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_522742" xlink:to="loc_us-gaapAwardDateDomain_bec2f7" order="10" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_JanuaryOneTwoThousandNineteenMember" xlink:label="loc_admaJanuaryOneTwoThousandNineteenMember_12f3bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_bec2f7" xlink:to="loc_admaJanuaryOneTwoThousandNineteenMember_12f3bf" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_bfbc7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b1fb1d" xlink:to="loc_us-gaapLeaseAndRentalExpense_bfbc7a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_LeaseDescription" xlink:label="loc_admaLeaseDescription_9b5c28" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b1fb1d" xlink:to="loc_admaLeaseDescription_9b5c28" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_e82238" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b1fb1d" xlink:to="loc_us-gaapOperatingLeaseLiability_e82238" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_6c3e33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b1fb1d" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_6c3e33" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_fa4151" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b1fb1d" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_fa4151" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_IncrementalBorrowingRate" xlink:label="loc_admaIncrementalBorrowingRate_e0b050" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b1fb1d" xlink:to="loc_admaIncrementalBorrowingRate_e0b050" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:title="000054 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_9f504d" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalCashFlowElementsAbstract" xlink:label="loc_us-gaapAdditionalCashFlowElementsAbstract_c49ee6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_9f504d" xlink:to="loc_us-gaapAdditionalCashFlowElementsAbstract_c49ee6" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_124d87" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAbstract_c49ee6" xlink:to="loc_us-gaapInterestPaidNet_124d87" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_508eff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAbstract_c49ee6" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_508eff" order="3" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_admaEquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_eb9c5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_508eff" xlink:to="loc_admaEquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_eb9c5c" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_74cf0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_508eff" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_74cf0b" order="5" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_WarrantsIssuedInConnectionWithNotePayable" xlink:label="loc_admaWarrantsIssuedInConnectionWithNotePayable_c6b9af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_508eff" xlink:to="loc_admaWarrantsIssuedInConnectionWithNotePayable_c6b9af" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEventsDetailsNarrative" xlink:title="000055 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_8faf21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f31e25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_8faf21" xlink:to="loc_us-gaapStatementTable_f31e25" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_3348be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f31e25" xlink:to="loc_us-gaapStatementLineItems_3348be" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_e280df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f31e25" xlink:to="loc_us-gaapSubsequentEventTypeAxis_e280df" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_d3a6d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_e280df" xlink:to="loc_us-gaapSubsequentEventTypeDomain_d3a6d3" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_27159f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f31e25" xlink:to="loc_us-gaapPlanNameAxis_27159f" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_1bd0bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_27159f" xlink:to="loc_us-gaapPlanNameDomain_1bd0bb" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis_9ce2c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f31e25" xlink:to="loc_srtConsolidatedEntitiesAxis_9ce2c1" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_dd4bf2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis_9ce2c1" xlink:to="loc_srtConsolidatedEntitiesDomain_dd4bf2" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_abe8cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f31e25" xlink:to="loc_srtRangeAxis_abe8cc" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_879ff5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_abe8cc" xlink:to="loc_srtRangeMember_879ff5" order="60" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_dad882" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_d3a6d3" xlink:to="loc_us-gaapSubsequentEventMember_dad882" order="61" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_SaleAgreementMember" xlink:label="loc_admaSaleAgreementMember_8c2cff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_1bd0bb" xlink:to="loc_admaSaleAgreementMember_8c2cff" order="62" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_JefferiesLLCMember" xlink:label="loc_admaJefferiesLLCMember_347cb4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain_dd4bf2" xlink:to="loc_admaJefferiesLLCMember_347cb4" order="63" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_bd70d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_879ff5" xlink:to="loc_srtMaximumMember_bd70d3" order="64" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_5c65d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3348be" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_5c65d1" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommonStockOffering" xlink:label="loc_admaCommonStockOffering_b20d8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3348be" xlink:to="loc_admaCommonStockOffering_b20d8a" order="2" />
    <link:loc xlink:type="locator" xlink:href="adma-20200630.xsd#adma_CommissionDescription" xlink:label="loc_admaCommissionDescription_0e3bbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3348be" xlink:to="loc_admaCommissionDescription_0e3bbc" order="3" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>adma_ex51img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adma_ex51img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  G -H# 2(  A$! Q$!_\0
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ML_C)+HLEYX@GT?\ LI9@HBMUE\SS-G7+#&-GZUZU:6_V2QM[7=O$,:Q[CQG
MQF@#XJ_;<_Y&_P &_P#7G/\ ^C%KZOT_Q[X%73+16\::"&$* @ZE#Q\H_P!J
MN$^,WP%L?C!JNDW]YXDGT@Z;"\*I%;K*'W,#GEACI7EW_##^B_\ 10;W_P
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>adma_ex51img5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adma_ex51img5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !1 3(# 2(  A$! Q$!_\0
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MIT:..2-,-+(QP$FD 7I\W3@8 ,=?B[H,:W\^H:7J>FV5JM\T=Y=_9UBNC:7
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M<@<]=?#SPS=Q7T-S%J4EO?V[VMU;'5KSR)D=-CEHO-V%V'5\;R26SN.:[2@
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M!V5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>adma_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adma="http://admabiologics.com/20200630"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adma-20200630.xsd" xlink:type="simple"/>
    <context id="From2020-01-01to2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="From2004-06-01to2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2004-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_adma_JanuaryOneTwoThousandNineteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">adma:JanuaryOneTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_adma_BiotestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adma:BiotestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_adma_BiotestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adma:BiotestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_CustomerThreeMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">adma:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_adma_CustomerTwoMember_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">adma:CustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_CustomerThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">adma:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_adma_CustomerThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">adma:CustomerThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_adma_RightToIntermediatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_adma_RightToIntermediatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CustomerContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CustomerContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_PropertyAndEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adma:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-11to2019-05-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="From2019-02-01to2019-02-11_adma_PerceptiveCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-11</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:PerceptiveCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_BPCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:BPCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-11to2019-05-02_adma_PerceptiveTrancheIIIWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">adma:PerceptiveTrancheIIIWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-05-02</endDate>
        </period>
    </context>
    <context id="From2019-04-11to2019-05-03_adma_MarathonHealthcareFinanceFundLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:MarathonHealthcareFinanceFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_adma_MarathonHealthcareFinanceFundLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:MarathonHealthcareFinanceFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-05-03_adma_MarathonHealthcareFinanceFundLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:MarathonHealthcareFinanceFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-03</instant>
        </period>
    </context>
    <context id="From2019-04-11to2019-05-03_adma_PerceptiveTrancheIIILoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">adma:PerceptiveTrancheIIILoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="From2019-04-11to2019-05-03_adma_PerceptiveTrancheIILoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">adma:PerceptiveTrancheIILoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_PerceptiveTrancheILoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">adma:PerceptiveTrancheILoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_adma_PlasmaCentersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">adma:PlasmaCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_PlasmaCentersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">adma:PlasmaCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_adma_PlasmaCentersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">adma:PlasmaCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_adma_PlasmaCentersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">adma:PlasmaCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_us-gaap_CostOfGoodsTotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_us-gaap_CostOfGoodsTotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_us-gaap_CostOfGoodsTotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_us-gaap_CostOfGoodsTotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2020-02-21</instant>
        </period>
    </context>
    <context id="AsOf2020-02-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="From2020-02-01to2020-02-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-21</endDate>
        </period>
    </context>
    <context id="From2020-02-01to2020-02-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_adma_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_adma_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_ArethLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_adma_ArethLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2017-09-09to2017-10-01_adma_ArethLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-09</startDate>
            <endDate>2017-10-01</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_adma_ConsolidatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ConsolidatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_ConsolidatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ConsolidatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_adma_ConsolidatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ConsolidatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_adma_ConsolidatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ConsolidatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:AdmaBiomanufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:AdmaBiomanufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:AdmaBiomanufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:AdmaBiomanufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="From2020-07-01to2020-07-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_adma_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:SaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_srt_MaximumMember_adma_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">adma:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:SaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-06-30">0001368514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-06-30">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="4"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="0" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-06-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-06-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="4"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="0" unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2019-12-31_adma_BiotestMember"
      decimals="6"
      unitRef="USD">15.0</us-gaap:DebtInstrumentFairValue>
    <adma:AmortizationExpense
      contextRef="From2019-04-01to2019-06-30"
      decimals="6"
      unitRef="USD">0.2</adma:AmortizationExpense>
    <adma:AmortizationExpense
      contextRef="From2019-01-01to2019-06-30"
      decimals="6"
      unitRef="USD">0.4</adma:AmortizationExpense>
    <us-gaap:SubordinatedDebt contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">14925760</us-gaap:SubordinatedDebt>
    <us-gaap:SubordinatedDebt contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">14908053</us-gaap:SubordinatedDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-01to2019-06-30_adma_MarathonHealthcareFinanceFundLPMember"
      decimals="0"
      unitRef="USD">-9962495</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-06-30_adma_PlasmaCentersMember"
      decimals="0"
      unitRef="USD">15754</us-gaap:ShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2019-12-31" decimals="0" unitRef="Shares">2138160</us-gaap:ClassOfWarrantOrRightOutstanding>
    <adma:CompensationExpense
      contextRef="From2019-04-01to2019-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="6"
      unitRef="USD">0.1</adma:CompensationExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-01-01to2020-06-30_adma_ArethLLCMember"
      decimals="0"
      unitRef="USD">60000</us-gaap:LeaseAndRentalExpense>
    <adma:CapitalExpenditure
      contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      unitRef="USD">6243284</adma:CapitalExpenditure>
    <adma:CapitalExpenditure
      contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      unitRef="USD">6243284</adma:CapitalExpenditure>
    <adma:CapitalExpenditure
      contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      unitRef="USD">245675</adma:CapitalExpenditure>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-04-01to2019-06-30"
      decimals="6"
      unitRef="USD">0.1</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-01-01to2019-06-30"
      decimals="6"
      unitRef="USD">0.2</us-gaap:LeaseAndRentalExpense>
    <dei:DocumentType contextRef="From2020-01-01to2020-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2020-01-01to2020-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-06-30">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2020-01-01to2020-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2020-01-01to2020-06-30">001-36728</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-06-30">ADMA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-06-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-01-01to2020-06-30">56-2590442</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-01-01to2020-06-30">465 State Route 17,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2020-01-01to2020-06-30">Ramsey</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-01-01to2020-06-30">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-01-01to2020-06-30">07446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-01-01to2020-06-30">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-01-01to2020-06-30">478-5552</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2020-01-01to2020-06-30">Common Stock </dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-01-01to2020-06-30">ADMA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-01-01to2020-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-06-30">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-08-03" decimals="INF" unitRef="Shares">86349981</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_467"
      unitRef="USD">75781122</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_468"
      unitRef="USD">26752135</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_469"
      unitRef="USD">6514165</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_470"
      unitRef="USD">3469919</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_471"
      unitRef="USD">56001348</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_472"
      unitRef="USD">53064734</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_473"
      unitRef="USD">4693427</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_474"
      unitRef="USD">2533593</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_475"
      unitRef="USD">142990062</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_476"
      unitRef="USD">85820381</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_477"
      unitRef="USD">37373366</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_478"
      unitRef="USD">31741317</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_479"
      unitRef="USD">2801797</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_480"
      unitRef="USD">3159474</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_481"
      unitRef="USD">3529509</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_482"
      unitRef="USD">3529509</us-gaap:Goodwill>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_483"
      unitRef="USD">4846834</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_484"
      unitRef="USD">2840044</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNet
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_485"
      unitRef="USD">191541568</us-gaap:AssetsNet>
    <us-gaap:AssetsNet
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_486"
      unitRef="USD">127090725</us-gaap:AssetsNet>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_489"
      unitRef="USD">6909659</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_490"
      unitRef="USD">9174591</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_491"
      unitRef="USD">5616666</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_492"
      unitRef="USD">4481395</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_493"
      unitRef="USD">142834</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_494"
      unitRef="USD">142834</us-gaap:DeferredRevenueCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_495"
      unitRef="USD">210870</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_496"
      unitRef="USD">229073</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_497"
      unitRef="USD">12880029</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_498"
      unitRef="USD">14027893</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_499"
      unitRef="USD">81648187</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_500"
      unitRef="USD">68291163</us-gaap:LongTermNotesPayable>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_501"
      unitRef="USD">2190115</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_502"
      unitRef="USD">2261532</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:SubordinatedLongTermDebt
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_503"
      unitRef="USD">14925760</us-gaap:SubordinatedLongTermDebt>
    <us-gaap:SubordinatedLongTermDebt
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_504"
      unitRef="USD">14908053</us-gaap:SubordinatedLongTermDebt>
    <us-gaap:CapitalLeaseObligationsNoncurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_505"
      unitRef="USD">2937292</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:CapitalLeaseObligationsNoncurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_506"
      unitRef="USD">1302361</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_507"
      unitRef="USD">80730</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_508"
      unitRef="USD">106574</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_509"
      unitRef="USD">114662113</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_510"
      unitRef="USD">100897576</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-06-30"
      decimals="4"
      id="fid_526"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_528"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_512"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_513"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-06-30"
      decimals="4"
      id="fid_534"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_536"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_538"
      unitRef="Shares">86349981</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_537"
      unitRef="Shares">59318355</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_514"
      unitRef="USD">8635</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_515"
      unitRef="USD">5932</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_516"
      unitRef="USD">381010696</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_517"
      unitRef="USD">290903772</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_518"
      unitRef="USD">-304139876</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_519"
      unitRef="USD">-264716555</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_520"
      unitRef="USD">76879455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_521"
      unitRef="USD">26193149</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_522"
      unitRef="USD">191541568</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_523"
      unitRef="USD">127090725</us-gaap:LiabilitiesAndStockholdersEquity>
    <adma:ProductRevenue
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_879"
      unitRef="USD">7751885</adma:ProductRevenue>
    <adma:ProductRevenue
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_880"
      unitRef="USD">6525233</adma:ProductRevenue>
    <adma:ProductRevenue
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_881"
      unitRef="USD">17915921</adma:ProductRevenue>
    <adma:ProductRevenue
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_882"
      unitRef="USD">10018114</adma:ProductRevenue>
    <adma:LicenseRevenue
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_883"
      unitRef="USD">35709</adma:LicenseRevenue>
    <adma:LicenseRevenue
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_884"
      unitRef="USD">35709</adma:LicenseRevenue>
    <adma:LicenseRevenue
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_885"
      unitRef="USD">71417</adma:LicenseRevenue>
    <adma:LicenseRevenue
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_886"
      unitRef="USD">71417</adma:LicenseRevenue>
    <us-gaap:Revenues
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_887"
      unitRef="USD">7787594</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_888"
      unitRef="USD">6560942</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_889"
      unitRef="USD">17987338</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_890"
      unitRef="USD">10089531</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_892"
      unitRef="USD">13495629</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_893"
      unitRef="USD">10491236</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_894"
      unitRef="USD">30324855</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_895"
      unitRef="USD">19896415</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_896"
      unitRef="USD">1656420</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_897"
      unitRef="USD">516986</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_898"
      unitRef="USD">3185158</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_899"
      unitRef="USD">1387621</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_900"
      unitRef="USD">877902</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_901"
      unitRef="USD">594113</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_902"
      unitRef="USD">1378546</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_903"
      unitRef="USD">1248599</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_904"
      unitRef="USD">178838</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_905"
      unitRef="USD">211234</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_906"
      unitRef="USD">357676</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_907"
      unitRef="USD">422469</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_908"
      unitRef="USD">8702630</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_909"
      unitRef="USD">6086047</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_910"
      unitRef="USD">16634714</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_911"
      unitRef="USD">11681517</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_912"
      unitRef="USD">24911419</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_913"
      unitRef="USD">17899616</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_914"
      unitRef="USD">51880949</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_915"
      unitRef="USD">34636621</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_916"
      unitRef="USD">-17123825</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_917"
      unitRef="USD">-11338674</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_918"
      unitRef="USD">-33893611</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_919"
      unitRef="USD">-24547090</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_921"
      unitRef="USD">19411</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_922"
      unitRef="USD">209808</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_923"
      unitRef="USD">267479</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_924"
      unitRef="USD">337207</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_925"
      unitRef="USD">3067306</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_926"
      unitRef="USD">2072578</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_927"
      unitRef="USD">5784397</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_928"
      unitRef="USD">3613085</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_929"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_931"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_930"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_932"
      unitRef="USD">9962495</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_933"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_934"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_935"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_936"
      unitRef="USD">11527421</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:OtherIncome
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_937"
      unitRef="USD">-6371</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_938"
      unitRef="USD">-10428</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_939"
      unitRef="USD">-12792</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_940"
      unitRef="USD">-21785</us-gaap:OtherIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_941"
      unitRef="USD">-3054266</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_942"
      unitRef="USD">-1873198</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_943"
      unitRef="USD">-5529710</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_944"
      unitRef="USD">-1732737</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_945"
      unitRef="USD">-20178091</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_946"
      unitRef="USD">-13211872</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_947"
      unitRef="USD">-39423321</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_948"
      unitRef="USD">-26279827</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-04-01to2020-06-30"
      decimals="2"
      id="fid_949"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-04-01to2019-06-30"
      decimals="2"
      id="fid_950"
      unitRef="USDPShares">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-01to2020-06-30"
      decimals="2"
      id="fid_951"
      unitRef="USDPShares">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-01-01to2019-06-30"
      decimals="2"
      id="fid_952"
      unitRef="USDPShares">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_953"
      unitRef="Shares">86347467</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_954"
      unitRef="Shares">52206204</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_955"
      unitRef="Shares">80064641</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_956"
      unitRef="Shares">49295805</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_971"
      unitRef="Shares">59318355</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_972"
      unitRef="USD">5932</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_973"
      unitRef="USD">290903772</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_974"
      unitRef="USD">-264716555</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_975"
      unitRef="USD">26193149</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_976"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_977"
      unitRef="USD">676548</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_978"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_979"
      unitRef="USD">676548</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_980"
      unitRef="Shares">27025000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_981"
      unitRef="USD">2703</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_982"
      unitRef="USD">88701336</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_983"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_984"
      unitRef="USD">88704039</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_985"
      unitRef="Shares">1958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_986"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_987"
      unitRef="USD">7177</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_988"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_989"
      unitRef="USD">7177</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_990"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_991"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_992"
      unitRef="USD">-19245230</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-03-31"
      decimals="0"
      id="fid_993"
      unitRef="USD">-19245230</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_994"
      unitRef="Shares">86345313</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_995"
      unitRef="USD">8635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_996"
      unitRef="USD">380288833</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_997"
      unitRef="USD">-283961785</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31"
      decimals="0"
      id="fid_998"
      unitRef="USD">96335683</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_999"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1000"
      unitRef="USD">715608</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1001"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_1002"
      unitRef="USD">715608</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1003"
      unitRef="Shares">4668</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1004"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1005"
      unitRef="USD">6255</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1006"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_1007"
      unitRef="USD">6255</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1008"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1009"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1010"
      unitRef="USD">-20178091</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_1011"
      unitRef="USD">-20178091</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1012"
      unitRef="Shares">86349981</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1013"
      unitRef="USD">8635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1014"
      unitRef="USD">381010696</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1015"
      unitRef="USD">-304139876</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_1016"
      unitRef="USD">76879455</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1017"
      unitRef="Shares">46353068</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1018"
      unitRef="USD">4635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1019"
      unitRef="USD">236203041</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1020"
      unitRef="USD">-216437238</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="fid_1021"
      unitRef="USD">19770438</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1022"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1023"
      unitRef="USD">637263</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1024"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-01to2019-03-31"
      decimals="0"
      id="fid_1025"
      unitRef="USD">637263</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1026"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1027"
      unitRef="USD">2699208</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1028"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-01-01to2019-03-31"
      decimals="0"
      id="fid_1029"
      unitRef="USD">2699208</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1030"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1031"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1032"
      unitRef="USD">-13067955</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-03-31"
      decimals="0"
      id="fid_1033"
      unitRef="USD">-13067955</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1034"
      unitRef="Shares">46353068</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1035"
      unitRef="USD">4635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1036"
      unitRef="USD">239539512</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1037"
      unitRef="USD">-229505193</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31"
      decimals="0"
      id="fid_1038"
      unitRef="USD">10038954</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1039"
      unitRef="Shares">27238</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1040"
      unitRef="USD">3</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1041"
      unitRef="USD">75045</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1042"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_1043"
      unitRef="USD">75048</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1044"
      unitRef="Shares">12937500</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1045"
      unitRef="USD">1294</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1046"
      unitRef="USD">48395794</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1047"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_1048"
      unitRef="USD">48397088</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1049"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1050"
      unitRef="USD">879907</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1051"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_1052"
      unitRef="USD">879907</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1053"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1054"
      unitRef="USD">726736</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1055"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_1056"
      unitRef="USD">726736</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1057"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1058"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1059"
      unitRef="USD">-13211872</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_1060"
      unitRef="USD">-13211872</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1061"
      unitRef="Shares">59317806</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1062"
      unitRef="USD">5932</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1063"
      unitRef="USD">289616994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1064"
      unitRef="USD">-242717065</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30"
      decimals="0"
      id="fid_1065"
      unitRef="USD">46905861</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_715"
      unitRef="USD">-39423321</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_716"
      unitRef="USD">-26279827</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_718"
      unitRef="USD">1674490</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_719"
      unitRef="USD">1611422</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_720"
      unitRef="USD">3518</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_721"
      unitRef="USD">8788</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_722"
      unitRef="USD">1392156</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_723"
      unitRef="USD">1363999</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_724"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_725"
      unitRef="USD">11527421</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_726"
      unitRef="USD">874732</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_727"
      unitRef="USD">340481</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_728"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_729"
      unitRef="USD">9962495</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <adma:AmortizationOfLicenseRevenue
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_730"
      unitRef="USD">-71417</adma:AmortizationOfLicenseRevenue>
    <adma:AmortizationOfLicenseRevenue
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_731"
      unitRef="USD">-71417</adma:AmortizationOfLicenseRevenue>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_733"
      unitRef="USD">-3044246</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_734"
      unitRef="USD">-3694222</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_735"
      unitRef="USD">-2936614</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_736"
      unitRef="USD">-5175148</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_737"
      unitRef="USD">-2159834</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_738"
      unitRef="USD">163747</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_739"
      unitRef="USD">-283195</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_740"
      unitRef="USD">118832</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_741"
      unitRef="USD">-2264932</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_742"
      unitRef="USD">887753</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_743"
      unitRef="USD">399295</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_744"
      unitRef="USD">-529589</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_745"
      unitRef="USD">-92067</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_746"
      unitRef="USD">-91029</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_747"
      unitRef="USD">-45931435</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_748"
      unitRef="USD">-32911136</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_750"
      unitRef="USD">-6243284</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_751"
      unitRef="USD">-245675</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_752"
      unitRef="USD">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_753"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_754"
      unitRef="USD">-6241284</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_755"
      unitRef="USD">-245675</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_757"
      unitRef="USD">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_758"
      unitRef="USD">-30000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:PaymentsForFees
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_759"
      unitRef="USD">0</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_760"
      unitRef="USD">2760000</us-gaap:PaymentsForFees>
    <adma:PaymentOfDebtRefinancingFees
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_761"
      unitRef="USD">0</adma:PaymentOfDebtRefinancingFees>
    <adma:PaymentOfDebtRefinancingFees
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_762"
      unitRef="USD">6499867</adma:PaymentOfDebtRefinancingFees>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_763"
      unitRef="USD">12500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_764"
      unitRef="USD">72500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_766"
      unitRef="USD">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_765"
      unitRef="USD">1679661</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_767"
      unitRef="USD">88704039</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_768"
      unitRef="USD">48397088</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_769"
      unitRef="USD">13432</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_770"
      unitRef="USD">75048</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsForLeasingCosts
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_771"
      unitRef="USD">15765</us-gaap:PaymentsForLeasingCosts>
    <us-gaap:PaymentsForLeasingCosts
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_772"
      unitRef="USD">-14740</us-gaap:PaymentsForLeasingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_774"
      unitRef="USD">101201706</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_775"
      unitRef="USD">80017868</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_776"
      unitRef="USD">49028987</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_777"
      unitRef="USD">46861057</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_778"
      unitRef="USD">26752135</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="fid_779"
      unitRef="USD">26754852</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_780"
      unitRef="USD">75781122</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2019-06-30"
      decimals="0"
      id="fid_781"
      unitRef="USD">73615909</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_782">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;1.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;ADMA Biologics, Inc. (&#x201c;ADMA&#x201d; or the &#x201c;Company&#x201d;) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#x2019;s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#x201c;ADMA BioManufacturing&#x201d;) and ADMA BioCenters Georgia Inc. (&#x201c;ADMA BioCenters&#x201d;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (&#x201c;BTBU&#x201d;) from BPC Plasma, Inc. (formerly Biotest Pharmaceuticals Corporation) (&#x201c;BPC&#x201d; and, together with Biotest AG, &#x201c;Biotest&#x201d;) as more fully described below. BTBU had been the Company&#x2019;s third-party manufacturer for its then-lead pipeline product candidate, ASCENIV, previously referred to as &#x201c;RI-002.&#x201d; ADMA BioCenters is the Company&#x2019;s source plasma collection business with a plasma collection facility located in the U.S., which holds an approved license with the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;). &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company has three FDA-approved products, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (&#x201c;IVIG&#x201d;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#x201c;PI&#x201d;), also known as Primary Immunodeficiency Disease (&#x201c;PIDD&#x201d;), and for which we received FDA approval on May 9, 2019 for the commercial re-launch of the product and commenced the commercial re-launch in August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#x2013; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#x201c;HBsAg&#x201d;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin products, the Company provides contract manufacturing services for certain clients and generates revenues from the sale of intermediate by-products that result from the immunoglobulin production process. The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;On June 6, 2017, ADMA completed the acquisition of certain assets (the &#x201c;Biotest Assets&#x201d;) of BTBU, which included the FDA-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#x201c;Boca Facility&#x201d;) (the &#x201c;Biotest Transaction&#x201d;).&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;As of June 30, 2020, the Company had working capital of $130.1 million, including $75.8 million of cash and cash equivalents. Based upon the Company&#x2019;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#x2019;s commercialization and expansion activities, as well as certain other assumptions, the Company&#x2019;s management currently believes that its cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund ADMA&#x2019;s operations, as currently conducted, into the second quarter of 2021. In order to have sufficient cash to fund its operations thereafter, the Company anticipates it will need to raise additional capital before the end of the second quarter of 2021. These estimates may change based upon several factors, including the success of the Company&#x2019;s commercial sales of its products, manufacturing ramp-up activities, the acceptability of ADMA&#x2019;s immune globulin products by physicians, patients or payers and the various financing options that may be available to the Company. In addition, the Company&#x2019;s end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months, requiring substantial investments in raw material plasma and other manufacturing materials. The Company currently has no firm commitments for additional financing, and there can be no assurance that the Company will be able to secure additional financing on terms that are acceptable to the Company, or at all. Furthermore, if the Company&#x2019;s assumptions underlying its estimated expenses and revenues are incorrect, it may have to raise additional capital sooner than currently anticipated. &lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Due to numerous risks and uncertainties associated with FDA approvals related to the Company&#x2019;s products or the labeled indications of such products, ongoing compliance requirements and capacity expansion efforts at the Company&#x2019;s Boca Facility and future commercialization of the Company&#x2019;s products, including the Company&#x2019;s ability to obtain adequate quantities of FDA-approved plasma with proper specifications on acceptable terms for use in the Company&#x2019;s manufacturing process, as well as the additional uncertainties surrounding the COVID-19 pandemic (see Note 9) the Company is unable to estimate with certainty the amounts of increased capital outlays and operating expenditures required to fund its commercial and development activities. The Company&#x2019;s current estimates may be subject to change as circumstances regarding its business requirements evolve. Failure to secure any necessary financing in a timely manner and on commercially reasonable terms could have a material adverse effect on the Company&#x2019;s business plan and financial performance and it could be forced to delay or discontinue its commercialization, product development or clinical activities or delay or discontinue the approval efforts for any of the Company&#x2019;s products or product candidates. The Company has reported cumulative losses since inception in June 2004 through June 30, 2020 of $304.1 million. As such, these factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of asset carrying amounts and the classification of liabilities that might be necessary from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company may decide to raise capital through public or private equity offerings or debt financings, or obtain a bank credit facility or enter into corporate collaboration and licensing arrangements. The sale of additional equity or debt securities, if convertible, could result in dilution to the Company&#x2019;s existing stockholders and, in such event, the market value of its common stock may decline. The incurrence of additional indebtedness would result in increased fixed obligations and could also result in covenants that would restrict the Company&#x2019;s operations or other financing alternatives. In addition, the Company is exploring additional contract manufacturing arrangements and other business development opportunities, which may provide additional liquidity to the Company. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;There can be no assurance that the Company&#x2019;s approved products will be commercially viable, or that research and development, plant capacity expansion, plasma center build-outs or other capital improvements will be successfully completed or that any product developed in the future will be approved. The Company is subject to risks common to companies in the biotechnology and pharmaceutical manufacturing industries including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <adma:WorkingCapital
      contextRef="AsOf2020-06-30"
      decimals="-5"
      id="fid_5"
      unitRef="USD">130100000</adma:WorkingCapital>
    <us-gaap:NetIncomeLoss
      contextRef="From2004-06-01to2020-06-30"
      decimals="-5"
      id="fid_1066"
      unitRef="USD">304100000</us-gaap:NetIncomeLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_783">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;2.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Basis of presentation&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 13, 2020.The accompanying consolidated balance sheet as of December 31, 2019 was derived from the audited financial statements for the year ended December 31, 2019. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of June 30, 2020 and its results of operations, changes in equity and cash flows for the three and six months ended June 30, 2020. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;During the three and six months ended June 30, 2020 and 2019, comprehensive loss was equal to the net loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under the Company&#x2019;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#x2019;s deferred tax assets.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#x2019;s senior secured term loan (see Note 6) approximates fair value due to the variable interest rate on this debt. With respect to the subordinated note payable in the amount of $15.0 million as of June 30, 2020 and December 31, 2019 held by Biotest, a principal stockholder of the Company at the time the note was issued concurrent with an acquisition transaction with an affiliate of such stockholder (see Note 6), the Company has concluded that an estimation of fair value for this note is not practicable.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers based upon an evaluation of each customer's financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis. Based on these evaluations, the Company has concluded that its credit risk is minimal. At June 30, 2020, three customers accounted for an aggregate of 76% of the Company&#x2019;s total accounts receivable, and at December 31, 2019, two customers accounted for 89% of the Company&#x2019;s total accounts receivable.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#x2019;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Due to previous uncertainties surrounding certain prior submissions made to the FDA, all costs related to the production of BIVIGAM and ASCENIV prior to their FDA approval dates of May 9, 2019 and April 1, 2019, respectively, have been charged to cost of product revenue in the accompanying consolidated statements of operations during the period the product was produced. In addition, costs associated with the production of conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at June 30, 2020 and December 31, 2019 was $3.5 million. All of the Company&#x2019;s goodwill is attributable to its ADMA BioManufacturing business segment and is related to a 2017acquisition transaction.&#160;&lt;/p&gt;&lt;p style="margin:0px"&gt;&#160;&#160; &lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Goodwill is not amortized, but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company&#x2019;s annual goodwill impairment test as of October 1, 2019 did not result in a goodwill impairment charge, and the Company did not record any impairment charges related to goodwill for the three and six months ended June 30, 2020 and 2019.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company assesses the recoverability of its long-lived assets, which include property and equipment and definite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset&#x2019;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the three and six months ended June 30, 2020 and 2019, the Company determined that there was no impairment of its long-lived assets.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Revenues for the three and six months ended June 30, 2020 and 2019 are comprised of (i) revenues from the sale of the Company&#x2019;s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#x2019;s Plasma Collection Centers business segment, (iii) contract manufacturing revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#x2019;s immunoglobulin products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;For the six months ended June 30, 2020, three customers represented an aggregate of 81% of the Company&#x2019;s consolidated revenues. For the six months ended June 30, 2019, three customers represented an aggregate of 84% of the Company&#x2019;s consolidated revenues.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Cost of product revenue&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Cost of product revenue includes costs associated with the manufacture of the Company&#x2019;s FDA approved products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Loss per common share&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts as the Company reported a net loss for all periods presented. For the six months ended June 30, 2020 and 2019, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;For the Six Months Ended June 30, &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Stock options&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,801,779&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,624,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Restricted stock units&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;326,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Warrants&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,138,160&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,138,160&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,265,939&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,762,763&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Stock-based compensation&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#x2019;s equity incentive plans generally have a four-year vesting period and a term of 10 years. Pursuant to ASU No. 2016-09, &lt;em&gt;Improvements to Employee Share-Based Payment Accounting (Topic 718)&lt;/em&gt;, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2015 and for previous periods as it relates to the Company&#x2019;s net operating loss carryforwards. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of June 30, 2020 and December 31, 2019, and during the three and six months ended June 30, 2020 and 2019, the Company recognized no adjustments for uncertain tax positions.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;em&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/em&gt; (&#x201c;ASU 2016-13&#x201d;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#x2019;s statement of operations is required to reflect the measurement of credit losses for newly recognized financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.The Company adopted ASU No. 2016-13, and the adoption of this update did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;em&gt;Leases (Topic 842)&lt;/em&gt; (&#x201c;ASU 2016-02&#x201d;), which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company adopted ASU 2016-02 on January 1, 2019 using the option to recognize the cumulative-effect adjustment, if any, as of the date of application, which was also January 1, 2019. The Company recognized right-to-use assets of $1.4 million and corresponding lease liabilities of approximately $1.6 million at the date of adoption (see Note 12). The Company also elected the &#x201c;package of practical expedients,&#x201d; which permits the Company to not reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease recognition exemption for all leases that qualify, including the agreement under which the Company occupies certain office space as discussed in Note 8. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), &lt;em&gt;Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815)&lt;/em&gt;&#x201d; (&#x201c;ASU 2017-11&#x201d;). ASU 2017-11 changed the classification analysis of certain equity-linked financial instruments (or embedded features within such instruments) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#x2019;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) will no longer be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (&#x201c;EPS&#x201d;) in accordance with ASC 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. In addition, convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features in ASC 470-20, &#x201c;Debt&#x2014;Debt with Conversion and Other Options.&#x201d; ASU 2017-11 became effective for the Company on January 1, 2019, and this update did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_795">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Basis of presentation&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 13, 2020.The accompanying consolidated balance sheet as of December 31, 2019 was derived from the audited financial statements for the year ended December 31, 2019. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of June 30, 2020 and its results of operations, changes in equity and cash flows for the three and six months ended June 30, 2020. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;During the three and six months ended June 30, 2020 and 2019, comprehensive loss was equal to the net loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year. &lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-06-30" id="fid_796">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under the Company&#x2019;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#x2019;s deferred tax assets.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2020-01-01to2020-06-30" id="fid_797">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#x2019;s senior secured term loan (see Note 6) approximates fair value due to the variable interest rate on this debt. With respect to the subordinated note payable in the amount of $15.0 million as of June 30, 2020 and December 31, 2019 held by Biotest, a principal stockholder of the Company at the time the note was issued concurrent with an acquisition transaction with an affiliate of such stockholder (see Note 6), the Company has concluded that an estimation of fair value for this note is not practicable.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2020-06-30_adma_BiotestMember"
      decimals="-5"
      id="fid_19"
      unitRef="USD">15000000.0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_798">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers based upon an evaluation of each customer's financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis. Based on these evaluations, the Company has concluded that its credit risk is minimal. At June 30, 2020, three customers accounted for an aggregate of 76% of the Company&#x2019;s total accounts receivable, and at December 31, 2019, two customers accounted for 89% of the Company&#x2019;s total accounts receivable.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-01to2020-06-30_adma_CustomerThreeMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      id="fid_1067"
      unitRef="Pure">76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-01to2019-12-31_adma_CustomerTwoMember_us-gaap_AccountsReceivableMember"
      decimals="INF"
      id="fid_22"
      unitRef="Pure">89</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_799">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#x2019;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Due to previous uncertainties surrounding certain prior submissions made to the FDA, all costs related to the production of BIVIGAM and ASCENIV prior to their FDA approval dates of May 9, 2019 and April 1, 2019, respectively, have been charged to cost of product revenue in the accompanying consolidated statements of operations during the period the product was produced. In addition, costs associated with the production of conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2020-01-01to2020-06-30" id="fid_800">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at June 30, 2020 and December 31, 2019 was $3.5 million. All of the Company&#x2019;s goodwill is attributable to its ADMA BioManufacturing business segment and is related to a 2017acquisition transaction.&#160;&lt;/p&gt;&lt;p style="margin:0px"&gt;&#160;&#160; &lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Goodwill is not amortized, but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company&#x2019;s annual goodwill impairment test as of October 1, 2019 did not result in a goodwill impairment charge, and the Company did not record any impairment charges related to goodwill for the three and six months ended June 30, 2020 and 2019.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_801">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company assesses the recoverability of its long-lived assets, which include property and equipment and definite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset&#x2019;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the three and six months ended June 30, 2020 and 2019, the Company determined that there was no impairment of its long-lived assets.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_802">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Revenues for the three and six months ended June 30, 2020 and 2019 are comprised of (i) revenues from the sale of the Company&#x2019;s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#x2019;s Plasma Collection Centers business segment, (iii) contract manufacturing revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#x2019;s immunoglobulin products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;For the six months ended June 30, 2020, three customers represented an aggregate of 81% of the Company&#x2019;s consolidated revenues. For the six months ended June 30, 2019, three customers represented an aggregate of 84% of the Company&#x2019;s consolidated revenues.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-01to2020-06-30_adma_CustomerThreeMember"
      decimals="INF"
      id="fid_28"
      unitRef="Pure">81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-01to2019-06-30_adma_CustomerThreeMember"
      decimals="INF"
      id="fid_26"
      unitRef="Pure">84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_803">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Cost of product revenue&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Cost of product revenue includes costs associated with the manufacture of the Company&#x2019;s FDA approved products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses. &lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_804">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Loss per common share&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts as the Company reported a net loss for all periods presented. For the six months ended June 30, 2020 and 2019, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;For the Six Months Ended June 30, &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Stock options&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,801,779&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,624,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Restricted stock units&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;326,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Warrants&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,138,160&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,138,160&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,265,939&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,762,763&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_808">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;For the Six Months Ended June 30, &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Stock options&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,801,779&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,624,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Restricted stock units&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;326,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Warrants&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,138,160&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,138,160&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,265,939&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;7,762,763&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-06-30_us-gaap_StockOptionMember"
      decimals="0"
      id="fid_11"
      unitRef="Shares">6801779</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-01to2019-06-30_us-gaap_StockOptionMember"
      decimals="0"
      id="fid_12"
      unitRef="Shares">5624603</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_15"
      unitRef="Shares">326000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-01to2019-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_16"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-06-30_us-gaap_WarrantMember"
      decimals="0"
      id="fid_13"
      unitRef="Shares">2138160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-01to2019-06-30_us-gaap_WarrantMember"
      decimals="0"
      id="fid_14"
      unitRef="Shares">2138160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_9"
      unitRef="Shares">9265939</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_10"
      unitRef="Shares">7762763</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_805">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Stock-based compensation&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#x2019;s equity incentive plans generally have a four-year vesting period and a term of 10 years. Pursuant to ASU No. 2016-09, &lt;em&gt;Improvements to Employee Share-Based Payment Accounting (Topic 718)&lt;/em&gt;, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="From2020-01-01to2020-06-30" id="fid_1069">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_806">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2015 and for previous periods as it relates to the Company&#x2019;s net operating loss carryforwards. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of June 30, 2020 and December 31, 2019, and during the three and six months ended June 30, 2020 and 2019, the Company recognized no adjustments for uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_807">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;em&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/em&gt; (&#x201c;ASU 2016-13&#x201d;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#x2019;s statement of operations is required to reflect the measurement of credit losses for newly recognized financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.The Company adopted ASU No. 2016-13, and the adoption of this update did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;em&gt;Leases (Topic 842)&lt;/em&gt; (&#x201c;ASU 2016-02&#x201d;), which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company adopted ASU 2016-02 on January 1, 2019 using the option to recognize the cumulative-effect adjustment, if any, as of the date of application, which was also January 1, 2019. The Company recognized right-to-use assets of $1.4 million and corresponding lease liabilities of approximately $1.6 million at the date of adoption (see Note 12). The Company also elected the &#x201c;package of practical expedients,&#x201d; which permits the Company to not reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease recognition exemption for all leases that qualify, including the agreement under which the Company occupies certain office space as discussed in Note 8. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), &lt;em&gt;Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815)&lt;/em&gt;&#x201d; (&#x201c;ASU 2017-11&#x201d;). ASU 2017-11 changed the classification analysis of certain equity-linked financial instruments (or embedded features within such instruments) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#x2019;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) will no longer be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (&#x201c;EPS&#x201d;) in accordance with ASC 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. In addition, convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features in ASC 470-20, &#x201c;Debt&#x2014;Debt with Conversion and Other Options.&#x201d; ASU 2017-11 became effective for the Company on January 1, 2019, and this update did not have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-06-30_adma_JanuaryOneTwoThousandNineteenMember"
      decimals="-5"
      id="fid_1089"
      unitRef="USD">1400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2020-06-30_adma_JanuaryOneTwoThousandNineteenMember"
      decimals="-5"
      id="fid_1090"
      unitRef="USD">1600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_784">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;3.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;INVENTORIES&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;The following table provides the components of inventories:&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;June 30,&lt;br/&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;December 31,&lt;br/&gt;2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Raw materials&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,830,796&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;33,381,806&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Work-in-progress&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,066,417&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,455,665&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Finished goods&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,104,135&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,227,263&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Total inventories&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;56,001,348&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;53,064,734&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160; &#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB, as there are alternative uses for these materials that provide a probable future benefit or will be consumed in the production of goods expected to be available for sale. All other activities and materials associated with the production of inventories used in research and development activities are expensed as incurred. &lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#x2019;s immunoglobulin products. Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company&#x2019;s plasma collection center which is expected to be sold to third-party customers. &lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_809">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;June 30,&lt;br/&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;December 31,&lt;br/&gt;2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Raw materials&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,830,796&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;33,381,806&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Work-in-progress&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,066,417&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,455,665&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Finished goods&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,104,135&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,227,263&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Total inventories&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;56,001,348&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;53,064,734&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_32"
      unitRef="USD">24830796</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_31"
      unitRef="USD">33381806</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_34"
      unitRef="USD">22066417</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_33"
      unitRef="USD">14455665</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_36"
      unitRef="USD">9104135</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_35"
      unitRef="USD">5227263</us-gaap:InventoryFinishedGoods>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_785">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;4.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;INTANGIBLE ASSETS &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 30px; text-align:left;"&gt;Intangible assets at June 30, 2020 and December 31, 2019 consist of the following:&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;June 30, 2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;December 31, 2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Accumulated &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Accumulated &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Cost &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Amortization&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Net &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Cost &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Amortization&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Net&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Trademark and other intangible rights related to Nabi-HB&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4,100,046&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,805,973&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,294,073&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4,100,046&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,513,112&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,586,934&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Rights to intermediates&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;907,421&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;399,697&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;507,724&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;907,421&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;334,881&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;572,540&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Customer contract&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;1,076,557&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;1,076,557&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;1,076,557&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;1,076,557&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;6,084,024&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;3,282,227&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;2,801,797&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;6,084,024&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;2,924,550&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;3,159,474&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;All of the Company&#x2019;s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets for the three months ended June 30, 2020 and 2019 was $0.2 million, and amortization expense for the six months ended June 30, 2020 and 2019 was $0.4 million. Estimated aggregate future aggregate amortization expense for the next five years is expected to be as follows:&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Remainder of 2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;357,676&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;2021 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;715,352&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;2022 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;715,352&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;2023 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;715,352&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;2024 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;298,065&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_811">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;June 30, 2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;December 31, 2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Accumulated &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Accumulated &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:6%;"/&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Cost &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Amortization&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Net &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Cost &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Amortization&lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Net&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Trademark and other intangible rights related to Nabi-HB&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4,100,046&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,805,973&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,294,073&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4,100,046&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,513,112&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,586,934&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Rights to intermediates&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;907,421&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;399,697&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;507,724&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;907,421&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;334,881&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;572,540&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Customer contract&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;1,076,557&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;1,076,557&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;1,076,557&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;1,076,557&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;6,084,024&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;3,282,227&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;2,801,797&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;6,084,024&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;2,924,550&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;"&gt;3,159,474&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-06-30_us-gaap_TrademarksMember"
      decimals="0"
      id="fid_59"
      unitRef="USD">4100046</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-06-30_us-gaap_TrademarksMember"
      decimals="0"
      id="fid_67"
      unitRef="USD">1805973</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-06-30_us-gaap_TrademarksMember"
      decimals="0"
      id="fid_75"
      unitRef="USD">2294073</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="fid_60"
      unitRef="USD">4100046</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="fid_68"
      unitRef="USD">1513112</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="fid_76"
      unitRef="USD">2586934</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-06-30_adma_RightToIntermediatesMember"
      decimals="0"
      id="fid_61"
      unitRef="USD">907421</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-06-30_adma_RightToIntermediatesMember"
      decimals="0"
      id="fid_69"
      unitRef="USD">399697</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-06-30_adma_RightToIntermediatesMember"
      decimals="0"
      id="fid_77"
      unitRef="USD">507724</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_adma_RightToIntermediatesMember"
      decimals="0"
      id="fid_62"
      unitRef="USD">907421</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_adma_RightToIntermediatesMember"
      decimals="0"
      id="fid_70"
      unitRef="USD">334881</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_adma_RightToIntermediatesMember"
      decimals="0"
      id="fid_78"
      unitRef="USD">572540</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-06-30_us-gaap_CustomerContractsMember"
      decimals="0"
      id="fid_63"
      unitRef="USD">1076557</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-06-30_us-gaap_CustomerContractsMember"
      decimals="0"
      id="fid_71"
      unitRef="USD">1076557</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-06-30_us-gaap_CustomerContractsMember"
      decimals="0"
      id="fid_79"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_us-gaap_CustomerContractsMember"
      decimals="0"
      id="fid_64"
      unitRef="USD">1076557</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_us-gaap_CustomerContractsMember"
      decimals="0"
      id="fid_72"
      unitRef="USD">1076557</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_us-gaap_CustomerContractsMember"
      decimals="0"
      id="fid_80"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_57"
      unitRef="USD">6084024</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_66"
      unitRef="USD">3282227</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_74"
      unitRef="USD">2801797</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_58"
      unitRef="USD">6084024</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_65"
      unitRef="USD">2924550</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_73"
      unitRef="USD">3159474</us-gaap:FiniteLivedIntangibleAssetsNet>
    <adma:AmortizationExpense
      contextRef="From2020-04-01to2020-06-30"
      decimals="-5"
      id="fid_286"
      unitRef="USD">200000</adma:AmortizationExpense>
    <adma:AmortizationExpense
      contextRef="From2020-01-01to2020-06-30"
      decimals="-5"
      id="fid_284"
      unitRef="USD">400000</adma:AmortizationExpense>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_810">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Remainder of 2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;357,676&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;2021 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;715,352&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;2022 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;715,352&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;2023 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;715,352&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;2024 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;298,065&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_81"
      unitRef="USD">357676</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_82"
      unitRef="USD">715352</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_83"
      unitRef="USD">715352</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_84"
      unitRef="USD">715352</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_85"
      unitRef="USD">298065</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_786">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;5.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;Property and equipment and related accumulated depreciation are summarized as follows:&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;June 30, 2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;December 31, 2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Manufacturing and laboratory equipment &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,898,186&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,831,817&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Office equipment and computer software &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,220,856&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,690,248&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Furniture and fixtures &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,400,129&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;582,088&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Construction in process &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,672,211&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,285,915&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Leasehold improvements &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,011,009&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,673,084&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Land &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,339,441&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,339,441&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Buildings and building improvements &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"&gt;16,869,821&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"&gt;16,063,680&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;44,411,653&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;37,466,273&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Less: Accumulated depreciation &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,038,287&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(5,724,956&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Total property and equipment, net &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;37,373,366&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;31,741,317&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#x2019;s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of 30 years. Property and equipment other than land and buildings have useful lives ranging from three to 10 years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;The Company recorded depreciation expense on property and equipment for the three and six months ended June 30, 2020 of $0.7 million and $1.3 million, respectively. Depreciation expense for the three and six months ended June 30, 2019 was $0.6 million and $1.2 million, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_812">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;June 30, 2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;December 31, 2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Manufacturing and laboratory equipment &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,898,186&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,831,817&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Office equipment and computer software &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,220,856&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,690,248&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Furniture and fixtures &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,400,129&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;582,088&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Construction in process &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,672,211&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,285,915&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Leasehold improvements &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,011,009&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,673,084&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Land &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,339,441&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,339,441&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Buildings and building improvements &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"&gt;16,869,821&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"&gt;16,063,680&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;44,411,653&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;37,466,273&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Less: Accumulated depreciation &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,038,287&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(5,724,956&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Total property and equipment, net &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;37,373,366&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;31,741,317&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-06-30_us-gaap_EquipmentMember"
      decimals="0"
      id="fid_88"
      unitRef="USD">9898186</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_EquipmentMember"
      decimals="0"
      id="fid_89"
      unitRef="USD">8831817</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-06-30_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="fid_90"
      unitRef="USD">2220856</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      id="fid_91"
      unitRef="USD">1690248</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-06-30_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="fid_92"
      unitRef="USD">1400129</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="fid_93"
      unitRef="USD">582088</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-06-30_us-gaap_ConstructionInProgressMember"
      decimals="0"
      id="fid_100"
      unitRef="USD">6672211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_ConstructionInProgressMember"
      decimals="0"
      id="fid_101"
      unitRef="USD">4285915</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-06-30_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="fid_94"
      unitRef="USD">3011009</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="fid_95"
      unitRef="USD">1673084</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-06-30_us-gaap_LandMember"
      decimals="0"
      id="fid_96"
      unitRef="USD">4339441</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_LandMember"
      decimals="0"
      id="fid_97"
      unitRef="USD">4339441</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-06-30_us-gaap_BuildingMember"
      decimals="0"
      id="fid_98"
      unitRef="USD">16869821</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_BuildingMember"
      decimals="0"
      id="fid_99"
      unitRef="USD">16063680</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_87"
      unitRef="USD">44411653</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_86"
      unitRef="USD">37466273</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_103"
      unitRef="USD">7038287</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_102"
      unitRef="USD">5724956</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="From2020-01-01to2020-06-30_us-gaap_BuildingMember"
      id="fid_290">P30Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="From2020-01-01to2020-06-30_adma_PropertyAndEquipmentMember_srt_MaximumMember"
      id="fid_291">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:Depreciation
      contextRef="From2020-04-01to2020-06-30"
      decimals="-5"
      id="fid_288"
      unitRef="USD">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-06-30"
      decimals="-5"
      id="fid_106"
      unitRef="USD">1300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-04-01to2019-06-30"
      decimals="-5"
      id="fid_289"
      unitRef="USD">600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-01to2019-06-30"
      decimals="-5"
      id="fid_107"
      unitRef="USD">1200000</us-gaap:Depreciation>
    <us-gaap:LongTermDebtTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_787">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;6.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;DEBT&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Senior Notes Payable&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;A summary of outstanding senior notes payable is as follows:&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;June 30, 2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;December 31, 2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Notes payable&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,000,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;72,500,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Less: &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 15px;vertical-align:top;"&gt;Debt discount &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,351,813&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,208,837&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Senior notes payable&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;81,648,187&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;68,291,163&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;On February 11, 2019 (the &#x201c;Perceptive Closing Date&#x201d;), the Company and all of its subsidiaries entered into a Credit Agreement and Guaranty (the &#x201c;Perceptive Credit Agreement&#x201d;) with Perceptive Credit Holdings II, LP, as the lender and administrative agent (&#x201c;Perceptive&#x201d;). The Perceptive Credit Agreement, as amended, provides for a senior secured term loan facility in a principal amount of up to $85.0 million (the &#x201c;Perceptive Credit Facility&#x201d;), comprised of (i) a term loan made on the Perceptive Closing Date in the principal amount of $45.0 million, as evidenced by the Company&#x2019;s issuance of a promissory note (the &#x201c;Perceptive Tranche I Note&#x201d;) in favor of Perceptive on the Perceptive Closing Date (the &#x201c;Perceptive Tranche I Loan&#x201d;), (ii) a term loan in the principal amount of up to $27.5 million (the &#x201c;Perceptive Tranche II Loan&#x201d;) evidenced by the Company&#x2019;s issuance of a promissory note (the &#x201c;Perceptive Tranche II Note&#x201d;) in favor of Perceptive on May 3, 2019; and (iii) a term loan in the principal amount of up to $12.5 million evidenced by the Company&#x2019;s issuance of a promissory note (the &#x201c;Perceptive Tranche III Note&#x201d;) in favor of Perceptive on March 20, 2020 (the &#x201c;Perceptive Tranche III Loan,&#x201d; and together with the Perceptive Tranche I Loan and the Perceptive Tranche II Loan, the &#x201c;Perceptive Loans&#x201d;). The Perceptive Tranche III Loan is the result of an amendment to the Perceptive Credit Agreement (the &#x201c;Perceptive Amendment&#x201d;) that the Company and Perceptive entered into on May 3, 2019, and the Perceptive Tranche III Loan became available to the Company upon the approval of BIVIGAM on May 9, 2019. The Perceptive Credit Facility has a maturity date of March 1, 2022 (the &#x201c;Maturity Date&#x201d;), subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default (as defined in the Perceptive Credit Agreement).&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;On the Perceptive Closing Date, the Company used $30.0 million of the Perceptive Tranche I Loan to terminate and pay in full all of the outstanding obligations under its previously existing credit agreement with Marathon Healthcare Finance Fund, L.P. (&#x201c;Marathon&#x201d;) (the &#x201c;Marathon Credit Facility&#x201d;). The Company also used proceeds from the Perceptive Tranche I Loan to: (i) pay a deferred facility fee to Marathon in the amount of $2.8 million, (ii) pay a prepayment penalty to Marathon in the amount of $6.5 million, (iii) pay outstanding accrued interest to Marathon in the amount of $0.7 million, and (iv) pay certain fees and expenses incurred in connection with the Perceptive Credit Facility of approximately $1.5 million. In addition, Marathon released $4.0 million of cash to the Company that was held in a debt service reserve account per the terms of the Marathon Credit Facility. In connection with the Perceptive Amendment, the Company paid an additional facility fee to Perceptive in the amount of $0.1 million on May 3, 2019.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;As a result of the Company&#x2019;s entering into the Perceptive Credit Agreement and terminating the Marathon Credit Facility, the Company recognized a loss on the extinguishment of debt for the six months ended June 30, 2019 in the amount of approximately $10.0 million, comprised of the $6.5 million prepayment penalty and the write-off of unamortized debt discount related to the Marathon Credit Facility in the amount of $3.5 million.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Borrowings under the Perceptive Credit Agreement bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will automatically increase by an additional 400 basis points. Accrued interest is payable to Perceptive on the last day of each month during the term of the Perceptive Credit Facility.The rate of interest in effect as of the Perceptive Closing Date and at June 30, 2020 was 11.0%. &lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;On the Maturity Date, the Company will pay Perceptive the entire outstanding principal amount underlying the Perceptive Loans and any accrued and unpaid interest thereon. Prior to the Maturity Date, there will be no scheduled principal payments on the Perceptive Loans. The Company may prepay outstanding principal on the Perceptive Loans at any time and from time to time upon three business days&#x2019; prior written notice, subject to the payment to Perceptive of (A) any accrued but unpaid interest on the prepaid principal amount plus (B) a redemption premium amount equal to (i) 5.0% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Perceptive Closing Date, (ii) 4.0% of the prepaid principal amount, if prepaid after the first anniversary of the Perceptive Closing Date and on or prior to the second anniversary of the Perceptive Closing Date, or (iii) 3.0% of the prepaid principal amount, if prepaid after the second anniversary of the Perceptive Closing Date and on or prior to the third anniversary of the Perceptive Closing Date.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;All of the Company&#x2019;s obligations under the Perceptive Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#x2019;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#x2019;s subsidiaries. The Perceptive Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among other things and subject to certain exceptions contained in the Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#x2019;s or its subsidiaries&#x2019; business activities; make certain Investments or Restricted Payments (each as defined in the Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#x2019;s ability to make loan repayments under the Perceptive Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ended June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $7.0 million for the fiscal quarter ended June 30, 2019 to $55.0 million for the fiscal quarter ending December 31, 2021. At June 30, 2020, the Company was in compliance with all of the covenants contained in the Perceptive Credit Agreement. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;As consideration for the Perceptive Credit Agreement, the Company issued to Perceptive a warrant to purchase 1,360,000 shares of the Company&#x2019;s common stock (the &#x201c;Perceptive Warrant&#x201d;) on the Perceptive Closing Date. The Perceptive Warrant has an exercise price equal to $3.28 per share, which is equal to the trailing 10-day volume weighted average price (&#x201c;VWAP&#x201d;) of the Company&#x2019;s common stock on the business day immediately prior to the Perceptive Closing Date multiplied by 1.15. The Company valued the Perceptive Warrant at $2.7 million as of the Perceptive Closing Date and it has an expiration date of February 11, 2029. In connection with the Perceptive Amendment, the Company issued an additional warrant (the &#x201c;Perceptive Tranche III Warrant&#x201d; and, together with the Perceptive Warrant, the &#x201c;Perceptive Warrants&#x201d;) to purchase 250,000 shares of the Company&#x2019;s common stock to Perceptive with an exercise price equal to $4.64 per share, which represents the trailing 10-day VWAP of the Company&#x2019;s common stock as of May 2, 2019. The Perceptive Tranche III Warrant was valued by the Company at $0.9 million and has an expiration date of May 3, 2029. Perceptive has represented to the Company, among other things, that it was an &#x201c;accredited investor&#x201d; (as such term is defined in Rule 501(a) of Regulation D under the Securities Act) and the Company issued the Perceptive Warrants in reliance upon an exemption from registration contained in Section 4(2) under the Securities Act. The Perceptive Warrants and the shares of common stock issuable thereunder may not be offered, sold, pledged or otherwise transferred in the U.S. absent registration or an applicable exemption from the registration requirements under the Securities Act.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;As a result of the fees paid to Perceptive and the value of the Perceptive Warrants, the Company recognized an aggregate discount on the Perceptive Tranche I Note and Perceptive Tranche II Note in the amount of $5.3 million. The Company records debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. Based on the fair value of the Perceptive Warrants and the aggregate amount of fees and expenses associated with obtaining the Perceptive Credit Facility, the effective interest rate on the Perceptive Loans as of May 3, 2019 was approximately 14.1%. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Subordinated Note Payable&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;A summary of the outstanding subordinated note payable is as follows:&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;June 30, 2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;December 31, 2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Subordinated note payable to Biotest&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Less: &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 15px;vertical-align:top;"&gt;Debt discount &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(74,240&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(91,947&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Subordinated note payable &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,925,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,908,053&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In connection with the acquisition of the Biotest Assets (see Note 1), ADMA BioManufacturing issued a subordinated note payable to BPC and in connection therewith received cash proceeds of $15.0 million. This note has since been assigned from BPC to Biotest AG. The note bears interest at a rate of 6.0% per annum and matures on June 6, 2022.The Company is obligated to make semi-annual interest payments, with all principal and unpaid interest due at maturity. The note is subordinate to all amounts outstanding under the Perceptive Credit Agreement. In the event of default, all principal and unpaid interest is due on demand. The subordinated note also contains several non-financial covenants with which the Company was in compliance as of June 30, 2020.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_814">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;June 30, 2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;December 31, 2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Notes payable&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,000,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;72,500,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Less: &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 15px;vertical-align:top;"&gt;Debt discount &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(3,351,813&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,208,837&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Senior notes payable&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;81,648,187&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;68,291,163&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_109"
      unitRef="USD">85000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_108"
      unitRef="USD">72500000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_112"
      unitRef="USD">-3351813</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_111"
      unitRef="USD">-4208837</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2019-02-01to2019-02-11_adma_PerceptiveCreditAgreementMember"
      decimals="-5"
      id="fid_875"
      unitRef="USD">85000000.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-06-30_adma_PerceptiveTrancheILoanMember"
      decimals="-5"
      id="fid_826"
      unitRef="USD">45000000.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2019-04-11to2019-05-03_adma_PerceptiveTrancheIILoanMember"
      decimals="-5"
      id="fid_830"
      unitRef="USD">27500000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2019-04-11to2019-05-03_adma_PerceptiveTrancheIIILoanMember"
      decimals="-5"
      id="fid_832"
      unitRef="USD">12500000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <adma:PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid
      contextRef="From2020-01-01to2020-06-30"
      decimals="-5"
      id="fid_1074"
      unitRef="USD">30000000.0</adma:PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid>
    <adma:DeferredFacilityFee
      contextRef="From2019-04-11to2019-05-03_adma_MarathonHealthcareFinanceFundLPMember"
      decimals="-5"
      id="fid_834"
      unitRef="USD">2800000</adma:DeferredFacilityFee>
    <adma:PrepaymentPenalty
      contextRef="From2019-04-11to2019-05-03_adma_MarathonHealthcareFinanceFundLPMember"
      decimals="-5"
      id="fid_835"
      unitRef="USD">6500000</adma:PrepaymentPenalty>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2019-05-03_adma_MarathonHealthcareFinanceFundLPMember"
      decimals="-5"
      id="fid_838"
      unitRef="USD">700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LegalFees
      contextRef="From2019-04-11to2019-05-03_adma_MarathonHealthcareFinanceFundLPMember"
      decimals="-5"
      id="fid_839"
      unitRef="USD">1500000</us-gaap:LegalFees>
    <adma:DebtServiceReserve
      contextRef="AsOf2019-05-03_adma_MarathonHealthcareFinanceFundLPMember"
      decimals="-5"
      id="fid_840"
      unitRef="USD">4000000.0</adma:DebtServiceReserve>
    <adma:AdditionalFacilityFee
      contextRef="From2019-04-11to2019-05-03_adma_MarathonHealthcareFinanceFundLPMember"
      decimals="-5"
      id="fid_841"
      unitRef="USD">100000</adma:AdditionalFacilityFee>
    <adma:PrepaymentPenalty
      contextRef="From2019-01-01to2019-06-30_adma_MarathonHealthcareFinanceFundLPMember"
      decimals="-5"
      id="fid_1071"
      unitRef="USD">6500000</adma:PrepaymentPenalty>
    <adma:UnamortizedDebtDiscount
      contextRef="From2019-01-01to2019-06-30_adma_MarathonHealthcareFinanceFundLPMember"
      decimals="-5"
      id="fid_1072"
      unitRef="USD">3500000</adma:UnamortizedDebtDiscount>
    <adma:InterestRateDescription
      contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember"
      id="fid_866">Perceptive Credit Agreement bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will automatically increase by an additional 400 basis points. Accrued interest is payable to Perceptive on the last day of each month during the term of the Perceptive Credit Facility.The rate of interest in effect as of the Perceptive Closing Date and at June 30, 2020 was 11.0%. </adma:InterestRateDescription>
    <adma:DescriptionOfPrepaidPrincipalAmount contextRef="From2020-01-01to2020-06-30" id="fid_1073">(i) 5.0% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Perceptive Closing Date, (ii) 4.0% of the prepaid principal amount, if prepaid after the first anniversary of the Perceptive Closing Date and on or prior to the second anniversary of the Perceptive Closing Date, or (iii) 3.0% of the prepaid principal amount, if prepaid after the second anniversary of the Perceptive Closing Date and on or prior to the third anniversary of the Perceptive Closing Date.</adma:DescriptionOfPrepaidPrincipalAmount>
    <adma:AdditionlalDescription
      contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember"
      id="fid_868">In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ended June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $7.0 million for the fiscal quarter ended June 30, 2019 to $55.0 million for the fiscal quarter ending December 31, 2021.</adma:AdditionlalDescription>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember"
      decimals="0"
      id="fid_848"
      unitRef="Shares">1360000</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember"
      decimals="2"
      id="fid_850"
      unitRef="USDPShares">3.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember"
      decimals="-5"
      id="fid_852"
      unitRef="USD">2700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adma:ExpirationDate
      contextRef="From2020-01-01to2020-06-30_adma_PerceptiveCreditAgreementMember"
      id="fid_854">February 11, 2029</adma:ExpirationDate>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="From2019-04-11to2019-05-02_adma_PerceptiveTrancheIIIWarrantMember"
      decimals="0"
      id="fid_858"
      unitRef="Shares">250000</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-04-11to2019-05-02_adma_PerceptiveTrancheIIIWarrantMember"
      decimals="2"
      id="fid_861"
      unitRef="USDPShares">4.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-04-11to2019-05-02_adma_PerceptiveTrancheIIIWarrantMember"
      decimals="-5"
      id="fid_864"
      unitRef="USD">900000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adma:PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid
      contextRef="From2019-04-11to2019-05-03"
      decimals="-5"
      id="fid_845"
      unitRef="USD">5300000</adma:PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2019-04-11to2019-05-03"
      decimals="INF"
      id="fid_846"
      unitRef="Pure">1.41</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:ScheduleOfSubordinatedBorrowingTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_813">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;June 30, 2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;December 31, 2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Subordinated note payable to Biotest&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Less: &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 15px;vertical-align:top;"&gt;Debt discount &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(74,240&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(91,947&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Subordinated note payable &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,925,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,908,053&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSubordinatedBorrowingTextBlock>
    <adma:SubordinatedDebtCarryingValue
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_115"
      unitRef="USD">15000000</adma:SubordinatedDebtCarryingValue>
    <adma:SubordinatedDebtCarryingValue
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_116"
      unitRef="USD">15000000</adma:SubordinatedDebtCarryingValue>
    <adma:SubordinatedDebtInstrumentUnamortizedDiscount
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_119"
      unitRef="USD">-74240</adma:SubordinatedDebtInstrumentUnamortizedDiscount>
    <adma:SubordinatedDebtInstrumentUnamortizedDiscount
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_118"
      unitRef="USD">-91947</adma:SubordinatedDebtInstrumentUnamortizedDiscount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2020-01-01to2020-06-30_adma_BPCMember"
      decimals="-5"
      id="fid_870"
      unitRef="USD">15000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="From2020-01-01to2020-06-30_adma_BPCMember"
      decimals="INF"
      id="fid_872"
      unitRef="Pure">0.60</us-gaap:DebtConversionConvertedInstrumentRate>
    <adma:ExpirationDate
      contextRef="From2020-01-01to2020-06-30_adma_BPCMember"
      id="fid_873">June 6, 2022</adma:ExpirationDate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_788">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;7.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;STOCKHOLDERS&#x2019; EQUITY &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Preferred Stock&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share. There were no shares of preferred stock outstanding at June 30, 2020 and December 31, 2019.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160; &#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;As of June 30, 2020 and December 31, 2019, the Company was authorized to issue 150,000,000 shares of its common stock, $0.0001 par value per share, and 86,349,981 and 59,318,355 shares of common stock were outstanding as of June 30, 2020 and December 31, 2019, respectively. After giving effect to the 9,265,939 shares reserved for outstanding warrants and awards issued under the Company&#x2019;s equity incentive plans, as of June 30, 2020 there were 54,384,080 shares of common stock available for issuance.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;On February 11, 2020, the Company completed an underwritten public offering of 23,500,000 shares of its common stock for gross proceeds of $82.3 million. On February 21, 2020, the Company sold an additional 3,525,000 shares pursuant to the underwriters&#x2019; exercise of their option to purchase additional shares of the Company&#x2019;s common stock for additional gross proceeds of $12.3 million. The Company received net proceeds, after underwriting discounts and other expenses associated with the offering, of approximately $88.7 million.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Warrants&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;At June 30, 2020 and December 31, 2019, the Company had outstanding warrants to purchase an aggregate of 2,138,160 shares of common stock, with a weighted average exercise price of $3.81 per share and expiration dates ranging between June 2022 and May 2029.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The fair value of stock options granted under the Company&#x2019;s 2007 Employee Stock Option Plan (the &#x201c;2007 Plan&#x201d;) and the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan, as amended and restated (the &#x201c;2014 Plan&#x201d;), was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2020 and 2019:&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Six Months Ended June 30, &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:77%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019 &lt;/strong&gt;&lt;/td&gt;&lt;td style="width:2%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;Expected term&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;5.5 - 6.3 years &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;5.8 - 6.3 years &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;Volatility&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;62%-67% &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;54%-62% &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Dividend yield&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td colspan="2" style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td colspan="2" style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;0.38-1.68% &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;1.80-2.92% &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;During the six months ended June 30, 2020 and 2019, the Company granted options to purchase an aggregate of 1,232,500 and 1,429,100 shares of common stock, respectively, to its directors, employees and certain third-party service providers. The weighted average remaining contractual life of stock options outstanding and expected to vest at June 30, 2020 is 6.9 years. The weighted average remaining contractual life of stock options exercisable at June 30, 2020 is 5.6 years.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin:0px"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;A summary of the Company&#x2019;s option activity under the 2007 Plan and 2014 Plan and related information is as follows: &lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Shares &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,630,351&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.76&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Forfeited&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(47,683&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.51&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Expired&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(6,763&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.34&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Granted&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,232,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.96&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Exercised&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(6,626&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.03&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Balance at June 30, 2020&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,801,779&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.45&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Options exercisable&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,030,098&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;5.19&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;As of June 30, 2020, the Company had $5.1 million of unrecognized compensation expense related to options granted under the Company&#x2019;s equity incentive plans, which is expected to be recognized over a weighted-average period of 2.6 years.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;During the six months ended June 30, 2020, the Company granted Restricted Stock Units (&#x201c;RSUs&#x201d;) to members of the Company&#x2019;s Board of Directors and to certain management employees of the Company. The total RSUs granted during the period represent an aggregate of 341,000 shares of the Company&#x2019;s common stock. The RSUs vest semi-annually over a period of one year for directors and annually over a period of four years for employees. Total compensation expense related to unvested RSUs for the three and six months ended June 30, 2020 was $0.1 million. A summary of the Company&#x2019;s unvested RSU activity and related information is as follows:&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Weighted Average Grant Date Fair Value&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Balance at December 31, 2019 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Granted &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;341,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Vested &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Forfeited &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(15,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.92&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Balance at June 30, 2020 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;326,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;As of June 30, 2020, the Company had $0.8 million of unrecognized compensation expense related to unvested RSUs granted under the Company&#x2019;s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.5 years.&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for the three and six months ended June 30, 2020 and 2019 is as follows:&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Three Months Ended June 30, &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Six Months Ended June 30, &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Research and development&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;105,029&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;89,543&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;198,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;176,066&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Plasma centers&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,510&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,213&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,754&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,753&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;539,256&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;569,349&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,063,145&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,067,820&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Cost of product revenue&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;62,813&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,631&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;114,654&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;95,360&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 15px;vertical-align:top;"&gt;Total stock-based compensation expense &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;715,608&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;726,736&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,392,156&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,363,999&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-06-30"
      decimals="4"
      id="fid_165"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_175"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-06-30"
      decimals="4"
      id="fid_173"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_179"
      unitRef="Shares">86349981</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_178"
      unitRef="Shares">59318355</us-gaap:CommonStockSharesOutstanding>
    <adma:CommonStockReservedForOutstanding
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_305"
      unitRef="Shares">9265939</adma:CommonStockReservedForOutstanding>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_306"
      unitRef="Shares">54384080</us-gaap:CommonStockSharesSubscribedButUnissued>
    <adma:UnderwrittenPublicOffering
      contextRef="AsOf2020-02-11"
      decimals="0"
      id="fid_310"
      unitRef="Shares">23500000</adma:UnderwrittenPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-02-01to2020-02-11"
      decimals="-5"
      id="fid_308"
      unitRef="USD">82300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <adma:UnderwrittenPublicOffering
      contextRef="AsOf2020-02-21"
      decimals="0"
      id="fid_314"
      unitRef="Shares">3525000</adma:UnderwrittenPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-02-01to2020-02-21"
      decimals="-5"
      id="fid_312"
      unitRef="USD">12300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-01-01to2020-06-30"
      decimals="-5"
      id="fid_316"
      unitRef="USD">88700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_317"
      unitRef="Shares">2138160</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2020-06-30"
      decimals="2"
      id="fid_319"
      unitRef="USDPShares">3.81</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_815">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Six Months Ended June 30, &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:77%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019 &lt;/strong&gt;&lt;/td&gt;&lt;td style="width:2%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;Expected term&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;5.5 - 6.3 years &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;5.8 - 6.3 years &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;Volatility&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;62%-67% &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;54%-62% &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Dividend yield&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td colspan="2" style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td colspan="2" style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;0.38-1.68% &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;1.80-2.92% &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2020-01-01to2020-06-30_srt_MinimumMember"
      id="fid_122">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2020-01-01to2020-06-30_srt_MaximumMember"
      id="fid_124">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2019-01-01to2019-06-30_srt_MinimumMember"
      id="fid_123">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2019-01-01to2019-06-30_srt_MaximumMember"
      id="fid_125">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-01to2020-06-30_srt_MinimumMember"
      decimals="INF"
      id="fid_1080"
      unitRef="Pure">62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-01to2020-06-30_srt_MaximumMember"
      decimals="INF"
      id="fid_1079"
      unitRef="Pure">67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-01to2019-06-30_srt_MinimumMember"
      decimals="INF"
      id="fid_1082"
      unitRef="Pure">54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-01to2019-06-30_srt_MaximumMember"
      decimals="INF"
      id="fid_1081"
      unitRef="Pure">62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-01to2020-06-30"
      decimals="INF"
      id="fid_128"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-01to2019-06-30"
      decimals="INF"
      id="fid_129"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-01to2020-06-30_srt_MinimumMember"
      decimals="INF"
      id="fid_1076"
      unitRef="Pure">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-01to2020-06-30_srt_MaximumMember"
      decimals="INF"
      id="fid_1075"
      unitRef="Pure">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-01to2019-06-30_srt_MinimumMember"
      decimals="INF"
      id="fid_1077"
      unitRef="Pure">0.0180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-01to2019-06-30_srt_MaximumMember"
      decimals="INF"
      id="fid_1078"
      unitRef="Pure">0.0292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2020-01-01to2020-06-30_adma_EquityIncentivePlanMember"
      decimals="0"
      id="fid_320"
      unitRef="Shares">1232500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2019-01-01to2019-06-30_adma_EquityIncentivePlanMember"
      decimals="0"
      id="fid_322"
      unitRef="Shares">1429100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2020-01-01to2020-06-30_adma_EquityIncentivePlanMember"
      id="fid_324">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2020-01-01to2020-06-30_adma_EquityIncentivePlanMember"
      id="fid_326">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_817">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Shares &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,630,351&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.76&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Forfeited&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(47,683&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.51&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Expired&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(6,763&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.34&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Granted&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,232,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.96&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Exercised&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(6,626&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.03&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Balance at June 30, 2020&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,801,779&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.45&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Options exercisable&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,030,098&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;5.19&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_135"
      unitRef="Shares">5630351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31"
      decimals="2"
      id="fid_145"
      unitRef="USDPShares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_137"
      unitRef="Shares">-47683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-06-30"
      decimals="2"
      id="fid_147"
      unitRef="USDPShares">3.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_138"
      unitRef="Shares">-6763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-06-30"
      decimals="2"
      id="fid_148"
      unitRef="USDPShares">4.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_139"
      unitRef="Shares">1232500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-06-30"
      decimals="2"
      id="fid_149"
      unitRef="USDPShares">2.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_140"
      unitRef="Shares">-6626</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-06-30"
      decimals="2"
      id="fid_150"
      unitRef="USDPShares">2.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_142"
      unitRef="Shares">6801779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30"
      decimals="2"
      id="fid_152"
      unitRef="USDPShares">4.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_1083"
      unitRef="Shares">4030098</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-06-30"
      decimals="2"
      id="fid_1084"
      unitRef="USDPShares">5.19</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2020-06-30_adma_EquityIncentivePlanMember"
      decimals="-5"
      id="fid_180"
      unitRef="USD">5100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2020-01-01to2020-06-30_adma_EquityIncentivePlanMember"
      id="fid_315">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <adma:CommonStockGranted
      contextRef="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_327"
      unitRef="Shares">341000</adma:CommonStockGranted>
    <adma:CompensationExpense
      contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="fid_329"
      unitRef="USD">100000</adma:CompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_816">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Weighted Average Grant Date Fair Value&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Balance at December 31, 2019 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Granted &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;341,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Vested &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Forfeited &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(15,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.92&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Balance at June 30, 2020 &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;326,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_436"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_441"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_443"
      unitRef="Shares">341000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="fid_459"
      unitRef="USDPShares">2.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_452"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_457"
      unitRef="USDPShares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_439"
      unitRef="Shares">-15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="fid_455"
      unitRef="USDPShares">2.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="fid_448"
      unitRef="Shares">326000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="fid_464"
      unitRef="USDPShares">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="fid_333"
      unitRef="USD">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2020-01-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="fid_332">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy contextRef="From2020-01-01to2020-06-30" id="fid_818">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Three Months Ended June 30, &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Six Months Ended June 30, &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020 &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Research and development&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;105,029&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;89,543&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;198,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;176,066&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Plasma centers&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,510&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,213&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,754&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;24,753&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;539,256&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;569,349&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,063,145&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,067,820&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;Cost of product revenue&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;62,813&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,631&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;114,654&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;95,360&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 15px;vertical-align:top;"&gt;Total stock-based compensation expense &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;715,608&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;726,736&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,392,156&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,363,999&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-01to2020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="fid_297"
      unitRef="USD">105029</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-01to2019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="fid_301"
      unitRef="USD">89543</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-01to2019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="fid_157"
      unitRef="USD">176066</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-01to2020-06-30_adma_PlasmaCentersMember"
      decimals="0"
      id="fid_298"
      unitRef="USD">8510</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-01to2019-06-30_adma_PlasmaCentersMember"
      decimals="0"
      id="fid_302"
      unitRef="USD">13213</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="fid_156"
      unitRef="USD">15754</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-01to2019-06-30_adma_PlasmaCentersMember"
      decimals="0"
      id="fid_159"
      unitRef="USD">24753</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-01to2020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="fid_299"
      unitRef="USD">539256</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-01to2019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="fid_303"
      unitRef="USD">569349</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="fid_160"
      unitRef="USD">1063145</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-01to2019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="fid_161"
      unitRef="USD">1067820</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-01to2020-06-30_us-gaap_CostOfGoodsTotalMember"
      decimals="0"
      id="fid_300"
      unitRef="USD">62813</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-01to2019-06-30_us-gaap_CostOfGoodsTotalMember"
      decimals="0"
      id="fid_304"
      unitRef="USD">54631</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-06-30_us-gaap_CostOfGoodsTotalMember"
      decimals="0"
      id="fid_162"
      unitRef="USD">114654</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-01to2019-06-30_us-gaap_CostOfGoodsTotalMember"
      decimals="0"
      id="fid_163"
      unitRef="USD">95360</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-01to2020-06-30"
      decimals="0"
      id="fid_295"
      unitRef="USD">715608</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-01to2019-06-30"
      decimals="0"
      id="fid_296"
      unitRef="USD">726736</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_969"
      unitRef="USD">1392156</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_970"
      unitRef="USD">1363999</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_789">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;8.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;The Company leases an office building and equipment from Areth, LLC (&#x201c;Areth&#x201d;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time. Effective October 1, 2017, monthly rent on this facility was set at $10,000. On November 7, 2019, an additional amendment was entered into between Areth and the Company to extend the term of this agreement through September 30, 2020, and to provide for automatic one-year renewals unless ADMA gives written notice of termination to Areth 60 days prior to the end of the term, which expires each year on September 30. The Company did not provide a written notice of termination to Areth as of July 31, 2020. Rent expense for the six months ended June 30, 2020 and 2019 amounted to $60,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#x2019;s Board of Directors, and Adam S. Grossman, the Company&#x2019;s President and Chief Executive Officer. The Company also reimburses Areth for office and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the three and six months ended June 30, 2020 and 2019. &lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;See Note 6 for a discussion of the Company&#x2019;s credit facility and related transactions with Perceptive, a holder of more than 10% of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;In connection with the February 2020 public offering of the Company&#x2019;s common stock (see Note 7) on February 11, 2020: (i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an entity he controls (v) Brian Lenz, the Company&#x2019;s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common stock, and (vi) James Mond, the Company&#x2019;s Chief Scientific Officer and Chief Medical Officer, purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="From2017-09-09to2017-10-01_adma_ArethLLCMember"
      id="fid_1087">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments
      contextRef="From2017-09-09to2017-10-01_adma_ArethLLCMember"
      decimals="0"
      id="fid_1086"
      unitRef="USD">10000</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-01-01to2019-06-30_adma_ArethLLCMember"
      decimals="0"
      id="fid_1085"
      unitRef="USD">60000</us-gaap:LeaseAndRentalExpense>
    <adma:CreditFacilityPercentage
      contextRef="From2020-01-01to2020-06-30"
      decimals="INF"
      id="fid_335"
      unitRef="Pure">10</adma:CreditFacilityPercentage>
    <adma:PublicOfferingDescription contextRef="From2020-01-01to2020-06-30" id="fid_336">(i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an entity he controls (v) Brian Lenz, the Company&#x2019;s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common stock, and (vi) James Mond, the Company&#x2019;s Chief Scientific Officer and Chief Medical Officer, purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share.</adma:PublicOfferingDescription>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_790">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;9.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;General Legal Matters&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;From time to time the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#x2019;s liquidity, results of operations or financial condition. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160; &#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company continues to monitor the ongoing developments related to &#160;the COVID-19 pandemic,&#160;and its impacts to&#160;the Company&#x2019;s supply-chain operations, including procurement of raw materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale.&#160; A substantial portion of such testing has historically been performed by contract laboratories outside the United States.&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company has experienced some delays with final drug product release testing by third-party vendors. In response to these delays, the Company added additional release testing laboratories to its FDA approved consortium listed in its drug approval documents which the Company believes has adequately addressed this issue. In addition, due to previous state and local &#x201c;shelter-in-place&#x201d; orders, the Company experienced lower than normal donor collections at its FDA approved plasma collection center during the three months ended June 30, 2020. The Company was also subject to delays in shipments of source plasma from its contracted third-party suppliers, as well as delays in deliveries for personal protective equipment, reagents and other non-plasma raw materials and supplies used in the manufacture of its products. The COVID-19 pandemic has also impacted, to a certain degree, the Company&#x2019;s customer engagement initiatives, whereby ADMA&#x2019;s sales and medical affairs field personnel have faced difficulties communicating directly with physicians and other healthcare professionals, as well as the cancellation or postponement of a number of key scientific and medical meetings, further limiting the Company&#x2019;s ability to communicate with potential customers.&#160; The Company has implemented a comprehensive suite of virtual engagement initiatives, however, clinician engagement has been reduced due to rapidly evolving COVID-19 priorities at U.S. medical centers.&lt;/p&gt;&lt;p style="margin:0px 0px 0px 0in;text-indent:0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"&gt;Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on the Company&#x2019;s financial condition or results of operations, and the Company does not believe that its production operations at the Boca Facility, the Company&#x2019;s contract fill/finishers or its plasma collection facility have been significantly impacted by the COVID-19 pandemic. As a result, the Company does not anticipate any material impairments with respect to any of its long-lived assets, including the Company&#x2019;s property and equipment, goodwill or intangible assets.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;"&gt;Although the COVID-19 pandemic has not, to date, materially adversely impacted the Company&#x2019;s capital and financial resources, because the Company is unable to determine the ultimate severity or duration of the pandemic or its long-term effects on, among other things, the global, national or local economies, the capital and credit markets or the Company&#x2019;s workforce, customers or our suppliers, at this time the Company is unable to predict whether COVID-19 will have a material adverse impact on the Company&#x2019;s business, financial condition, liquidity and results of operations.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Vendor and Licensor Commitments&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Pursuant to the terms of a plasma purchase agreement with BPC dated as of November 17, 2011 (the &#x201c;2011 Plasma Purchase Agreement&#x201d;), the Company agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum volume from BPC, but may also collect high-titer RSV plasma from up to five wholly-owned ADMA plasma collection facilities. During 2015, the Company and BPC amended the 2011 Plasma Purchase Agreement to allow the Company the ability to collect its raw material RSV high-titer plasma from other third-party collection organizations, thus allowing the Company to expand its reach for raw material supply as it continues its commercialization activities for ASCENIV. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June 2027, after which it may be renewed for two additional five-year periods if agreed to by the parties. As part of the closing of the Biotest Transaction, the parties amended the 2011 Plasma Purchase Agreement to extend the initial term through the ten-year anniversary of the closing date of the Biotest Transaction. On December 10, 2018, BPC assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#x201c;Grifols&#x201d;) as its successor-in-interest, effective January 1, 2019. On January 1, 2019, Grifols and the Company entered into an additional amendment to the 2011 Plasma Purchase Agreement for the purchase of source plasma containing antibodies to RSV from Grifols. Pursuant to this amendment, until January 1, 2022, the Company may purchase RSV plasma from Grifols from the two plasma collection centers that were transferred to BPC on January 1, 2019 at a price equal to cost plus 5% without any additional increase due to inflation.&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;On June 6, 2017, the Company and BPC entered into a Plasma Supply Agreement pursuant to which BPC supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July 19, 2018, the Company and BPC entered into an amendment to the Plasma Supply Agreement to provide, among other things, that in the event BPC elects not to supply in excess of ADMA BioManufacturing&#x2019;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double digit percentage of the price that ADMA BioManufacturing pays to BPC, then BPC shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;On June 6, 2017, the Company and BPC entered into a Plasma Purchase Agreement (the &#x201c;2017 Plasma Purchase Agreement&#x201d;), pursuant to which ADMA BioManufacturing purchases normal source plasma (&#x201c;NSP&#x201d;) from BPC at agreed upon annual quantities and prices. The 2017 Plasma Purchase Agreement had an initial term of five years after which the 2017 Plasma Purchase Agreement may be renewed for two additional terms of two years each upon the mutual written consent of the parties. On July 19, 2018, the Company and BPC entered into an amendment to the 2017 Plasma Purchase Agreement to, among other things, provide agreed upon amounts of NSP to be supplied by BPC to ADMA BioManufacturing in calendar year 2019 at a specified price per liter, provided that ADMA BioManufacturing delivers a valid purchase order to BPC. Additionally, pursuant to the amendment to the 2017 Plasma Purchase Agreement, BPC agrees that, for calendar years 2020 and 2021, it shall supply no less than a high double digit percentage of ADMA BioManufacturing&#x2019;s requested NSP amounts, provided that such requested NSP amounts are within an agreed range, at a price per liter to be mutually determined. Furthermore, pursuant to the amendment to the 2017 Plasma Purchase Agreement, in the event BPC fails to supply ADMA BioManufacturing with at least a high double digit percentage of ADMA BioManufacturing&#x2019;s requested NSP amounts, BPC shall promptly reimburse ADMA BioManufacturing the difference in price ADMA BioManufacturing incurs due to BPC&#x2019;s election not to supply NSP to ADMA BioManufacturing in such amounts as requested. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Purchase Agreement to Grifols, effective January 1, 2019.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company purchases substantially all of its raw material plasma from Grifols. For the six months ended June 30, 2020, plasma purchases from Grifols totaled approximately $3.7 million, representing approximately 42% of the Company&#x2019;s total inventory purchases. For the six months ended June 30, 2019, plasma purchases from BPC totaled $5.0 million, or approximately 67% of the Company&#x2019;s total inventory purchases.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Post-marketing commitments&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In connection with the approval of the BLA for BIVIGAM, on December 19, 2012 Biotest committed to perform two additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in BIVIGAM-treated patients with primary humoral immunodeficiency. These studies are still pending completion, as such ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and development expenses. The Company currently expects both studies to be completed by the end of 2021. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In connection with the FDA&#x2019;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. This study is required to be completed by June of 2023.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;span style="text-decoration:underline"&gt;Employment contracts &lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company has entered into employment agreements with its executive management team consisting of its President and Chief Executive Officer, its Executive Vice President, Chief Medical Officer and Chief Scientific Officer and its Executive Vice President and Chief Financial Officer.&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Other commitments&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#x2019;s request in such capacities. The Company&#x2019;s maximum exposure under these arrangements is unknown as of June 30, 2020. The Company does not anticipate recognizing any significant losses relating to these arrangements.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <adma:PlasmaSupplyAgreementTerm contextRef="From2020-01-01to2020-06-30" id="fid_1088">P10Y</adma:PlasmaSupplyAgreementTerm>
    <adma:PurchaseOfRawMaterial
      contextRef="From2020-01-01to2020-06-30"
      decimals="-5"
      id="fid_338"
      unitRef="USD">3700000</adma:PurchaseOfRawMaterial>
    <adma:PurchasePercentageFromInventory
      contextRef="From2020-01-01to2020-06-30"
      decimals="INF"
      id="fid_342"
      unitRef="Pure">42</adma:PurchasePercentageFromInventory>
    <adma:PurchaseOfRawMaterial
      contextRef="From2019-01-01to2019-06-30"
      decimals="-5"
      id="fid_340"
      unitRef="USD">5000000.0</adma:PurchaseOfRawMaterial>
    <adma:PurchasePercentageFromInventory
      contextRef="From2019-01-01to2019-06-30"
      decimals="INF"
      id="fid_341"
      unitRef="Pure">67</adma:PurchasePercentageFromInventory>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_791">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;10.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;SEGMENTS&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company&#x2019;s ADMA BioManufacturing segment reflects the Company&#x2019;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1).The Plasma Collection Centers segment consists of one FDA-licensed source plasma collection facility, another plasma collection facility for which an FDA license is pending and a plasma collection center currently under construction. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;) to analyze performance and allocate resources. The Company&#x2019;s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="17" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended June 30, 2020 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;ADMA BioManufacturing &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Plasma Collection Centers &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Corporate &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Consolidated&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Revenues&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,502,865&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,249,020&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,709&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,787,594&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Cost of product revenue&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,237,141&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,258,488&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,495,629&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Loss from operations&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(12,852,835&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(919,309&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,351,681&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(17,123,825&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Interest and other expense, net&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(235,442&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,818,791&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,054,266&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Net loss &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(13,088,277&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(919,342&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(6,170,472&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(20,178,091&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Depreciation and amortization expense &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;772,241&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;111,106&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,305&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;885,652&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Total assets&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;109,105,418&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,542,486&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;74,893,664&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;191,541,568&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="16" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended June 30, 2019&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;ADMA BioManufacturing&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Plasma Collection Centers&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Corporate&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Consolidated&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Revenues &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,002,445&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,522,788&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,709&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,560,942&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Cost of product revenue &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,170,381&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,320,855&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,491,236&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Loss from operations &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(8,671,783&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(392,181&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,274,710&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(11,338,674&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Interest and other expense, net &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(246,603&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(59&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,626,536&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,873,198&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Net loss &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(8,918,386&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(392,240&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,901,246&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(13,211,872&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Depreciation and amortization expense &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;688,848&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;113,958&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,287&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;806,093&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Total assets &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;67,236,416&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,835,999&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;72,201,705&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;143,274,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="16" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Six Months Ended June 30, 2020&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;ADMA BioManufacturing&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Plasma Collection Centers&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Corporate&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Consolidated&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Revenues &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,246,139&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,669,782&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;71,417&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,987,338&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Cost of product revenue &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,689,094&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,635,761&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,324,855&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Loss from operations &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(25,328,980&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,376,464&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(7,188,167&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(33,893,611&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Interest and other expense, net &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(474,314&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(5,055,363&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(5,529,710&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Net loss &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(25,803,294&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,376,497&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(12,243,530&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(39,423,321&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Capital expenditures &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,064,494&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,178,790&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,243,284&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Depreciation and amortization expense &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,447,214&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;222,395&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,881&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,674,490&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="17" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Six Months Ended June 30, 2019 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;ADMA BioManufacturing &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Plasma Collection Centers &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Corporate &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Consolidated&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Revenues&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,346,428&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,671,686&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;71,417&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,089,531&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Cost of product revenue&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,110,727&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,785,688&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,896,415&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Loss from operations&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(19,292,591&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(362,601&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,891,898&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(24,547,090&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Interest and other (expense) income, net&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(416,216&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,560&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,895,007&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,297,663&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Gain on transfer of plasma center assets&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,527,421&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,527,421&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Loss on extinguishment of debt&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(9,962,495&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(9,962,495&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Net (loss) income &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(19,708,807&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,178,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(17,749,400&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(26,279,827&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Capital expenditures &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;224,440&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,235&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;245,675&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Depreciation and amortization expense &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,376,240&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;228,199&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,983&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,611,422&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_819">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="17" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended June 30, 2020 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;ADMA BioManufacturing &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Plasma Collection Centers &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Corporate &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Consolidated&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Revenues&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,502,865&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,249,020&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,709&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,787,594&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Cost of product revenue&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12,237,141&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,258,488&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,495,629&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Loss from operations&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(12,852,835&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(919,309&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,351,681&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(17,123,825&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Interest and other expense, net&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(235,442&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,818,791&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,054,266&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Net loss &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(13,088,277&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(919,342&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(6,170,472&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(20,178,091&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Depreciation and amortization expense &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;772,241&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;111,106&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,305&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;885,652&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Total assets&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;109,105,418&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7,542,486&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;74,893,664&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;191,541,568&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="16" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months Ended June 30, 2019&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;ADMA BioManufacturing&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Plasma Collection Centers&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Corporate&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Consolidated&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Revenues &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,002,445&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,522,788&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;35,709&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,560,942&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Cost of product revenue &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,170,381&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,320,855&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,491,236&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Loss from operations &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(8,671,783&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(392,181&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,274,710&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(11,338,674&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Interest and other expense, net &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(246,603&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(59&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,626,536&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,873,198&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Net loss &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(8,918,386&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(392,240&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,901,246&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(13,211,872&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Depreciation and amortization expense &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;688,848&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;113,958&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,287&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;806,093&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Total assets &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;67,236,416&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,835,999&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;72,201,705&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;143,274,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="16" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Six Months Ended June 30, 2020&lt;/strong&gt; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;ADMA BioManufacturing&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Plasma Collection Centers&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Corporate&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Consolidated&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Revenues &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,246,139&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,669,782&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;71,417&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,987,338&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Cost of product revenue &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,689,094&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,635,761&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,324,855&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Loss from operations &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(25,328,980&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,376,464&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(7,188,167&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(33,893,611&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Interest and other expense, net &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(474,314&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(33&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(5,055,363&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(5,529,710&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Net loss &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(25,803,294&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,376,497&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(12,243,530&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(39,423,321&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Capital expenditures &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,064,494&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,178,790&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,243,284&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Depreciation and amortization expense &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,447,214&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;222,395&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,881&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,674,490&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160; &lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="17" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Six Months Ended June 30, 2019 &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;ADMA BioManufacturing &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Plasma Collection Centers &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Corporate &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;strong&gt;&#160; &lt;/strong&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Consolidated&lt;/strong&gt; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Revenues&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,346,428&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,671,686&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;71,417&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,089,531&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Cost of product revenue&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,110,727&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,785,688&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,896,415&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Loss from operations&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(19,292,591&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(362,601&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,891,898&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(24,547,090&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Interest and other (expense) income, net&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(416,216&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,560&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,895,007&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(3,297,663&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Gain on transfer of plasma center assets&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,527,421&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,527,421&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Loss on extinguishment of debt&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(9,962,495&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(9,962,495&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Net (loss) income &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(19,708,807&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,178,380&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(17,749,400&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(26,279,827&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Capital expenditures &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;224,440&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,235&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;245,675&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Depreciation and amortization expense &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,376,240&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;228,199&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,983&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,611,422&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_189"
      unitRef="USD">6502865</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_184"
      unitRef="USD">1249020</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_186"
      unitRef="USD">35709</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_182"
      unitRef="USD">7787594</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_197"
      unitRef="USD">12237141</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_192"
      unitRef="USD">1258488</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_194"
      unitRef="USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_190"
      unitRef="USD">13495629</us-gaap:CostOfRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_205"
      unitRef="USD">-12852835</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_200"
      unitRef="USD">-919309</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_202"
      unitRef="USD">-3351681</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_198"
      unitRef="USD">-17123825</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_213"
      unitRef="USD">-235442</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_208"
      unitRef="USD">-33</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_210"
      unitRef="USD">-2818791</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_206"
      unitRef="USD">-3054266</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_237"
      unitRef="USD">-13088277</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_232"
      unitRef="USD">-919342</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_234"
      unitRef="USD">-6170472</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_230"
      unitRef="USD">-20178091</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_253"
      unitRef="USD">772241</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_248"
      unitRef="USD">111106</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_250"
      unitRef="USD">2305</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_246"
      unitRef="USD">885652</us-gaap:DepreciationAndAmortization>
    <adma:TotalAssets
      contextRef="From2020-04-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_351"
      unitRef="USD">109105418</adma:TotalAssets>
    <adma:TotalAssets
      contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_347"
      unitRef="USD">7542486</adma:TotalAssets>
    <adma:TotalAssets
      contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_349"
      unitRef="USD">74893664</adma:TotalAssets>
    <adma:TotalAssets
      contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_345"
      unitRef="USD">191541568</adma:TotalAssets>
    <us-gaap:Revenues
      contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_188"
      unitRef="USD">4002445</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_185"
      unitRef="USD">2522788</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_187"
      unitRef="USD">35709</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_183"
      unitRef="USD">6560942</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_196"
      unitRef="USD">8170381</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_193"
      unitRef="USD">2320855</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_195"
      unitRef="USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_191"
      unitRef="USD">10491236</us-gaap:CostOfRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_204"
      unitRef="USD">-8671783</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_201"
      unitRef="USD">-392181</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_203"
      unitRef="USD">-2274710</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_199"
      unitRef="USD">-11338674</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_212"
      unitRef="USD">-246603</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_209"
      unitRef="USD">-59</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_211"
      unitRef="USD">-1626536</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_207"
      unitRef="USD">-1873198</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_236"
      unitRef="USD">-8918386</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_233"
      unitRef="USD">-392240</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_235"
      unitRef="USD">-3901246</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_231"
      unitRef="USD">-13211872</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_252"
      unitRef="USD">688848</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_249"
      unitRef="USD">113958</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_251"
      unitRef="USD">3287</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_247"
      unitRef="USD">806093</us-gaap:DepreciationAndAmortization>
    <adma:TotalAssets
      contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_352"
      unitRef="USD">67236416</adma:TotalAssets>
    <adma:TotalAssets
      contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_348"
      unitRef="USD">3835999</adma:TotalAssets>
    <adma:TotalAssets
      contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_350"
      unitRef="USD">72201705</adma:TotalAssets>
    <adma:TotalAssets
      contextRef="From2019-04-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_346"
      unitRef="USD">143274120</adma:TotalAssets>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_378"
      unitRef="USD">14246139</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_366"
      unitRef="USD">3669782</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_373"
      unitRef="USD">71417</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_343"
      unitRef="USD">17987338</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_379"
      unitRef="USD">26689094</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_367"
      unitRef="USD">3635761</us-gaap:CostOfRevenue>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2020-04-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_214"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:CostOfRevenue
      contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_353"
      unitRef="USD">30324855</us-gaap:CostOfRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_380"
      unitRef="USD">-25328980</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_368"
      unitRef="USD">-1376464</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_374"
      unitRef="USD">-7188167</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_354"
      unitRef="USD">-33893611</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_381"
      unitRef="USD">-474314</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_369"
      unitRef="USD">-33</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_375"
      unitRef="USD">-5055363</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_355"
      unitRef="USD">-5529710</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_382"
      unitRef="USD">-25803294</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_370"
      unitRef="USD">-1376497</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_376"
      unitRef="USD">-12243530</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_356"
      unitRef="USD">-39423321</us-gaap:NetIncomeLoss>
    <adma:CapitalExpenditure
      contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_383"
      unitRef="USD">5064494</adma:CapitalExpenditure>
    <adma:CapitalExpenditure
      contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_371"
      unitRef="USD">1178790</adma:CapitalExpenditure>
    <adma:CapitalExpenditure
      contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_242"
      unitRef="USD">0</adma:CapitalExpenditure>
    <adma:CapitalExpenditure
      contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_1102"
      unitRef="USD">6243284</adma:CapitalExpenditure>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-01to2020-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_384"
      unitRef="USD">1447214</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_385"
      unitRef="USD">222395</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_377"
      unitRef="USD">4881</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-01to2020-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_386"
      unitRef="USD">1674490</us-gaap:DepreciationAndAmortization>
    <us-gaap:Revenues
      contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_387"
      unitRef="USD">5346428</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_402"
      unitRef="USD">4671686</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_396"
      unitRef="USD">71417</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_344"
      unitRef="USD">10089531</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_388"
      unitRef="USD">16110727</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_403"
      unitRef="USD">3785688</us-gaap:CostOfRevenue>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2020-04-01to2020-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_216"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:CostOfRevenue
      contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_358"
      unitRef="USD">19896415</us-gaap:CostOfRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_389"
      unitRef="USD">-19292591</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_404"
      unitRef="USD">-362601</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_397"
      unitRef="USD">-4891898</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_359"
      unitRef="USD">-24547090</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_390"
      unitRef="USD">-416216</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_405"
      unitRef="USD">13560</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_398"
      unitRef="USD">-2895007</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_360"
      unitRef="USD">-3297663</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2019-04-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_217"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_361"
      unitRef="USD">11527421</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2020-04-01to2020-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_218"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_406"
      unitRef="USD">11527421</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_219"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2019-04-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_220"
      unitRef="USD">0</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_362"
      unitRef="USD">-9962495</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_399"
      unitRef="USD">-9962495</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_391"
      unitRef="USD">-19708807</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_407"
      unitRef="USD">11178380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_400"
      unitRef="USD">-17749400</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_363"
      unitRef="USD">-26279827</us-gaap:NetIncomeLoss>
    <adma:CapitalExpenditure
      contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_392"
      unitRef="USD">224440</adma:CapitalExpenditure>
    <adma:CapitalExpenditure
      contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_408"
      unitRef="USD">21235</adma:CapitalExpenditure>
    <adma:CapitalExpenditure
      contextRef="From2019-04-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_243"
      unitRef="USD">0</adma:CapitalExpenditure>
    <adma:CapitalExpenditure
      contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_1103"
      unitRef="USD">245675</adma:CapitalExpenditure>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-01to2019-06-30_adma_AdmaBiomanufacturingMember"
      decimals="0"
      id="fid_393"
      unitRef="USD">1376240</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-01to2019-06-30_adma_PlasmaCollectionCenterMember"
      decimals="0"
      id="fid_409"
      unitRef="USD">228199</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-01to2019-06-30_us-gaap_CorporateMember"
      decimals="0"
      id="fid_401"
      unitRef="USD">6983</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-01to2019-06-30_adma_ConsolidatedMember"
      decimals="0"
      id="fid_410"
      unitRef="USD">1611422</us-gaap:DepreciationAndAmortization>
    <adma:TransferOfPlasmaCenterAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_792">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;11.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;TRANSFER OF PLASMA CENTER ASSETS&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;As part of the purchase price for the Biotest Transaction (see Note 1), the Company transferred its Marietta, GA and Norcross, GA plasma collection centers to BPC effective January 1, 2019. The Company had estimated the combined fair value of the two facilities to be $12.6 million, and the Company recorded an obligation for this amount as of the date of the Biotest Transaction. On January 1, 2019, upon the transfer of the two plasma collection facilities to BPC, the Company recorded a gain in the amount of $11.5 million, which reflects the derecognition of the obligation to transfer ownership of the two facilities net of the carrying value of the assets associated with these facilities, primarily property and equipment and inventory, in the amount of $1.1 million. &lt;/p&gt;</adma:TransferOfPlasmaCenterAssetsDisclosureTextBlock>
    <us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized
      contextRef="AsOf2020-06-30"
      decimals="-5"
      id="fid_411"
      unitRef="USD">12600000</us-gaap:BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized>
    <adma:GainUponTransferFacilities
      contextRef="AsOf2019-01-01"
      decimals="-5"
      id="fid_414"
      unitRef="USD">11500000</adma:GainUponTransferFacilities>
    <adma:NetCarryingValueOfAssets
      contextRef="AsOf2019-01-01"
      decimals="-5"
      id="fid_415"
      unitRef="USD">1100000</adma:NetCarryingValueOfAssets>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_793">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;12.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;LEASE OBLIGATIONS&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company leases certain properties and equipment for its ADMA BioCenters subsidiary and certain equipment for its ADMA BioManufacturing subsidiary, which leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2030. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease. Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#x2019;s incremental borrowing rate of 13%. The Company&#x2019;s operating lease expense is recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. Aggregate lease expense and cash paid for the Company&#x2019;s operating leases for the three months ended June 30, 2020 and 2019 was approximately $0.1 million, and aggregate rent expense and cash paid for the Company&#x2019;s operating leases for the six months ended June 30, 2020 and 2019 was approximately $0.2 million. &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;In connection with the adoption of ASU 2016-02 on January 1, 2019 (see Note 2), the Company recognized right to use assets of $1.4 million and lease liabilities of approximately $1.6 million. During the six months ended June 30, 2020, the Company entered into two new property leases where the Company has opened or intends to open two new plasma collection facilities. In connection with these leases, the Company recognized aggregate lease liabilities and corresponding right-to-use assets in the approximate amount of $1.7 million. The right-to-use assets are reflected in Deposits and other assets in the accompanying consolidated balance sheets. Including a finance lease the Company entered into in June 2018, the Company has aggregate lease liabilities of $3.1 million and $1.5 million as of June 30, 2020 and December 31, 2019, respectively, which are comprised primarily of the leases for the Company&#x2019;s plasma collection centers and an administrative office lease in Roswell, GA related to the Company&#x2019;s ADMA BioCenters subsidiary. The Company&#x2019;s operating leases have a weighted average remaining term of 8.4 years. Scheduled payments under the Company&#x2019;s lease obligations are as follows:&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Remainder of 2020 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:60%;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;262,076&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Year ended December 31, 2021 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;699,752&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;2022 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;721,005&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;706,919&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;2024 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;603,858&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Thereafter &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;2,205,047&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Total payments &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;5,198,657&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Less: imputed interest &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;(2,050,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Current portion &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;(210,870&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Balance at June 30, 2020 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;2,937,292&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;As of July 15, 2020, the Company had entered into two additional property leases where the Company intends to construct additional new plasma collection facilities. The Company has not taken possession of these two leased properties and their lease commencement dates have not been determined. With the exception of advance deposits and initial months&#x2019; rent totaling approximately $74,000, no payments have been made under these leases. The initial terms of each lease are from 11 to 13 years with monthly rental payments varying between approximately $17,000 and $21,000, including common area maintenance charges.&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <adma:IncrementalBorrowingRate
      contextRef="From2020-01-01to2020-06-30"
      decimals="INF"
      id="fid_418"
      unitRef="Pure">13</adma:IncrementalBorrowingRate>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-01to2020-06-30"
      decimals="-5"
      id="fid_423"
      unitRef="USD">100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-01-01to2020-06-30"
      decimals="-5"
      id="fid_419"
      unitRef="USD">200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-06-30_adma_JanuaryOneTwoThousandNineteenMember"
      decimals="-5"
      id="fid_959"
      unitRef="USD">1400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2020-06-30_adma_JanuaryOneTwoThousandNineteenMember"
      decimals="-5"
      id="fid_964"
      unitRef="USD">1600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-06-30"
      decimals="-5"
      id="fid_960"
      unitRef="USD">1700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2020-06-30"
      decimals="-5"
      id="fid_1092"
      unitRef="USD">3100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2019-12-31"
      decimals="-5"
      id="fid_1094"
      unitRef="USD">1500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-06-30" id="fid_968">P8Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_820">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Remainder of 2020 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:60%;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;262,076&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Year ended December 31, 2021 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;699,752&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;2022 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;721,005&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;706,919&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;2024 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;603,858&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Thereafter &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;2,205,047&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Total payments &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;5,198,657&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Less: imputed interest &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;(2,050,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Current portion &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;(210,870&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;"&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="MARGIN: 0px; text-align:right;"&gt;Balance at June 30, 2020 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;2,937,292&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_263"
      unitRef="USD">262076</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_264"
      unitRef="USD">699752</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_265"
      unitRef="USD">721005</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_266"
      unitRef="USD">706919</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_267"
      unitRef="USD">603858</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_268"
      unitRef="USD">2205047</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_269"
      unitRef="USD">5198657</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <adma:InterestPortionOfMinimumLeasePayments
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_270"
      unitRef="USD">-2050495</adma:InterestPortionOfMinimumLeasePayments>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_271"
      unitRef="USD">-210870</us-gaap:OperatingLeaseLiabilityCurrent>
    <adma:OperatingLeaseLiabilityTotal
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_272"
      unitRef="USD">2937292</adma:OperatingLeaseLiabilityTotal>
    <adma:LeaseDescription contextRef="From2020-07-01to2020-07-15" id="fid_434">With the exception of advance deposits and initial months&#x2019; rent totaling approximately $74,000, no payments have been made under these leases. The initial terms of each lease are from 11 to 13 years with monthly rental payments varying between approximately $17,000 and $21,000, including common area maintenance charges.</adma:LeaseDescription>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_794">&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;strong&gt;&lt;span style="mso-list:ignore"&gt;13.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION&lt;/span&gt;&lt;/strong&gt; &lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;"&gt;Supplemental cash flow information for the six months ended June 30, 2020 and 2019 is as follows:&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/strong&gt; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 30px;vertical-align:top;"&gt;Cash paid for interest &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,912,165&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,574,304&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Noncash Financing and Investing Activities:&lt;/strong&gt; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 30px;vertical-align:top;"&gt;Equipment acquired reflected in accounts payable and accrued liabilities &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,228,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;290,389&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="TEXT-INDENT: 30px;vertical-align:top;"&gt;Right-to-use assets obtained in exchange for lease obligations &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,723,594&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,421,669&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 30px;vertical-align:top;"&gt;Warrants issued in connection with notes payable &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,579,115&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="margin:0px"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_821">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;2019&lt;/strong&gt; &lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/strong&gt; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 30px;vertical-align:top;"&gt;Cash paid for interest &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,912,165&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,574,304&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;strong&gt;Noncash Financing and Investing Activities:&lt;/strong&gt; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 30px;vertical-align:top;"&gt;Equipment acquired reflected in accounts payable and accrued liabilities &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,228,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;290,389&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="TEXT-INDENT: 30px;vertical-align:top;"&gt;Right-to-use assets obtained in exchange for lease obligations &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,723,594&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,421,669&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="TEXT-INDENT: 30px;vertical-align:top;"&gt;Warrants issued in connection with notes payable &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&#160; &lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,579,115&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="margin:0px"&gt;&#160; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_274"
      unitRef="USD">4912165</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_275"
      unitRef="USD">3574304</us-gaap:InterestPaidNet>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_277"
      unitRef="USD">1228000</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_278"
      unitRef="USD">290389</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_279"
      unitRef="USD">1723594</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_280"
      unitRef="USD">1421669</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <adma:WarrantsIssuedInConnectionWithNotePayable
      contextRef="From2020-01-01to2020-06-30"
      decimals="0"
      id="fid_281"
      unitRef="USD">0</adma:WarrantsIssuedInConnectionWithNotePayable>
    <adma:WarrantsIssuedInConnectionWithNotePayable
      contextRef="From2019-01-01to2019-06-30"
      decimals="0"
      id="fid_282"
      unitRef="USD">3579115</adma:WarrantsIssuedInConnectionWithNotePayable>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-01-01to2020-06-30" id="fid_1097">&lt;strong style="MARGIN: 0px"&gt;&lt;span style="mso-list:ignore"&gt;14.&lt;span style="font:7pt &amp;quot;times new roman&amp;quot;"&gt;&#160; &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/strong&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;"&gt;&#160;On August 5, 2020, the Company entered into an Open Market Sale Agreement&lt;sup&gt;SM&lt;/sup&gt; (the &#x201c;Sale Agreement&#x201d;) with Jefferies LLC, as agent (the &#x201c;Agent&#x201d;), pursuant to which the Company may offer and sell (the &#x201c;Offering&#x201d;), from time to time, at its option, through or to the Agent, up to an aggregate of $50,000,000 of shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Shares&#x201d;). Any Shares to be offered and sold under the Sale Agreement will be issued and sold pursuant to the Company&#x2019;s Registration Statement on Form S-3 (File No. 333-234107), filed with the SEC on October 4, 2019, and declared effective on October 15, 2019 (the &#x201c;Registration Statement&#x201d;) and the prospectus supplement relating to the Offering, dated August 5, 2020, that will be filed with the SEC, by methods deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, (the "Securities Act"), or if specified by the Company, by any other method permitted by law, including, but not limited to, in negotiated and block transactions. &lt;/p&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;span style="mso-tab-count:1"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the terms of the Sale Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company&#x2019;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company cannot provide any assurances that it will issue any Shares pursuant to the Sale Agreement. The Company will pay the Agent a commission of up to 3.0% of the gross proceeds from each sale of the Shares under the Sale Agreement. The Company will also reimburse the Agent for certain expenses incurred in connection with the Sale Agreement and agreed to provide the Agent with customary indemnification rights with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="MARGIN: 0px; text-align:left;"&gt;&lt;span style="mso-tab-count:1"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Through the date of this report, no shares have been sold under the Sale Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <adma:CommonStockOffering
      contextRef="From2020-01-01to2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_srt_MaximumMember_adma_JefferiesLLCMember"
      decimals="0"
      id="fid_1099"
      unitRef="Shares">50000000</adma:CommonStockOffering>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_adma_JefferiesLLCMember"
      decimals="4"
      id="fid_1100"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <adma:CommissionDescription
      contextRef="From2020-01-01to2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_srt_MaximumMember_adma_JefferiesLLCMember"
      id="fid_1101">The Company will pay the Agent a commission of up to 3.0% of the gross proceeds from each sale of the Shares under the Sale Agreement.</adma:CommissionDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266579192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADMA BIOLOGICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001368514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,349,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2590442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">07446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">465 State Route 17,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Ramsey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-5552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADMA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266036520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 75,781,122<span></span>
</td>
<td class="nump">$ 26,752,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">6,514,165<span></span>
</td>
<td class="nump">3,469,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">56,001,348<span></span>
</td>
<td class="nump">53,064,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,693,427<span></span>
</td>
<td class="nump">2,533,593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">142,990,062<span></span>
</td>
<td class="nump">85,820,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">37,373,366<span></span>
</td>
<td class="nump">31,741,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,801,797<span></span>
</td>
<td class="nump">3,159,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,529,509<span></span>
</td>
<td class="nump">3,529,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">4,846,834<span></span>
</td>
<td class="nump">2,840,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">TOTAL ASSETS</a></td>
<td class="nump">191,541,568<span></span>
</td>
<td class="nump">127,090,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,909,659<span></span>
</td>
<td class="nump">9,174,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,616,666<span></span>
</td>
<td class="nump">4,481,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">142,834<span></span>
</td>
<td class="nump">142,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Current portion of lease obligations</a></td>
<td class="nump">210,870<span></span>
</td>
<td class="nump">229,073<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,880,029<span></span>
</td>
<td class="nump">14,027,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Senior notes payable, net of discount</a></td>
<td class="nump">81,648,187<span></span>
</td>
<td class="nump">68,291,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">2,190,115<span></span>
</td>
<td class="nump">2,261,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedLongTermDebt', window );">Subordinated note payable, net of discount</a></td>
<td class="nump">14,925,760<span></span>
</td>
<td class="nump">14,908,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">2,937,292<span></span>
</td>
<td class="nump">1,302,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">80,730<span></span>
</td>
<td class="nump">106,574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">114,662,113<span></span>
</td>
<td class="nump">100,897,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.0001 par value, 150,000,000 shares authorized, 86,349,981 and 59,318,355 shares issued and outstanding</a></td>
<td class="nump">8,635<span></span>
</td>
<td class="nump">5,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">381,010,696<span></span>
</td>
<td class="nump">290,903,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(304,139,876)<span></span>
</td>
<td class="num">(264,716,555)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">76,879,455<span></span>
</td>
<td class="nump">26,193,149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 191,541,568<span></span>
</td>
<td class="nump">$ 127,090,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net assets (liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77885760&amp;loc=SL35686385-199418<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 205<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118262037&amp;loc=d3e9915-115836<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637345&amp;loc=SL114874367-224272<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604008-122996<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637345&amp;loc=SL114874367-224272<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of collateralized/uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Subordinated debt places a lender in a lien position behind the primary lender of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266944824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, shares par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, shares par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">86,349,981<span></span>
</td>
<td class="nump">59,318,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">86,349,981<span></span>
</td>
<td class="nump">59,318,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014265874248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ProductRevenue', window );">Product revenue</a></td>
<td class="nump">$ 7,751,885<span></span>
</td>
<td class="nump">$ 6,525,233<span></span>
</td>
<td class="nump">$ 17,915,921<span></span>
</td>
<td class="nump">$ 10,018,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_LicenseRevenue', window );">License revenue</a></td>
<td class="nump">35,709<span></span>
</td>
<td class="nump">35,709<span></span>
</td>
<td class="nump">71,417<span></span>
</td>
<td class="nump">71,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">7,787,594<span></span>
</td>
<td class="nump">6,560,942<span></span>
</td>
<td class="nump">17,987,338<span></span>
</td>
<td class="nump">10,089,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue (exclusive of amortization expense shown below)</a></td>
<td class="nump">13,495,629<span></span>
</td>
<td class="nump">10,491,236<span></span>
</td>
<td class="nump">30,324,855<span></span>
</td>
<td class="nump">19,896,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,656,420<span></span>
</td>
<td class="nump">516,986<span></span>
</td>
<td class="nump">3,185,158<span></span>
</td>
<td class="nump">1,387,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="nump">877,902<span></span>
</td>
<td class="nump">594,113<span></span>
</td>
<td class="nump">1,378,546<span></span>
</td>
<td class="nump">1,248,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">178,838<span></span>
</td>
<td class="nump">211,234<span></span>
</td>
<td class="nump">357,676<span></span>
</td>
<td class="nump">422,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">8,702,630<span></span>
</td>
<td class="nump">6,086,047<span></span>
</td>
<td class="nump">16,634,714<span></span>
</td>
<td class="nump">11,681,517<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">24,911,419<span></span>
</td>
<td class="nump">17,899,616<span></span>
</td>
<td class="nump">51,880,949<span></span>
</td>
<td class="nump">34,636,621<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(17,123,825)<span></span>
</td>
<td class="num">(11,338,674)<span></span>
</td>
<td class="num">(33,893,611)<span></span>
</td>
<td class="num">(24,547,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest and other income</a></td>
<td class="nump">19,411<span></span>
</td>
<td class="nump">209,808<span></span>
</td>
<td class="nump">267,479<span></span>
</td>
<td class="nump">337,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,067,306)<span></span>
</td>
<td class="num">(2,072,578)<span></span>
</td>
<td class="num">(5,784,397)<span></span>
</td>
<td class="num">(3,613,085)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,962,495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on transfer of plasma center assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,527,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other expense, net</a></td>
<td class="num">(6,371)<span></span>
</td>
<td class="num">(10,428)<span></span>
</td>
<td class="num">(12,792)<span></span>
</td>
<td class="num">(21,785)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(3,054,266)<span></span>
</td>
<td class="num">(1,873,198)<span></span>
</td>
<td class="num">(5,529,710)<span></span>
</td>
<td class="num">(1,732,737)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (20,178,091)<span></span>
</td>
<td class="num">$ (13,211,872)<span></span>
</td>
<td class="num">$ (39,423,321)<span></span>
</td>
<td class="num">$ (26,279,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER COMMON SHARE</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and Diluted</a></td>
<td class="nump">86,347,467<span></span>
</td>
<td class="nump">52,206,204<span></span>
</td>
<td class="nump">80,064,641<span></span>
</td>
<td class="nump">49,295,805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ProductRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ProductRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014334313784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,353,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2018</a></td>
<td class="nump">$ 19,770,438<span></span>
</td>
<td class="nump">$ 4,635<span></span>
</td>
<td class="nump">$ 236,203,041<span></span>
</td>
<td class="num">$ (216,437,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">637,263<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">637,263<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Warrants issued in connection with note payable</a></td>
<td class="nump">2,699,208<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,699,208<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,067,955)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,067,955)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,353,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2019</a></td>
<td class="nump">10,038,954<span></span>
</td>
<td class="nump">$ 4,635<span></span>
</td>
<td class="nump">239,539,512<span></span>
</td>
<td class="num">(229,505,193)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,353,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2018</a></td>
<td class="nump">19,770,438<span></span>
</td>
<td class="nump">$ 4,635<span></span>
</td>
<td class="nump">236,203,041<span></span>
</td>
<td class="num">(216,437,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,279,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,317,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2019</a></td>
<td class="nump">46,905,861<span></span>
</td>
<td class="nump">$ 5,932<span></span>
</td>
<td class="nump">289,616,994<span></span>
</td>
<td class="num">(242,717,065)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,353,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2019</a></td>
<td class="nump">10,038,954<span></span>
</td>
<td class="nump">$ 4,635<span></span>
</td>
<td class="nump">239,539,512<span></span>
</td>
<td class="num">(229,505,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">726,736<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">726,736<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, net of offering expenses, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,937,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Warrants issued in connection with note payable</a></td>
<td class="nump">879,907<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">879,907<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock, net of offering expenses, amount</a></td>
<td class="nump">48,397,088<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">48,395,794<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,211,872)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,211,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, amount</a></td>
<td class="nump">75,048<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">75,045<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,317,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2019</a></td>
<td class="nump">46,905,861<span></span>
</td>
<td class="nump">$ 5,932<span></span>
</td>
<td class="nump">289,616,994<span></span>
</td>
<td class="num">(242,717,065)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,318,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2019</a></td>
<td class="nump">26,193,149<span></span>
</td>
<td class="nump">$ 5,932<span></span>
</td>
<td class="nump">290,903,772<span></span>
</td>
<td class="num">(264,716,555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">676,548<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">676,548<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, net of offering expenses, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock, net of offering expenses, amount</a></td>
<td class="nump">88,704,039<span></span>
</td>
<td class="nump">$ 2,703<span></span>
</td>
<td class="nump">88,701,336<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,245,230)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,245,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, amount</a></td>
<td class="nump">7,177<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,345,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2020</a></td>
<td class="nump">96,335,683<span></span>
</td>
<td class="nump">$ 8,635<span></span>
</td>
<td class="nump">380,288,833<span></span>
</td>
<td class="num">(283,961,785)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,318,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2019</a></td>
<td class="nump">26,193,149<span></span>
</td>
<td class="nump">$ 5,932<span></span>
</td>
<td class="nump">290,903,772<span></span>
</td>
<td class="num">(264,716,555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(39,423,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,349,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2020</a></td>
<td class="nump">76,879,455<span></span>
</td>
<td class="nump">$ 8,635<span></span>
</td>
<td class="nump">381,010,696<span></span>
</td>
<td class="num">(304,139,876)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,345,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2020</a></td>
<td class="nump">96,335,683<span></span>
</td>
<td class="nump">$ 8,635<span></span>
</td>
<td class="nump">380,288,833<span></span>
</td>
<td class="num">(283,961,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">715,608<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">715,608<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,178,091)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,178,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, amount</a></td>
<td class="nump">6,255<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,255<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,349,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2020</a></td>
<td class="nump">$ 76,879,455<span></span>
</td>
<td class="nump">$ 8,635<span></span>
</td>
<td class="nump">$ 381,010,696<span></span>
</td>
<td class="num">$ (304,139,876)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266038680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (39,423,321)<span></span>
</td>
<td class="num">$ (26,279,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,674,490<span></span>
</td>
<td class="nump">1,611,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">3,518<span></span>
</td>
<td class="nump">8,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,392,156<span></span>
</td>
<td class="nump">1,363,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on transfer of plasma center assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,527,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">874,732<span></span>
</td>
<td class="nump">340,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,962,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_AmortizationOfLicenseRevenue', window );">Amortization of license revenue</a></td>
<td class="num">(71,417)<span></span>
</td>
<td class="num">(71,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisition:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(3,044,246)<span></span>
</td>
<td class="num">(3,694,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(2,936,614)<span></span>
</td>
<td class="num">(5,175,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,159,834)<span></span>
</td>
<td class="nump">163,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Deposits and other assets</a></td>
<td class="num">(283,195)<span></span>
</td>
<td class="nump">118,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,264,932)<span></span>
</td>
<td class="nump">887,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">399,295<span></span>
</td>
<td class="num">(529,589)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current and non-current liabilities</a></td>
<td class="num">(92,067)<span></span>
</td>
<td class="num">(91,029)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(45,931,435)<span></span>
</td>
<td class="num">(32,911,136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(6,243,284)<span></span>
</td>
<td class="num">(245,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(6,241,284)<span></span>
</td>
<td class="num">(245,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Principal payments on notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment of end of term fee</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,760,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PaymentOfDebtRefinancingFees', window );">Payment of debt refinancing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,499,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of note payable</a></td>
<td class="nump">12,500,000<span></span>
</td>
<td class="nump">72,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,679,661)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of offering expenses</a></td>
<td class="nump">88,704,039<span></span>
</td>
<td class="nump">48,397,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">13,432<span></span>
</td>
<td class="nump">75,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLeasingCosts', window );">Payments on finance lease obligations</a></td>
<td class="num">(15,765)<span></span>
</td>
<td class="nump">14,740<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">101,201,706<span></span>
</td>
<td class="nump">80,017,868<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">49,028,987<span></span>
</td>
<td class="nump">46,861,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, including restricted cash - beginning of period</a></td>
<td class="nump">26,752,135<span></span>
</td>
<td class="nump">26,754,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">$ 75,781,122<span></span>
</td>
<td class="nump">$ 73,615,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AmortizationOfLicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AmortizationOfLicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PaymentOfDebtRefinancingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PaymentOfDebtRefinancingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLeasingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLeasingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014264690904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">1. ORGANIZATION AND BUSINESS</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">1.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">ORGANIZATION AND BUSINESS</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#8217;s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA BioManufacturing&#8221;) and ADMA BioCenters Georgia Inc. (&#8220;ADMA BioCenters&#8221;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (&#8220;BTBU&#8221;) from BPC Plasma, Inc. (formerly Biotest Pharmaceuticals Corporation) (&#8220;BPC&#8221; and, together with Biotest AG, &#8220;Biotest&#8221;) as more fully described below. BTBU had been the Company&#8217;s third-party manufacturer for its then-lead pipeline product candidate, ASCENIV, previously referred to as &#8220;RI-002.&#8221; ADMA BioCenters is the Company&#8217;s source plasma collection business with a plasma collection facility located in the U.S., which holds an approved license with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company has three FDA-approved products, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;), and for which we received FDA approval on May 9, 2019 for the commercial re-launch of the product and commenced the commercial re-launch in August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin products, the Company provides contract manufacturing services for certain clients and generates revenues from the sale of intermediate by-products that result from the immunoglobulin production process. The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On June 6, 2017, ADMA completed the acquisition of certain assets (the &#8220;Biotest Assets&#8221;) of BTBU, which included the FDA-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;) (the &#8220;Biotest Transaction&#8221;).</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of June 30, 2020, the Company had working capital of $130.1 million, including $75.8 million of cash and cash equivalents. Based upon the Company&#8217;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#8217;s commercialization and expansion activities, as well as certain other assumptions, the Company&#8217;s management currently believes that its cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund ADMA&#8217;s operations, as currently conducted, into the second quarter of 2021. In order to have sufficient cash to fund its operations thereafter, the Company anticipates it will need to raise additional capital before the end of the second quarter of 2021. These estimates may change based upon several factors, including the success of the Company&#8217;s commercial sales of its products, manufacturing ramp-up activities, the acceptability of ADMA&#8217;s immune globulin products by physicians, patients or payers and the various financing options that may be available to the Company. In addition, the Company&#8217;s end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months, requiring substantial investments in raw material plasma and other manufacturing materials. The Company currently has no firm commitments for additional financing, and there can be no assurance that the Company will be able to secure additional financing on terms that are acceptable to the Company, or at all. Furthermore, if the Company&#8217;s assumptions underlying its estimated expenses and revenues are incorrect, it may have to raise additional capital sooner than currently anticipated. </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Due to numerous risks and uncertainties associated with FDA approvals related to the Company&#8217;s products or the labeled indications of such products, ongoing compliance requirements and capacity expansion efforts at the Company&#8217;s Boca Facility and future commercialization of the Company&#8217;s products, including the Company&#8217;s ability to obtain adequate quantities of FDA-approved plasma with proper specifications on acceptable terms for use in the Company&#8217;s manufacturing process, as well as the additional uncertainties surrounding the COVID-19 pandemic (see Note 9) the Company is unable to estimate with certainty the amounts of increased capital outlays and operating expenditures required to fund its commercial and development activities. The Company&#8217;s current estimates may be subject to change as circumstances regarding its business requirements evolve. Failure to secure any necessary financing in a timely manner and on commercially reasonable terms could have a material adverse effect on the Company&#8217;s business plan and financial performance and it could be forced to delay or discontinue its commercialization, product development or clinical activities or delay or discontinue the approval efforts for any of the Company&#8217;s products or product candidates. The Company has reported cumulative losses since inception in June 2004 through June 30, 2020 of $304.1 million. As such, these factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of asset carrying amounts and the classification of liabilities that might be necessary from the outcome of this uncertainty.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company may decide to raise capital through public or private equity offerings or debt financings, or obtain a bank credit facility or enter into corporate collaboration and licensing arrangements. The sale of additional equity or debt securities, if convertible, could result in dilution to the Company&#8217;s existing stockholders and, in such event, the market value of its common stock may decline. The incurrence of additional indebtedness would result in increased fixed obligations and could also result in covenants that would restrict the Company&#8217;s operations or other financing alternatives. In addition, the Company is exploring additional contract manufacturing arrangements and other business development opportunities, which may provide additional liquidity to the Company. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">There can be no assurance that the Company&#8217;s approved products will be commercially viable, or that research and development, plant capacity expansion, plasma center build-outs or other capital improvements will be successfully completed or that any product developed in the future will be approved. The Company is subject to risks common to companies in the biotechnology and pharmaceutical manufacturing industries including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263156664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">2.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Basis of presentation</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 13, 2020.The accompanying consolidated balance sheet as of December 31, 2019 was derived from the audited financial statements for the year ended December 31, 2019. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of June 30, 2020 and its results of operations, changes in equity and cash flows for the three and six months ended June 30, 2020. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">During the three and six months ended June 30, 2020 and 2019, comprehensive loss was equal to the net loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year. </p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Use of estimates</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#8217;s deferred tax assets.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Fair value of financial instruments</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#8217;s senior secured term loan (see Note 6) approximates fair value due to the variable interest rate on this debt. With respect to the subordinated note payable in the amount of $15.0 million as of June 30, 2020 and December 31, 2019 held by Biotest, a principal stockholder of the Company at the time the note was issued concurrent with an acquisition transaction with an affiliate of such stockholder (see Note 6), the Company has concluded that an estimation of fair value for this note is not practicable.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Accounts receivable</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers based upon an evaluation of each customer's financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis. Based on these evaluations, the Company has concluded that its credit risk is minimal. At June 30, 2020, three customers accounted for an aggregate of 76% of the Company&#8217;s total accounts receivable, and at December 31, 2019, two customers accounted for 89% of the Company&#8217;s total accounts receivable.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Inventories</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Due to previous uncertainties surrounding certain prior submissions made to the FDA, all costs related to the production of BIVIGAM and ASCENIV prior to their FDA approval dates of May 9, 2019 and April 1, 2019, respectively, have been charged to cost of product revenue in the accompanying consolidated statements of operations during the period the product was produced. In addition, costs associated with the production of conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Goodwill</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at June 30, 2020 and December 31, 2019 was $3.5 million. All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment and is related to a 2017acquisition transaction.&#160;</p><p style="margin:0px">&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Goodwill is not amortized, but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company&#8217;s annual goodwill impairment test as of October 1, 2019 did not result in a goodwill impairment charge, and the Company did not record any impairment charges related to goodwill for the three and six months ended June 30, 2020 and 2019.</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Impairment of long-lived assets</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and definite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the three and six months ended June 30, 2020 and 2019, the Company determined that there was no impairment of its long-lived assets.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Revenue recognition</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Revenues for the three and six months ended June 30, 2020 and 2019 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">For the six months ended June 30, 2020, three customers represented an aggregate of 81% of the Company&#8217;s consolidated revenues. For the six months ended June 30, 2019, three customers represented an aggregate of 84% of the Company&#8217;s consolidated revenues.</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Cost of product revenue</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA approved products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses. </p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Loss per common share</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts as the Company reported a net loss for all periods presented. For the six months ended June 30, 2020 and 2019, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>For the Six Months Ended June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock options</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,801,779</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,624,603</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Restricted stock units</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">326,000</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,138,160</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,138,160</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">9,265,939</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">7,762,763</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Stock-based compensation</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a four-year vesting period and a term of 10 years. Pursuant to ASU No. 2016-09, <em>Improvements to Employee Share-Based Payment Accounting (Topic 718)</em>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Income Taxes</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2015 and for previous periods as it relates to the Company&#8217;s net operating loss carryforwards. </p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of June 30, 2020 and December 31, 2019, and during the three and six months ended June 30, 2020 and 2019, the Company recognized no adjustments for uncertain tax positions.</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Recent Accounting Pronouncements </span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In June 2016, the FASB issued ASU No. 2016-13, <em>Financial Instruments &#8211; Credit Losses (Topic 326)</em> (&#8220;ASU 2016-13&#8221;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#8217;s statement of operations is required to reflect the measurement of credit losses for newly recognized financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.The Company adopted ASU No. 2016-13, and the adoption of this update did not have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In February 2016, the FASB issued ASU No. 2016-02, <em>Leases (Topic 842)</em> (&#8220;ASU 2016-02&#8221;), which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company adopted ASU 2016-02 on January 1, 2019 using the option to recognize the cumulative-effect adjustment, if any, as of the date of application, which was also January 1, 2019. The Company recognized right-to-use assets of $1.4 million and corresponding lease liabilities of approximately $1.6 million at the date of adoption (see Note 12). The Company also elected the &#8220;package of practical expedients,&#8221; which permits the Company to not reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease recognition exemption for all leases that qualify, including the agreement under which the Company occupies certain office space as discussed in Note 8. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), <em>Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815)</em>&#8221; (&#8220;ASU 2017-11&#8221;). ASU 2017-11 changed the classification analysis of certain equity-linked financial instruments (or embedded features within such instruments) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) will no longer be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (&#8220;EPS&#8221;) in accordance with ASC 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. In addition, convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features in ASC 470-20, &#8220;Debt&#8212;Debt with Conversion and Other Options.&#8221; ASU 2017-11 became effective for the Company on January 1, 2019, and this update did not have a significant impact on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014264781368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">3. INVENTORIES</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">3.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">INVENTORIES</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;">The following table provides the components of inventories:&#160;</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>June 30,<br/>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>December 31,<br/>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Raw materials</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,830,796</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,381,806</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Work-in-progress</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,066,417</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,455,665</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,104,135</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,227,263</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total inventories</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">56,001,348</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">53,064,734</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB, as there are alternative uses for these materials that provide a probable future benefit or will be consumed in the production of goods expected to be available for sale. All other activities and materials associated with the production of inventories used in research and development activities are expensed as incurred. </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#8217;s immunoglobulin products. Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection center which is expected to be sold to third-party customers. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263225704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">4. INTANGIBLE ASSETS</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">4.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">INTANGIBLE ASSETS </span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 30px; text-align:left;">Intangible assets at June 30, 2020 and December 31, 2019 consist of the following:</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Accumulated </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Accumulated </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Cost </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Amortization</strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Net </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Cost </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Amortization</strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Net</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Trademark and other intangible rights related to Nabi-HB</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4,100,046</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,805,973</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,294,073</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4,100,046</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,513,112</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,586,934</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Rights to intermediates</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">907,421</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">399,697</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">507,724</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">907,421</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">334,881</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">572,540</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Customer contract</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,076,557</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,076,557</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,076,557</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,076,557</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">6,084,024</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">3,282,227</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">2,801,797</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">6,084,024</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">2,924,550</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">3,159,474</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">All of the Company&#8217;s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets for the three months ended June 30, 2020 and 2019 was $0.2 million, and amortization expense for the six months ended June 30, 2020 and 2019 was $0.4 million. Estimated aggregate future aggregate amortization expense for the next five years is expected to be as follows:</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><strong>Remainder of 2020 </strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,676</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2021 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">715,352</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2022 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">715,352</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2023 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">715,352</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2024 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">298,065</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263374632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">5. PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">5.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">PROPERTY AND EQUIPMENT</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Property and equipment and related accumulated depreciation are summarized as follows:</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Manufacturing and laboratory equipment </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,898,186</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,831,817</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Office equipment and computer software </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,220,856</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,690,248</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Furniture and fixtures </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400,129</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">582,088</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Construction in process </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,672,211</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,285,915</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Leasehold improvements </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,011,009</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,673,084</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Land </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,339,441</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,339,441</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Buildings and building improvements </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">16,869,821</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">16,063,680</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,411,653</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,466,273</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: Accumulated depreciation </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,038,287</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,724,956</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total property and equipment, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">37,373,366</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">31,741,317</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Fixed assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#8217;s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of 30 years. Property and equipment other than land and buildings have useful lives ranging from three to 10 years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The Company recorded depreciation expense on property and equipment for the three and six months ended June 30, 2020 of $0.7 million and $1.3 million, respectively. Depreciation expense for the three and six months ended June 30, 2019 was $0.6 million and $1.2 million, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014264662328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">6. DEBT</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">6.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">DEBT</span></strong></p><p style="margin:0px">&#160; </p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Senior Notes Payable</span></em></p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">A summary of outstanding senior notes payable is as follows:&#160;</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,000,000</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,500,000</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Debt discount </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,351,813</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,208,837</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Senior notes payable</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">81,648,187</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">68,291,163</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">On February 11, 2019 (the &#8220;Perceptive Closing Date&#8221;), the Company and all of its subsidiaries entered into a Credit Agreement and Guaranty (the &#8220;Perceptive Credit Agreement&#8221;) with Perceptive Credit Holdings II, LP, as the lender and administrative agent (&#8220;Perceptive&#8221;). The Perceptive Credit Agreement, as amended, provides for a senior secured term loan facility in a principal amount of up to $85.0 million (the &#8220;Perceptive Credit Facility&#8221;), comprised of (i) a term loan made on the Perceptive Closing Date in the principal amount of $45.0 million, as evidenced by the Company&#8217;s issuance of a promissory note (the &#8220;Perceptive Tranche I Note&#8221;) in favor of Perceptive on the Perceptive Closing Date (the &#8220;Perceptive Tranche I Loan&#8221;), (ii) a term loan in the principal amount of up to $27.5 million (the &#8220;Perceptive Tranche II Loan&#8221;) evidenced by the Company&#8217;s issuance of a promissory note (the &#8220;Perceptive Tranche II Note&#8221;) in favor of Perceptive on May 3, 2019; and (iii) a term loan in the principal amount of up to $12.5 million evidenced by the Company&#8217;s issuance of a promissory note (the &#8220;Perceptive Tranche III Note&#8221;) in favor of Perceptive on March 20, 2020 (the &#8220;Perceptive Tranche III Loan,&#8221; and together with the Perceptive Tranche I Loan and the Perceptive Tranche II Loan, the &#8220;Perceptive Loans&#8221;). The Perceptive Tranche III Loan is the result of an amendment to the Perceptive Credit Agreement (the &#8220;Perceptive Amendment&#8221;) that the Company and Perceptive entered into on May 3, 2019, and the Perceptive Tranche III Loan became available to the Company upon the approval of BIVIGAM on May 9, 2019. The Perceptive Credit Facility has a maturity date of March 1, 2022 (the &#8220;Maturity Date&#8221;), subject to acceleration pursuant to the Perceptive Credit Agreement, including upon an Event of Default (as defined in the Perceptive Credit Agreement).</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On the Perceptive Closing Date, the Company used $30.0 million of the Perceptive Tranche I Loan to terminate and pay in full all of the outstanding obligations under its previously existing credit agreement with Marathon Healthcare Finance Fund, L.P. (&#8220;Marathon&#8221;) (the &#8220;Marathon Credit Facility&#8221;). The Company also used proceeds from the Perceptive Tranche I Loan to: (i) pay a deferred facility fee to Marathon in the amount of $2.8 million, (ii) pay a prepayment penalty to Marathon in the amount of $6.5 million, (iii) pay outstanding accrued interest to Marathon in the amount of $0.7 million, and (iv) pay certain fees and expenses incurred in connection with the Perceptive Credit Facility of approximately $1.5 million. In addition, Marathon released $4.0 million of cash to the Company that was held in a debt service reserve account per the terms of the Marathon Credit Facility. In connection with the Perceptive Amendment, the Company paid an additional facility fee to Perceptive in the amount of $0.1 million on May 3, 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As a result of the Company&#8217;s entering into the Perceptive Credit Agreement and terminating the Marathon Credit Facility, the Company recognized a loss on the extinguishment of debt for the six months ended June 30, 2019 in the amount of approximately $10.0 million, comprised of the $6.5 million prepayment penalty and the write-off of unamortized debt discount related to the Marathon Credit Facility in the amount of $3.5 million.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Borrowings under the Perceptive Credit Agreement bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will automatically increase by an additional 400 basis points. Accrued interest is payable to Perceptive on the last day of each month during the term of the Perceptive Credit Facility.The rate of interest in effect as of the Perceptive Closing Date and at June 30, 2020 was 11.0%. </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On the Maturity Date, the Company will pay Perceptive the entire outstanding principal amount underlying the Perceptive Loans and any accrued and unpaid interest thereon. Prior to the Maturity Date, there will be no scheduled principal payments on the Perceptive Loans. The Company may prepay outstanding principal on the Perceptive Loans at any time and from time to time upon three business days&#8217; prior written notice, subject to the payment to Perceptive of (A) any accrued but unpaid interest on the prepaid principal amount plus (B) a redemption premium amount equal to (i) 5.0% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Perceptive Closing Date, (ii) 4.0% of the prepaid principal amount, if prepaid after the first anniversary of the Perceptive Closing Date and on or prior to the second anniversary of the Perceptive Closing Date, or (iii) 3.0% of the prepaid principal amount, if prepaid after the second anniversary of the Perceptive Closing Date and on or prior to the third anniversary of the Perceptive Closing Date.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">All of the Company&#8217;s obligations under the Perceptive Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#8217;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s subsidiaries. The Perceptive Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among other things and subject to certain exceptions contained in the Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or its subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#8217;s ability to make loan repayments under the Perceptive Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ended June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $7.0 million for the fiscal quarter ended June 30, 2019 to $55.0 million for the fiscal quarter ending December 31, 2021. At June 30, 2020, the Company was in compliance with all of the covenants contained in the Perceptive Credit Agreement. </p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As consideration for the Perceptive Credit Agreement, the Company issued to Perceptive a warrant to purchase 1,360,000 shares of the Company&#8217;s common stock (the &#8220;Perceptive Warrant&#8221;) on the Perceptive Closing Date. The Perceptive Warrant has an exercise price equal to $3.28 per share, which is equal to the trailing 10-day volume weighted average price (&#8220;VWAP&#8221;) of the Company&#8217;s common stock on the business day immediately prior to the Perceptive Closing Date multiplied by 1.15. The Company valued the Perceptive Warrant at $2.7 million as of the Perceptive Closing Date and it has an expiration date of February 11, 2029. In connection with the Perceptive Amendment, the Company issued an additional warrant (the &#8220;Perceptive Tranche III Warrant&#8221; and, together with the Perceptive Warrant, the &#8220;Perceptive Warrants&#8221;) to purchase 250,000 shares of the Company&#8217;s common stock to Perceptive with an exercise price equal to $4.64 per share, which represents the trailing 10-day VWAP of the Company&#8217;s common stock as of May 2, 2019. The Perceptive Tranche III Warrant was valued by the Company at $0.9 million and has an expiration date of May 3, 2029. Perceptive has represented to the Company, among other things, that it was an &#8220;accredited investor&#8221; (as such term is defined in Rule 501(a) of Regulation D under the Securities Act) and the Company issued the Perceptive Warrants in reliance upon an exemption from registration contained in Section 4(2) under the Securities Act. The Perceptive Warrants and the shares of common stock issuable thereunder may not be offered, sold, pledged or otherwise transferred in the U.S. absent registration or an applicable exemption from the registration requirements under the Securities Act.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As a result of the fees paid to Perceptive and the value of the Perceptive Warrants, the Company recognized an aggregate discount on the Perceptive Tranche I Note and Perceptive Tranche II Note in the amount of $5.3 million. The Company records debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. Based on the fair value of the Perceptive Warrants and the aggregate amount of fees and expenses associated with obtaining the Perceptive Credit Facility, the effective interest rate on the Perceptive Loans as of May 3, 2019 was approximately 14.1%. </p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Subordinated Note Payable</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">A summary of the outstanding subordinated note payable is as follows:</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Subordinated note payable to Biotest</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Debt discount </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(74,240</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(91,947</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Subordinated note payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">14,925,760</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">14,908,053</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In connection with the acquisition of the Biotest Assets (see Note 1), ADMA BioManufacturing issued a subordinated note payable to BPC and in connection therewith received cash proceeds of $15.0 million. This note has since been assigned from BPC to Biotest AG. The note bears interest at a rate of 6.0% per annum and matures on June 6, 2022.The Company is obligated to make semi-annual interest payments, with all principal and unpaid interest due at maturity. The note is subordinate to all amounts outstanding under the Perceptive Credit Agreement. In the event of default, all principal and unpaid interest is due on demand. The subordinated note also contains several non-financial covenants with which the Company was in compliance as of June 30, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263373064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">7. STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">7.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY </span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Preferred Stock</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share. There were no shares of preferred stock outstanding at June 30, 2020 and December 31, 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Common Stock</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of June 30, 2020 and December 31, 2019, the Company was authorized to issue 150,000,000 shares of its common stock, $0.0001 par value per share, and 86,349,981 and 59,318,355 shares of common stock were outstanding as of June 30, 2020 and December 31, 2019, respectively. After giving effect to the 9,265,939 shares reserved for outstanding warrants and awards issued under the Company&#8217;s equity incentive plans, as of June 30, 2020 there were 54,384,080 shares of common stock available for issuance.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On February 11, 2020, the Company completed an underwritten public offering of 23,500,000 shares of its common stock for gross proceeds of $82.3 million. On February 21, 2020, the Company sold an additional 3,525,000 shares pursuant to the underwriters&#8217; exercise of their option to purchase additional shares of the Company&#8217;s common stock for additional gross proceeds of $12.3 million. The Company received net proceeds, after underwriting discounts and other expenses associated with the offering, of approximately $88.7 million.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Warrants</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">At June 30, 2020 and December 31, 2019, the Company had outstanding warrants to purchase an aggregate of 2,138,160 shares of common stock, with a weighted average exercise price of $3.81 per share and expiration dates ranging between June 2022 and May 2029.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Equity Incentive Plans</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The fair value of stock options granted under the Company&#8217;s 2007 Employee Stock Option Plan (the &#8220;2007 Plan&#8221;) and the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan, as amended and restated (the &#8220;2014 Plan&#8221;), was determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. The following assumptions were used to determine the fair value of options granted during the six months ended June 30, 2020 and 2019:</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160; </p></td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:bottom;text-align:center;"><strong>Six Months Ended June 30, </strong></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td style="width:77%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020 </strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019 </strong></td><td style="width:2%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Expected term</td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">5.5 - 6.3 years </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">5.8 - 6.3 years </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Volatility</td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">62%-67% </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">54%-62% </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Dividend yield</td><td style="white-space: nowrap;">&#160; </td><td colspan="2" style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:center;">0.0 </p></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td colspan="2" style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:center;">0.0 </p></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="white-space: nowrap;">&#160; </td><td colspan="2"><p style="MARGIN: 0px; text-align:center;">0.38-1.68% </p></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td colspan="2"><p style="MARGIN: 0px; text-align:center;">1.80-2.92% </p></td><td style="white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">During the six months ended June 30, 2020 and 2019, the Company granted options to purchase an aggregate of 1,232,500 and 1,429,100 shares of common stock, respectively, to its directors, employees and certain third-party service providers. The weighted average remaining contractual life of stock options outstanding and expected to vest at June 30, 2020 is 6.9 years. The weighted average remaining contractual life of stock options exercisable at June 30, 2020 is 5.6 years.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="margin:0px">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">A summary of the Company&#8217;s option activity under the 2007 Plan and 2014 Plan and related information is as follows: </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Shares </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Weighted Average Exercise Price</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2019</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,630,351</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.76</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(47,683</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.51</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,763</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.34</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,232,500</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.96</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(6,626</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.03</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at June 30, 2020</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">6,801,779</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.45</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercisable</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">4,030,098</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5.19</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">As of June 30, 2020, the Company had $5.1 million of unrecognized compensation expense related to options granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of 2.6 years.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">During the six months ended June 30, 2020, the Company granted Restricted Stock Units (&#8220;RSUs&#8221;) to members of the Company&#8217;s Board of Directors and to certain management employees of the Company. The total RSUs granted during the period represent an aggregate of 341,000 shares of the Company&#8217;s common stock. The RSUs vest semi-annually over a period of one year for directors and annually over a period of four years for employees. Total compensation expense related to unvested RSUs for the three and six months ended June 30, 2020 was $0.1 million. A summary of the Company&#8217;s unvested RSU activity and related information is as follows:</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Shares</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2019 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">341,000</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vested </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.92</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at June 30, 2020 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">326,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of June 30, 2020, the Company had $0.8 million of unrecognized compensation expense related to unvested RSUs granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.5 years.</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three and six months ended June 30, 2020 and 2019 is as follows:</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Three Months Ended June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Six Months Ended June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Research and development</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">105,029</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">89,543</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">198,603</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">176,066</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Plasma centers</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,510</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,213</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,754</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,753</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Selling, general and administrative</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">539,256</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">569,349</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,063,145</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,067,820</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cost of product revenue</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">62,813</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,631</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">114,654</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">95,360</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Total stock-based compensation expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">715,608</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">726,736</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">1,392,156</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">1,363,999</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014264662328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">8. RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">8.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The Company leases an office building and equipment from Areth, LLC (&#8220;Areth&#8221;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time. Effective October 1, 2017, monthly rent on this facility was set at $10,000. On November 7, 2019, an additional amendment was entered into between Areth and the Company to extend the term of this agreement through September 30, 2020, and to provide for automatic one-year renewals unless ADMA gives written notice of termination to Areth 60 days prior to the end of the term, which expires each year on September 30. The Company did not provide a written notice of termination to Areth as of July 31, 2020. Rent expense for the six months ended June 30, 2020 and 2019 amounted to $60,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#8217;s Board of Directors, and Adam S. Grossman, the Company&#8217;s President and Chief Executive Officer. The Company also reimburses Areth for office and building related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the three and six months ended June 30, 2020 and 2019. </p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">See Note 6 for a discussion of the Company&#8217;s credit facility and related transactions with Perceptive, a holder of more than 10% of the Company&#8217;s common stock.</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">In connection with the February 2020 public offering of the Company&#8217;s common stock (see Note 7) on February 11, 2020: (i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an entity he controls (v) Brian Lenz, the Company&#8217;s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common stock, and (vi) James Mond, the Company&#8217;s Chief Scientific Officer and Chief Medical Officer, purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014344164728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENT AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENT AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">9. COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">9.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">General Legal Matters</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">From time to time the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s liquidity, results of operations or financial condition. </p><p style="MARGIN: 0px; text-align:left;">&#160; &#160;&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">COVID-19 Pandemic</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">The Company continues to monitor the ongoing developments related to &#160;the COVID-19 pandemic,&#160;and its impacts to&#160;the Company&#8217;s supply-chain operations, including procurement of raw materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale.&#160; A substantial portion of such testing has historically been performed by contract laboratories outside the United States.&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">The Company has experienced some delays with final drug product release testing by third-party vendors. In response to these delays, the Company added additional release testing laboratories to its FDA approved consortium listed in its drug approval documents which the Company believes has adequately addressed this issue. In addition, due to previous state and local &#8220;shelter-in-place&#8221; orders, the Company experienced lower than normal donor collections at its FDA approved plasma collection center during the three months ended June 30, 2020. The Company was also subject to delays in shipments of source plasma from its contracted third-party suppliers, as well as delays in deliveries for personal protective equipment, reagents and other non-plasma raw materials and supplies used in the manufacture of its products. The COVID-19 pandemic has also impacted, to a certain degree, the Company&#8217;s customer engagement initiatives, whereby ADMA&#8217;s sales and medical affairs field personnel have faced difficulties communicating directly with physicians and other healthcare professionals, as well as the cancellation or postponement of a number of key scientific and medical meetings, further limiting the Company&#8217;s ability to communicate with potential customers.&#160; The Company has implemented a comprehensive suite of virtual engagement initiatives, however, clinician engagement has been reduced due to rapidly evolving COVID-19 priorities at U.S. medical centers.</p><p style="margin:0px 0px 0px 0in;text-indent:0.5in">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on the Company&#8217;s financial condition or results of operations, and the Company does not believe that its production operations at the Boca Facility, the Company&#8217;s contract fill/finishers or its plasma collection facility have been significantly impacted by the COVID-19 pandemic. As a result, the Company does not anticipate any material impairments with respect to any of its long-lived assets, including the Company&#8217;s property and equipment, goodwill or intangible assets.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:left;">Although the COVID-19 pandemic has not, to date, materially adversely impacted the Company&#8217;s capital and financial resources, because the Company is unable to determine the ultimate severity or duration of the pandemic or its long-term effects on, among other things, the global, national or local economies, the capital and credit markets or the Company&#8217;s workforce, customers or our suppliers, at this time the Company is unable to predict whether COVID-19 will have a material adverse impact on the Company&#8217;s business, financial condition, liquidity and results of operations.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Vendor and Licensor Commitments</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Pursuant to the terms of a plasma purchase agreement with BPC dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase Agreement&#8221;), the Company agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum volume from BPC, but may also collect high-titer RSV plasma from up to five wholly-owned ADMA plasma collection facilities. During 2015, the Company and BPC amended the 2011 Plasma Purchase Agreement to allow the Company the ability to collect its raw material RSV high-titer plasma from other third-party collection organizations, thus allowing the Company to expand its reach for raw material supply as it continues its commercialization activities for ASCENIV. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June 2027, after which it may be renewed for two additional five-year periods if agreed to by the parties. As part of the closing of the Biotest Transaction, the parties amended the 2011 Plasma Purchase Agreement to extend the initial term through the ten-year anniversary of the closing date of the Biotest Transaction. On December 10, 2018, BPC assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. On January 1, 2019, Grifols and the Company entered into an additional amendment to the 2011 Plasma Purchase Agreement for the purchase of source plasma containing antibodies to RSV from Grifols. Pursuant to this amendment, until January 1, 2022, the Company may purchase RSV plasma from Grifols from the two plasma collection centers that were transferred to BPC on January 1, 2019 at a price equal to cost plus 5% without any additional increase due to inflation.</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On June 6, 2017, the Company and BPC entered into a Plasma Supply Agreement pursuant to which BPC supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July 19, 2018, the Company and BPC entered into an amendment to the Plasma Supply Agreement to provide, among other things, that in the event BPC elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double digit percentage of the price that ADMA BioManufacturing pays to BPC, then BPC shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">On June 6, 2017, the Company and BPC entered into a Plasma Purchase Agreement (the &#8220;2017 Plasma Purchase Agreement&#8221;), pursuant to which ADMA BioManufacturing purchases normal source plasma (&#8220;NSP&#8221;) from BPC at agreed upon annual quantities and prices. The 2017 Plasma Purchase Agreement had an initial term of five years after which the 2017 Plasma Purchase Agreement may be renewed for two additional terms of two years each upon the mutual written consent of the parties. On July 19, 2018, the Company and BPC entered into an amendment to the 2017 Plasma Purchase Agreement to, among other things, provide agreed upon amounts of NSP to be supplied by BPC to ADMA BioManufacturing in calendar year 2019 at a specified price per liter, provided that ADMA BioManufacturing delivers a valid purchase order to BPC. Additionally, pursuant to the amendment to the 2017 Plasma Purchase Agreement, BPC agrees that, for calendar years 2020 and 2021, it shall supply no less than a high double digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts, provided that such requested NSP amounts are within an agreed range, at a price per liter to be mutually determined. Furthermore, pursuant to the amendment to the 2017 Plasma Purchase Agreement, in the event BPC fails to supply ADMA BioManufacturing with at least a high double digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts, BPC shall promptly reimburse ADMA BioManufacturing the difference in price ADMA BioManufacturing incurs due to BPC&#8217;s election not to supply NSP to ADMA BioManufacturing in such amounts as requested. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Purchase Agreement to Grifols, effective January 1, 2019.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company purchases substantially all of its raw material plasma from Grifols. For the six months ended June 30, 2020, plasma purchases from Grifols totaled approximately $3.7 million, representing approximately 42% of the Company&#8217;s total inventory purchases. For the six months ended June 30, 2019, plasma purchases from BPC totaled $5.0 million, or approximately 67% of the Company&#8217;s total inventory purchases.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Post-marketing commitments</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In connection with the approval of the BLA for BIVIGAM, on December 19, 2012 Biotest committed to perform two additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in BIVIGAM-treated patients with primary humoral immunodeficiency. These studies are still pending completion, as such ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and development expenses. The Company currently expects both studies to be completed by the end of 2021. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In connection with the FDA&#8217;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. This study is required to be completed by June of 2023.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><span style="text-decoration:underline">Employment contracts </span></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company has entered into employment agreements with its executive management team consisting of its President and Chief Executive Officer, its Executive Vice President, Chief Medical Officer and Chief Scientific Officer and its Executive Vice President and Chief Financial Officer.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Other commitments</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown as of June 30, 2020. The Company does not anticipate recognizing any significant losses relating to these arrangements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014264662328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">10. SEGMENTS</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">10.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">SEGMENTS</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company&#8217;s ADMA BioManufacturing segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1).The Plasma Collection Centers segment consists of one FDA-licensed source plasma collection facility, another plasma collection facility for which an FDA license is pending and a plasma collection center currently under construction. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) to analyze performance and allocate resources. The Company&#8217;s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:</p><p style="MARGIN: 0px; text-align:left;">&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="17" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong>Three Months Ended June 30, 2020 </strong></p></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>ADMA BioManufacturing </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Plasma Collection Centers </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Corporate </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Consolidated</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,502,865</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,249,020</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,709</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,787,594</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,237,141</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,258,488</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,495,629</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,852,835</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(919,309</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,351,681</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(17,123,825</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other expense, net</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(235,442</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,818,791</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,054,266</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,088,277</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(919,342</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,170,472</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(20,178,091</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">772,241</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">111,106</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,305</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">885,652</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total assets</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,105,418</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,542,486</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">74,893,664</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">191,541,568</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="16" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="MARGIN: 0px; text-align:center;"><strong>Three Months Ended June 30, 2019</strong> </p></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>ADMA BioManufacturing</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Plasma Collection Centers</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Corporate</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Consolidated</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,002,445</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,522,788</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,709</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,560,942</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,170,381</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,320,855</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,491,236</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,671,783</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(392,181</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,274,710</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,338,674</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other expense, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(246,603</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(59</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,626,536</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,873,198</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,918,386</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(392,240</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,901,246</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,211,872</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">688,848</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">113,958</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,287</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">806,093</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">67,236,416</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,835,999</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,201,705</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">143,274,120</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="16" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="MARGIN: 0px; text-align:center;"><strong>Six Months Ended June 30, 2020</strong> </p></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>ADMA BioManufacturing</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Plasma Collection Centers</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Corporate</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Consolidated</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,246,139</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,669,782</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,417</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,987,338</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,689,094</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,635,761</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,324,855</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(25,328,980</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,376,464</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,188,167</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(33,893,611</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other expense, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(474,314</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,055,363</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,529,710</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(25,803,294</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,376,497</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,243,530</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(39,423,321</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Capital expenditures </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,064,494</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,178,790</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,243,284</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,447,214</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">222,395</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,881</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,674,490</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="17" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong>Six Months Ended June 30, 2019 </strong></p></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>ADMA BioManufacturing </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Plasma Collection Centers </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Corporate </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Consolidated</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,346,428</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,671,686</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,417</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,089,531</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,110,727</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,785,688</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,896,415</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,292,591</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(362,601</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,891,898</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(24,547,090</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other (expense) income, net</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(416,216</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,560</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,895,007</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,297,663</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gain on transfer of plasma center assets</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,527,421</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,527,421</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss on extinguishment of debt</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,962,495</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,962,495</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net (loss) income </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,708,807</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,178,380</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(17,749,400</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(26,279,827</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Capital expenditures </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">224,440</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,235</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">245,675</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,376,240</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">228,199</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,983</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,611,422</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263499288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRANSFER OF PLASMA CENTER ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>TRANSFER OF PLASMA CENTER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock', window );">11. TRANSFER OF PLASMA CENTER ASSETS</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">11.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">TRANSFER OF PLASMA CENTER ASSETS</span></strong></p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As part of the purchase price for the Biotest Transaction (see Note 1), the Company transferred its Marietta, GA and Norcross, GA plasma collection centers to BPC effective January 1, 2019. The Company had estimated the combined fair value of the two facilities to be $12.6 million, and the Company recorded an obligation for this amount as of the date of the Biotest Transaction. On January 1, 2019, upon the transfer of the two plasma collection facilities to BPC, the Company recorded a gain in the amount of $11.5 million, which reflects the derecognition of the obligation to transfer ownership of the two facilities net of the carrying value of the assets associated with these facilities, primarily property and equipment and inventory, in the amount of $1.1 million. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263347736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">12. LEASE OBLIGATIONS</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">12.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">LEASE OBLIGATIONS</span></strong></p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company leases certain properties and equipment for its ADMA BioCenters subsidiary and certain equipment for its ADMA BioManufacturing subsidiary, which leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2030. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease payments arising from the lease. Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s incremental borrowing rate of 13%. The Company&#8217;s operating lease expense is recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. Aggregate lease expense and cash paid for the Company&#8217;s operating leases for the three months ended June 30, 2020 and 2019 was approximately $0.1 million, and aggregate rent expense and cash paid for the Company&#8217;s operating leases for the six months ended June 30, 2020 and 2019 was approximately $0.2 million. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In connection with the adoption of ASU 2016-02 on January 1, 2019 (see Note 2), the Company recognized right to use assets of $1.4 million and lease liabilities of approximately $1.6 million. During the six months ended June 30, 2020, the Company entered into two new property leases where the Company has opened or intends to open two new plasma collection facilities. In connection with these leases, the Company recognized aggregate lease liabilities and corresponding right-to-use assets in the approximate amount of $1.7 million. The right-to-use assets are reflected in Deposits and other assets in the accompanying consolidated balance sheets. Including a finance lease the Company entered into in June 2018, the Company has aggregate lease liabilities of $3.1 million and $1.5 million as of June 30, 2020 and December 31, 2019, respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers and an administrative office lease in Roswell, GA related to the Company&#8217;s ADMA BioCenters subsidiary. The Company&#8217;s operating leases have a weighted average remaining term of 8.4 years. Scheduled payments under the Company&#8217;s lease obligations are as follows:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Remainder of 2020 </p></td><td style="width:60%;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="MARGIN: 0px; text-align:left;">$</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">262,076</p></td><td style="width:1%;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Year ended December 31, 2021 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">699,752</p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">2022 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">721,005</p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">2023 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">706,919</p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">2024 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">603,858</p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Thereafter </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">2,205,047</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Total payments </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">5,198,657</p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Less: imputed interest </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">(2,050,495</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="MARGIN: 0px; text-align:left;">)</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Current portion </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">(210,870</p></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;"><p style="MARGIN: 0px; text-align:left;">)</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Balance at June 30, 2020 </p></td><td style="white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">2,937,292</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="margin:0px">&#160;&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">As of July 15, 2020, the Company had entered into two additional property leases where the Company intends to construct additional new plasma collection facilities. The Company has not taken possession of these two leased properties and their lease commencement dates have not been determined. With the exception of advance deposits and initial months&#8217; rent totaling approximately $74,000, no payments have been made under these leases. The initial terms of each lease are from 11 to 13 years with monthly rental payments varying between approximately $17,000 and $21,000, including common area maintenance charges.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263103656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">13. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><strong><span style="mso-list:ignore">13.<span style="font:7pt &quot;times new roman&quot;"> </span></span></strong><strong><span style="text-decoration:underline">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></strong> </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Supplemental cash flow information for the six months ended June 30, 2020 and 2019 is as follows:</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td style="vertical-align:top;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Cash paid for interest </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,912,165</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,574,304</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Noncash Financing and Investing Activities:</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Equipment acquired reflected in accounts payable and accrued liabilities </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,228,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">290,389</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Right-to-use assets obtained in exchange for lease obligations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,723,594</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,421,669</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Warrants issued in connection with notes payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,579,115</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160; </p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263121848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">14. SUBSEQUENT EVENTS</a></td>
<td class="text"><strong style="MARGIN: 0px"><span style="mso-list:ignore">14.<span style="font:7pt &quot;times new roman&quot;">&#160; </span></span></strong><strong><span style="text-decoration:underline">SUBSEQUENT EVENTS</span></strong><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">&#160;On August 5, 2020, the Company entered into an Open Market Sale Agreement<sup>SM</sup> (the &#8220;Sale Agreement&#8221;) with Jefferies LLC, as agent (the &#8220;Agent&#8221;), pursuant to which the Company may offer and sell (the &#8220;Offering&#8221;), from time to time, at its option, through or to the Agent, up to an aggregate of $50,000,000 of shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;). Any Shares to be offered and sold under the Sale Agreement will be issued and sold pursuant to the Company&#8217;s Registration Statement on Form S-3 (File No. 333-234107), filed with the SEC on October 4, 2019, and declared effective on October 15, 2019 (the &#8220;Registration Statement&#8221;) and the prospectus supplement relating to the Offering, dated August 5, 2020, that will be filed with the SEC, by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, (the "Securities Act"), or if specified by the Company, by any other method permitted by law, including, but not limited to, in negotiated and block transactions. </p><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the terms of the Sale Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company cannot provide any assurances that it will issue any Shares pursuant to the Sale Agreement. The Company will pay the Agent a commission of up to 3.0% of the gross proceeds from each sale of the Shares under the Sale Agreement. The Company will also reimburse the Agent for certain expenses incurred in connection with the Sale Agreement and agreed to provide the Agent with customary indemnification rights with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. </span></p><p style="margin:0px">&#160;</p><p style="MARGIN: 0px; text-align:left;"><span style="mso-tab-count:1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Through the date of this report, no shares have been sold under the Sale Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266578280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Basis of presentation</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2019 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 13, 2020.The accompanying consolidated balance sheet as of December 31, 2019 was derived from the audited financial statements for the year ended December 31, 2019. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of June 30, 2020 and its results of operations, changes in equity and cash flows for the three and six months ended June 30, 2020. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">During the three and six months ended June 30, 2020 and 2019, comprehensive loss was equal to the net loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Use of estimates</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#8217;s deferred tax assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Fair value of financial instruments</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at cost which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#8217;s senior secured term loan (see Note 6) approximates fair value due to the variable interest rate on this debt. With respect to the subordinated note payable in the amount of $15.0 million as of June 30, 2020 and December 31, 2019 held by Biotest, a principal stockholder of the Company at the time the note was issued concurrent with an acquisition transaction with an affiliate of such stockholder (see Note 6), the Company has concluded that an estimation of fair value for this note is not practicable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts receivable</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Accounts receivable</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers based upon an evaluation of each customer's financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis. Based on these evaluations, the Company has concluded that its credit risk is minimal. At June 30, 2020, three customers accounted for an aggregate of 76% of the Company&#8217;s total accounts receivable, and at December 31, 2019, two customers accounted for 89% of the Company&#8217;s total accounts receivable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Inventories</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Due to previous uncertainties surrounding certain prior submissions made to the FDA, all costs related to the production of BIVIGAM and ASCENIV prior to their FDA approval dates of May 9, 2019 and April 1, 2019, respectively, have been charged to cost of product revenue in the accompanying consolidated statements of operations during the period the product was produced. In addition, costs associated with the production of conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Goodwill</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at June 30, 2020 and December 31, 2019 was $3.5 million. All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment and is related to a 2017acquisition transaction.&#160;</p><p style="margin:0px">&#160;&#160; </p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Goodwill is not amortized, but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company&#8217;s annual goodwill impairment test as of October 1, 2019 did not result in a goodwill impairment charge, and the Company did not record any impairment charges related to goodwill for the three and six months ended June 30, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Impairment of long-lived assets</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and definite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the three and six months ended June 30, 2020 and 2019, the Company determined that there was no impairment of its long-lived assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Revenue recognition</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Revenues for the three and six months ended June 30, 2020 and 2019 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">For the six months ended June 30, 2020, three customers represented an aggregate of 81% of the Company&#8217;s consolidated revenues. For the six months ended June 30, 2019, three customers represented an aggregate of 84% of the Company&#8217;s consolidated revenues.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of product revenue</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Cost of product revenue</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA approved products, intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per common share</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Loss per common share</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">Basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, using the treasury stock method. Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts as the Company reported a net loss for all periods presented. For the six months ended June 30, 2020 and 2019, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</p><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>For the Six Months Ended June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock options</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,801,779</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,624,603</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Restricted stock units</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">326,000</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,138,160</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,138,160</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">9,265,939</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">7,762,763</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Stock-based compensation</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a four-year vesting period and a term of 10 years. Pursuant to ASU No. 2016-09, <em>Improvements to Employee Share-Based Payment Accounting (Topic 718)</em>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Income Taxes</span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2015 and for previous periods as it relates to the Company&#8217;s net operating loss carryforwards. </p><p style="MARGIN: 0px; text-align:left;">&#160;&#160;&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of June 30, 2020 and December 31, 2019, and during the three and six months ended June 30, 2020 and 2019, the Company recognized no adjustments for uncertain tax positions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Recent Accounting Pronouncements </span></em></p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In June 2016, the FASB issued ASU No. 2016-13, <em>Financial Instruments &#8211; Credit Losses (Topic 326)</em> (&#8220;ASU 2016-13&#8221;), which requires financial assets to be presented at the net amount expected to be collected, with an allowance for credit losses to be deducted from the amortized cost basis of the financial asset such that the net carrying value of the asset is presented as the amount expected to be collected. Under ASU 2016-13, the entity&#8217;s statement of operations is required to reflect the measurement of credit losses for newly recognized financial assets, as well as expected increases or decreases in expected credit losses that have taken place during the period. For public business entities, ASU 2016-13 is effective for fiscal years beginning after December 15, 2019.The Company adopted ASU No. 2016-13, and the adoption of this update did not have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In February 2016, the FASB issued ASU No. 2016-02, <em>Leases (Topic 842)</em> (&#8220;ASU 2016-02&#8221;), which requires lessees to recognize assets and liabilities for the rights and obligations created by most leases on their balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASU 2016-02 requires modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company adopted ASU 2016-02 on January 1, 2019 using the option to recognize the cumulative-effect adjustment, if any, as of the date of application, which was also January 1, 2019. The Company recognized right-to-use assets of $1.4 million and corresponding lease liabilities of approximately $1.6 million at the date of adoption (see Note 12). The Company also elected the &#8220;package of practical expedients,&#8221; which permits the Company to not reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease recognition exemption for all leases that qualify, including the agreement under which the Company occupies certain office space as discussed in Note 8. </p><p style="MARGIN: 0px; text-align:left;">&#160;</p><p style="MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:left;">In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), <em>Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815)</em>&#8221; (&#8220;ASU 2017-11&#8221;). ASU 2017-11 changed the classification analysis of certain equity-linked financial instruments (or embedded features within such instruments) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) will no longer be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (&#8220;EPS&#8221;) in accordance with ASC 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. In addition, convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features in ASC 470-20, &#8220;Debt&#8212;Debt with Conversion and Other Options.&#8221; ASU 2017-11 became effective for the Company on January 1, 2019, and this update did not have a significant impact on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266831208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of dilutive securities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>For the Six Months Ended June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock options</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,801,779</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,624,603</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Restricted stock units</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">326,000</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Warrants</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,138,160</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,138,160</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">9,265,939</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">7,762,763</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014264677032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>June 30,<br/>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>December 31,<br/>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Raw materials</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,830,796</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33,381,806</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Work-in-progress</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,066,417</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,455,665</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished goods</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,104,135</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,227,263</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total inventories</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">56,001,348</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">53,064,734</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014265361880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Intangible asset future aggregate amortization expense</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><strong>Remainder of 2020 </strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,676</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2021 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">715,352</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2022 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">715,352</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2023 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">715,352</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2024 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">298,065</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="10" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Accumulated </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Accumulated </strong></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Cost </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Amortization</strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Net </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Cost </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Amortization</strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:6%;vertical-align:bottom;text-align:center;"><strong>Net</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Trademark and other intangible rights related to Nabi-HB</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4,100,046</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,805,973</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,294,073</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4,100,046</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,513,112</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,586,934</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Rights to intermediates</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">907,421</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">399,697</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">507,724</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">907,421</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">334,881</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">572,540</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Customer contract</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,076,557</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,076,557</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,076,557</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,076,557</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">6,084,024</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">3,282,227</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">2,801,797</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">6,084,024</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">2,924,550</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:6%;vertical-align:bottom;text-align:right;">3,159,474</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014264750328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Manufacturing and laboratory equipment </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,898,186</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,831,817</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Office equipment and computer software </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,220,856</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,690,248</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Furniture and fixtures </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400,129</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">582,088</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Construction in process </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,672,211</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,285,915</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Leasehold improvements </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,011,009</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,673,084</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Land </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,339,441</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,339,441</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Buildings and building improvements </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">16,869,821</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">16,063,680</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,411,653</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,466,273</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: Accumulated depreciation </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,038,287</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,724,956</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total property and equipment, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">37,373,366</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">31,741,317</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263329432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSubordinatedBorrowingTextBlock', window );">Summary of subordinated note payable</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td class="ffcell"><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Subordinated note payable to Biotest</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Debt discount </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(74,240</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(91,947</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Subordinated note payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">14,925,760</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">14,908,053</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of notes payable</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>June 30, 2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>December 31, 2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Notes payable</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,000,000</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,500,000</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Debt discount </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,351,813</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,208,837</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Senior notes payable</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">81,648,187</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">68,291,163</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubordinatedBorrowingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings under subordinated debt agreements that qualify as available in computing net capital under SEC uniform net capital rules for broker-dealers, including restrictive covenants, collateral, interest rates and due dates, amounts due by date and amount owed in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6479118&amp;loc=d3e64650-112822<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubordinatedBorrowingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014269060088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160; </p></td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:bottom;text-align:center;"><strong>Six Months Ended June 30, </strong></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td style="width:77%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020 </strong></td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019 </strong></td><td style="width:2%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Expected term</td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">5.5 - 6.3 years </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">5.8 - 6.3 years </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Volatility</td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">62%-67% </td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;">54%-62% </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Dividend yield</td><td style="white-space: nowrap;">&#160; </td><td colspan="2" style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:center;">0.0 </p></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td colspan="2" style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:center;">0.0 </p></td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="white-space: nowrap;">&#160; </td><td colspan="2"><p style="MARGIN: 0px; text-align:center;">0.38-1.68% </p></td><td style="white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td colspan="2"><p style="MARGIN: 0px; text-align:center;">1.80-2.92% </p></td><td style="white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of compensation expense</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Shares</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2019 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">341,000</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Vested </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.92</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at June 30, 2020 </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">326,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Shares </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Weighted Average Exercise Price</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2019</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,630,351</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.76</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Forfeited</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(47,683</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.51</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,763</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.34</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,232,500</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.96</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(6,626</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.03</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at June 30, 2020</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">6,801,779</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.45</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercisable</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">4,030,098</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5.19</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Three Months Ended June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="6" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Six Months Ended June 30, </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020 </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Research and development</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">105,029</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">89,543</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">198,603</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">176,066</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Plasma centers</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,510</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,213</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,754</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,753</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Selling, general and administrative</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">539,256</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">569,349</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,063,145</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,067,820</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cost of product revenue</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">62,813</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,631</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">114,654</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">95,360</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Total stock-based compensation expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">715,608</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">726,736</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">1,392,156</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">1,363,999</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014265390696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summarized segment financial information</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="17" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong>Three Months Ended June 30, 2020 </strong></p></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>ADMA BioManufacturing </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Plasma Collection Centers </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Corporate </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Consolidated</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,502,865</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,249,020</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,709</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,787,594</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,237,141</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,258,488</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,495,629</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,852,835</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(919,309</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,351,681</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(17,123,825</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other expense, net</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(235,442</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,818,791</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,054,266</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,088,277</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(919,342</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(6,170,472</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(20,178,091</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">772,241</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">111,106</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,305</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">885,652</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total assets</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,105,418</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,542,486</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">74,893,664</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">191,541,568</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="16" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="MARGIN: 0px; text-align:center;"><strong>Three Months Ended June 30, 2019</strong> </p></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>ADMA BioManufacturing</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Plasma Collection Centers</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Corporate</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Consolidated</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,002,445</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,522,788</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,709</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,560,942</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,170,381</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,320,855</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,491,236</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,671,783</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(392,181</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,274,710</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,338,674</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other expense, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(246,603</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(59</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,626,536</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,873,198</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,918,386</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(392,240</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,901,246</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,211,872</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">688,848</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">113,958</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,287</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">806,093</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total assets </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">67,236,416</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,835,999</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,201,705</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">143,274,120</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="16" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="MARGIN: 0px; text-align:center;"><strong>Six Months Ended June 30, 2020</strong> </p></td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>ADMA BioManufacturing</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Plasma Collection Centers</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Corporate</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Consolidated</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,246,139</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,669,782</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,417</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,987,338</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,689,094</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,635,761</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,324,855</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(25,328,980</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,376,464</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(7,188,167</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(33,893,611</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other expense, net </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(474,314</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,055,363</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,529,710</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(25,803,294</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,376,497</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,243,530</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(39,423,321</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Capital expenditures </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,064,494</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,178,790</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,243,284</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,447,214</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">222,395</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,881</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,674,490</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><p style="MARGIN: 0px; text-align:left;">&#160;&#160; </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="17" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong>Six Months Ended June 30, 2019 </strong></p></td></tr><tr style="height:15px"><td><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>ADMA BioManufacturing </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Plasma Collection Centers </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Corporate </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td style="white-space: nowrap;"><strong>&#160; </strong></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Consolidated</strong> </td><td style="white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,346,428</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,671,686</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,417</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,089,531</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cost of product revenue</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,110,727</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,785,688</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,896,415</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss from operations</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,292,591</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(362,601</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,891,898</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(24,547,090</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest and other (expense) income, net</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(416,216</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,560</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,895,007</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,297,663</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Gain on transfer of plasma center assets</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,527,421</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,527,421</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss on extinguishment of debt</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,962,495</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,962,495</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net (loss) income </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,708,807</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,178,380</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(17,749,400</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(26,279,827</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Capital expenditures </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">224,440</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,235</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">245,675</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td>&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation and amortization expense </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,376,240</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">228,199</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,983</td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,611,422</td><td style="width:1%;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8721-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263399320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Remainder of 2020 </p></td><td style="width:60%;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><p style="MARGIN: 0px; text-align:left;">$</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">262,076</p></td><td style="width:1%;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Year ended December 31, 2021 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">699,752</p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">2022 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">721,005</p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">2023 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">706,919</p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">2024 </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">603,858</p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Thereafter </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">2,205,047</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Total payments </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">5,198,657</p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Less: imputed interest </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">(2,050,495</p></td><td style="vertical-align:bottom;white-space: nowrap;"><p style="MARGIN: 0px; text-align:left;">)</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Current portion </p></td><td style="white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="MARGIN: 0px; text-align:right;">&#160; </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><p style="MARGIN: 0px; text-align:right;">(210,870</p></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;"><p style="MARGIN: 0px; text-align:left;">)</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:right;">Balance at June 30, 2020 </p></td><td style="white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">2,937,292</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;">&#160; </td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263404632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td>&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2020</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td><td style="white-space: nowrap;">&#160; </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>2019</strong> </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;">&#160; </td></tr><tr style="height:15px"><td style="vertical-align:top;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" colspan="2" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Cash paid for interest </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,912,165</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,574,304</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><strong>Noncash Financing and Investing Activities:</strong> </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td class="ffcell" style="width:9%;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Equipment acquired reflected in accounts payable and accrued liabilities </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,228,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">290,389</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Right-to-use assets obtained in exchange for lease obligations </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,723,594</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,421,669</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 30px;vertical-align:top;">Warrants issued in connection with notes payable </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;">&#160; </td><td style="width:1%;white-space: nowrap;">&#160; </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,579,115</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="margin:0px">&#160; </p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014334170552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">193 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BUSINESS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 75,781,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,615,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,781,122<span></span>
</td>
<td class="nump">$ 73,615,909<span></span>
</td>
<td class="nump">$ 75,781,122<span></span>
</td>
<td class="nump">$ 26,752,135<span></span>
</td>
<td class="nump">$ 26,754,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,178,091)<span></span>
</td>
<td class="num">$ (19,245,230)<span></span>
</td>
<td class="num">$ (13,211,872)<span></span>
</td>
<td class="num">$ (13,067,955)<span></span>
</td>
<td class="num">(39,423,321)<span></span>
</td>
<td class="num">$ (26,279,827)<span></span>
</td>
<td class="nump">304,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_WorkingCapital', window );">Working capital</a></td>
<td class="nump">$ 130,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266491400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">9,265,939<span></span>
</td>
<td class="nump">7,762,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">6,801,779<span></span>
</td>
<td class="nump">5,624,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">326,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">2,138,160<span></span>
</td>
<td class="nump">2,138,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266117464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,529,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,529,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Vesting term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=adma_CustomerThreeMember', window );">Customer Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk concentration</a></td>
<td class="nump">8100.00%<span></span>
</td>
<td class="nump">8400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=adma_CustomerThreeMember', window );">Customer Three [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk concentration</a></td>
<td class="nump">7600.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=adma_CustomerTwoMember', window );">Customer Two [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8900.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=adma_BiotestMember', window );">Biotest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Note payable</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=adma_JanuaryOneTwoThousandNineteenMember', window );">January 1, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=adma_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=adma_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=adma_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=adma_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=adma_BiotestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=adma_BiotestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=adma_JanuaryOneTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=adma_JanuaryOneTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014270067592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 24,830,796<span></span>
</td>
<td class="nump">$ 33,381,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">22,066,417<span></span>
</td>
<td class="nump">14,455,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">9,104,135<span></span>
</td>
<td class="nump">5,227,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 56,001,348<span></span>
</td>
<td class="nump">$ 53,064,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266748312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 6,084,024<span></span>
</td>
<td class="nump">$ 6,084,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">3,282,227<span></span>
</td>
<td class="nump">2,924,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,801,797<span></span>
</td>
<td class="nump">3,159,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademark and other intangible rights related to Nabi-HB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">4,100,046<span></span>
</td>
<td class="nump">4,100,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">1,805,973<span></span>
</td>
<td class="nump">1,513,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,294,073<span></span>
</td>
<td class="nump">2,586,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember', window );">Right to intermediates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">907,421<span></span>
</td>
<td class="nump">907,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">399,697<span></span>
</td>
<td class="nump">334,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">507,724<span></span>
</td>
<td class="nump">572,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember', window );">Customer contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">1,076,557<span></span>
</td>
<td class="nump">1,076,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">1,076,557<span></span>
</td>
<td class="nump">1,076,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014270145896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 357,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">715,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">715,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">715,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="nump">$ 298,065<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263389832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_AmortizationExpense', window );">Amortization expense</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266672328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 44,411,653<span></span>
</td>
<td class="nump">$ 37,466,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(7,038,287)<span></span>
</td>
<td class="num">(5,724,956)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">37,373,366<span></span>
</td>
<td class="nump">31,741,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing and laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">9,898,186<span></span>
</td>
<td class="nump">8,831,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment and computer software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">2,220,856<span></span>
</td>
<td class="nump">1,690,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,400,129<span></span>
</td>
<td class="nump">582,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">3,011,009<span></span>
</td>
<td class="nump">1,673,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">4,339,441<span></span>
</td>
<td class="nump">4,339,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">16,869,821<span></span>
</td>
<td class="nump">16,063,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 6,672,211<span></span>
</td>
<td class="nump">$ 4,285,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014344477832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adma_PropertyAndEquipmentMember', window );">Property and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adma_PropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adma_PropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014264892712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="nump">$ 72,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="num">(3,351,813)<span></span>
</td>
<td class="num">(4,208,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Senior notes payable</a></td>
<td class="nump">$ 81,648,187<span></span>
</td>
<td class="nump">$ 68,291,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014270120840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_SubordinatedDebtCarryingValue', window );">Subordinated note payable to Biotest</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_SubordinatedDebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="num">(74,240)<span></span>
</td>
<td class="num">(91,947)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedDebt', window );">Subordinated note payable</a></td>
<td class="nump">$ 14,925,760<span></span>
</td>
<td class="nump">$ 14,908,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SubordinatedDebtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SubordinatedDebtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SubordinatedDebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SubordinatedDebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of subordinated debt (with initial maturities beyond one year or beyond the operating cycle if longer). Subordinated debt places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014341849960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2019</div></th>
<th class="th"><div>May 03, 2019</div></th>
<th class="th"><div>May 02, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid', window );">Perceptive Tranche I Note and Perceptive Tranche II fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_DescriptionOfPrepaidPrincipalAmount', window );">Description of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) 5.0% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Perceptive Closing Date, (ii) 4.0% of the prepaid principal amount, if prepaid after the first anniversary of the Perceptive Closing Date and on or prior to the second anniversary of the Perceptive Closing Date, or (iii) 3.0% of the prepaid principal amount, if prepaid after the second anniversary of the Perceptive Closing Date and on or prior to the third anniversary of the Perceptive Closing Date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Warrant, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,255<span></span>
</td>
<td class="nump">$ 7,177<span></span>
</td>
<td class="nump">$ 75,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on the extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,962,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheIIIWarrantMember', window );">Perceptive Tranche III Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Warrant, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheIIILoanMember', window );">Perceptive Tranche III Loan (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal amount of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheIILoanMember', window );">Perceptive Tranche II Loan (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal amount of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheILoanMember', window );">Perceptive Tranche I Loan (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal amount of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adma_BPCMember', window );">BPC (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June 6, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Net Cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adma_MarathonHealthcareFinanceFundLPMember', window );">Marathon Healthcare Finance Fund, L.P. (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_DeferredFacilityFee', window );">Deferred facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on the extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,962,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PrepaymentPenalty', window );">Prepayment Penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_UnamortizedDebtDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_AdditionalFacilityFee', window );">Additional facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_DebtServiceReserve', window );">Debt service reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adma_PerceptiveCreditAgreementMember', window );">Perceptive Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal amount of term loan</a></td>
<td class="nump">$ 85,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_AdditionlalDescription', window );">Additionlal description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ended June 30, 2019, report revenues for the trailing 12-month period that exceed the amounts set forth in the Perceptive Credit Agreement, which range from $7.0 million for the fiscal quarter ended June 30, 2019 to $55.0 million for the fiscal quarter ending December 31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_InterestRateDescription', window );">Interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Perceptive Credit Agreement bear interest at a rate per annum equal to 7.5% plus the greater of (i) one-month LIBOR and (ii) 3.5%; provided, however, that upon, and during the continuance of, an Event of Default, the interest rate will automatically increase by an additional 400 basis points. Accrued interest is payable to Perceptive on the last day of each month during the term of the Perceptive Credit Facility.The rate of interest in effect as of the Perceptive Closing Date and at June 30, 2020 was 11.0%. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Warrant, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">February 11, 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AdditionalFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AdditionalFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AdditionlalDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AdditionlalDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtServiceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtServiceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DeferredFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DeferredFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DescriptionOfPrepaidPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DescriptionOfPrepaidPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_InterestRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_InterestRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_UnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_UnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheIIIWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheIIIWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheIIILoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheIIILoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheIILoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheIILoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheILoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=adma_PerceptiveTrancheILoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_BPCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_BPCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_MarathonHealthcareFinanceFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_MarathonHealthcareFinanceFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adma_PerceptiveCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adma_PerceptiveCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266514360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">6700.00%<span></span>
</td>
<td class="nump">6200.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">2.92%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">6200.00%<span></span>
</td>
<td class="nump">5400.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014264974872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 1)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period | shares</a></td>
<td class="nump">5,630,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(47,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired | shares</a></td>
<td class="num">(6,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">1,232,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod', window );">Exercised | shares</a></td>
<td class="num">(6,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period | shares</a></td>
<td class="nump">6,801,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod', window );">Options exercisable | shares</a></td>
<td class="nump">4,030,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period | $ / shares</a></td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited | $ / shares</a></td>
<td class="nump">3.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired | $ / shares</a></td>
<td class="nump">4.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">2.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">2.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period | $ / shares</a></td>
<td class="nump">4.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice', window );">Options exercisable | $ / shares</a></td>
<td class="nump">$ 5.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266767720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 2)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period | shares</a></td>
<td class="nump">5,630,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">1,232,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(47,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period | shares</a></td>
<td class="nump">6,801,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period | $ / shares</a></td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">2.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited | $ / shares</a></td>
<td class="nump">3.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period | $ / shares</a></td>
<td class="nump">$ 4.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">341,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period | shares</a></td>
<td class="nump">326,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">2.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited | $ / shares</a></td>
<td class="nump">2.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period | $ / shares</a></td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266856792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 715,608<span></span>
</td>
<td class="nump">$ 726,736<span></span>
</td>
<td class="nump">$ 1,392,156<span></span>
</td>
<td class="nump">$ 1,363,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">105,029<span></span>
</td>
<td class="nump">89,543<span></span>
</td>
<td class="nump">15,754<span></span>
</td>
<td class="nump">176,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=adma_PlasmaCentersMember', window );">Plasma centers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,510<span></span>
</td>
<td class="nump">13,213<span></span>
</td>
<td class="nump">15,754<span></span>
</td>
<td class="nump">24,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">539,256<span></span>
</td>
<td class="nump">569,349<span></span>
</td>
<td class="nump">1,063,145<span></span>
</td>
<td class="nump">1,067,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfGoodsTotalMember', window );">Cost of product revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 62,813<span></span>
</td>
<td class="nump">$ 54,631<span></span>
</td>
<td class="nump">$ 114,654<span></span>
</td>
<td class="nump">$ 95,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=adma_PlasmaCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=adma_PlasmaCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfGoodsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfGoodsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014334102792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2020</div></th>
<th class="th"><div>Feb. 21, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_UnderwrittenPublicOffering', window );">Underwritten public offering</a></td>
<td class="nump">23,500,000<span></span>
</td>
<td class="nump">3,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,349,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,318,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from public offering</a></td>
<td class="nump">$ 82,300,000<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,349,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,318,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CommonStockReservedForOutstanding', window );">Common stock reserved for outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,265,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,384,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,138,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,138,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CommonStockGranted', window );">Common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember', window );">Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,232,500<span></span>
</td>
<td class="nump">1,429,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of stock options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_CommonStockGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_CommonStockGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_CommonStockReservedForOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_CommonStockReservedForOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_CompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_CompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_UnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_UnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263229544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2017</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CreditFacilityPercentage', window );">Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PublicOfferingDescription', window );">Public offering description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) Perceptive Advisors, a principal stockholder of ADMA, purchased 4,563,700 shares of common stock through one of its affiliates, (ii) Dr. Grossman purchased 22,857 shares of common stock directly and 22,857 shares indirectly through an entity he controls (iii) Lawrence P. Guiheen, a director of the Company, purchased 20,000 shares of common stock, (iv) Mr. Grossman purchased 28,571 shares of common stock directly and 57,143 shares indirectly through an entity he controls (v) Brian Lenz, the Company&#8217;s Executive Vice President and Chief Financial Officer, purchased 7,142 shares of common stock, and (vi) James Mond, the Company&#8217;s Chief Scientific Officer and Chief Medical Officer, purchased 4,285 shares of common stock, all at the public offering price of $3.50 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_ArethLLCMember', window );">Areth, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionMonthlyRentalPayments', window );">Monthly Rent</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt instrument, frequency of periodic payment</a></td>
<td class="text">monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_CreditFacilityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_CreditFacilityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PublicOfferingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PublicOfferingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the monthly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77913982&amp;loc=d3e50796-112755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_ArethLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_ArethLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014263175944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENT AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PurchasePercentageFromInventory', window );">Purchase percentage from inventory</a></td>
<td class="nump">4200.00%<span></span>
</td>
<td class="nump">6700.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PurchaseOfRawMaterial', window );">Purchase of raw material</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_PlasmaSupplyAgreementTerm', window );">Plasma supply agreement term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaSupplyAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaSupplyAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PurchaseOfRawMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PurchaseOfRawMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PurchasePercentageFromInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PurchasePercentageFromInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014261934568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">193 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 7,787,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,560,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,987,338<span></span>
</td>
<td class="nump">$ 10,089,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">13,495,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,491,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,324,855<span></span>
</td>
<td class="nump">19,896,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,123,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,338,674)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,893,611)<span></span>
</td>
<td class="num">(24,547,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on transfer of plasma center assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,527,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on the extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,962,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,178,091)<span></span>
</td>
<td class="num">$ (19,245,230)<span></span>
</td>
<td class="num">(13,211,872)<span></span>
</td>
<td class="num">$ (13,067,955)<span></span>
</td>
<td class="num">(39,423,321)<span></span>
</td>
<td class="num">(26,279,827)<span></span>
</td>
<td class="nump">$ 304,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674,490<span></span>
</td>
<td class="nump">1,611,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_ConsolidatedMember', window );">Consolidated (member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">7,787,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,560,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,987,338<span></span>
</td>
<td class="nump">10,089,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">13,495,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,491,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,324,855<span></span>
</td>
<td class="nump">19,896,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,123,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,338,674)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,893,611)<span></span>
</td>
<td class="num">(24,547,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(3,054,266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,873,198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,529,710)<span></span>
</td>
<td class="num">(3,297,663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on transfer of plasma center assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,527,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on the extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,962,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,178,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,211,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,423,321)<span></span>
</td>
<td class="num">(26,279,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CapitalExpenditure', window );">Capital expenditure</a></td>
<td class="nump">6,243,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,243,284<span></span>
</td>
<td class="nump">245,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">885,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674,490<span></span>
</td>
<td class="nump">1,611,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_TotalAssets', window );">TOTAL ASSETS</a></td>
<td class="nump">191,541,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,274,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCenterMember', window );">Plasma Collection Centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,249,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,522,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,669,782<span></span>
</td>
<td class="nump">4,671,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">1,258,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,320,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,635,761<span></span>
</td>
<td class="nump">3,785,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(919,309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(392,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,376,464)<span></span>
</td>
<td class="num">(362,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="nump">13,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on transfer of plasma center assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,527,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on the extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(919,342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(392,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,376,497)<span></span>
</td>
<td class="nump">11,178,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CapitalExpenditure', window );">Capital expenditure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,178,790<span></span>
</td>
<td class="nump">21,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">111,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,395<span></span>
</td>
<td class="nump">228,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_TotalAssets', window );">TOTAL ASSETS</a></td>
<td class="nump">7,542,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">35,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,417<span></span>
</td>
<td class="nump">71,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,351,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,274,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,188,167)<span></span>
</td>
<td class="num">(4,891,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(2,818,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,626,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,055,363)<span></span>
</td>
<td class="num">(2,895,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on transfer of plasma center assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on the extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,962,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,170,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,901,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,243,530)<span></span>
</td>
<td class="num">(17,749,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CapitalExpenditure', window );">Capital expenditure</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,243,284<span></span>
</td>
<td class="nump">245,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,881<span></span>
</td>
<td class="nump">6,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_TotalAssets', window );">TOTAL ASSETS</a></td>
<td class="nump">74,893,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,201,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=adma_AdmaBiomanufacturingMember', window );">ADMA BioManufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">6,502,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,002,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,246,139<span></span>
</td>
<td class="nump">5,346,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">12,237,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,170,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,689,094<span></span>
</td>
<td class="nump">16,110,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,852,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,671,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,328,980)<span></span>
</td>
<td class="num">(19,292,591)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(235,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(246,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(474,314)<span></span>
</td>
<td class="num">(416,216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on transfer of plasma center assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,088,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,918,386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,803,294)<span></span>
</td>
<td class="num">(19,708,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CapitalExpenditure', window );">Capital expenditure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,064,494<span></span>
</td>
<td class="nump">224,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">772,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,447,214<span></span>
</td>
<td class="nump">$ 1,376,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_TotalAssets', window );">TOTAL ASSETS</a></td>
<td class="nump">$ 109,105,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,236,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_CapitalExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_CapitalExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_TotalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_TotalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_ConsolidatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_ConsolidatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_AdmaBiomanufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_AdmaBiomanufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014270056024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TRANSFER OF PLASMA CENTER ASSETS (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>TRANSFER OF PLASMA CENTER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_GainUponTransferFacilities', window );">Gain upon transfer facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_NetCarryingValueOfAssets', window );">Net carrying value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized', window );">Combined fair value of obligation</a></td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_GainUponTransferFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_GainUponTransferFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NetCarryingValueOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NetCarryingValueOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount, measured at acquisition-date fair value, of all the assets acquired and liabilities assumed that arise from contingencies and were recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014265300152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 262,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2021</a></td>
<td class="nump">699,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2022</a></td>
<td class="nump">721,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2023</a></td>
<td class="nump">706,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2024</a></td>
<td class="nump">603,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">2,205,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total payments</a></td>
<td class="nump">5,198,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_InterestPortionOfMinimumLeasePayments', window );">Less: imputed interest</a></td>
<td class="nump">2,050,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">210,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_OperatingLeaseLiabilityTotal', window );">Total</a></td>
<td class="nump">$ 2,937,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_InterestPortionOfMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_InterestPortionOfMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OperatingLeaseLiabilityTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OperatingLeaseLiabilityTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266408936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 15, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease and rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_LeaseDescription', window );">Lease description</a></td>
<td class="text">With the exception of advance deposits and initial months&#8217; rent totaling approximately $74,000, no payments have been made under these leases. The initial terms of each lease are from 11 to 13 years with monthly rental payments varying between approximately $17,000 and $21,000, including common area maintenance charges.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asstes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_IncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=adma_JanuaryOneTwoThousandNineteenMember', window );">January 1, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asstes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_IncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_IncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=adma_JanuaryOneTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=adma_JanuaryOneTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014270042856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 4,912,165<span></span>
</td>
<td class="nump">$ 3,574,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash Financing and Inesting Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities', window );">Equipment acquired reflected in accounts payable and accrued liabilities</a></td>
<td class="nump">1,228,000<span></span>
</td>
<td class="nump">290,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-to-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">1,723,594<span></span>
</td>
<td class="nump">1,421,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_WarrantsIssuedInConnectionWithNotePayable', window );">Warrants issued in connection with note payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,579,115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WarrantsIssuedInConnectionWithNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WarrantsIssuedInConnectionWithNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140014266392744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sale Agreement [Member] | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sale Agreement [Member] | Jefferies LLC [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CommonStockOffering', window );">Common stock offering</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adma_CommissionDescription', window );">Commission description</a></td>
<td class="text">The Company will pay the Agent a commission of up to 3.0% of the gross proceeds from each sale of the Shares under the Sale Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_CommissionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_CommissionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_CommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_CommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adma_SaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adma_SaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=adma_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=adma_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@AW:#F13*;9AXE=W+2[Y_ ,C*RL"Q5W\462%?"T2U$MP$:_7;W<Z'72@EN6
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M@@9;=V6QV,PU%)5GE6^4+U2V!D1MP!2VYTLI.0E#?MY]/MX"%R<XY92Q4]S
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MK.K+I4H6JC0 ^/ZQ*/3;C9E@_WO+Y;]02P,$%     @ YHH%47K&<XN@!P
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M MJCH?")Q 6NMP04'5-. Q)@WS(\B>($Q$T*'C,^"43KCM6J4)NX8?LQ$Y1
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M6B$;$#ZNH#^=/)K/3M (5Y4FK:+-:-%/3WZ>/<T/V!_2;R/,T0L%7P$(*1K
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M.-J*B-^4;*2\+32KR-1ER.4)7*L\@3MT\R[M$L-&IB!0R\R]V2((64#&=@
MUFPLES'B.)I]&Z-3U1T=Q4U1\9'Y?3%2:T1.G,@=TF5$$V+_UE)E/%#D[H&N
M7L,QXMWQ=P(E&,6N(A$KH3^18OPU@5&,#AFWZ#&=V,CX" 4A,LUU;RDS"DH.
M5TH6,- \=#A06@<IF7CUJ%8SEO81-'8^4@O!8?J;?OAZ<3Y%SX9#2E7K0CP
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M57#%BZ3KQAE.#?PCGN&388Z+DYO3.,G@[W(#-S-M78$C",P6P06^M0W#,?D
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M@^R3UJ-9:PW;6G6AN]">-*'-)F-MGHE,"_B2";<DCC4% $>+ @]4=B/V!*@
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MR%J(%X-2Z"$04.R M(RB&IR"!5R]-@NB==0P)D+%:01SG.:8Q+4@^!B_**O
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M!Z<W7/I;/2G3W#E"/]%\;94/G+ME,3;:)I,^T\\]_;HM=RFKO_3.R*J=@D#
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M1^T4Z'REZ"WM&>?@^$]B]@]02P,$%     @ YHH%4480A*M1!   I@D  !D
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M)_;SY!I?()E&?H>Z)[,]\O#ZFIR-3I[25[U<=[V_6X#/EN!7^2BF+C1<LL]
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M5F3 MX:JX]H+^@P;K^:Y0AD@J.L9EPDGWXHI[X=V1]W'['33=XHM.^<=V.,
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MN,T3NKB0J'BI&(FQ3C9DQXS<_'&%SV*_C>Y& %6DU.[."!-GU%9-=,3+]L1
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MF*-R(0S+<M*%T.PH6,L^N=XR\>:8?+F)GH)7LZWT2\!;'W;\9]BC#N"/"#E
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MF!_?W\=)[U;QG?G.]7@#CT.Z0UM/!OA^[O &LIG0!KL?4<[^ E!+ P04
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ME2DTG-_0V#F]\8,HJQ6:I3*J7'>V1[3;J'33  *0>Y5)<L!JF/KD-%4VW*C
M!),_L@%AK70!K&&G1@8+M!6/[-]B@]'5>A,L2;N5OE'K58BAL+5G^;#E[<+1
MO3!*5Y8RX>3>0!*/XGXW>=]_-T^&LQ]M;4NLC93!9Z:IU(Y2$)>SP8E&ATNC
M1,X85%;AQ[W(*TGK2AB!7,(1,M5=Y8P*4%-]+TNLL0?>(0Z,'A6WI%;P0<+
MTMI#(,4Y(2ZF<)RG&B(>E*G<LF*!&2'5.^4VO%B5RK%KMDIZ1<.$BM!Y )9+
M"XM(#\=E9*H-FI&@>YS6I<@%S)+7B3XM\IPT[INFF+SOQ3TUAE!+(Z'_%D$P
M[J^JOR<9/]@7U3,B7.9*+%6N/*F?V-;+7*V%5W X*,3G)_P!%RRO7AE=[)WT
MR0^8-TZ_850=&CYUVH2_+M7_D0 488\UU07<I*%HS#<_!-HLU6AKKJ H1^#
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M 9ZO-(XA]04[:+^<7?X#4$L#!!0    ( .:*!5&VFA2""P,  ,$&   9
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M-+Z\&@2@N\#L!E8U/J3VRE+D^;*B_QC4;@.M'Q39[P=.X/RO-?L'4$L#!!0
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M5Q=94O4X<;J++\1>.TI"'+;TP*,)!VB_UMH=)\'!Z2_#Z@M02P,$%     @
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M,0EA@:DR#%1_7G"!16&(=!J_CYQ.)VF Y_:)_=;6KFO94HD+7CRQ3.539^1
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M8\&=PD^5^%1)""]RRE)!+O1#3/T0%_NQQK51#=@-9/1S;\RYLB_"G2^;X,6
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MH@4'6N@O+N'\<4693GL6=0M9F,$8>,C@"84V-"]>S6]4(ZQLI'T"GAR,>7X
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M<%\OS25>D'R?!^#_10AIU\D+[%^YIO\"4$L#!!0    ( .:*!5%,YR3)I@(
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MDHLD<D ,FAX,Q3NKHRU76I5V6>IG$(5QT.<%Y^IHF #CP[KX U!+ P04
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M"%.@WZ^XSJF:F WJEM[_"U!+ P04    " #FB@511ZJ8*X(#  "7#   &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6RM5V%OXC@0_2NCZ%;:E>Z:.$"
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M:+/+E7YS0&$6Z/L+KO]MQ< $*-]%>C\!4$L#!!0    ( .:*!5$NS.4T9P(
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M=C<YTQ[@UI=*V;?"7Q;]MR'[ U!+ P04    " #FB@519E(QQU8#  #^"P
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M $DL*,^PY[H#G!/*G"BTL96(0EZJC#)8"23+/"?BYP0R7HV<OG,(W--MJDP
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M#O+51(MU>1:>"VU.UN5P95Y^F+0!YGXBA'Z9V.-U\SHU_@502P,$%     @
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M4!/*%-P2*8D]RPMX#[.[",[/+N ,*(<Q9<P<M>KZVN1AV?Q%'G.0Q0Q?B=F
ML>!ZK6#$8XQ+\%$UOEV!]XW^H@CAO@B#L)+P<\IKT C>01B$04D^PY/A]<LR
M.6^+/OKOZ$?%:!0WHN'XFJ_P16@:SH(2]QWCSC0DA65GG+%<.A;;C9[Z0:W3
M]9\.ZU;FTS[VB?[UJ=<:QSZC,I^P\#F2V2QD-BME#E+*8LI7"GZ.,9FC_%51
MNU9!VJHDG2E<I@P879:5+*H&-P)X1B)511[M(H]V)=5$FD$B]3,0'@,^IG1C
M6KLNE,)O&),=3=+D%/&=(FCG+>*KP?4*\?Y!>TM0KMQ<4; 0*=?9O2ZLQ>BZ
M=AW[A7U0OQK62^R1&7799/I+G\W),9$KRA4P7)I0YH*;(Y39[,DV6FQ<<YT+
M;5JU6Z[-N$9I'<S[I1!ZO[$!BC\ _3]02P,$%     @ YHH%44;.I)D[ @
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MJ>]8$"9!KV^YAF@#T\;=K9W]!5!+ P04    " #FB@519A(H4SL"  #;!0
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M!J#/=UQGZ LSX,-]GOT%4$L#!!0    ( .:*!5&27)OJP <  (0?   9
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M@K =BX0@*=AD\S@* 5W*GJAO@*O!"1'D>#6,)Z>!CH>\1KY!P3?HO,IZD2]
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MA^=7%KUX,= BL[WC2FCL1.UCC)\O5!H#7%\+H8\#(U!^$ W_ 5!+ P04
M" #FB@51!5K&590"  ",!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6R-56UOVC 0_BNG:)-::2,AO*T5()67;4R"HM)NG]UP$*N.G=D&RK_?V8&,
M=BGKE\1GW_/X><[QI;M3^LFDB!:>,R%-+TBMS:_#T"0I9LS45(Z25E9*9\Q2
MJ->AR36RI0=E(HRCJ!UFC,N@W_5S<]WOJHT57.)<@]ED&=/[ 0JUZP7UX#AQ
MQ]>I=1-AOYNS-2[0/N1S35%8LBQYAM)P)4'CJA?<U*^';9?O$WYRW)F3,3@G
MCTH]N6"R[ 61$X0"$^L8&+VV.$0A'!')^'W@#,HM'?!T?&3_ZKV3ET=F<*C$
M+[ZT:2_X$L 25VPC[)W:?<>#GY;C2Y0P_@F[(K?3#"#9&*NR Y@49%P6;_9\
MJ,,)@'BJ ?$!$+\&O+5#XP!H>*.%,F]KQ"SK=[7:@7;9Q.8&OC8>36ZX=*>X
ML)I6.>%L?W@[G4[NI^/9_0)N9B,8WL[N)[-OX]EP,E[ Q0@MX\+ C&G-7,$O
MX3,\+$9P\>$2/@"7,.5"T'F8;FA)CB,-D\/6@V+K^(VMVS!5TJ8&QG*)RY?X
MD&R47N*CET%\EO#'1M:@$7V".(JC"CW#=\/K5V?D-,K2-CQ?X[^E_;>R9^B;
M)7W3TS??H)]O=)+2!PPYZ@2EI3L'*ZTR.I0MA4KOJX[D/&>3+G\MBCY6%>\\
MLMVI0KXPUBJ-M=YG3*U LQU][18U9Z+*3L%TY9E<P]KV&[5.-]R>"B]RVB<Y
MK3+CA<!V*;!]7J!@)F/4^/)<[(&M-2+U-0LD,ZL2>9ZM'L$>F395E0M/+G:&
M>NW[G8%$;:0M[D4Y6[;4&]])7LT/J-46G?$O3=&GITRON30@<$644:U#Y=)%
M[RL"JW+?/AZ5I6;DARG]+E"[!%I?*66/@=N@_ 'U_P!02P,$%     @ YHH%
M40QG<E$G"0  %#$  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULM9M=
M;]LX%H;_BA#L10M,:O+PNT@#)''LSF R6S2=W6LU9A)C;"DKR4UW?_T>V8YE
MDT>TQVEST=K*>T@>DN+[D%+.GLOJK_K1^R;[/I\5]8>3QZ9Y>C\8U'>/?I[7
M[\HG7^!O[LMJGC?XM7H8U$^5SR?+H/EL (SIP3R?%B?G9\MKGZKSLW+1S*:%
M_U1E]6(^SZO_7OI9^?SAA)^\7/@\?7ALV@N#\[.G_,'?^N;/IT\5?AML2IE,
MY[ZHIV615?[^P\D%?_]101NP5/QKZI_KK<]9F\K7LORK_?+KY,,):UOD9_ZN
M:8O(\;]O_LK/9FU)V([_K L]V=39!FY_?BE]M$P>D_F:U_ZJG/U[.FD>/YS8
MDVSB[_/%K/E</G_TZX146]Y=.:N7_V;/*ZW$&N\6=5/.U\'X?3XM5O_GW]<=
ML16 Y= !L Z ,$#V!(AU@#@T0*X#Y*$!:AV@#LU!KP/TH368=8 ) TQ/@%T'
MV.7HKH9C.9;#O,G/SZKR.:M:-9;6?EA.B&4T#N&T:.?N;5/A;Z<8UYS?7H]O
MKO_X<IN]&?HFG\[JM]EI]N?M,'OSC[=G@P9K:'6#NW5IEZO2H*<TD=V41?-8
M9]?%Q$^(^%$Z7N^+_YB.YR[5@@'VS::#X*6#+B%9Y&^+XETFV"\9,&!$BZ[2
MX3=YA>&\-WQX<.W<$>'7!]=.AH]>E_OX=8W_>'3M.R,I-E-=+,N3/>5]]M]\
ML? U-:U7D7H9V2[WW\Z-L48Y>3;XMCU:L4XKS9R$7=THUG'CK!'"[@K'A) Q
MZY3@&^%.LG*3K$PF>U7635;>9T]5.5G<-6@SR^2IW%<%J>TF".F4!A<D3PB9
M=!R$#K*/A8()D%:I('NB1&>=EES1V:M-]BJ9_>]E76?W53G/T.2KO'5)<MA5
M5/\I-YB0A:"E0TK)<3BU":;(B%"BS@G->9 ]H02II&&.T>GK3?HZF?X8F25#
M,&BJO*CO?;6<"+.\GN?9G2\:O)#7M6_(+M%1HUC0%7L5H[V*<:S@7(&1T#/M
MS29SLW_@V\P??>:_-]/B83&M'Y&UEC?#Q']MJ)S-WISW*D9[%>-8X9P&O-/H
ME.TF99M,^0\$W!FF325FB1G&N+',!7/QRD;KT"EW.!M!A%U!E,D%<&Y-L A>
M4V4*IHT+UX$14:; 154(".\9*B,-N+:"V55^C&L73.+BBC]TA[M-A[MDAP\]
M[A+NIOF*O8M)EL_+JIG^;W7!?\=M14TMM",73WI</J0+)PJEXUP"T.WFK&,]
MML<4BKJ<32=YXR?9F[F??_75VX2S\BV*Y$=[ZSIT.Q_:7 DA[:Z$L,=>*672
M7SET*<./<MAU20=8+*6D/990]I@L56;297E'5#R-5(?Z[+J80XR6E-).2TE[
MK):2IKV6=Z3%TZCU:^NH'B=#NQ:4Z#S5RR+P2U9XTG!X##ZG@BD)6H?=02AQ
MJ14X@F%O$$JEP!D>KB]D[2C46O3T1<==/ U>KR$/'O-0U/)8DN8&WB$33S/3
M4>0PYC'(G"9=G7<DP],HD_)U'K-$C[$/*2GMUR-*VF/#9 -"']Y-O.,9G@::
MJ_QIVN2SU4TTF3:+BEY48Q3 ?A=@HV7B0.&8$.(:H4W?4'; P'\.,5SR& 6L
M55I!.,B$CJ%SBK K#D404IA@$.@8!-(,\N6?7RY^SRYN;Z^_W%(IK\-WW8HK
M-"L=K'A#2HKC:B2'GD4=.J"!--!\6BU:5^7LY93U:KE^U:DCI8X=(,T.*5P"
MPJYQ/6$0@C@A! 5@;.@,A%!H[8P-IM&8$$IMN+:ZISL[4( T*/P-6(+8JCDH
M*\.TAH00!+ (@$:$4&BAC Y7-4IH\'[;JGHW_XX1(,T(AX(2$-;LN!,L!$5*
M*!QPR\/D*8 01DL=+G]DD1HTZ_%6Z*@ TE1P!"$!>8P2=@(A4B[L@ -*&A,B
M+G#OT9-Y1Q7P\TYB8/]1S'[)F)"DD0DZ0H&?<=@"^T];DI+=QG94 <<?DP!Q
MJM#>=>'&<T@)\:X#&9X&4<+E7>=,.#ZQDG,D.6'[4NZP ]+8<1A(C8#P>FR
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M;3?T'J*R 71>2&F>##MR_0N;_ 102P,$%     @ YHH%46L>IO:= @  R <
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MQ*0R?C,LU54+7 >H_8(Q^3;1[C]<WMD_4$L#!!0    ( .:*!5$58 4*Z ,
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MKPJ@RK7L&%4D:6&;[RX%^WFN,@3#59#\P30XQLQQ/X#.K,767@+18R*10%F
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MJM2CRE3]WWC0_L[D@.Q4KG;JNUR/!Z,!J;;%RUU1JN]%7J>96)5%EHT'UN'
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M0@JQD172)"R]4)!';&2/]&4NO9"016SL=<4/^?:"01:QD2URHK=>0D@@-KI
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M"Y(M!&8+HBT$:@NR+01N"\(M!'(+TBT$=@OB+01Z*^JM!'HKZJT$>NOH89M
M;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T6]E4!O0[V-0&]#O8U
M;T.]C4!O&[TL(=#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU!O(]#;46\G
MT-M1;R?0VU%O)]#;46\GT-M'+[L)]';4VPGT=M3;"?1VU-L)]';4VPGT=M3;
M"?2.J'<DT#NBWI% [XAZ1P*](^H="?2.J'<DT#N./E;^I]ZYG'8I7WN^UWC]
M_Z2ZG,]-U\M?EM\[1S?4!>< /S<\?@%02P,$%     @ YHH%4134<>30 0
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .:*!5%Q1,$B[P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .:*
M!5&97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ YHH%4:,Y09,@!0  0!4  !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .:*
M!5'2YH38;@8  ($8   8              " @60-  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " #FB@51_@K^8=4"  !9"0  &
M        @($(%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ YHH%4>ZZQ[:P!@  >QD  !@              ("!$Q<  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .:*!5%ZQG.+H <  !TJ   8
M              " @?D=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " #FB@51OW+6UV('  "9'   &               @('/)0  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ YHH%44UGA%T;#@
M)24  !@              ("!9RT  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( .:*!5$'')BD6A4  'E    8              " @;@[
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #FB@51-7$\
M4_H#  "2"   &               @(%(40  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ YHH%42,LU1*N P  50@  !D
M ("!>%4  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #F
MB@511A"$JU$$  "F"0  &0              @(%=60  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .:*!5&+='V;O X  &DN   9
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M970Q-BYX;6Q02P$"% ,4    " #FB@510''MX50#  "F!P  &0
M    @($GE   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M .:*!5$"4/E%: <  $43   9              " @;*7  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ YHH%4;::%((+ P  P08  !D
M             ("!49\  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " #FB@51V^!TCZ,#   ^"   &0              @(&3H@  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .:*!5$W GS)0A8
M  %'   9              " @6VF  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ YHH%427?.?MX @  ,P4  !D              ("!
MYKP  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #FB@51
M43_J<6\"  #_!   &0              @(&5OP  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( .:*!5&QZ3C4+0,  "('   9
M      " @3O"  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ YHH%40G0:7HS P  9@8  !D              ("!G\4  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #FB@51N=A=WY$"  !/!@
M&0              @($)R0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( .:*!5$A7=X)1P0  %\*   9              " @='+  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ YHH%45?Y:$>L
M!0  ?@T  !D              ("!3]   'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " #FB@513.<DR:8"  !D!0  &0
M@($RU@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .:*
M!5&/-::J^ (  "X&   9              " @0_9  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ YHH%44CA'15  P  S L  !D
M         ("!/MP  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " #FB@510;-Z%+D"  #>!P  &0              @(&UWP  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .:*!5%'JI@K@@,  )<,
M   9              " @:7B  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ YHH%42[,Y31G @  )P8  !D              ("!7N8
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #FB@519E(Q
MQU8#  #^"P  &0              @('\Z   >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( .:*!5$LA+[B%0(  &@%   9
M  " @8GL  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
MYHH%4=2;J;Q8 @  >08  !D              ("!U>X  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " #FB@510;,]^[\#  !:#0  &0
M            @(%D\0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( .:*!5&6J;V@N@(   P(   9              " @5KU  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ YHH%44;.I)D[ @
MP04  !D              ("!2_@  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " #FB@519A(H4SL"  #;!0  &0              @(&]
M^@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .:*!5&2
M7)OJP <  (0?   9              " @2_]  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ YHH%4=9.L*O2 @  +@H  !D
M     ("!)@4! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .:*!5&CM$SJ8@0  !P-   9              "
M@2,8 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ YHH%
M405:QE64 @  C 8  !D              ("!O!P! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " #FB@51#&=R42<)   4,0  &0
M        @(&''P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( .:*!5%392RN4P(  &T%   9              " @>4H 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ YHH%46L>IO:= @  R <
M !D              ("!;RL! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " #FB@51%6 %"N@#  "5#   &0              @(%#+@$
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .:*!5'QG2;'
M(P,  .X'   9              " @6(R 0!X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ YHH%41<[=I[@ @  UP<  !D
M ("!O#4! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #F
MB@51@['<J$0"  " "P  #0              @ '3. $ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( .:*!5&7BKL<P    !,"   +              "  4([
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .:*!5%$&F%A8P0  #DD   /
M          "  2L\ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #FB@51
MO '6P> !  #L(   &@              @ &[0 $ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #FB@51%-1QY- !  "M(   $P
M        @ '30@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /P _ # 1
(  #41 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>143</ContextCount>
  <ElementCount>332</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - ORGANIZATION AND BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OrganizationAndBusiness</Role>
      <ShortName>ORGANIZATION AND BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - COMMITMENT AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CommitmentAndContingencies</Role>
      <ShortName>COMMITMENT AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SEGMENTS</Role>
      <ShortName>SEGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/TransferOfPlasmaCenterAssets</Role>
      <ShortName>TRANSFER OF PLASMA CENTER ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - LEASE OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligations</Role>
      <ShortName>LEASE OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/INVENTORIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/IntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/DEBT</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - SEGMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsTables</Role>
      <ShortName>SEGMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SEGMENTS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - LEASE OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsTables</Role>
      <ShortName>LEASE OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligations</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/OrganizationAndBusiness</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/InventoriesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000035 - Disclosure - INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000036 - Disclosure - INTANGIBLE ASSETS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>INTANGIBLE ASSETS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000040 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DebtDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/DebtTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000041 - Disclosure - DEBT (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DebtDetails1</Role>
      <ShortName>DEBT (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/DebtTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000042 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/DebtTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000043 - Disclosure - STOCKHOLDERS EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000044 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>000045 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>000046 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>000047 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>000050 - Disclosure - SEGMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsDetails</Role>
      <ShortName>SEGMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SegmentsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>000051 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative</Role>
      <ShortName>TRANSFER OF PLASMA CENTER ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/TransferOfPlasmaCenterAssets</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>000052 - Disclosure - LEASE OBLIGATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsDetails</Role>
      <ShortName>LEASE OBLIGATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligationsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>000053 - Disclosure - LEASE OBLIGATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsDetailsNarrative</Role>
      <ShortName>LEASE OBLIGATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligationsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>000054 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="adma_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>000055 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SubsequentEvents</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="adma_10q.htm">adma_10q.htm</File>
    <File>adma-20200630.xsd</File>
    <File>adma-20200630_cal.xml</File>
    <File>adma-20200630_def.xml</File>
    <File>adma-20200630_lab.xml</File>
    <File>adma-20200630_pre.xml</File>
    <File>adma_ex11.htm</File>
    <File>adma_ex311.htm</File>
    <File>adma_ex312.htm</File>
    <File>adma_ex321.htm</File>
    <File>adma_ex322.htm</File>
    <File>adma_ex51.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "adma_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 143,
   "dts": {
    "calculationLink": {
     "local": [
      "adma-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adma-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "adma_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adma-20200630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adma-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "adma-20200630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 384,
   "entityCount": 1,
   "hidden": {
    "http://admabiologics.com/20200630": 6,
    "http://fasb.org/us-gaap/2019-01-31": 22,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 34
   },
   "keyCustom": 43,
   "keyStandard": 289,
   "memberCustom": 21,
   "memberStandard": 23,
   "nsprefix": "adma",
   "nsuri": "http://admabiologics.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://admabiologics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000010 - Disclosure - INTANGIBLE ASSETS",
     "role": "http://admabiologics.com/role/IntangibleAssets",
     "shortName": "INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000011 - Disclosure - PROPERTY AND EQUIPMENT",
     "role": "http://admabiologics.com/role/PropertyAndEquipment",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000012 - Disclosure - DEBT",
     "role": "http://admabiologics.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000013 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://admabiologics.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000014 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://admabiologics.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000015 - Disclosure - COMMITMENT AND CONTINGENCIES",
     "role": "http://admabiologics.com/role/CommitmentAndContingencies",
     "shortName": "COMMITMENT AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000016 - Disclosure - SEGMENTS",
     "role": "http://admabiologics.com/role/SEGMENTS",
     "shortName": "SEGMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adma:TransferOfPlasmaCenterAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000017 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS",
     "role": "http://admabiologics.com/role/TransferOfPlasmaCenterAssets",
     "shortName": "TRANSFER OF PLASMA CENTER ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adma:TransferOfPlasmaCenterAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000018 - Disclosure - LEASE OBLIGATIONS",
     "role": "http://admabiologics.com/role/LeaseObligations",
     "shortName": "LEASE OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000019 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000020 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://admabiologics.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000023 - Disclosure - INVENTORIES (Tables)",
     "role": "http://admabiologics.com/role/InventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000024 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "role": "http://admabiologics.com/role/IntangibleAssetsTables",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000025 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "role": "http://admabiologics.com/role/PropertyAndEquipmentTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSubordinatedBorrowingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000026 - Disclosure - DEBT (Tables)",
     "role": "http://admabiologics.com/role/DebtTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSubordinatedBorrowingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://admabiologics.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000028 - Disclosure - SEGMENTS (Tables)",
     "role": "http://admabiologics.com/role/SegmentsTables",
     "shortName": "SEGMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000029 - Disclosure - LEASE OBLIGATIONS (Tables)",
     "role": "http://admabiologics.com/role/LeaseObligationsTables",
     "shortName": "LEASE OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000030 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000031 - Disclosure - ORGANIZATION AND BUSINESS (Details Narrative)",
     "role": "http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative",
     "shortName": "ORGANIZATION AND BUSINESS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000033 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationRelatedCostsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000034 - Disclosure - INVENTORIES (Details)",
     "role": "http://admabiologics.com/role/InventoriesDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000035 - Disclosure - INTANGIBLE ASSETS (Details)",
     "role": "http://admabiologics.com/role/IntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000036 - Disclosure - INTANGIBLE ASSETS (Details 1)",
     "role": "http://admabiologics.com/role/IntangibleAssetsDetails1",
     "shortName": "INTANGIBLE ASSETS (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adma:AmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)",
     "role": "http://admabiologics.com/role/IntangibleAssetsDetailsNarrative",
     "shortName": "INTANGIBLE ASSETS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adma:AmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000038 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "role": "http://admabiologics.com/role/PropertyAndEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000039 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "role": "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:ProductRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:ProductRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000040 - Disclosure - DEBT (Details)",
     "role": "http://admabiologics.com/role/DebtDetails",
     "shortName": "DEBT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSubordinatedBorrowingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:SubordinatedDebtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000041 - Disclosure - DEBT (Details 1)",
     "role": "http://admabiologics.com/role/DebtDetails1",
     "shortName": "DEBT (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSubordinatedBorrowingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:SubordinatedDebtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2019-04-11to2019-05-03",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adma:PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000042 - Disclosure - DEBT (Details Narrative)",
     "role": "http://admabiologics.com/role/DebtDetailsNarrative",
     "shortName": "DEBT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2019-04-11to2019-05-03",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adma:PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000043 - Disclosure - STOCKHOLDERS EQUITY (Details)",
     "role": "http://admabiologics.com/role/StockholdersEquityDetails",
     "shortName": "STOCKHOLDERS EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000044 - Disclosure - STOCKHOLDERS EQUITY (Details 1)",
     "role": "http://admabiologics.com/role/StockholdersEquityDetails1",
     "shortName": "STOCKHOLDERS EQUITY (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000045 - Disclosure - STOCKHOLDERS EQUITY (Details 2)",
     "role": "http://admabiologics.com/role/StockholdersEquityDetails2",
     "shortName": "STOCKHOLDERS EQUITY (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000046 - Disclosure - STOCKHOLDERS EQUITY (Details 3)",
     "role": "http://admabiologics.com/role/StockholdersEquityDetails3",
     "shortName": "STOCKHOLDERS EQUITY (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000047 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)",
     "role": "http://admabiologics.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-02-11",
      "decimals": "0",
      "lang": null,
      "name": "adma:UnderwrittenPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:CreditFacilityPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000048 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:CreditFacilityPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:PurchasePercentageFromInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:PurchasePercentageFromInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2019-01-01to2019-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000050 - Disclosure - SEGMENTS (Details)",
     "role": "http://admabiologics.com/role/SegmentsDetails",
     "shortName": "SEGMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30_adma_ConsolidatedMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "adma:TransferOfPlasmaCenterAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2019-01-01",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adma:GainUponTransferFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000051 - Disclosure - TRANSFER OF PLASMA CENTER ASSETS (Details Narrative)",
     "role": "http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative",
     "shortName": "TRANSFER OF PLASMA CENTER ASSETS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "adma:TransferOfPlasmaCenterAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2019-01-01",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adma:GainUponTransferFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000052 - Disclosure - LEASE OBLIGATIONS (Details)",
     "role": "http://admabiologics.com/role/LeaseObligationsDetails",
     "shortName": "LEASE OBLIGATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-04-01to2020-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000053 - Disclosure - LEASE OBLIGATIONS (Details Narrative)",
     "role": "http://admabiologics.com/role/LeaseObligationsDetailsNarrative",
     "shortName": "LEASE OBLIGATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-07-01to2020-07-15",
      "decimals": null,
      "lang": "en-US",
      "name": "adma:LeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000054 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)",
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000055 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://admabiologics.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "AsOf2020-06-30_us-gaap_SubsequentEventMember_adma_SaleAgreementMember_adma_JefferiesLLCMember",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GainLossOnDispositionOfAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - ORGANIZATION AND BUSINESS",
     "role": "http://admabiologics.com/role/OrganizationAndBusiness",
     "shortName": "ORGANIZATION AND BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - INVENTORIES",
     "role": "http://admabiologics.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adma_10q.htm",
      "contextRef": "From2020-01-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 44,
   "tag": {
    "adma_AdditionalFacilityFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Additional facility fee"
       }
      }
     },
     "localname": "AdditionalFacilityFee",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_AdditionlalDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Additionlal description"
       }
      }
     },
     "localname": "AdditionlalDescription",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_AdmaBiomanufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ADMA BioManufacturing"
       }
      }
     },
     "localname": "AdmaBiomanufacturingMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_AmortizationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationExpense",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_AmortizationOfLicenseRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Amortization of license revenue"
       }
      }
     },
     "localname": "AmortizationOfLicenseRevenue",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ArethLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Areth, LLC [Member]"
       }
      }
     },
     "localname": "ArethLLCMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_BPCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "BPC (Member)"
       }
      }
     },
     "localname": "BPCMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_BiotestMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Biotest [Member]"
       }
      }
     },
     "localname": "BiotestMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_CapitalExpenditure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Capital expenditure"
       }
      }
     },
     "localname": "CapitalExpenditure",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_CommissionDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commission description"
       }
      }
     },
     "localname": "CommissionDescription",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_CommonStockGranted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common stock granted"
       }
      }
     },
     "localname": "CommonStockGranted",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_CommonStockOffering": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common stock offering"
       }
      }
     },
     "localname": "CommonStockOffering",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_CommonStockReservedForOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common stock reserved for outstanding"
       }
      }
     },
     "localname": "CommonStockReservedForOutstanding",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_CompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Compensation expense"
       }
      }
     },
     "localname": "CompensationExpense",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ConsolidatedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated (member)"
       }
      }
     },
     "localname": "ConsolidatedMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_CreditFacilityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Credit facility"
       }
      }
     },
     "localname": "CreditFacilityPercentage",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer Three [Member]"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer Two [Member]"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_DebtServiceReserve": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt service reserve"
       }
      }
     },
     "localname": "DebtServiceReserve",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_DeferredFacilityFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred facility fee"
       }
      }
     },
     "localname": "DeferredFacilityFee",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_DescriptionOfPrepaidPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Description of prepaid principal amount"
       }
      }
     },
     "localname": "DescriptionOfPrepaidPrincipalAmount",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Equipment acquired reflected in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Incentive Plans [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_ExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Expiration date"
       }
      }
     },
     "localname": "ExpirationDate",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_GainUponTransferFacilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Gain upon transfer facilities"
       }
      }
     },
     "localname": "GainUponTransferFacilities",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_IncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Incremental borrowing rate"
       }
      }
     },
     "localname": "IncrementalBorrowingRate",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_InterestPortionOfMinimumLeasePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "[Less: imputed interest]",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "InterestPortionOfMinimumLeasePayments",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_InterestRateDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Interest rate description"
       }
      }
     },
     "localname": "InterestRateDescription",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_JanuaryOneTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "January 1, 2019 [Member]"
       }
      }
     },
     "localname": "JanuaryOneTwoThousandNineteenMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Jefferies LLC [Member]"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_LeaseDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease description"
       }
      }
     },
     "localname": "LeaseDescription",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_LicenseRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "License revenue"
       }
      }
     },
     "localname": "LicenseRevenue",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_MarathonHealthcareFinanceFundLPMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Marathon Healthcare Finance Fund, L.P. (Member)"
       }
      }
     },
     "localname": "MarathonHealthcareFinanceFundLPMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_NetCarryingValueOfAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Net carrying value of assets"
       }
      }
     },
     "localname": "NetCarryingValueOfAssets",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_OperatingLeaseLiabilityTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "[Total]",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityTotal",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_PaymentOfDebtRefinancingFees": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "[Payment of debt refinancing fees]",
        "negatedLabel": "Payment of debt refinancing fees"
       }
      }
     },
     "localname": "PaymentOfDebtRefinancingFees",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_PerceptiveCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Perceptive Credit Agreement [Member]"
       }
      }
     },
     "localname": "PerceptiveCreditAgreementMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PerceptiveTrancheIIILoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Perceptive Tranche III Loan (Member)"
       }
      }
     },
     "localname": "PerceptiveTrancheIIILoanMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PerceptiveTrancheIIIWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Perceptive Tranche III Warrant [Member]"
       }
      }
     },
     "localname": "PerceptiveTrancheIIIWarrantMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PerceptiveTrancheIILoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Perceptive Tranche II Loan (Member)"
       }
      }
     },
     "localname": "PerceptiveTrancheIILoanMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PerceptiveTrancheILoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Perceptive Tranche I Loan (Member)"
       }
      }
     },
     "localname": "PerceptiveTrancheILoanMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Perceptive Tranche I Note and Perceptive Tranche II fees paid"
       }
      }
     },
     "localname": "PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_PlasmaCentersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Plasma centers [Member]"
       }
      }
     },
     "localname": "PlasmaCentersMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PlasmaCollectionCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Plasma Collection Centers"
       }
      }
     },
     "localname": "PlasmaCollectionCenterMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PlasmaSupplyAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Plasma supply agreement term"
       }
      }
     },
     "localname": "PlasmaSupplyAgreementTerm",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_PrepaymentPenalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Prepayment Penalty"
       }
      }
     },
     "localname": "PrepaymentPenalty",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ProductRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Product revenue"
       }
      }
     },
     "localname": "ProductRevenue",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_PropertyAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property and equipment [Member]"
       }
      }
     },
     "localname": "PropertyAndEquipmentMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PublicOfferingDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Public offering description"
       }
      }
     },
     "localname": "PublicOfferingDescription",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_PurchaseOfRawMaterial": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Purchase of raw material"
       }
      }
     },
     "localname": "PurchaseOfRawMaterial",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_PurchasePercentageFromInventory": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Purchase percentage from inventory"
       }
      }
     },
     "localname": "PurchasePercentageFromInventory",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_RightToIntermediatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Right to intermediates [Member]"
       }
      }
     },
     "localname": "RightToIntermediatesMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_SaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Sale Agreement [Member]"
       }
      }
     },
     "localname": "SaleAgreementMember",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "[Options exercisable]",
        "verboseLabel": "Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_SubordinatedDebtCarryingValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Subordinated note payable to Biotest"
       }
      }
     },
     "localname": "SubordinatedDebtCarryingValue",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_SubordinatedDebtInstrumentUnamortizedDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "[Debt discount]",
        "verboseLabel": "Debt discount"
       }
      }
     },
     "localname": "SubordinatedDebtInstrumentUnamortizedDiscount",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_TotalAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "[TOTAL ASSETS]",
        "verboseLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "TotalAssets",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_TransferOfPlasmaCenterAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "11. TRANSFER OF PLASMA CENTER ASSETS"
       }
      }
     },
     "localname": "TransferOfPlasmaCenterAssetsDisclosureTextBlock",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/TransferOfPlasmaCenterAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adma_UnamortizedDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Unamortized debt discount"
       }
      }
     },
     "localname": "UnamortizedDebtDiscount",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_UnderwrittenPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Underwritten public offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOffering",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_WarrantsIssuedInConnectionWithNotePayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "[Warrants issued in connection with note payable]",
        "verboseLabel": "Warrants issued in connection with note payable"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithNotePayable",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://admabiologics.com/20200630",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [],
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://admabiologics.com/role/StockholdersEquityDetails",
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://admabiologics.com/role/StockholdersEquityDetails",
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://admabiologics.com/role/StockholdersEquityDetails",
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r112",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r18",
      "r113",
      "r114",
      "r160"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SUPPLEMENTAL INFORMATION:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 23.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Warrants issued in connection with note payable"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r164",
      "r165",
      "r189",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r60",
      "r73",
      "r208"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r73",
      "r128",
      "r134"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails2",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails2",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r48"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets, Current]",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNet": {
     "auth_ref": [
      "r1",
      "r258",
      "r259",
      "r260",
      "r261"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net assets (liabilities).",
        "label": "[Net Assets]",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "AssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r166",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Buildings [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount, measured at acquisition-date fair value, of all the assets acquired and liabilities assumed that arise from contingencies and were recognized by the entity.",
        "label": "Combined fair value of obligation"
       }
      }
     },
     "localname": "BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/TransferOfPlasmaCenterAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TRANSFER OF PLASMA CENTER ASSETS"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r85",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "1. ORGANIZATION AND BUSINESS"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r14",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.",
        "label": "Current portion of lease obligations"
       }
      }
     },
     "localname": "CapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsNoncurrent": {
     "auth_ref": [
      "r39",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.",
        "label": "Lease obligations, net of current portion"
       }
      }
     },
     "localname": "CapitalLeaseObligationsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r30",
      "r75"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents - end of period",
        "periodStartLabel": "Cash and cash equivalents, including restricted cash - beginning of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "[Cash and Cash Equivalents, Period Increase (Decrease)]",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "13. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r152",
      "r244",
      "r253"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 27.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "COMMITMENT AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r151",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "9. COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CommitmentAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, shares par value",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative",
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common stock issuable"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, $0.0001 par value, 150,000,000 shares authorized, 86,349,981 and 59,318,355 shares issued and outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r96",
      "r97",
      "r205",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r96",
      "r97",
      "r205",
      "r206",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r96",
      "r97",
      "r205",
      "r206",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r96",
      "r97",
      "r205",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Risk concentration"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r96",
      "r97",
      "r205",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in process [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsTotalMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.",
        "label": "Cost of product revenue [Member]"
       }
      }
     },
     "localname": "CostOfGoodsTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of product revenue (exclusive of amortization expense shown below)",
        "verboseLabel": "Cost of product revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of product revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerContractsMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Customer contract [Member]"
       }
      }
     },
     "localname": "CustomerContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "auth_ref": [
      "r77",
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "auth_ref": [
      "r77",
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Warrant"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Note payable"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "auth_ref": [
      "r39",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).",
        "label": "Debt instrument, frequency of periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Principal amount of term loan"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r208",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Less:",
        "verboseLabel": "Less:"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/DebtDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r73",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r73",
      "r141"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "BASIC AND DILUTED LOSS PER COMMON SHARE"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Loss per common share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Manufacturing and laboratory equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r81",
      "r202",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Remainder of 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r129",
      "r130",
      "r133",
      "r137",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class Axis"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r133",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r129",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures [member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r73",
      "r140",
      "r145"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain on transfer of plasma center assets",
        "negatedLabel": "Gain on transfer of plasma center assets",
        "verboseLabel": "Gain on transfer of plasma center assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r73",
      "r154",
      "r155"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "[Gain (Loss) on Extinguishment of Debt]",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on the extinguishment of debt",
        "verboseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://admabiologics.com/role/DebtDetailsNarrative",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "Selling, general and administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r124",
      "r125"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r81",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location Axis"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r81",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "[Increase (Decrease) in Inventories]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Changes in operating assets and liabilities, net of acquisition:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "[Increase (Decrease) in Other Operating Assets]",
        "verboseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "4. INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r127",
      "r131"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r52",
      "r106",
      "r207",
      "r209",
      "r246"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "[Interest Expense]",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest and other income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r67",
      "r69",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "3. INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r46",
      "r120"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories",
        "verboseLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r47",
      "r81",
      "r91",
      "r121",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Rent expense",
        "verboseLabel": "Lease and rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LEASE OBLIGATIONS"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "12. LEASE OBLIGATIONS"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Fees and expenses"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 26.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "[Liabilities]",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r243",
      "r251"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "[Liabilities and Equity]",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "[Liabilities, Current]",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "6. DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Senior notes payable, net of discount",
        "verboseLabel": "Senior notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 25.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 26.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r68",
      "r71",
      "r74"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 27.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r49",
      "r50",
      "r54",
      "r74",
      "r89",
      "r245",
      "r254"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "terseLabel": "Net loss",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://admabiologics.com/role/OrganizationAndBusinessDetailsNarrative",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Financing and Inesting Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "[Nonoperating Income (Expense)]",
        "totalLabel": "Other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r15",
      "r242",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office equipment and computer software [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "[Operating Expenses]",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "[Operating Income (Loss)]",
        "totalLabel": "LOSS FROM OPERATIONS",
        "verboseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Lease liability",
        "verboseLabel": "Operating Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "[Operating Lease, Liability, Current]",
        "negatedLabel": "Current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use assets",
        "verboseLabel": "Right of use asstes"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Total payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "[Operating Leases, Future Minimum Payments, Due in Five Years]",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "[Operating Leases, Future Minimum Payments, Due in Four Years]",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "[Operating Leases, Future Minimum Payments, Due in Three Years]",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "[Operating Leases, Future Minimum Payments, Due in Two Years]",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "[Operating Leases, Future Minimum Payments, Remainder of Fiscal Year]",
        "verboseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ORGANIZATION AND BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r85",
      "r86",
      "r101",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Basis of presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued interest"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Plasma center operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other expense, net"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "OTHER INCOME (EXPENSE):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Interest and other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "[Payments for Other Fees]",
        "negatedLabel": "Payment of end of term fee"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLeasingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement.",
        "label": "[Payments for Leasing Costs]",
        "negatedLabel": "Payments on finance lease obligations"
       }
      }
     },
     "localname": "PaymentsForLeasingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "[Payments of Debt Issuance Costs]",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r166",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative",
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative",
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, shares par value",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Gross proceeds from public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from the issuance of common stock, net of offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Net Cash proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from the sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Principal payments on notes payable"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r187"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type Axis"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "5. PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r144",
      "r252"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r115",
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r163",
      "r223",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r163",
      "r223",
      "r225",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "8. RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r191",
      "r264"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted stock units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails2",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r158",
      "r250"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 24.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r53",
      "r104",
      "r105",
      "r110"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "[Revenues]",
        "totalLabel": "Total Revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "REVENUES:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r220",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-to-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleLeasebackTransactionMonthlyRentalPayments": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the monthly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller.",
        "label": "Monthly Rent"
       }
      }
     },
     "localname": "SaleLeasebackTransactionMonthlyRentalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of dilutive securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of supplemental cash flow information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Summary of notes payable"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of future minimum lease payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r136",
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r103",
      "r107",
      "r108",
      "r109",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Summarized segment financial information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Schedule of compensation expense"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of option activity"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubordinatedBorrowingTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of borrowings under subordinated debt agreements that qualify as available in computing net capital under SEC uniform net capital rules for broker-dealers, including restrictive covenants, collateral, interest rates and due dates, amounts due by date and amount owed in total.",
        "label": "Summary of subordinated note payable"
       }
      }
     },
     "localname": "ScheduleOfSubordinatedBorrowingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Intangible asset future aggregate amortization expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEGMENTS"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "10. SEGMENTS"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SEGMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "[Share-based Payment Arrangement, Noncash Expense]",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://admabiologics.com/role/StockholdersEquityDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Shares",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1",
      "http://admabiologics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Forfeited",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1",
      "http://admabiologics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1",
      "http://admabiologics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r170",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number]",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1",
      "http://admabiologics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price]",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1",
      "http://admabiologics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "[Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price]",
        "verboseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "[Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price]",
        "verboseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "[Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price]",
        "terseLabel": "Forfeited",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails1",
      "http://admabiologics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Warrant exercise price",
        "terseLabel": "Granted",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative",
      "http://admabiologics.com/role/StockholdersEquityDetails1",
      "http://admabiologics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy": {
     "auth_ref": [
      "r81",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r181",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life of stock options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life of stock options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value]",
        "verboseLabel": "Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Weighted average exercise price of warrants"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r107",
      "r126",
      "r147",
      "r149",
      "r150",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r42",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited",
      "http://admabiologics.com/role/DebtDetailsNarrative",
      "http://admabiologics.com/role/IntangibleAssetsDetails",
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://admabiologics.com/role/SegmentsDetails",
      "http://admabiologics.com/role/StockholdersEquityDetails",
      "http://admabiologics.com/role/StockholdersEquityDetails2",
      "http://admabiologics.com/role/StockholdersEquityDetails3",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative",
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited",
      "http://admabiologics.com/role/DebtDetailsNarrative",
      "http://admabiologics.com/role/IntangibleAssetsDetails",
      "http://admabiologics.com/role/LeaseObligationsDetailsNarrative",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://admabiologics.com/role/SegmentsDetails",
      "http://admabiologics.com/role/StockholdersEquityDetails",
      "http://admabiologics.com/role/StockholdersEquityDetails2",
      "http://admabiologics.com/role/StockholdersEquityDetails3",
      "http://admabiologics.com/role/StockholdersEquityDetailsNarrative",
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock, net of offering expenses, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r157",
      "r158",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock, net of offering expenses, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r157",
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options, amount",
        "verboseLabel": "Warrant, amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited",
      "http://admabiologics.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r116"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 25.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodEndLabel": "Balance, amount",
        "periodStartLabel": "Balance, amount",
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://admabiologics.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "verboseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "7. STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubordinatedDebt": {
     "auth_ref": [
      "r14",
      "r15",
      "r242",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of subordinated debt (with initial maturities beyond one year or beyond the operating cycle if longer). Subordinated debt places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.",
        "label": "Subordinated note payable"
       }
      }
     },
     "localname": "SubordinatedDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubordinatedLongTermDebt": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of collateralized/uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Subordinated debt places a lender in a lien position behind the primary lender of the company.",
        "label": "Subordinated note payable, net of discount"
       }
      }
     },
     "localname": "SubordinatedLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "14. SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademark and other intangible rights related to Nabi-HB [Member]"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=77885760&loc=SL35686385-199418"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77913982&loc=d3e50796-112755"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6479118&loc=d3e64650-112822"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262037&loc=d3e9915-115836"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604008-122996"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=116637345&loc=SL114874367-224272"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=116637345&loc=SL114874367-224272"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r265": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r266": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r267": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r268": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r269": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001193805-20-000960-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193805-20-000960-xbrl.zip
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MD]L/O8 6S>V(J$(IH"53 :@I,C0HPC,E*0!U,%&K! 0%NQ>NU>HX >WP,3K
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M)WN:L_L&,YN23;2T32C>@+(32F 9V" 7PG0'^&JLM9-FQ %S",+E\)SC.*+
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M+$[QF*D\JR+^F=I^ZD3OO?ST7U!+ P04    " #FB@51W4:$M200  #HQ0
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MO[HIQ:=M6TY$_KK' ^:7_P-02P,$%     @ YHH%4;XV+G[^'P  U?<! !4
M  !A9&UA+3(P,C P-C,P7V1E9BYX;6SM75MWVSB2?M]S]C]P,P_;\^#X%J>3
M/I.90TN4HQE9U$AR>GI?^M D)'%"D6J"]&5^_0*4*/&&"RE> $=Y<&P)17Y5
M!12 0E7A+W][63O*$_"A[;E?WEV^OWBG -?T+-M=?GD7PC,#FK;]3H&!X5J&
MX[G@R[M7 -_][:___5]_^9^SLW_=3D=*WS/#-7 #I><#(P"6\FP'*P5_=6_
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M,['8JR7/\8N]BM3?DM"+9%XM48Y;YA5$_H8D7B3P:GENW (?>P%.Y<Y_80\
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M*]6U^N ).-X& \+Q_"XD9Z@>(B_8Q-VO++FZ;CZHA,U:;$=K+;<V<0RX-GH
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MPNC'K8UPN.$"A_Q@%Q3=.4PA$%RP+/@B5 ^>@B?@AK0K@@\M!! W[\+_ %J
M2BC;ZM$[2#2[D6HFD;0SR 7P(NMHZV%@W\BVVO>(>I5Z86.)Q%^(7P#_L1ZL
M@#_V7"^-C^G39]')I!H&*P*XA.\0O[C+Z"YV9^N+"+(*(:#Y]*E$$NF'RH<
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MA+8RR;0 ?C:*BA1GL/L<_\ 7&OWU_P%02P,$%     @ YHH%41124/)J4P
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M@-_W4O_G7WXZEJ*IHQ=!XB5OC^C9(QB"Y!YN$*<V?#$]W2Z#N.]]GHP!))#
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M7_[7[&FYN@>S^QMP_66]O%^LUR8,G.M=[ 4HCF]0;$?>-JWY-8R]F+QN.#;
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MZ,IU/1NIT4@@J_%MEPQL[F473Y#%O1D.)JX)-YP*$(OT8BH9(M%T&C2.)XI
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MJX#/V>XR!;9)LSJ3@0G1KVM +0?R9))-'E7/PR .?<\A!^/BXVJ>E+8;-1'
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MQ?XW+WFY#Q.4SB"EB519DWDQCMR1"<\;SX%>.D!+BP$>+8=TKWTH"7S%18$
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M6PHBQ&ZXRI3JAJOCI#?RB*9K?P:=D@<<0C9#SHYWLTV2S#^L%;,Y0R ;ZS@
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MT%ANJ,4S)8<T]VHZ(H+U $JJI+8LE,4(H4SW3;QF140SRNY=8[/T@@W$46H
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M*9CKV/.VZVWFD5BL0MN*J9RQD*UZ"KAKR?ELKH,+P'(JF+W0.B?NASRZHSE
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MZ)8N4@H9F2H@"1*0MEI(JN%\!+\H$AB6!\0I@T-F,4O*4(#X1:UPQ!)<USA
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MMD[/2"#'MS0W*GDIA_.\A.;_BBWE.@;9EJIH4,PG?$6B6UM&(\H<XDO_[(;
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MW[&SG_Z<O,0)8Y-$:5A.#V0:IFF4K%OP'RQL37.@;&6UQ)5YJ,@!?82'BE&
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M+'.:9GZ ==$/E6V10G37A7:9D"4U'XY\&L[];]C_7)R2__7_ 5!+ P04
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M,32-LK=Q$Q1C\$F]SLY6/Z3\AQ\W#KNO#XA&^^.^/:%F!Z9AKXVBHRG=@7\
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M!R3UK8L9G:C%C<W<D^/M2;,V3FSJ4>+4.)L]8_,6GN8^+_M!,Z(A.%LP*D^
M=)M&J?IQ,2HXW@^E406C<J)1:Q;XBXZ4[]Z1\H E. 6W<\3M](IW8ATX95%B
MRI,.&!#Z0C6#+:=WWV9 [9PW/>GILC&E_A$$=X9,%KW3 OS;-K\L_>X[GC&V
MJ2=UP?*3A%H;CIPM6)YIQNA=PJ!M+<4+EI\03M_@RWF24"/6E%Q3;(>2\T+<
MC?SE&<+P9#Z*ERZ8>4+^MV#F"7G6@IDGY#,]F/2=ZM0D&J"(CC)5==5B331?
MZ.D I5@S_"C>M6#[AXZ#"[9_*(]=L/U#QL.+3:J6W1]_-PS%&AJY/_0X%I^C
MI_31O'?!V!/USP5C3]0#%XP]1A^[J!:HE"I2#C8'+R^2XZ#\!Z50$H$[37,X
M22F%22Z<:B7@5'/"U57/%'-S\*H(I $YEJF3"W'8BSJ'V#J-31CL>8^=0 ,A
M!VY)SK=YC]@TO78.)XK HI/;!2>/SS,7W$O,O>Q*[;85X11%EODZY/V=0J7U
MOK1C4GMR=Y?3KA4+?D6>6FM=S8/?!-1Z>5H?RJ<6'#TVW^IRM%DJPR/;C*/-
MDH2R57!T?XZZ9(W#49?JF:X5\),^@2Z&IBI(EGQSU<])73F6JE/+&O!'! ]&
M"\_FHZP/%,P\7N\973M7,//HP.V& Y4+9AX;"MI:;VYH&F7 @E<1'C];-\WK
M0_G1@L$G[EL+!I^XORT8?+H^>%%88<X,$QY_U&Q=U%0LS>:C^-N"F2?D6PMF
MGI ?+9AY0CZ39^_AGRO5F!+=&1/9=LS<GX(3!Q*MG]5'\:$%<T_8IQ;,/6$?
M6S#WV'WNHDT\OCH'-;/+W=6#]$BCA+H9\#W-DE3/P817C7<SOO'&&:0E J&(
M=N",+/JG T/OOE#_4#JF\0.BT96SB?@7?Z/C,;R76KFOL5B97?A,PLCIKU7]
MV.^-*)R,H.;N[\&.I\'EK2Z2W:_:8^\+,RE-BY9M,\2U^9>$TAIJ#5W(;W[D
M=Z>6V/G7C'=!Z8ZN<AWZ,;CQ97E*B>68]%*UC%I%:E[ =][MWE?>WWA_Z%FL
M/M@*/<Z="OLRT?/@_8\KSV0'O=#@E0_.E)K$-LP=9Q&Z'S^\H;HQ5?6HQ\:=
MS=(COBR/?M.D'^%!:T@X@U\W$_"+^G8!XS(<4Z86_W-"B<(D$UY^^<TF(XT*
MECW7P#2-029*EOI?>B'-WKZ^JHH]N9#*Y;^>"3+5M!E1\/#=7\\0_MDC0P'Y
MM>%!MN+=/S),>'1I9-BV,;VHS]X$ID5?W3O94^'>+S:*(;MUP^V5U=N]+_ I
MWD>V,5OZ6Z-C>^D#4WV>+'T2'L07=RY?&"TNO\V\\=QWGK[W'BZ$,MPAH+*4
MB*8^ZQ?_<2PPRW-XRO_^16J4O_)_A6]?9C%NEME*%H[ LDU#?[[\\= ;=F^$
MP; S[ Z^?7$_W?%A@^[UCZ?>L-<=")V'&Z'[K^O?.@_?N\)U__Z^-QCT^@_[
MON&?G<%OO8?OP_Z#L'B4^U,4;LZOSX5*N5YK)WS/@J;>PWRJ[C?>Q<\9T2,$
MO36SSRYO^T_WPC=0#MW0F?ZKLJ 3]-8*52]N#-F9NLX35($;SB<ZW@0XSBZE
M<ND?3.$6SX0YX"@N W/:D4@["-[BYD_WQ/PI]'7Z>;?7\A<N60Y7=6%V,NI8
M^6N PN69S?]\(:8*P X(8DZ)QC][I4Q!@Q^Q1WJ?!(:!NOU5@SB\-%FZ::V=
M*@?ME#=2]UX)K--9T/CPI]3^^O6%FK8J$\U]*U@8E*9MLO$/!QPS-;7Y$YT9
MIAU;3(0Q3L+^]4R%>0(>O!@9AC8BFF; R-^0XNUFK?%U59 $;K\6PX\>=5#F
MIY91 IZ59,,!'H -_\>/SM.P^W3W;^&I^]A_&@J//YX&/SH/0V'8%\"0#,%:
M"%)5Z#\)4OV3\EGHWPK#W[I"P,;X]J5S/<2OI7:UYLMXV@9V-S-[:YB"/:'"
MGQZ#! Z$!,!'5!&62,3N5ZB,"R> !<&'@E"CQ 7,R39!>&1/[W+PM9,87"#L
MG,)]$X7,YQ1PA7YV^3='IT*U+ IX4X19\>T)TGXW2O6?XMW ]##*!!468<E;
MX(X,%>4H"Y-0R\0D#)\Z#X,>4_SWL@E38CZK^D5Y]N:)V(X*;_OT]S1^##07
M_G#_$VS#_WU/N8\_MFMC.E4MC#.%L0JZHCLL^DS-"+%8=7X+CWY@3XZ/5LKP
M6;71K+2VV9:=:;6SI8AP#%Q(.-HGCFUX'W"TSS[AVEO?SP1<]9]NND^EJ_YP
MV+^_$/Y29O\)DA^:\+>TR]%& JBO(=%^/:N>[89=-V#6+4+P1)]9BSC=QC1,
M?$'HW-QWA*M>_Z[_O7<]$(7>P_7Y-AC+F1H,Z]82-D"193N[CH9)Z/:I^T9D
M6\ )"\986)! ()8PF%$9DVF*H.I"S[:$ZPE#!)]71Y_ -!U8FEOU0TASK1[B
M!(^\@P)=V4V@-\LL-F7B92M@^-CBVS5Z)G-^;2B[82GF/RU\TLPT7O!]"*9N
MJ$9>">9.UMBZ@$BLX@$)Y#31W(.2LO+$_1F2 1.&Y*WG)IYY3ZRDKJ3>*%7J
M[7*M5HE#W]@&HW*V&=@D,!-,M 3 "7T "J;P-\=4+45EA<9H-Y;$D%UF/A-=
M_2_[^_,2)U,2A!2X^ZEW_G0^.!>ZTYEFS&%6RTP4'HSS^)8NYEP^EA%,+&<Q
M%:ZC*":U+/?''2 ]*;ZRU1IU@8OSD^' OU)3# <&L=Y_#;_VS:'QJL=_^Q.9
M6G2^^D(QYAO9N/OF(UAF59?3-/ /]%7X&S4CQI:)B5].66Y^Q9[RMS>DC,69
M1P-(JOT_=9;(\5Z6(2YMI&'TTS+T[G30J#^:(&/JC&A"]XW*K%>-T!^#>:16
MNB8] N'N/0_@A("LV >K[I8_C[A^)8FP(5[]M%;:T-AT3$J2R5<%%T*7I>OS
M>EN#/3VUQXFA)PZ&:\U6J5ZO1^&7E?1](I)^6@0D__N75D5J?K6$(=7H#,<H
M\$&*B#XT!QV;@ 3B; _'T<%_#Y:^^".=_Y*2[1;,/0 :#.M$P?W#TVRB*]Y'
MMZH%#!?^30E041UC?*<_0[@W0.<BW!'+%G@F+C-R[J1HBXY9@LGD@YHPZ)EC
M6@Y&KK8A#/@>.$&J?!I]1EN&Z:V.;%_LOVJ4"+6YWW-$%G9<R\NWX>_3!7U2
M$M#G#@U7B]>.FPTB_&UPV9B/I5K='QH.55MC.0I*Y(D@:P1$.0HM;!SX+NOB
ML2:[9M6<3[]226'Z)F$6;C"?C@SMTXH'SO'DT^"]EYYBK*=O,C-3 NCWZT2%
M3P)&(#%@RA7%]@Z?UCEVUV+.I<J(Z5%\QX[Y=R T:T$HA+U[SD4P,X*ZZLBU
M,5FJ.&(5ZJ-2T1/+KJO2B?+NH9@6#8,?SA)+(7\*WS5C!  'JS>HO8'PAUUT
M'W;_-2SU'FZZ#\,+H59?^]2>KF NB@JCN2!/*"C@%,M07B>4)>$0TY@^/KX0
M/DF?A0FQV#J9(A!-@V\1O"%*^M-1T3P"-!I1]P)XJ ^3JIBSX\N3+E@*8"R/
M.PB@\&M<GA04MFV#73HSJ4R9<Y(J EN%MX1/\#S@CV Y8)^MB8'+!MZBHCTA
M]LK@A5>R/$JVUL=N=N?P663 ]5.%SW$$7(;O1_^!&>#U[%*X"4?A/H=M.V&#
M8(-$,-LN"PJ96^?;LBW7CFG"W1S[HIK;Q':L^&K^;ZQK7!8V3S98;4J$N#P8
M@K]*O;?@O),(,LX 4Z:J;0,;*7:B@*@/38<V%RB8D3G$:B )V'7QA0HWQ"8"
M+KVN"NCB&4%0_^3 E;5RW5VH<C2>IAV4AL(GG''S:Z5:.7<OL">J!2,F,[9>
ME;&T\O'Z0DBMSUM%+$ ')(,K<<<F8N\E:,!;(F@0^5"!R!#D8/DQL )I;Z*A
MB/Q4 %J5(K^PIB"A\!;34WA@PW1&]#F:17@:V!(,LIZ%9]-XM2?>M^=@)2D;
MFD+'JLXJ)UCF#',5E?+7=0-D7TM?O<NV7K!V>-YU:!G=:]<,U;M2U;D: 1 L
M53Q;'S3PY_M$R,>XNN%&*>O6TN^B>1@J'7(C/98'=[5LS35K7Q6C1L6\AB$\
M&^9\#Y3$'L8F(;L/0\#469WAUF*IT(P;WHSWR54_1.FH_^ZUI(U\UF"M6B\R
MUYMISI[@;64]4(7J%NHMG+M/DJ6_-U*D&VT=UM$WI[!XO,$FBV#B(CV).HY"
M*PRC@)CI!H,8CL7M.;R6%[M&E,2!2\!W:7-\^:L*KT8*ZO05G85)7U2+B:U.
M=%F%V .$&2LR5+8P (::F(HEX,J;JJQ+6E8_D<^1MCF&_\X5'F1NVIJ ;?8E
M[1,0G7E+7E6TV1E]/@>8XZ:(MR@JON2:OR/KLM$-T*J1+_3>86BDXSS#)T*5
M5T*+2&63"J_XCTO56Y/W00\'0BS[PY(_?!=9W[&9%(,X+Y-YL=6Y52I7EZNS
M=6>J&+9"917,Z9G@_F+]>M9[N#T3<-L5>X2W3ZW5$*NUMMAN^4M7WO@N!;YI
MS),5U;(<:OHK0S+/55DL5V4L1IH"IEF+;-+= !;:P95L UAH_]BA-H!M!WL,
MYPFV.@7NH:TTL?_#OF7G;!4 /I^-)N9BT38!!%E2I'*8U&N=L"]-O\S(,RV-
M3$I^EL@88KH+@6BO9&[]<AD[%QT>>>:+U"L%LRXA(1 %M<8ME*!">,Y;5&DK
MVR8W^'$UZ-WT.D\]M@-OGRU:*Z4!>\X'F?FOM':+)0]D]A7HN)40WK2(,#'1
M=OYE!MQZ[#P-A9YPVWOH/%SW.G? +MRFUV%;$+Y](4%R1(/'S7\GJ%1.]N#X
M+_HZ(O)/0'R.KI3@=89Y\1<(%NAX'!73+=<DK5&=R*BFO2Y$\^FM KU[-IT*
MTKE+VCA;299NO_4QHM\UQXI\EBM4\4JLF/7>7#OISS')\Z0-U5]__7JV!P/'
M[+\5N[J%78FBG@791Q:N: &RUQ&D!WL6"%=$(UCU $B2 A\( QE+>\B$3S]T
MXB@J7/V9I5QNJ,Q[(50EO$)J+W$OV1!WX\,^\K"KDF7-(\M8RZ. G@!S^C/*
M"ZBL)<YX&?\A/(\R/@W4-^&>9WJ[+*I;9BM><BCN5=83**\Z0_^,R0]>/61A
M6,<BAHFA@:^T7'@N\%,,8[!JF@]654]=T>1Q7,82:R+<:L9KM*+E2+UJ[\*S
M RJC;F.*U 8MLXTE9JQAY%:,D1$CZD>C/'$!6\7%>Y7=\![<?D]TB!61!7[&
MXD:U9(?O;D4UZ>A$FULJ4[H%YY"U/ 6)USQ1R]%6'>#Y07Q7]1V=5UPZ5UTV
M57=C$]S^#\S'JGAVZPOW2?"!YOV-#-,,;!MD"9V1X=AN;8GPI%H_#\*%:CTE
M+F2I+#67"[7=N%!CC@E"58V7*S^:ADP5)/IQD3@@Z(F"X[VBO/3'FS054?%2
M$3VA/_RM^Y0\#Y$6(QOOC0?>/R>2MF[/*OME/MC]=_09'!M3:U:+<R"];N3?
M@0%YB$??SJX$AB>@/Q)NB6P;YI$1-U/9W0_%L?M_Z(%Z<^S0R;"8&]T&RB;1
M<?VP*-])QP3],(QHU(Y!RO?#:>S^&SHF# K_F&$9(-55"$@7##@N8F<J]?O!
M,7;_O0HQ_8",*0AY  2?^S,^'E)G*M=UE]3U'4D-]_,6"SV=+Z%#>'>,1,Y4
MGALND1M1E$GRE.[;1!VI]K&+\1Y@W5*?SRX'O>\/G>&/)US+/1PZ;VP+LQ*L
M@F]=.]Y<,N-N31UBT;C?E]+=^XK[S'"_K(#M2065[35&G^^86!VF4"R LD3^
M.RN@X:[?HN:+*E/!_9K5AA/+*]/M#*Z[#[W?OUG.#&;0JK4JV 0!_EBM_7T@
M([7TVY5[H=2LN==%E/Y>]7[O?>_<AR[U'\EWRQ$3B^ -FQ>^L;WG IEA#VZV
MT*WJ-F5G2#J T.&Z&3!Y+FCDE4\+[^9E].XW6&#$J@14$,MG5;;8?NQS$:OA
M0+.P-MY2%968S"4/#(T"97D1G?X"/IOJ,A7C4U( L:6F6W>OZKS.GQ=XP@5S
MG DE)JO+P^P,#C5,$"%,=QPN^W1P[WY@L;U=,)Z18WM;4>#5.%Z+D0%K!I%:
MO%#0\ L/L021U02^DKG(]P^\4AB1IK%;B 43LD6\ T<W=H#:ELU+#NTP/X#R
M(A,VIC:6X";=V5]>'53P<J"4;N%%[/$6C4_:<^&?5%",P+S8>[$FTL!^[]9,
M(XS?!G-0,U 3E?K+.^M>@]LJEAB(E,+R2;ZAAQ%VY146L$[C-9DCBG("]LAQ
M:>S>";S@VS^LB3ICW&8"!V.&>(?E6-F+9Y@+-]DU,&['$D:,(TB6I4ELJA!+
M5K87LV0DG^50*YU61AHXG< N02%4+A55D:/&>F6.*J@V5_OMT%$<V^:!\<1U
M&MRH1$RVW0A\R"O\6KHSC)]L)[>_().P2FFG/@JQ_-_ X/NL66WE G_Z=G:S
M:\1R4*+J;,\=FZGFSM1:+#VAIK*G@36@1,=OX7U>Y7.EV8G8?[C8=E@5T86"
M64&3R^V'?ZO4C;@5KXC:OAA\SKDP9 8A,$K7R<-54VSHPDP%^O#%%01S_Q<Q
M)21'FV52Z_![%L+;6YK_AAISCLE4U>87W,V>A=OL M?,DCV?4?>2K_@A_[44
M]0"@9ZOZ=5&,B#_B05;T<@"S-$S@@(]9'$Q&!1=3H: 35E],3:;;V#>%KPXM
M/@0&<34!;*0X,FNAB8X*U^L"GMHT7N ![M^/)B8M.MZG P<\.7=?")&\MX_F
M[.(?V*WNUC 47GUD.L]"1YFJ.BNW9UKP"2]SX>#M3<<%?I]Q^/?@6-N\3"F+
M[1T[R'$AD;M(I!LYI":1("9+4ND^WU^B]G&]<,>@)45IU;P>B?"_SLQ4-4'*
M0K0*H4I;J !?ZPR"*_2%:L9,#,J6R! ZA=A$(XZ.H2)($WV;$3<2"$@;H .3
M("SG0AD6.W8]W]3,OAT[[$)7$+EG1O$#_"^[_>98*$#'8]SN7\A1?N6(L8UE
M@D5D%WPOSSU1X4D%B&M<9.>)3L"8&2-$B>R;*?S"_C#Y=G[#G/NVB+=N"(K1
MDNQX%DW&+3Y8ZV2)ODQI9$19)PAX@$Z8W+&AS-TLC/>&P@\>@Z@1>:*"L>(Q
M_9A%^<MR)J(P//N][<Q%@90,4H#/]*P=/D-<?&J;*G$K3&8&9E_0LFT4Q;#4
M%3*4=QE"OBETAK$>UO<[N%C(DK<3%6)43 #-P<18-L2^)A>&%YY&\NR)ZF[X
M5=G^ +[C=Y%P"\A+L/%,3N2BB!4SD";T+G3L9W8G! L%>7=-JKC]0#0RMYBA
M,EF&6^%R@]O"P1IAY.:9DN_WCYC,I 13M=1B&\4AWEN54$\FX2O.#/8#,3BS
M6<OW@P,TV(&,*B\4QH<!SB]Q@T85EE/%E@C.5-"PE('MQ6:*@D/SPP'%/9BG
MD.83EN8(:*: (<--_G_R4EB5E[@L21 $$M:4<*GF:T&"Q8\+X9%A7D2F8'Z\
M>%#599/9$/S4PC24RW5^$JK+;]%=0W03I)X4R 9;,<2$ ,^&\ZC1KVL'^\2=
MIZ$O&37V'C!HWA'';-O=*[:+P$0%X'6V*&:Q+5Y>D[?%Q86$Y5W"V$*QCZS=
M]5'&S15 O2ZF*UB<=Q8'V?N"\..9N* $ES7]O.,B95BD=G+,31YORW1F>ZC
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MWA,AZC0=?>L#5I8*=JU.+E)=^9"G1;""L-0#&<AX#[N"H+B].;WZM+&C+<1
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M)903\F]F]SX2LV^RP[P4UCK_D9J#"3&WK)LOL%AM&8L]LINML\OR>;E<#F>
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MSJ5I-&HML=INBN7W/(@FS2(M^D9-6>7%G\P\",8,9W.RQB"<! SFE9$"?4Z
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M!R*:#<U1$+&:%*Y699NZEY6$$7U6=1V_PYV3C-II&Y"C#,+62VXH1QPMN1T
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M*)[.E*W2 F4UPT*,!=22&;"B,VZLW=13I5RN^2N62VF+C5D)J1QNG_1 [1X
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MY3?_I',$=H @=:HQ1&:[Q2CN>8$P&1M=U((,HK?D[45IBP#1U[EG=*0Z6Q;
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MSW9'8!^!WGOV3(3:=O?J7+?M:[MG[_EK TG(XHXD= '9[?GT3V96%104()#
M5MN<B#WCMB6HRLS*M\K\)7U9QB#1I9N'Y;,NW;E-%X@T-F.U;7[ B[JH?BXT
MY>DW%+OO)>3DC^0JB.>C \U^1A\A5N/)")5L,5*IQ0L]6$X#[W8?@,=L4NK2
MC1>CHN.+MS7._!DC!F?%<3QB4"/,-XJU#3.AVTTE?F\O4D'<34+W1NBFFM7B
MH*5 %W]UW1E6.X[6LS%8&J .;)+!5(@_'6&"1"SMM96D6 =ZV.PFCW5%V3]$
MU_EF"QH+FZ'AK*$$/O($03S!M[:CO.N4]R3%ZS1/M?!=5E HDL6S\[?V:5?J
MMF"X5VGZ]T$\'/$6@\!S)MNPVQB]S70\NK JVK<?F";&>^*8^K((/B4CU"T(
MQ1NB#U?%+1[D6BM,-O^%  I87NN0.HGP"_'>W?%8I3<Y\+Q09\**Y3P.18<)
M7=;2[,SE[_!K4RRHI2I^M2>(%2N(\G\>+@#%2 <%O(Z75B2Z[D,V49,4-U@0
M?S$4/8?V0*M:.G_:=.5OK6FK85EW7.[8G;[(N:/+AT]8(DOIJPSI(I;EDYV!
M<#ER(8E0(B+?JXWCF1(1R_AB44X(@S>%@T+!SYJ:RQ'1*Z)*)*(1C0E?9L*J
MO*W0D,3W&+]7H#V*B%+LC#Z+U7?RLYE"EZ-488XI/@U2'APU L:>3.H Y_3B
M2Z/%Z8PS+O\SRQ\QASE,Q4447@I8'EH$!?+RJ^/2Q:G&WLC%-I-^+#DFH,6,
M,(IFE_9I?8XEG\@5TLQAYB]J"4EG*B-\6,X4;BKZ/K*#ZOB5;\5T3_CPLN4G
M855'NCVNI,#\G18H]-](@<+.JH!W6Z^0 :6?69S 2Q!2BA.FG;[=ZF06)PQ:
MROB%<:@/KKUSQ]^XX)Y?SR]AD9=8#,K\VK&P7TF'ESFZ1YT?D%R2.<0OZX>3
M)56Y,EO[VNZP;(*X*^6G=<5RST-9?P((CV,9\ MTO O<A%XFHI1B"3[_ON)V
MX*/L-8)#T3C=L"#@40 L236+\49\ 8HI&Y<0Y\:=TBW.C+P:R<-S8ZX?^7LR
M%ABO","4@"]R@U)Y9%H4RWJ$+08RP>IIDVX+=Q-2?<'P$5D^"?=KB"M+6[0>
MH&5FT-^1'RLY0-12#4OAX34/^Q-/#GTN9HC91K T- R*) >-<JK"UT+4BV29
M(J(0[VF]XWET*<$CO&&/7=&MW9BOGR&<M<?F2C[XEN4-;MFE"E+\F'437ZVX
M SJ&#J+;$*9U7Q$*#Z!'$*8@&PC^G W_FA9;9P)UABCB*?">.D,Q3J204MZX
M( 3C. XXB3AKID];$(-RAU^'H.$"CCP9T.L<7SBC69JO"C_UF$>5+%!<#F$,
MWQ7XXU$@&3XM*II/)B8"!G9P$K7K8Q\6SXC"WP4 *1 =>&FRFCKJD"<)0!0;
MBCXC<&?M8HLF1_R=D9(4-N_'U:X@YEIHHSGU>HD(Y9LSF\&2+BR,\L5;%RQW
MR2:;RXI(!K*)0(<3."E\\GQ6EXA0KN)E(?T>0,#E5 QOS6?6 YX:#\4%8BVO
MWXDW03M1-<_*6<);W+68PS1=(!PFYL%%@9=TJ1NF541RDZ%1B,P7U;XD!A+P
MY>M1'HWLFT@)X^UT5!H#DF":%)V^TDR)FV3VVY<OOM'O8&:17\)I5)=CKQ@/
MR(V@\^0N(Z)P$3RE8 3_0M^);B3$77'X\%!FL<W,V6Q8@_O,1HN%_"#1=((E
MEODP-\R-+>I4NU6OX4G:UJ%?P;(,<SP&/#_#&TV8!R]+$JO^]UD/(D&><XM/
M7E;TLD,49A:=(QT)<LD=3K%-J1(1<30X9E"8IN3;YA40$?ZA9T_PTD3G65NI
MHUW!AXBX+(HNX_=EL.%-0"=/^'[DF[I+NC3SN.N#(Q[E?BSI W.;XPG%T%#Q
M&(92P:H8J$T?&>$YML!7R@&_3:97XABW#%HD]KH()(KY9%$U;\)]S8+6X"],
MLPK81,0EG_+#<[1&"9$-'R"#2$70(W04X"=_[J2>0D0=];'-">,2":I-B$\H
MFG&T-U>,QM'DV2%/0)"%BQ>:K"##U[:!PVYTDGG[(]!0Q=V&#/ /=<S(E'L,
MB:H?N0PN5')Q.J-=9/-9.*.]*+,JF"4"P:C_F@(O/_9\K(I;L)#P5%-VG+,P
M^")7E,\)E%3X!AX7/VOM_+8R?.UK\%:$0_D>K%KV$YI6L@[%BGY,=1QSG24_
M)8I05%2QS"*4V$6TD(\HK,RC(XLA*Z"CTD9S8*U/973L'$K'"J+B K&Q KMR
MYOK!]?S..O(:T;/T4H#7#HPSEB42;WY.=84T-2M+4*+J$UL>NQ2S]XHWP Q2
M;/!5#&PT;!>2+GCDV@YPV"(D6($,.4U"=E%@1[#WF!%DBT!0(O*=I+(4X3Y@
M1UGT6XI]$D%H.#%*;/14^Y?P/63LR7FQQ^%%3^3PKN.06>SR44!S>Q%2($O-
M919(B>_DM. V]UG[W6<-WLM]5C,J-_N"2\N_X>+W6"DW7+WNQ.Q,<FZX.DF[
M=V%Y.'C+!W?A#B)'^YB-'X+-8K 68E#B@E_;]"'4U92!,"27AF$<YGJW 0OC
M:$XJ32 /81L2VEH&UQ3@G#S^>Z)#BXH9KU@>;(1+G[ Z5'H9ZY:3P3GE3C*E
M+/)4.T>H4'A>]M*MY73+;..^BR>+RP!,)"0' ?<\YW"ECW82XY0&4>R]<=:.
MS)]<AB0W+BHZ!CR9_@ GJC6RLUY/+:](DW#PD?T#JSM9-[F\!+ZH301#*+IJ
M=6WKA]@AF"C90FS),5=YR7"!Q:*7P_L\PH!]ELMV)JZ6#"$;5B=1HP@O;9VP
ML7PGXL4$O6SQ.S8L1-(V:<OS)60G+W0/P^8>^>V$/Q7"9<<J@94ML+6'L,=^
M(@07S4J1Z%*CRG(9PI2$$5BQ,$ZY$YR[V.S$AOZ%.WS"^T"5 >)8\4WF\V-B
M3ZVM+SQCQXM3G9\D_]/> (9:;I2D1.MWTX4]VR[MZ_D(UB&6$>%U7?#=HJ$X
MBYAY/4^:F<,-3+Y_F-QUMK_(K.\)?NJ3M0U<\0N/?"3Z#7,I!]V]/,K(I*/3
M%'F+3PNL-L 5VY_@O#QYUN:W7Y0/"W=TAB_^)>%IWE_??**IV-L5/&%M_Z8E
M7% P6K!CYGZR30Q__8W HT$(.7DF;@#A?IHOBNDYM*W4#RM\('$\[N!X?&/'
MXR)^/"0OI\B.XWY@\ML[/=?<;Q_V[J,AOQFME'1/U;M\<S0RAN$R]SEWV4+W
M&]ZK/% OS@F\VO4^_<=T:H,6C@6"B>4'+K[A3K;URJ)8T/KK;\6TPG[?XHR:
MSV.,*DYTTHB_A<&%VM&IE,\=:"1&9- +9X%%2R)1^IH(70H.H"7E->G]_B^_
M]_1!R]#[?;5'\558>*2,5RJ-:F-\:MJZ#L9W]9[9T7NM=J6,+Z59YO1_NS7+
M+9]Y0&UQJ&1P,V]4Q2B8VJ^C8B*2D\PA>+-_>_?]8*EKFSV]U5*!1QIE$XF
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M9L(DELO:%D4K2\:Y-EH]Q323GB/H/YD[HZBKX/-S])$;)F8CW"3]OUN;X:B
M"B>>W-!J"A?>QO3RB6]//\VV'F[OE]^-5E+_B0Z;FZV'D-#49SJZ^ZY=N:=X
MD]H[:0UU#?7#6![""!^ZX,*DT49.&,XAWXH\ NK#O;L!:O6-P4?2#2KLH>C
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MVOVVWN[UCB#0^"D):.C]CJ&WL=ZHYFZ%.LO;(9)RUFD/^^+\H-)TP@.@@O6
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M(:A#[)F4[8,C9U/Z%CY81)<\+1S8@T?'@MS;O_4C H2+V+T!*D/K=@M]E[R
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M?_+!9LOL'FZTXJX \Y3VL3(]I7GXE:W,02S9;6<ZISUU])QJ9\($AY]J9M"
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M(I@:S4M88!P*;))4^U_ <:1+6TG5"RK< Q&*0XCZ7O#O;PS;-Z6H\<2WIY_
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M-RM@G2M\V02T\O+SL+XDH_Q8( >.-2C+E?4, 1\<00@YMI/_"XI*'E&UI.U
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M/H4Y.S9(N[MR;/Y!>6_\7@ZTTI]V0.*?1HTGU_L3],042!FJ:?PLSNV6_82
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M"EBJW!M7QM(ZG&73-/7VL %]S8UY#IUY\!(^6$<?#)HVU=R3J:26*SN9%8*
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M89ZTJ\D&9V?M^1V)ZE^<VU/2>UH[O ^) OYEF&% <43Q\C"FD!+K<BCA9SI
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MJ;-QO[#-X2*)E"CN,DG/TWFQI,OOGLHEO7!LRNP<+["NC._[ SJEYGC53,:
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M5]C:8-KC*5Z(:<IK+X.*;$Z<13)8</!/6'HL8KN$&6>,^,$K?5&4G_Y13<]
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M%<7^T#:W^!*.?=\B(G :E6)_%#:<O!>*_96GL$.$_#]([ZQ/H \F*%+HIO]
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M7TV_] :9XIU[YD_)JCG<*TG3.DZP)$7Y*JT]$S_NJ1VW;\Q =.1$"$LM@K*
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MKBUV+8$_.!"HPA%/C#L!FYYC+^0S/S%8;4K&X4I3W9%KBVPT5D+A,VZF3*_
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MP%)D6V%P>*$40ND:T5*S_JIK:2R'\9F2FBS"8"X)_<V2/%RPP);0"?1 "UK
M_=" UI$P\QKGWAJ4VY9JE,N;6P32X@4%&;$8Z^[AZYR));0EKTF7E=2V(O"$
MMA;:%2PZBZ;^!T2M?@F>$1L'*.SIOA;?7^P+[0;BJA?(-,*S)9RS'E'N(6V3
M/OW@CV:[3X6'3,TO_7FD<,.L*)6&T,7,25*T8I=QJ]ZD?P0;**@U-5XWT4V#
M)YT5/'K."JXSHRQ+=5CHP?4_K".<Q=^J-6J3/[0(A[/9%9\1 >BT&!%XG*=Z
M^%T^8!+*'(>OB"?PK"(/:*U;61,77[@!Y= CR!2^ZRZ:@GE]P $IJXDU SZ
M?03B^665J1AQ>X<<$G"M8^'5=9A@SY0BI9G;@U?ZP-I#,\)G2Q*)5!^S;,)
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M2$6^*,5CT"JQKQULT/_IN;3NFDFTW9WG)-H5233&R_J4;8^X%?FA7"N]%U
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M@Z6M_?_9^[+VMI%KV[_"A_2]]O=!BN5N]W#R)*LGY\1MW[:3?@9)4$(, @Q
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M0ZH01AX4,2%Z*YP2+2E7,I/5'NA)E#K8UP;<19/OK%$A2*94^93NA.NZ:I:
M"?%C17[#$Y__AS&>?_U9]=6E[E";Z;IW>_?*'X9)^?->#CI4=AUUWE9XPH#[
MQ?@HBZ%YJ?1N!$;TXZ_ '[/2]N4?N])V?[#D8*4N0=[&N<>#&W._W1N^#[(^
MMT#3WL_\AYGYF'%(>6Z&/ -QOP ?R#2M=@,3$PO>>Z9BZ%[2"RV$%#Y'(V;P
M\.1SBAOC(/)^T3[0HBVDZ5I/RWN<Z%$9\7[2)[UCTSY&$C "@C;E]?U]\:$6
M09I(:"T$] -*I*R!9$-""AS.*YKP?CT^R'HX"9FTM@2JQCS/=[\*'_P2YS91
M16B!0!O(F*[??J#[XGXAXC,U8S)4];]W??47QKG<3_3[)_)*>P!UNP^&[.">
MPZ0]4,O6'T?'ZC XX.>:NJJX6[D@#$QU-5OLPK^M*?YD<>P%=T0Q>BJ%7"B$
MDZM*W$ZAS,$E*]!R!P9CSK!GE'RCZ0:/7>/&UOC;BX/RW,S3F<MS%YYZW+6;
M ?I54PU/RC5<%/\,JO8_RJ89ZK?4;KJ]&&9,=/O775O-OGQ4S!X_>OR(RC1]
MY6>GKR*=);7(GI]3[6F+Q-FW)U\XY#72@"7K\"KK,NI&3^ON#.CM\#^:>L4+
M\VME56CY ;LW#8?UU3=?T+"^X"K=R5=?8-HWS)M*V^C0CW.ADEZ92&CE9;\/
MNV,]K_K9ER?TY)/O[O;"WSQZ]Q=^5;;!1YN]+(=M%;[_ZOCT>/9 .O3Y;]*>
M__#0E#S^FJ;D*YD2S,T=IN13;+Q3G)&[[#(YWC3?7T_/]\1ISZ?>]A?-DZ[#
M@8E]\B1,Y4G8T-AJMYO7B6$<STZW4[M,QI6\Z#??W/KM,*KGB_\-IB=8HK.N
M)T%#6'[=0OK'\28*3SSY\M:_].X*1;^78LB;Z3?5M=L=N W,,N> 9;X$(H4Z
MP3DG+7T1R]C56Y(/DYN33U_Q42X", +5;8UR/A%!Z+J<KME"L6TDP'7XCY?<
MX?B*81RGVAXA6_WE6<'X?[H@?=T=>2O",82/\&>9/59H]Z5Q$GW*J@]!P2,-
M!X%^OG^_9:!<.0@/1UM=$2N+H.<$^5PMK4./I7BEJ0-T__P"9?H"8A$=BN*0
MI3Z>/>_ZJ@-'!V$+(AP75+",$F(8M5D\3JGJV3-)AC;L/S@@H"<G(L<%JZY2
M*H]W0=VNFAT 0]QI/L;ZT[O:#A58TQ0HZS\/O_ .>JP?PN/-F@ERZ3AT021-
M#\&[_ .E/3[/5;!VU%55;L%>259 X6V1KFW4_^!;A3IT:UM#[F*K*?=5=JSN
ME_(#+B4O327L&4V-SF._3O^BB\5U342N*NI&)F "TW.TK/:!-4W63S7+?#7X
MOUVY^D,LK.M.E)KBNY-9J(,3#Z&$T75T>L!J= M?YQXQ\SX0,U_]81$S[]R_
MEW<QFI.>Q@83FQ(XXRP\C\%B83%6,3L#P#9\]V?6%^[@H_<U^]!/"4?;BK/8
M4H* %>U8M]G\3U8I4*DI0E[JN5(&'!KJKF_?*?A0A/HX_OBX2FY,*02W6//!
M!GAGE@QM.;C56T(E* VRM*=!Y=7RC@[^'3#'E19(ZE33ZJ^(RF6!G;'+&[0^
M!]ZN%XB26-)SI):DDYFS?,S^G_R!.;*XLQJM<T2!-PR"&N^[!B].%S2@\#HO
M:8^$:)4S\10M!*&PUU#@R7'F ,U7_24YW)Q^I;X&C>)<,T=%SD2YF!@ZO;#P
ME>;O+:L_Y74*"P%QD#%VG@?(4=J_)F:#^\R/9Z=Q$GL=(!,+N@9#<FM'G/Y&
M$FN*9+I=75N,]:-DP*K""910ZIMA)5PK"7\DWC_0*0UE.T7VMZ5>\R;A:!!.
ML;1W(S8%C:L [M&B D)MB.>B]Z.%-("-G5] H@(]$N_&_L7=-0LPFT6:3 4'
MI 1[:5VT>BM-.=,/(T'3\-INO<,-W<.^[5VU^;6<8U )>S0"MZ5S.X-3V8(7
MD[BLUL[/=D.-^&RSFX>1A1\M[F)+I"=Y%E7=XZ((0U6RT7QA@CE\$K(XT"+G
MDG,)19__T>1@<D,-?<1S'7QL;<_80U0(0(0[;Y0:5MK2RP4EXO"GG?2_CUY*
M9CB=UI&DY)0<1BX,[\3@C?)!;R$V)B4EQ#Z#^T U7";(XW4"UN52SD%QXVP;
MN4@ZW?4VG#W\DZ7*170W,??.,)?4 41I.=+0E;39?W"KSF<2P 7;*?EH\ RO
MD?E46>/9!1S0A1(V[UK8IMCN[A>_G*L\3'H+LQ6$TYBM[GW"[/VN)5VR1P=G
M?*8*V-I@)SV#]POR01:DO P^G=X.:*QU9)WC1"7N"N<)61NF.X:*>+Q/97V(
M5-;H\#A<7>[\"E>C^(/*TR.>I3E5\@7PJS'ETZ>"Q%#Y3V,,2W?O\QS1B%N#
M!)+I*N)5?942?"<9 64;][JOK(83.1HD-:(]AV\JSD[$?XZRYC$4(C*@\K+K
MF2:)JH4\G1 S^>A4(TWXCR.44#6 )"\GLN[E]2,#\PMWEL0DZDY1 +?JFKHS
MXA[G/J?DO0*_:H]DGYDX6D1CL<E(R<8FB%W97T\%YGS E/)LU*MTL?V@]" H
M-UZ,'4;NL=*+,FA8_R"L-!+<BC=,A#W'.6'4)TJ/9'%!\O9Q\40@'JRUX=C4
MK!&_1\1/F35^"9-P]//3PB@(:+95-H48H)C%"&5[:#RMJ1MA6)!T6B*?'!\+
MPA+IVT])Q.P];KWA=&V9A7=BWZ5ZRS=P:X)J3KKSTYV2D>G;TV%Y;_W\2!J%
M60-;X)XSV9>DJ;DH-_66V>&B$K0;U90F;.2QSV@M-.03QAD+!:VYBO7N5J,U
MGZ3$K%4I!J32Q,!IQU;8I\LMWRU*'8?JB\N%A)%^__P4.6=D](="C1$ RF$^
M?E_6]AV:5_Z899(G?]@RR>^Z);/=Y_>FLL%[<AU/SN[)O0&-,;%6(V81S37B
M>>,J2;"ZEY3O;<JK2/(/?X2@.<2=YY59D 349"1 ^Y#!2EFV%"M0IPGKSR!)
M<Z83H&\M_/2LM+PUNKM5M20I(U&4H%D(TW-,KJ#4EIZU2@OTDBCEYI%,[Y01
M>OI/IUSB/?GNNZ\-^??SLY>GIPK[@STL!4LF9$WV(W&97U>+B[9KNO-KW'\_
MA*7LM#I\IK>9?$]^\_&C1]^YWWS]P]G/[D>M1AQ1D^1 L,/E**@DQPU5ZFD*
MJV[>R(9(./V(55,9K-A,[P1!I[@^^668UYP-21:HF)%>3J^3&Q[3#BJY&%Z1
MM"$NZ^6.DX',_5_C,,ON]B?E@FAK(-QQ"0T/Y7K%DZ,_KCJPE.560:[D*]>J
MRE4/.M0U)%RO-S B6-XC%;_2+QW+XH1;J!W^7-/^P=WB@U2JW$"XI&K/646#
M<LH"T>&7U_+9@UIWX)\OXH/)J-=K(<57N1+.,-KY#:>QWDKZ<$D%H4*_Q:2Q
MQ:P*ZUGS_@W_T?;!ZM"W_QS"LOA?J$14?:^U >$1<W35'<JQ>OW/P[V.CC?V
M0<(@=FL=UR ;TN?-FJJDR_RB@_;9@R'LF,5%99"_EH+16=A@97CR]HHD<6RB
M0+'8M4?V#_C84(7?$1&U= .XA1YO UUL69PAEM%@4+.M], KEY1@1-;=+RSK
M?'8FMMM#IU59AGEMS^'+P KC?YE&4&'E-?P'.9E\+K8:@H@EFS@$:@]>_OS,
M@,?($H^W..C!2+:M61T_H^:Y)<.&FNJ<Y?YX1A#D#GBW\% .73%#<3\7MSYS
MK#F-FX\\N!#Z[%^9B$[5-=*7>QK-:T00YZ/":,.<UAO*N(<],&':V&IRXE[$
MHL/O;W"E2J[7C#F+NT%)[4'PTH,58F/^2@W8K^%O#Z.TC?2DBQ<Z-1=X*MD9
MQT;O=Q-ML7-F'EN-9Q@'10F=N]Y51_?O#I;A::5&JOB ,%W8E#:%1"N(?:&R
M.'[K'.NL<:D.3@0U".TXN@YCXT0Y%SZMH&J]3X7=AIA:KB:_J>3S2)>,^J7N
M,*ML:<XIT.&;/<0#7=]6UZ8;CF$J+2)SJY&<EOR^%[,MUV'^F3'4U8"!M63_
M(5C@'O>;.%$,<I$_\NN1WR7E>4KXR&!L0ZTT)P;AH)%*.=#DM#CVBWZ4#%[_
M^>=7LQ>4&V(7%Q_XE=SBP0[,B[-?[<!<E(/#9==@!5WLI)_<<"&NKB]ZL23=
MM'=*5YEL81@W.10$*SC[%3]).Q4,T?&WYQUMSS  #:?)'@3G8BM3EPV'/FDJ
M*^['Q-L(&TU^1/;--9H**NSM/STY?C1;AQ!88'"?2G?51?GYN4+M?&P$'7DH
M9J4 &R$)T[8R35' F/6WJ(=$'*TNQ@L_R@9ZW9.Q.Z.F ':S'M!'9)_\^/HL
MNI#D[NM3Z(!ZC=%A6VVP7D1":7&'X4M)?@29"6]\X.E53KB45";"CT!W@K43
MR/+A[JW1S,W8K3H*!Z+$?UEWC;D=K\26/7E0/E23O?=53XGV\.0))N0,9/5A
MK%_15T48^O69X)^'*(=L1U6\#+'V2ATK4M&TI;O6.H/\7(4A-W0<=7@#=:LC
M+<5.;W *=JQ%8/%;8K.W,]*[&PKI%ORW'DYRYM]*"87.1@1G:<J&; I,.!=<
M8#.)<9-R5@+32=SOO@+^^'+7T*E6>NSCV7,1.L$,0$ZL)2D*J'?+RU3\1V8(
MKWH:#\>!51^=_\&FV295Z8&YPS3.&K%Y8VC,%'J+[47Z%.'>:,J>6V\@Q!UU
MK33TPI%)[NSC1!(+%FZ0@"CL LCE;B5G>37H_>K'Y8>A.GOB3,3I24Z"D!W_
M_.P??WY5O>7PYK7Z>-1K$SSQ<C"9!V<#..$1K.XR8OO3%QC'MA9K)3N8MPFE
M6Q;4CK0U839)%431V"12C(S ?+.ACT@,3112@P"Z7'LRU82*FEBW1"^P S;4
MOL+(AC!NPFSV43):DJW\9Q+RBL5!#1+9*PT+7U,F5(*&"#^5/CM]Q/$KJ*[Y
MV4H'[]Z51 C"M'7E$@Y@J6984'=Z?;M)RQAZS\*]$%Z_K<MX*88+"SY;0^S)
M8MW4/00G?OR.Y3A>RD!AU<(/G)V]/+4O:>L9!([(06$DYU_+=D?>V GW??)Y
MI"].A_[LW7%2$IM')\?E!'!R]2J+HIF2BN:8BO/H_-6>79,PIF0B!JQ<DF%
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ME-U0:T9 :'D65EYR:<L]WKF[RY!F#.<,2N"E1 "N,+\DKZ^DQ,HS<'9':##
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MT6+@.SP0B;+\+'!]PDF)I%/D8MQ4CC>!_P0/J9!G<&#+=%O,PA468JW$><'
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MB'&17NTT"*=OR5R"R[Z\X@?;[;;O89)(C9RIS@=!U;$I89E#9,BX@S3;+&:
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MK6;RHO822N?N<RS\4V8[B*R&#[KVXP]ABS9+GLST9= F%45Y5N6:.M6E<0L
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MTPP=S;N>5&(TV+7YV^.R*16O ;'E#08W=LG2Y<KT/S_1\15N@',Z:V%\QSI
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M6==&>V&D,3!,1J(H/?ZBUQ3/^3>< ' J&,8SR;_)<=:\ N1.%YR\.KJBD?T
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MB&KJ5;7OM\#ISV(CKG_7Q^/9TMDW"$O/<8>!><-W68.,*W583;;A:>?E769
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MK\C%KOO%KM:WIQPN/NEEE[>N3ZU>:W-D+&/)UBM,BMVWS%:79;-3C7B!0AK
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M^.?[M7B_:T&4(><.&K%EA6FW0'W&>L1"74-4(Q]#[WGMNL'G2_2$WB_@^UW
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M.)F]@7C!K_$"UGVWR;HWXRPY5\_? 6O)AV%N#X5V:@@C(]WD7I?J0;RD5U^
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MW@7?X=YM>\2FTV)6P($?.&*XKEGR(:_Q$L9)HW*F)=-?MA=9FTR*&A9F=IW
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M*8PA:]H0<=\4\V99,AY?/S #'WN9G<-^_NOB_KB\]SQ+1EF#*6<O9#< ^;[
M9WA!'<3*)J=HFPVL@H9.V0 N5&L0PAH/=I3@"3-I/M@:.GT,P-/OX!G#70K
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ML*.@;++ZFEPS= +((O=^LWX6AP>B.LL9;(%!+=G6H<Q_Y KJ]KU&-.$_<35
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MIUJ$TW5JV&.O"77&_Q5_"(^U\AR284D3D9;BQKA/;-LGD1_.I]<<.N:0A"^
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M[_]R>/C!;.P</&M\DTTS]-)OBW-?N^/FJ\RM&E#";6TL1J?,(%1^&03''8.
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MBDP"JUQ1)OC-,<](NAHYPWT'0BHAFE/ [3(#LY3Z7U$-HSY.,Q".72A-?J_
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MJM#14,"$Z# V[NGK[F'NX=JX%DU/<)5=']N8ZS7M))J]'NTI]NDVW)(AR8W
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M/N\<%9/M]$]"7H+<<Y/V/(U"WI%E9O#9\$'K^N/(4L%+C'*,-W.)9/3&, "
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M,#<P3+1(R^X1H]MN0%1)$#+26JA*]U+HO9;VC$?H@] 3OG>>[$WW]R6&S>Z
MN.#B+?8&7S $OZS+HKE(Z,:#V5Z5KA(@@F3ZDQ3,NN\@6=$S^]XA<>4KVO5D
MB8G_Z5;\=D45JT"=I'(-3=^)#=K61$LD5)'#8K92RL+N"7&"B!D>I'FT 4.E
MWI(;LL[5<)(ND+@!5QE!?]5$[\<.=<LQ7(NI0-"_":;D'> ,A7S'K9\TVL0Z
M@[KBYA+#%^#-;K,-JM;B2)H\20-I?B[PJ ]:)T:BY)PU':3*[7HD%B,$S*>\
MAK"A8^MY#D:J>OH%['&W"WW3H%NJU>.E=A4Q3A0';H/AQ*'F_;X CZKHH#AY
M2J$:!E-DUF5@SF<Z84R"8PKQ%BH5K50/:P2FUNHA)JS-X.PNZ)12*)7=//WN
MP-R[78E]NIAN('F)4Q[K'NB %3V@%IJ4J"AY<35\SYF IM&.6L-I^4TV"I**
M0ZRBT9NHZ+2SPB=_$VHKOU7\\S<.O P$7;8M(#AX\@,6$ SU /*GA?A+!!K)
M.,@T0$!6AKT=_Z9\%<Z&@J_(-SH?3P-!-87)D;A&;3Q2"U7R?YO/EZ7 W&0E
M%+TDO6?T3FUZ "$9ZH&6=W6:S8O9]4_8P:99E@*%EP_,0-\LLW-0RO^ZN#\N
M^T#AW_JC;HZY_QR?',;QKZU>^&I>2H?1 4"1=L1E'[RV-&1=I!:%()":6D?<
M70^?;E1=<</_#&KWN+0G0 $&-0<4( O)//!(_T4.P-?YJ+MC^5F.)9VU@2,I
MI$KV.A0J2 I&;0D='[S9^Q/D#S[G&;^+4V\7IWYT%Z>^@4$\O5W=;/]YR;=U
MS_7)9U^?^^B^-J2 UN5ZA=J#_:L=5#BM\5133@_7WM[7)D:[F,6P5^L< QP(
M3W99FC:3^,V+?!8UMAW>9.^8((X=6_$2_1QA/A:%A_P/36CE2O.>QW"P5+M8
M>,H4,P&!EC +IB'JI<AI@!0KNHB\&*FTCJ8FACX=?/]X;\(A\J")3Q_G#"/9
MPK)/;(8B_4LYDU.$D]#0#Y>OVJ!K/Y1'J3PH%23$]?1O#-3)*RCP>IG/JL5<
M\+/=Y-"-=W##LX)YYUFAC7FY X#^KI^4VG606=^5TP(5^-$W"_4'H_L"L7\$
MFS!@D[ELL]8V+&9X0YR96H7DZDDNK33A8 8Y2G\I+=*EF;*K=^'=BE(,869F
MY?._I3Q-N%>NJ]W*O1*MAM2:0N"Y0_ZVQ?H8N N:#FS0UQ8V[@GP]LC-H+3=
MX'KV^:@M7K2+N_A;ZM]\?CM3UL$Y6=8^OVDKFX,EG6Q[F2[=5]*E6]NN!@E_
M*UWJ_OHH_F BH8NG?HQ&Q8I4P4VN9C/4B-/+8Q&N7"M:WX*I,X76D6K<CKOH
M*Y/2BUTD3E\Z$WC .D$E%&8FUL.S$UMK,4-<OYB&PA[\]=JW_3C(RE\B3@;I
M">) [+$)*I36IF:9_^Y R"N6F&LU^F#"D^!5\J0(K15]N]_CDL./!JHG V-P
M#R?KUAWUGNUQ2,K5N<*4VXZH>?4'/I'_N(&?U&W8],PQ0) ,VIY:0](UJ)KP
M\G9_<YP41+W5X9] F?@=?ME,"A8CZ_AP%7M@,*RAHS?D;.L8= ?JKGU9?MW7
MU89\L*DS[P2>KXX;)@.=U]7K4W512BVYJ$/V[RT\%V/\$A_Y9S=_>=,-C)R
MP 0B)C^<5FP PM0'KR-Q=)APRGZR*'=@BT+-)\5BKK!H0S0=2Q?=:_W8"1J
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MIC'Q(P2"!3#EVEF ^HP)PNO=1F4<7RD@?S9@&=_XRI@XK[;GX80S'YK8=]"
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M\$+NZ'AK*M%8"#IBW&,,G8$QP;@/EH4,A2&C.V_D-;W,YD2V<3MF-,,V,@/
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M=:#-^\(!YQPFF>( U[5-DTA?4MA9S&[CB 1-1BAMH$A]P10!@V%^G<0#J:(
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MI(R"8Q$R9G_%:Q.]-M&/[*9K$]W.J>24PKXP0^87("F11.EF?Q0!BB$N]@.
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M?1&>L\\>2J,/!:6]J_8>HO:O][V!!3#.9$AXX4:EG(B-&V"-1@P"$=?A,J&
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MS<*1;7F*:_YNM*%T!2@'KG7'1%6W@>/YD:@#7\RA-Y$AZMMUR!?#'$\>1%1
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MF.[LM?6\RAV:K@0,"!S9_RQ1@YZQBI3M;'EX?1E69!XV*8&I) #^/7A9LD0
MN^1XYQ?CG"^\$.'T&3F)-(9D5&9V>G;J7TKC_T^XAII0XV$(KF1HFC3%?P49
M8S49>V%.]<V,<QZ2^. 1^6<S'WFO2/&4_-,@I)V/VE,RM0]@#>%)$RV(H1G
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MIH:%QIXY?[5T5^M<D1LTIDC$H,U6@ @!JGF(""%EV*4+S<),C;L!F(X*97N
MNF-;&4E<:RQ!98R8*'MKIE:4+F"F-[0"0]XYJ6FR?;DW':6_U7O*K5R+3UV4
M99%(Y<VON%O:"]R>4!SAD]0FN)BX%#N=B\GNT@7711S_U/49G\]^$^ )&AFX
M2,VPKG^MP99NL;M$!1R!F8IGN/.*1^D5BKWW4>9T]7H\ELP'/W@>_!K9VWZ-
M[+?H,RQ]DZ6OO/\#4$L! A0#%     @ YHH%49A$ M!<#P  4:(  !$
M         ( !     &%D;6$M,C R,# V,S N>'-D4$L! A0#%     @ YHH%
M4=U&A+4D$   Z,4  !4              ( !BP\  &%D;6$M,C R,# V,S!?
M8V%L+GAM;%!+ 0(4 Q0    ( .:*!5&^-BY^_A\  -7W 0 5
M  "  >(?  !A9&UA+3(P,C P-C,P7V1E9BYX;6Q02P$"% ,4    " #FB@51
M%%)0\FI3  #15 0 %0              @ $30   861M82TR,#(P,#8S,%]L
M86(N>&UL4$L! A0#%     @ YHH%43A5*Q)910  Q>$# !4
M ( !L),  &%D;6$M,C R,# V,S!?<')E+GAM;%!+ 0(4 Q0    ( .:*!5$$
M1?\]NML! %9M#@ ,              "  3S9  !A9&UA7S$P<2YH=&U02P$"
M% ,4    " #FB@51X:-K:029   M2@, #0              @ $@M0( 861M
M85]E>#$Q+FAT;5!+ 0(4 Q0    ( .:*!5&WJ!9T50<  "T<   .
M      "  4]. P!A9&UA7V5X,S$Q+FAT;5!+ 0(4 Q0    ( .:*!5&VZ8Y#
M70<  &4=   .              "  =!5 P!A9&UA7V5X,S$R+FAT;5!+ 0(4
M Q0    ( .:*!5&6F-NP000  +(-   .              "  5E= P!A9&UA
M7V5X,S(Q+FAT;5!+ 0(4 Q0    ( .:*!5'D--4<2 0  *P-   .
M      "  <9A P!A9&UA7V5X,S(R+FAT;5!+ 0(4 Q0    ( .:*!5%KFE4;
MVP<  .P5   -              "  3IF P!A9&UA7V5X-3$N:'1M4$L%!@
0   ,  P ZP(  $!N P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
